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SUMMARY 
Invasive pneumococcal disease (IPD) and non-invasive pneumococcal 
pneumonia (NIPP) are important causes of morbidity and mortality worldwide, 
particularly among young children, the elderly and the immunocompromised. Two 
types of vaccines are available to prevent pneumococcal disease, but these target a 
limited number of the 97 pneumococcal serotypes described so far. One type is a 
strictly polysaccharide-based vaccine, which includes 23 serotypes and is primarily 
indicated for adults (23-valent pneumococcal polysaccharide vaccine, PPV23, 
targeting serotypes  1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 
19F, 20, 22F, 23F and 33F). The other type are pneumococcal conjugate vaccines 
(PCVs). Three PCVs have been licensed to date: a 7-valent formulation (PCV7), which 
covers serotypes 4, 6B, 9V, 14, 18C, 19F and 23F; a 10-formulation (PCV10), which 
includes all serotypes of PCV7, plus serotypes 1, 5 and 7F; and a 13-valent formulation 
(PCV13), which targets all serotypes of PCV10 and also serotypes 3, 6A and 19A. 
PCV7 became available in the USA in 2000 and in Europe in 2001. Several studies 
reported that the use of PCV7 in children was followed by decreases in the incidence 
of PCV7-type IPD in children. Since PCV7 reduced colonization due to the vaccine 
serotypes and because children are the main reservoirs of pneumococci in the 
community, PCV7 serotypes became less transmitted from children to the remaining 
population, with this resulting in decreases in the incidence of PCV7-type IPD also in 
non-vaccinated people, including adults (herd protection). However, at the same 
time, increases in the incidence of IPD due to particular non-PCV7 serotypes occurred 
in children and adults. 
In Portugal, PCV7 was used in children between 2001 and 2009, but was not 
included in the national immunization program. The uptake of PCV7 was initially low 
(43% in 2004), but increased steadily (75% in 2008). In mid-2009 and early-2010, 
PCV10 and PCV13, respectively, became available for children, with PCV13 replacing 
PCV7. PCV10 and PCV13 were given through the private market until June 2015, when 
PCV13 was included in the national immunization program for children. During the 
availability of PCV10 and PCV13 outside the national immunization program, PCV13 
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was the most frequently used PCV. Even though PPV23 and PCV13 are also available 
for adults, in Portugal, adult pneumococcal vaccination is estimated to be low. 
The studies presented in this thesis aimed to evaluate the characteristics of 
pneumococci causing adult IPD and adult NIPP in Portugal in a time of private PCVs 
use in children in the country. The isolates were collected by an epidemiological 
surveillance network, in work since 1999, which includes several laboratories 
throughout the country. All isolates analyzed were collected from adult patients (≥ 18 
yrs). 
For the characterization of adult IPD isolates we determined the serotype and 
antimicrobial susceptibility of isolates responsible for adult IPD between 2009 and 
2014 (n = 2428). The results were compared with previously published data from the 
same network (1999-2008, n = 2182). Adult IPD isolates were also characterized by 
Multi Locus Sequence Typing (MLST) and regarding the presence and type of two 
pilus islands (PI-1 and PI-2). For this characterization, 50% of adult IPD isolates 
recovered from 2008 to 2011 (n = 871), from each serotype, were randomly chosen. For 
the characterization of adult NIPP isolates, we determine the serotype and 
antimicrobial susceptibility of a collection of isolates responsible for adult NIPP 
between 1999 and 2015 (n = 2735).  
Previous studies from this epidemiological surveillance network, which 
analyzed the serotypes of adult IPD isolates recovered between 1999 and 2008, found 
that in Portugal there was a significant decrease in the proportion of PCV7 serotypes 
in adult IPD in the post-PCV7 period (from 30.3% in 1999-2003 to 16.4% in 2008, p < 
0.001), accompanied by increases in the proportion of specific non-PCV7 serotypes 
(serotypes 1, 7F and 19A). When analyzing adult IPD data from 2009 to 2014, we found 
further changes in the serotype distribution of pneumococci causing adult IPD. 
Comparing adult IPD isolates recovered in 2009-2011 with those recovered in 2012-
2014, a new but small decrease in the representation of PCV7 serotypes in adult IPD 
was noted (from 19% to 14%, p = 0.003). In what concerns the overall proportion of 
PCV13 serotypes, it peaked in 2008 (70%) and then started a significant and gradual 
decline until 2014 (38%, p < 0.001), the last year analyzed. Since PCV10 and PCV13 
became available in Portugal only in mid-2009 and early-2010, respectively, the initial 
decline in the overall proportion of PCV13 serotypes was independent of childhood 
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vaccination. The PCV13 serotypes that decreased the most from 2008 to 2011 were 
serotypes 1 (from 10.7% in 2009 to 4.1% in 2011, p < 0.001) and 5 (from 2.0% in 2008 to 
0% in 2011, p = 0.003). The early decreases of these two serotypes may be associated 
with long term fluctuations and outbreaks, described elsewhere. Other serotypes, 
instead, decreased when a herd effect with the use of PCV13 in children was expected. 
This was the case of serotype 7F (from 8.2% in 2012 to 2.7% in 2014, p < 0.001) and 19A 
(from 9.7% in 2012 to 5.6% in 2014, p = 0.027). In the post-PCV13 period, there were 
also significant increases in some of the serotypes not covered by PCV13 (i.e. serotypes 
8, 15A, 20 and 22F). In what concerns antimicrobial resistance, and considering 
current Clinical Laboratory Standards Institute (CLSI) breakpoints, in 2012-2014, o.5% 
of the isolates were considered penicillin non-susceptible pneumococci (PNSP) and 
17% erythromycin resistant pneumococci (ERP). 
 Regarding the characterization of adult IPD isolates by MLST we found high 
genetic diversity, with 206 different sequence types (STs) detected. The STs 
represented 80 different clonal complexes (CCs), but the six more frequent CCs 
accounted for half of the isolates (CC156, CC191, CC180, CC306, CC62 and CC230). 
Most of the STs detected related to STs described in other countries. We found the 
changes in serotypes occurring in adult IPD following PCV7 use in children were 
mostly driven by the expansion of previously circulating clones or to decreases in 
most of the lineages expressing a given serotype.  Concerning the presence and type 
of PI-1 and PI-2, only a small proportion of isolates was positive for any of the PIs 
(31.9%). Most of the isolates expressing PCV7 serotypes presented PI-1 (87.9%), while 
PI-2 positive isolates were mainly found among isolates expressing serotypes 1 and 7F, 
which are serotypes included in PCV10 and PCV13.  
In what concerns the characterization of adult NIPP isolates, we found 
significant declines in the proportion of vaccines serotypes following the use of PCVs 
in children, although these declines were less marked than those occurring in adult 
IPD. In adult NIPP, the proportion of PCV7 serotypes declined from 31% in 1999-2003 
to 11% in 2011 (p < 0.001), while the overall proportion of PCV13 serotypes declined 
from 44% in 2010 to 30% in 2015 (p < 0.001). When considering the 2012-2015 period, 
and according to current CLSI breakpoints, 1% of adult NIPP isolates were PNSP and 
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21.7% were ERP. Comparison of NIPP serotypes with IPD serotypes identified 
associations of several serotypes with either disease presentation. 
The studies presented in this thesis showed that in Portugal in the time of PCVs 
use in children outside the national immunization program there were several 
changes in the characteristics of pneumococci causing disease in adults. While some 
of the changes suggested herd protection with the use of PCVs in children, others 
were independent. The inclusion of PCV13 in the national immunization program for 
children in June 2015 may be further reducing the importance of PCV13 serotypes in 
adult IPD and adult NIPP. However, increases of particular non-PCV13 serotypes in 
adult IPD are concerning and should be monitored. Continued IPD and NIPP 
epidemiological surveillance is important due to different serotype distribution and 
dynamics of pneumococci causing each disease presentation. 
 
Key-words: Streptococcus pneumoniae; pneumococcal disease in adults; 
pneumococcal conjugate vaccines; herd protection. 
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RESUMO 
Streptococcus pneumoniae (pneumococo) é um agente bacteriano colonizador 
da nasofaringe humana, sobretudo das crianças mais jovens, mas que tem também a 
capacidade de causar infeção em indivíduos de todas as idades. Comparando com a 
frequência de colonização, a infeção pneumocócica pode ser considerada rara. Ainda 
assim, as infeções pneumocócicas são das infeções bacterianas mais comuns em todo 
o mundo. Alguns indivíduos, como as crianças mais jovens e os adultos mais velhos, 
são particularmente suscetíveis ao desenvolvimento de infeção por pneumococos. As 
infeções pneumocócicas invasivas e a pneumonia pneumocócica não bacteriémica 
causam elevada morbilidade e mortalidade em todo o mundo, ocorrendo mortes por 
estas infeções mesmo nos países onde existem antibióticos eficazes no seu 
tratamento.  
A maioria das estirpes1 de pneumococos apresenta uma cápsula polissacarídica. 
Os polissacáridos capsulares são diversos e com base nessa diversidade definem-se 
serotipos em pneumococos, tendo já sido descritos 97 serotipos. Estima-se que todos 
os serotipos de pneumococos sejam capazes de causar doença no homem, mas alguns 
fazem-no muito mais frequentemente que os outros. As vacinas disponíveis para 
prevenir a infeção pneumocócica baseiam-se num número limitado de serotipos, 
escolhidos por serem frequentes em infeção invasiva. A vacina Pn23 é exclusivamente 
polissacarídica, cobre 23 serotipos de pneumococos (serotipos 1, 2, 3, 4, 5, 6B, 7F, 8, 
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F e 33F) e está indicada 
sobretudo para adultos. Não é usada em crianças menores de dois anos, por não ser 
imunogénica neste grupo etário. As outras vacinas pneumocócicas em uso têm os 
polissacáridos capsulares acoplados a proteínas transportadoras adjuvantes e já são 
indicadas para crianças menores de dois anos. Até ao momento, já se licenciaram três 
vacinas deste tipo: a vacina Pn7, que cobre sete serotipos de pneumococos (4, 6B, 9V, 
14, 18C, 19F e 23F), a vacina Pn10, que cobre os serotipos da vacina Pn7 e ainda os 
serotipos 1, 5 e 7F, e a vacina Pn13, que cobre os serotipos da vacina Pn10 e ainda os 
serotipos 3, 6A e 19A.  
                                                     
1 Neste trabalho, a palavra estirpe é utilizada para referir um microrganismo isolado de um 
determinado produto biológico.  
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A vacina Pn7 foi a primeira vacina pneumocócica conjugada a ser 
comercializada, tendo sido licenciada nos Estados Unidos da América no ano de 2000 
e na Europa em 2001. Estudos em vários países reportaram que o uso da vacina Pn7 
em crianças foi acompanhado por uma diminuição na incidência de infeção invasiva, 
pelos serotipos vacinais, em crianças. Como ocorreu redução da colonização 
nasofaríngea pelos serotipos da vacina Pn7 nas crianças vacinadas, menos destes 
serotipos foram transmitidos das crianças para a restante comunidade, e menor foi a 
incidência de infeção invasiva por estes serotipos nos indivíduos não vacinados, 
incluindo nos adultos (imunidade de grupo). Contudo, ocorreram também aumentos 
na incidência de infeção invasiva por serotipos não cobertos pela vacina Pn7, em 
crianças e adultos.  
Em Portugal, a vacina Pn7 foi usada em crianças entre 2001 e 2009, mas não fez 
parte do plano nacional de vacinação (PNV). A cobertura vacinal foi inicialmente 
baixa (ex. 43% em 2004), mas aumentou progressivamente (ex. 75% em 2008). No 
final de 2009 e no início de 2010 disponibilizaram-se as vacinas Pn10 e Pn13, 
respetivamente, sendo que a vacina Pn13 veio substituir a vacina Pn7. As vacinas Pn10 
e Pn13 foram usadas fora do PNV até Junho de 2015, altura em que a vacina Pn13 
integrou o PNV das crianças. Durante o período de uso das vacinas Pn10 e Pn13 fora 
do PNV, a vacina mais usada foi a vacina Pn13. Embora as vacinas pneumocócicas 
também estejam disponíveis para adultos em Portugal (Pn23, desde 1996 e Pn13, desde 
2012), estima-se que a grande maioria dos adultos não as receba. 
Os estudos apresentados nesta tese tiveram como objetivo avaliar as 
características dos pneumococos responsáveis por infeções invasivas ou por 
pneumonia não bacteriémica em indivíduos adultos (≥ 18 anos) em Portugal, num 
contexto de uso das vacinas pneumocócicas conjugadas em crianças, fora do PNV. As 
estirpes analisadas nestes estudos foram obtidas através de um sistema de vigilância 
epidemiológica, em curso desde 1999, e que integra vários laboratórios distribuídos 
por todo o país.  
Para a caracterização das estirpes responsáveis por infeção invasiva em adultos 
determinou-se o serotipo e a suscetibilidade aos antimicrobianos de todas as estirpes 
invasivas recolhidas de adultos entre os anos de 2009 e 2014 (n =2428). Os resultados 
obtidos foram comparados com resultados anteriores (1999-2008, n =2182), da mesma 
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rede de vigilância epidemiológica. As estirpes responsáveis por infeção invasiva em 
adultos foram ainda caracterizadas quanto à sua estrutura clonal, através da técnica 
de Multi Locus Sequence Typing (MLST), e quanto à presença e distribuição de duas 
ilhas genéticas (PI-1 e PI-2), envolvidas na codificação de estruturas do tipo pilus. Para 
esta caracterização escolheu-se, de forma aleatória e para cada serotipo, pelo menos 
50% das estirpes isoladas entre os anos de 2008 e 2011 (n =871). No que respeita à 
caracterização das estirpes isoladas de adultos com pneumonia não bacteriémica 
determinou-se o serotipo e a suscetibilidade aos antimicrobianos de uma coleção de 
estirpes isoladas entre os anos de 1999 e 2015 (n =2735). 
Em estudos prévios deste sistema de vigilância epidemiológica, em que se 
analisaram as estirpes isoladas de adultos com infeção invasiva entre os anos de 1999 
e 2008, reportou-se que, mesmo numa situação de baixa a moderada cobertura 
vacinal em crianças com a vacina Pn7, ocorreu uma diminuição significativa na 
proporção dos serotipos da vacina Pn7 (de 30,3% em 1999-2003 para 16,4% em 2008, 
p <0.001), acompanhada por um aumento significativo na proporção de alguns 
serotipos não incluídos nesta vacina (serotipos 1, 7F e 19A). Neste trabalho, com a 
análise das estirpes isoladas de infeção invasiva em adultos entre os anos de 2009 e 
2014, verificou-se que continuaram a ocorrer alterações significativas na importância 
relativa dos diferentes serotipos. Quando comparando as estirpes de pneumococos 
isoladas em 2009-2011 com as isoladas em 2012-2014 detetou-se uma nova diminuição 
na representação dos serotipos da vacina Pn7 (de 19% para 14%, p =0,003). Quanto 
aos serotipos da vacina Pn13, que no seu conjunto causaram 70% das infeções 
pneumocócicas invasivas em adultos em 2008, verificou-se que iniciaram uma descida 
gradual na sua proporção, até 38% em 2014 (p <0,001), o último ano estudado para as 
infeções invasivas. Os serotipos 1 (diminuiu de 10,7% em 2008 para 4,1% em 2011, p 
<0,001) e 5 (diminuiu de 2,0% em 2008 para 0% em 2011, p = 0,003) foram os que mais 
contribuíram para a descida inicial na proporção geral dos serotipos da vacina Pn13. 
A diminuição destes serotipos ocorreu antes de se esperar um efeito de imunidade de 
grupo pelo uso das vacinas Pn10/Pn13 em crianças e poderá estar relacionada com 
características intrínsecas destes serotipos, nomeadamente, flutuações prolongadas 
de prevalência e capacidade para causar surtos. Os serotipos 7F (diminuiu de 8,2% 
em 2012 para 2,7% em 2014, p <0,001) e 19A (diminuiu de 9,7% em 2012 para 5,6% em 
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2014, p =0,027) foram os que mais contribuíram para a diminuição geral na proporção 
dos serotipos da vacina Pn13, no período em que já se esperava um efeito de 
imunidade de grupo pelo uso da vacina Pn13 em crianças. Entre os anos de 2008 e 
2014 ocorreram também aumentos importantes e significativos em alguns dos 
serotipos não cobertos pela vacina Pn13 (serotipos 8, 15A, 20 e 22F). Considerando as 
normas do Clinical Laboratory Standards Institute (CLSI), disponibilizadas em 2008 e 
ainda em vigor, a não suscetibilidade à penicilina foi rara entre as estirpes invasivas 
não responsáveis por meningite (0,5% de não suscetibilidade à penicilina em 2012-
2014), mas considerável entre as estirpes responsáveis por meningite (20,3% de 
resistência em 2012-2014). A resistência à eritromicina, que tinha aumentado durante 
o período de uso da vacina Pn7 em crianças, diminuiu entre os anos de 2010 e 2014 
(de 24,8% para 15,7%, p =0,005). 
Quanto à caracterização por MLST das estirpes isoladas de adultos com infeção 
invasiva detetou-se uma elevada diversidade genética, com 206 perfis alélicos (STs), 
organizados em 80 complexos clonais (CCs). Contudo, metade das estirpes distribuiu-
se por apenas 6 CCs (CC156, CC191, CC180, CC306, CC62 e CC230). Muitos dos STs 
encontrados relacionaram-se com STs descritos noutros países. Verificou-se que as 
mudanças na distribuição de serotipos que ocorreram no período pós-Pn7 deveram-
se à expansão de linhagens genéticas previamente existentes, ou à diminuição da 
maioria das linhagens genéticas associadas a um dado serotipo. Relativamente à 
presença e distribuição das ilhas PI-1 e PI-2 verificou-se que apenas 31,9% das estirpes 
apresentavam pelo menos uma das ilhas genéticas. A maioria dos serotipos cobertos 
pela vacina Pn7 apresentaram a ilha PI-1 (87,9%), enquanto a ilha PI-2 surgiu 
sobretudo entre as estirpes de serotipo 1 e 7F, que são serotipos incluídos nas vacinas 
Pn10 e Pn13. 
Relativamente à caracterização dos pneumococos isolados de adultos com 
pneumonia não bacteriémica detetaram-se mudanças significativas na distribuição 
de serotipos durante o uso das vacinas conjugadas em crianças, embora estas 
alterações tenham sido menos pronunciadas que aquelas encontradas entre as 
estirpes causadoras de infeção invasiva. Quanto à representação dos serotipos da 
vacina Pn7 verificou-se que passou de 31% em 1999-2003 para 11% em 2011 (p <0,001). 
Relativamente à proporção geral dos serotipos da vacina Pn13, esta diminuiu de 44% 
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em 2010 para 30% em 2015 (p <0,001). A descida na representação dos serotipos da 
vacina Pn13 foi principalmente provocada por descidas pouco acentuadas na 
proporção relativa dos serotipos 3 e 19A. Tendo em conta as normas de CLSI atuais, 
no período de 2012-2015, 1,0% das estirpes apresentaram não suscetibilidade à 
penicilina e 21,7% das estirpes apresentaram resistência à eritromicina. Comparando 
a distribuição de serotipos das estirpes isoladas de adultos com pneumonia não 
bacteriémica com as isoladas de adultos com infeção invasiva verificou-se uma 
distribuição de serotipos própria, com vários serotipos a estarem significativamente 
mais associados a um ou outro tipo de infeção. 
Os trabalhos apresentados nesta tese mostraram que após a disponibilização e 
uso das vacinas pneumocócicas conjugadas em crianças, fora do PNV, ocorreram 
diversas alterações na distribuição de serotipos de pneumococos responsáveis por 
infeções em adultos em Portugal. Algumas das alterações detetadas sugeriram um 
efeito de imunidade de grupo, enquanto outras foram independentes. Com a 
introdução, em Junho de 2015, da vacina Pn13 no PNV das crianças espera-se uma 
representação cada vez menor dos serotipos vacinais entre os pneumococos 
responsáveis por infeções em adultos. Contudo, o aumento significativo de alguns dos 
serotipos não cobertos pela vacina Pn13 é preocupante e deve ser monitorizado. Dada 
a diferente distribuição de serotipos em infeção invasiva e em pneumonia não 
bacteriémica torna-se importante continuar a vigilância epidemiológica de ambas as 
populações pneumocócicas. 
 
Palavras-chave: Streptococcus pneumoniae; infeção pneumocócica em adultos; 
vacinas pneumocócicas conjugadas; imunidade de grupo. 
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THESIS OUTLINE 
This thesis is composed of five chapters. Chapter I corresponds to a general 
introduction focusing on Streptococcus pneumoniae, the human-pneumococcal 
interaction and the available strategies to treat and prevent pneumococcal infections. 
At the end of this chapter the aims of the thesis are described. Chapter II, III and IV 
are composed of full reproductions of the publications produced during the PhD 
work. A rationale is provided at the beginning of chapters II, III and IV. Chapter II is 
composed of two publications evaluating the serotype and antimicrobial 
susceptibility of pneumococcal isolates causing invasive disease in adults in Portugal 
in two different periods (2009-2011 and 2012-2014, respectively). Chapter III is 
composed of one publication that studies the clonal structure of pneumococcal 
isolates causing invasive disease in adults in Portugal in 2008-2011. Chapter IV 
presents two manuscripts that study the serotype and antimicrobial susceptibility of 
pneumococcal isolates causing non-invasive pneumonia in adults in Portugal in two 
different periods (1999-2011 and 2012-2015, respectively). Chapter V corresponds to a 
general discussion where the main findings obtained in the studies of the previous 
chapters are approached and discussed. Concluding remarks and future perspectives 
are presented at the end of this chapter. All references used throughout the thesis are 
presented together in a section called “References”. Facsimiles of all published 
manuscripts are presented in the last section of this thesis, which was named 
“Publications”. 
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Early History of Streptococcus pneumoniae 
The first observation of S. pneumoniae (pneumococcus) is attributed to Klebs, 
which in 1875 saw cocci in the lung fluid of a men dying with pneumonia. Later, in 
1880, Ebert and Mátray may have made independent observations of pneumococci. 
Ebert, who examined the biological samples of a patient with pneumonia and 
meningitis, described bacteria consistent with pneumococci. However, probably 
ignoring the novelty of his observation, he misclassified pneumococci as other species 
known at that time. Mátray described cocci in the sputum of a patient with 
pneumonia and named the microorganism “Pneumoniekokken”. The first two reports 
of animal passage and isolation of pneumococci date to 1881. These reports were 
made, independently, by Pasteur and Sternberg and were based on the inoculation of 
human saliva in rabbits. Associations of pneumococci with several human diseases 
occurred during the following decade and were made by several scientists, including 
Friedländer and Fraenkel (White et al., 1938). 
The name “pneumococcus” was given by Fraenkel in 1886 and has been widely 
used since then. Several other names were attributed to this species, with 
“Diplococcus pneumoniae” being the most frequently used in most part of the 20th 
century. Pneumococcus was reclassified into the streptococcal genus in 1974 gaining 
its current name, “Streptococcus pneumoniae” (Watson et al., 1993).  
The historical importance of S. pneumoniae went beyond its implications on 
disease, as this microorganism was involved in some of the most important scientific 
discoveries of the past century (Austrian, 1981). One example is the identification of 
DNA as the hereditary material by Avery, MacLeod and McCarty in 1944 (Avery et al., 
1944). 
 
General Features and Microbiological Identification of S. pneumoniae 
Pneumococci are Gram positive, catalase-negative, facultative anaerobes. Based 
on its 16S rRNA sequence, S. pneumoniae is included in the mitis phylogenetic group 
of the viridans streptococcus group (Kawamura et al., 1995; Kilian et al., 2008). The 
more closely related species to S. pneumoniae are S. pseudopneumoniae and S. mitis 
(Arbique et al., 2004; Yahiaoui et al., 2016). Distinct properties of pneumococcal cells 
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are their lancet-shaped appearance and their propensity to occur in pairs. Less often, 
pneumococcal cells group into small chains. This microbe grows optimally at 35-37 
ºC and in an atmosphere of 5% CO2 in air. Pneumococcus usually has a 
polysaccharide capsule, and this structure is thought to be its major virulence factor. 
There are several types of capsular polysaccharides (CPS) in pneumococci, each 
producing a distinct immunological reaction. This forms the basis for pneumococcal 
serotype classification. So far, based on the different capsular polysaccharides 
detected, a total of 97 distinct pneumococcal serotypes have been described (Geno et 
al., 2017). Some pneumococci do not present a capsule or have it downregulated. Such 
isolates cannot be serotyped and are called non-typable isolates (NTs). 
Pneumococcus is naturally transformable, which means it can incorporate exogenous 
DNA into its chromosome. DNA exchanges may occur within the species or with 
other streptococci (Kilian et al., 2008).  
Microbiological identification of pneumococci is sometimes complicated by the 
fact that all tests lack 100% specificity and sensitivity. Moreover, closely related 
species to S. pneumoniae may not only resemble pneumococci in the laboratory, but 
also share its habitat and, more rarely, cause pneumococcal-like diseases (Richter et 
al., 2008). The classical microbiological approach for the identification of 
pneumococci from culture relies on the examination of colony morphology on blood 
agar plates and on two additional tests: optochin susceptibility and bile solubility 
tests (Lund, 1960; Alonso De Velasco et al., 1995). On blood agar plates, pneumococcal 
colonies are α-hemolytic, translucent and grayish, with 1-2 mm in diameter. They 
usually present a central depression after 24-48h incubation, which is due to autolysis. 
Some serotypes present mucoid colonies (Lund, 1960). S. pneumoniae is usually 
sensitive to optochin (ethylhydrocupreine hydrochloride) and this feature, combined 
with the observation of typical colonies, is sufficient to identify an isolate as S. 
pneumoniae (Perilla et al., 2003). However, non-encapsulated pneumococci produce 
atypical colonies (rough, smaller and flat), resembling other closely related species. 
Moreover, optochin resistance exists (Kontiainen and Sivonen, 1987) and is increasing 
(Aguiar et al., 2006; Yahiaoui et al., 2016). Therefore, doubtful results should be tested 
by bile solubility test. Pneumococci are usually soluble in bile or deoxycholate. For 
bile-insoluble isolates (Pease et al., 1986), an alternative approach is to test the 
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microorganism with anti-capsular serum that reacts with all pneumococcal capsules 
(Omni-serum) (Richter et al., 2008). However, again, specificity and sensitivity are 
not total, since closely related species to S. pneumoniae may react with pneumococcal 
anti-capsular serum (Lee et al., 1984) and non-encapsulated pneumococci will not 
react (Melchiorre et al., 2012). There are other approaches for the identification of 
pneumococci from culture, such as molecular tests (Richter et al., 2008), but 
generally, these are less frequently used. 
 
Pneumococcal Infection 
Pneumococcus behaves both as a human pathogen and as a common colonizer 
of the human respiratory tract. Comparing with the frequency of colonization, 
pneumococcal disease can be considered a relatively rare event of the human-
pneumococcal interaction.  However, due to the high prevalence of pneumococcal 
carriage in children and the fact that children serve as a source of pneumococci for 
the surrounding community, the global burden of pneumococcal disease turns out to 
be huge. 
 
Pneumococcal Colonization 
Pneumococcal colonization is a transient and highly frequent event. All humans 
are thought to be colonized at least once in life with S. pneumoniae with the highest 
rates of colonization occurring during early childhood (Bogaert et al., 2004). There 
are reports of pneumococcal colonization in other animal species such as horses 
(Burrell et al., 1986) cats and dogs (van der Linden et al., 2009), but nonetheless, 
humans are considered the reservoir of pneumococci. In the human host, S. 
pneumoniae resides in the upper airway, including nasal passages, oropharynx and 
nasopharynx. Transmission to a susceptible host occurs through direct contact with 
respiratory secretions of infected individuals (Kadioglu et al., 2008). 
Colonization rates vary with several factors, such as age, socioeconomic 
conditions and ethnicity (Bogaert et al., 2004). In children, the incidence of 
colonization is highest in the first two to three years of life (Simell et al., 2012), 
reaching 70% among children attending day care centers (Rodrigues et al., 2009). 
After the peak, carriage rates decline gradually, stabilizing in individuals > 5 years old 
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at ~ 10%. (Almeida et al., 2014; Short and Diavatopoulos, 2015). Pneumococcal 
colonization rates are higher in developing countries for all age groups. The first onset 
of colonization generally occurs at 6 months of age, but in low income countries 
colonization can start earlier (Short and Diavatopoulos, 2015). Crowding conditions, 
like those found in day care centers or in large families with young children, increase 
the likelihood of carriage (Bogaert et al., 2004). For this reason, parents and 
grandparents that are in close contact with infants may become more frequently 
colonized than non-caregivers. Some ethnical groups, such as native American and 
African American population, exhibit higher prevalence of pneumococcal carriage 
(Bogaert et al., 2004). Colonization may last from days to months in young children 
(Raymond et al., 2000) and this variability is serotype dependent (Valente et al., 2016). 
Co-colonization by two or more pneumococcal strains may occur, but is less common 
than colonization with a single pneumococcal strain (Valente et al., 2016).  
 
Pneumococcal Disease 
Progression from carriage to disease is sporadic, but outbreaks of disease have 
been documented in crowded settings with susceptible individuals. When human 
natural defense mechanisms are circumvented, pneumococci may spread from the 
nasopharynx to related anatomical sites, such as the sinuses, middle year and lungs. 
If pneumococci reach the bloodstream, they can spread to less readily accessible sites 
of the body, such as the brain, joints and peritoneal cavity. If there is a fracture of the 
skull, pneumococci may spread directly into the central nervous system, but in most 
cases, meningitis is secondary to hematogenous spread (Goldblatt and O’Brien, 2015).  
When the bacterial infection is confined to the mucosal surfaces, the infection 
is considered “non-invasive” and when there is involvement of normally sterile body 
sites, such as blood or cerebrospinal fluid (CSF), the infection is called “invasive” 
(Drijkoningen and Rohde, 2014). Pneumococcal pneumonia can be classified either 
as an invasive or a non-invasive infection, depending on the presence or absence of 
bacteria in blood, respectively. The proportion of pneumococcal pneumonia that is 
bacteremic varies widely among studies. Even so, it is generally accepted that non-
invasive pneumococcal pneumonia (NIPP) is more frequent than bacteremic 
pneumonia and that there are at least three cases of NIPP for every case of bacteremic 
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pneumonia (Said et al., 2013). In adults, invasive pneumococcal disease (IPD) is 
mainly represented by bacteremic pneumonia (Drijkoningen and Rohde, 2013). 
Acute otitis media (AOM) and sinusitis are the most common diseases caused 
by S. pneumoniae. For example, of the four million pneumococcal disease episodes 
estimated to have occurred in the USA in 2004, 75% was due to either AOM or 
sinusitis (Huang et al., 2011). However, in that study, pneumococcal pneumonia was 
estimated to account for > 90% of pneumococcal-related hospitalizations 
(401,000/445,000) and > 80% of pneumococcal-associated deaths (19,000/22,000). 
Importantly, among the estimated 19,000 deaths due to pneumococcal pneumonia, 
16,000 were in people ≥ 65 years. In this age group, pneumonia was in fact the most 
frequent manifestation of pneumococcal disease (even more frequent than sinusitis) 
(Huang et al., 2011).  
The true burden of pneumococcal pneumonia is globally underestimated, and 
the reasons are numerous. First, microbiological investigation is usually reserved for 
the more severe cases, which are those requiring hospitalization. Second, even when 
microbiological investigation is performed, only < 40% will result in a definitive 
diagnosis, since determining the etiology of pneumonia is, by itself, challenging. 
Third, the clinical diagnosis is difficult and the clinical presentation of community 
acquired pneumonia (CAP) overlaps with other lower respiratory tract infections, 
such as acute bronchitis and acute exacerbations of chronic obstructive lung disease 
(Goldblatt and O’Brien, 2015).  
Given that microbiological diagnosis of IPD is unambiguous, the incidence of 
IPD is commonly used as an indicator of the overall burden of pneumococcal disease 
(WHO, 2008).  However, it is important to bear in mind that this approach fails to 
include the major portion of the burden of serious pneumococcal disease, which is 
represented by NIPP.  
The incidence of IPD has been changing continuously since the beginning of the 
21st century due to the availability of effective vaccines against S. pneumoniae for 
children (discussed later in this introduction). Before the availability of these 
vaccines, the incidence of IPD in the USA was > 150 cases per 100,o00 population 
among children < 2 years and almost 60 cases per 100,000 population among adults ≥ 
65 years (Robinson et al., 2001). In Western Europe, in a similar period, IPD incidence 
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was highly variable by country. However, several countries reported IPD incidence 
among young children to be above 50 cases per 100,000 population (Steens et al., 2013; 
Harboe et al., 2014; Guevara et al., 2014) and around 30 cases per 100,000 population 
among older adults (Harboe et al., 2014; Guevara et al., 2014; Lepoutre et al., 2015).  
Rates of pneumococcal disease vary with several factors, such as sex, ethnicity 
and the previous health state of the patient. Concerning sex, males are more often 
affected by pneumococcal disease than females. Regarding ethnicity, some specific 
ethnicities present higher incidence of pneumococcal disease (e.g. African Americans 
and Native American populations), perhaps due to socioeconomic conditions and 
higher prevalence of underlying risk factors for pneumococcal disease. In temperate 
climate regions, higher rates of pneumococcal disease occur in colder than in warmer 
months (Goldblatt and O’Brien, 2015). Numerous medical conditions also increase 
the risk of pneumococcal infection. Some examples are individuals with a debilitated 
immune system, such as those with HIV, asplenia, sickle cell disease, hematological 
cancer and under treatment with immunosuppressive drugs. Individuals with 
reduced ability to eliminate pneumococci from the airways, such as those with 
chronic obstructive pulmonary disease or asthma are also in increased risk for the 
development of pneumococcal disease. People with underlying comorbidities such as 
chronic kidney, liver or heart disease and individuals with diabetes are more prone to 
pneumococcal disease. The lifestyle of the patient is also important. For example, 
smoking and alcohol abuse increase the risk of pneumococcal disease (Kyaw et al., 
2005; Goldblatt and O’Brien, 2015; Torres et al., 2015). The age of the patient is also 
very important, with younger children and the elderly being the most affected by 
pneumococcal disease. Young children are at increased risk for pneumococcal disease 
due to their likelihood of being colonized by pneumococci and the lack of a 
completely developed immune system. The elderly are more likely to have health 
conditions that increase the risk for pneumococcal disease (Vila‑Corcoles et al., 2015). 
However, old age is itself a risk factor for the development of pneumococcal disease 
(Regev-Yochay et al., 2017). In addition, previous viral respiratory disease (e.g. 
influenza infection) also puts individuals more vulnerable for pneumococcal 
infections (Goldblatt and O’Brien, 2015). 
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Pneumococcal Virulence Factors 
Pneumococci present a vast array of virulence factors, which are important for 
the different stages of the human-pneumococcal interaction. Examples of virulence 
factors in pneumococci are the polysaccharide capsule, pili, teichoic acids, IgA1 
protease and pneumolysin (Kadioglu et al., 2008). The initial colonization of the 
nasopharynx is mediated by the binding of pneumococci to epithelial cells through 
surface protein adhesins. The bacterial adhesins include phosphorylcholine (ChoP), 
which is a constituent of cell-wall teichoic acids and membrane-bound lipoteichoic 
acids (Cundell et al., 1995). ChoP mediates bacterial adherence to the receptor for 
platelet-activating factor (rPAF). The natural ligand for rPAF is the platelet-activating 
factor (PAF), which also contains ChoP. Therefore, the pneumococcus might mimic 
PAF to use its receptor, which is extensively distributed on host tissues including the 
epithelial surface of the nasopharynx (Kadioglu et al., 2008). Subsequent migration of 
pneumococci to the lower respiratory tract can be prevented if the pneumococcal 
cells are enveloped in mucus and removed from the airways by the action of ciliated 
epithelial cells. Pneumococcal cells prevent this envelopment in mucus by producing 
secretory IgA protease and pneumolysin. Secretory IgA traps bacteria in mucus by 
binding the bacteria to mucin with the Fc region of the antibody. The bacterial IgA 
protease prevents this interaction (Wani et al., 1996). Pneumolysin is a cholesterol-
activated cytolysin, which binds cholesterol in the host cell membrane creating pores 
(Tilley et al., 2005). This activity can destroy the ciliated epithelial cells and 
phagocytic cells. The polysaccharide capsule and pili are the most relevant 
pneumococcal virulence factors for the context of this thesis and are therefore 
discussed in more detail below. 
 
Polysaccharide Capsule 
The polysaccharide capsule is considered the most important virulence factor 
in S. pneumoniae. It forms the outermost layer of pneumococci (Skov Sørensen et al. 
1988) being thus the primary target of host’s immune system. A high degree of 
encapsulation act as a barrier that hides pneumococcal surface structures that 
otherwise would be recognized by antibodies (Hyams et al., 2010). Immune 
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components that already identified pneumococcal surface antigens but still need to 
be recognized by phagocytic cells are also more easily hidden in strongly encapsulated 
pneumococci (Kadioglu et al., 2008). Additionally, a high degree of encapsulation can 
protect pneumococci against non-opsonic killing by neutrophils during carriage 
(Weinberger et al., 2009). The expression of a capsule reduces pneumococcal trapping 
in neutrophil extracellular traps (Wartha et al., 2007) and neutralizes cationic 
antimicrobial peptides (Llobet et al. 2008). During colonization, pneumococcal 
capsule was shown to interfere with mucus-mediated clearance. The heavily charged 
pneumococcal CPS is electrostatically repulsed by mucopolysaccharides and this may 
impair clearance by mucociliary flow (Nelson et al., 2007). The expression of a thick 
capsule may not be needed during colonization due to its inhibitory effect on 
pneumococcal adherence. Most pneumococcal isolates present phase variation 
between two forms that can be distinguished by their opaque or transparent colony 
morphologies (Weiser et al., 1994). A thinner capsule (transparent variant) is more 
advantageous for colonization, as it facilitates pneumococcal biding to host tissues. 
Therefore, transparent variants prevail over opaque variants during colonization 
(Weiser et al., 1994). Oxygen availability, which changes in various tissues, can affect 
CPS production (Weiser et al., 2001). This may be a possible signal for pneumococci 
to progress from colonization to disease. Despite the general importance of 
pneumococcal capsules, the ability of pneumococci to colonize, invade or cause 
severe disease is highly dependent on the serotype, meaning that different CPS may 
interact differently with the human host (Weinberger et al., 2009). 
 
Pili  
Two types of pilus-like structures were identified in pneumococci – pilus 1 and 
pilus 2. Pilus 1 was shown to influence pneumococcal adherence to lung epithelial 
cells (Barocchi et al., 2006; Hemsley et al., 2003). In addition, mouse models of 
pneumococcal pneumonia and bacteremia proposed a role of pilus 1 in virulence and 
host inflammatory responses (Barocchi et al., 2006; Hava et al., 2002). Immunization 
of mice with pilus structural antigens induced protection against lethal challenge by 
piliated strains. Therefore, pilus 1 not only contribute to pneumococcal adherence 
and virulence but also stimulate the host inflammatory response. (Gianfaldoni et al., 
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2007). Pilus 2 was shown to be involved in adherence of pneumococci to host 
epithelial cells. However, its attachment to host cells was lower than that observed 
for PI-1 (Bagnoli et al. 2008). 
Pilus 1 is encoded in the rlrA pathogenicity islet, also known as pilus islet 1 (PI-
1). This islet is 14 kilobases (kb) in size and is flanked by IS1167 elements. It contains 
seven genes, which are necessary for the formation of pilus 1 on the cell surface of 
pneumococci: the rlrA gene encodes a transcriptional regulator, the rrgA, rrgB and 
rrgC genes encode the proteins composing the pilus itself and the srtB, srtC and srtD 
genes encode three sortases (Barocchi et al., 2006). Three variants of PI-1 are known. 
These variants are called clades I, II and III. With the exception of the rlrA gene, all 
other PI-1 genes show some genetic variability. Amplification of the rlrA gene can be 
used to determine the presence or absence of PI-1 (Moschioni et al., 2008). In the case 
of rlrA negative isolates, DNA fragments of three different sizes can be obtained. The 
fragments of rlrA negative isolates and the clades of rlrA positive isolates associate 
with pneumococcal genotypes and serotypes (Aguiar et al., 2008b).  
The PI-2 pathogenicity islet, also known as pilus islet 2, is ~ 7 kb in size and is 
composed of five genes: pitA, sipA, pitB, srtG1 and srtG2. The pitB gene encodes the 
polymers composing pilus 2, the sipA gene encodes a signal peptidase, and the srtG1 
gene encodes a sortase. The distribution of PI-2 also correlates with the genotype and 
serotype (Bagnoli et al. 2008).  
 
Pneumococcal Typing 
In 1897, Banzançon and Griffon realized the diversity of pneumococci while 
using rabbit anti-pneumococcal serum to agglutinate with different pneumococcal 
isolates. Shortly after, several methods of serotyping were developed and distinct 
serotypes started being recognized. The interest in serotyping suffered some 
fluctuations during the 20th century. Before the World War II, the main goals of 
serotyping were to develop serum treatment, to study the relationships between 
pneumococcal isolates and to trace the spread of pneumococcal infections (White et 
al., 1938). Later, the availability of effective antibiotics for the treatment of 
pneumococcal disease, namely sulfonamides and penicillin, decreased the need for 
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serum therapy and, consequently, the attention given to pneumococcal serotyping 
(Austrian, 1976). Moreover, the relatively low discriminatory power of serotyping was 
revealed when researchers found that only a limited number of pneumococcal 
serotypes caused most of infections. A renewed interest in serotyping arose with the 
emergence of antimicrobial resistant pneumococci and the subsequent search for an 
effective polysaccharide-based vaccine. Today, serotyping is a key element of 
surveillance studies evaluating the impact of the pneumococcal vaccines in use and 
monitoring the remaining disease (Ramirez et al., 2015).  
The discovery that only a fraction of isolates expressing certain serotypes were 
associated with antimicrobial resistance promoted a search for a method that would 
allow discriminating isolates within serotypes. Genotyping methods were used for 
that purpose and revealed also superior to serotyping for the detection and 
monitoring of outbreaks. Pneumococcal genotyping has also been of critical value in 
evolutionary studies. Pulsed field gel-electrophoresis (PFGE) and multi-locus 
sequence typing (MLST) were for several years the most frequently adopted 
genotyping methods and are still in use today. However, great developments in whole 
genome sequencing (WGS) have been made more recently, making WGS the most 
promising future of pneumococcal typing (Ramirez et al., 2015). 
 
Serotyping 
Of all the techniques developed to assess the diversity of pneumococcal 
capsules, the one that stood out before, and remains today, as the gold standard of 
serotyping is the serological method developed by Neufeld in 1902, namely the 
quellung reaction test. “Quellung” stands for “swelling” in German and this term was 
applied by Neufeld when he witnessed the rapid development of a swollen appearance 
in a droplet containing pneumococcal broth culture and agglutinating serum 
(Austrian, 1976). With his method, Neufeld identified the first two types of 
pneumococci, which were extended to four types in 1913, by Dochez and Gillespie. 
Types I and II correspond today to serotypes 1 and 2, type III included all mucoid 
pneumococci and type IV was an heterogeneous group encompassing all the 
remaining discovered types (White et al., 1938). Later, the detection of new 
pneumococcal types continued independently by several investigators in different 
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countries. By 1929, a total of 32 different pneumococcal types had already been 
described by Cooper et al. in the USA, interestingly, using different serotyping 
techniques than the one developed by Neufeld (Austrian, 1976). The method of 
Neufeld gained more importance only in the 1930s. Using this serotyping method, 
several serotypes were identified by Mörch in Denmark and by Eddy in the USA, 
giving rise to two different nomenclatures. While the American nomenclature 
numbered the serotypes by the order of their discovery, the Danish system allowed 
also for the grouping of serotypes sharing serological properties into serogroups. 
Based on this approach, serogroups are denoted with a number, and a letter is added 
to distinguish between the individual serotypes occurring within a serogroup. After 
some debate, the Danish classification became the globally adopted nomenclature 
(Henrichsen, 1999).  
Pneumococcal serotyping by the Neufeld method was improved by the 
development of sera able to react with more than one type of polysaccharide (pooled 
sera). Since only a restricted number of serotypes are responsible for most 
pneumococcal disease, Sørensen developed an ordered method for using sera, the 
chessboard system, which enables to spare time and reagents (Sørensen, 1993). 
However, the quellung reaction technique is still time-consuming when working with 
large collections of isolates, requires experienced staff, and to have the complete set 
of sera reveals unaffordable for most laboratories. Therefore, the Neufeld test is more 
often used in reference and research laboratories (Slotved et al., 2004). 
To overcome the issues associated with the Neufeld test, several other 
serotyping methods became available. One of the most frequently used techniques is 
the Pneumotest-Latex, developed at the Statens Serum Institute by Slotved et al. 
(2004). This protocol uses the chessboard system described by Sørensen (1993), but 
in this case the pooled pneumococcus sera are applied to latex particles. The main 
advantages of this method over the quellung reaction technique are that less-
experienced workers are also able to serotype and that the time required for 
serotyping is reduced. Assays that discriminate capsular polysaccharides in patient’s 
urine are also of great value, not only for serotyping but also to help in the diagnosis 
of pneumonia. The serotype specific urinary antigen detection assay (UAD) (Huijts et 
al., 2013) detect all the 13 serotypes targeted by the most recently available 
Chapter I 
14 
 
pneumococcal vaccine, while the Bio-Plex assay (Sheppard et al., 2011) detects these 
serotypes plus serotype 8. However, the Bio-Plex assay does not allow the distinction 
between serotypes 6A and 6C, 7F and 7A nor the serotypes composing serogroup 18. 
Moreover, both tests share the important limitation of not being able to discriminate 
all the remaining serotypes. Polymerase chain reaction (PCR) based serotyping 
protocols are also worth consideration. An example of this approach is the sequential 
multiplex PCR assay developed in the Centers for Disease Control and Prevention (Pai 
et al., 2006). This method proved to be cost-effective and to greatly reduce the time 
needed to serotype large collections of isolates. 
   
Pulsed-Field Gel Electrophoresis Macrorestriction Profiling 
The begging of pneumococcal genotyping was dominated by PFGE (Ramirez et 
al., 2015). In this method, the total DNA of each isolate is subjected to digestion with 
an infrequently cutting endonuclease (e.g. SmaI) and separation by pulsed-field 
electrophoresis, generating DNA band profiles that can be compared. The relatedness 
between isolates is inferred by the number of differences in the band profiles 
(Figueiredo et al., 1995; Tenover et al., 1995). Initially, the comparisons had to be 
directly ascertained by the operator, but later, bioinformatics tools were developed to 
assist in the analysis. This last improvement enabled to decrease the time and error 
associated with data inspection and allowed the comparison of large collection of 
isolates within laboratories. A frequently used protocol is to apply a cutoff value of 
80% to a dendrogram constructed by the unweighted pair group method with 
arithmetic means (UPGMA) and DICE coefficient. To be considered clonally-related 
by PFGE, two pneumococcal isolates must show > 80% similarity. The isolates that 
are 100% similar by this method are considered identical (Carriço et al., 2005; Ramirez 
et al., 2015).  
With the use of PFGE some important traits of pneumococci were recognized. 
For example, using this typing system, investigators found that only a few 
pneumococcal clones led to the global emergence of antimicrobial resistance in 
pneumococci and that capsular switching occurs naturally in pneumococci, 
independently of vaccine use (Ramirez et al., 2015).  
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PFGE is of great use for local epidemic and outbreak surveillance studies. The 
main benefits of FPGE are its high discriminatory power, intra-laboratory 
reproducibility and relatively low cost. The major limitations are the low portability 
of data and its labor-intensive and time-consuming character (Sabat et al., 2013). 
 
Multilocus Sequence Typing 
MLST is based on the sequence of internal fragments of seven housekeeping 
genes, namely, aroE, xpt, gki, gdh, spi, ddl and recP. The sequence of each gene is 
compared to those deposited in a public database (http://www.mlst.net/) to assign 
an allele number. Sequences corresponding to those in the database are assigned the 
same allele number, while those differing even at a single nucleotide will give rise to 
a new allele number. For every unique set of alleles, a distinct sequence type (ST) is 
defined (Ramirez et al., 2015). This method is globally recognized and up to August 
11, 2017, more than 13000 STs were already included in the public database.  
A frequent approach for the analysis of MLST data is the eBURST method. Using 
eBURST, the relationships of the isolates analyzed are represented in an unrooted 
tree constructed considering the number of differences in the STs. The isolates are 
distributed into clonal complexes (CCs), which have a founder genotype. According 
to the eBURST model, a CC emerges in the population either due to a fitness 
advantage or to random genetic drift. The expansion of a genotype is accompanied 
by its gradual diversification by mutation and recombination. To be part of a CC, 
isolates need to share at least 6 alleles with one other isolate of the CC. Therefore, 
some CCs may be composed of isolates sharing no alleles with each other and having 
n0 recent genetic relatedness (Feil, 2004). More recently, a new algorithm was 
proposed to extend that of eBURST. This later method is called goeBURST, uses all 
eBURST rules, but considers as a last tie-break, the number attributed to the STs. The 
foundation of this choice is that the most frequent genotypes will be reported first 
and, therefore, are more likely to present lower ST numbers (Francisco et al., 2009). 
MLST data can be analyzed using the freely available software PHILOViZ 
(www.phyloviz.net). This user-friendly program enables to integrate additional 
information, such as capsular types, antimicrobial susceptibility patterns and 
presence of virulence factors (Francisco et al., 2012).  
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Unlike PFGE, MSLT generates data that is easily comparable in a global scale. 
Moreover, MLST data is highly reproducible between laboratories and the technique 
is less demanding than that of PFGE (Sabat el al., 2013). Following its introduction, 
MLST was used as a complement of PFGE, but since MLST results reinforced the 
findings previously obtained with PFGE and have all the aforementioned advantages, 
it became the most commonly used typing method in pneumococcal epidemiological 
studies. Additionally, the results obtained with MLST may be useful for selection of 
isolates to be studied by WGS (Ramirez et al., 2015). 
 
Other Genotyping Methods 
Other genotyping methods are available for the distinction of pneumococcal 
isolates, but their use has been more limited. Examples are multilocus enzyme 
electrophoresis (MLEE) and multilocus variable number of tandem repeat analysis 
(MLVA).  In MLEE, cell lysates go through electrophoresis and multiple assays with 
specific enzymes. Protein polymorphisms are distinguished based on the position of 
the resultant staining in the gel. (Selander et al., 1986). MLVA is based on the 
comparison of repetitive DNA sequences from multiple loci. Pneumococcal isolates 
may present different number of repeat sequences and these sequences may differ is 
size (Koeck et al., 2005). Online databases are available to compare MLVA results 
between laboratories (e.g. http://www.mlva.net/spneumoniae/default.asp). 
 
Antimicrobial Therapy and Resistance in S. pneumoniae 
Antimicrobial Therapy 
In Portugal, empirical antimicrobial therapy of adult patients with CAP not 
requiring hospitalization is made with β-lactams, more specifically, with amoxicillin. 
Patients with comorbidities or patients that have taken antimicrobials in the past 3 
months are recommended to receive a combination of amoxicillin with a macrolide 
(i.e. clarithromycin or azithromycin). The use of wide spectrum antibiotics, such as 
cephalosporins and fluoroquinolones, is restricted to hospitalized patients with 
severe pneumonia (Direção-Geral da Saúde, 2011). Antimicrobial therapy of 
pneumococcal meningitis is usually made with ceftriaxone or cefotaxime. 
General Introduction 
17 
 
Vancomycin is added to the treatment for patients who have been in countries where 
cephalosporin non-susceptibility is significant (Goldblatt and O’Brien, 2015). 
 
Availability of Antibiotics and Emergence of Resistance  
Before the availability of antibiotics mortality due to bacteremic pneumococcal 
pneumonia was > 75%, while after, from the 1950s to 1970s, mortality declined to < 
30% (Klugman, 1990). Antimicrobial treatment of pneumococcal infections was 
initially made using optochin. However, this approach did not last for too long, for a 
number of reasons: optochin is specific for pneumococci, its use in clinical doses leads 
to the emergence of resistant strains, and optic toxicity is a frequent and serious 
secondary effect. Later, sulfapyridine, a sulfanilamide derivate, was used for the 
treatment of pneumococcal infections, until its replacement by penicillin in the 1940s. 
Fleming discovered penicillin in 1928, but since it was difficult at the time to acquire 
enough amounts of penicillin for an effective treatment and because sulfapyridine 
was an effective drug, the importance of penicillin for the treatment of pneumococcal 
infections remained poorly noticed for more than a decade. The interest in penicillin 
was renewed in 1940, associated in part with the detection of pneumococci resistant 
to sulfapyridine (Watson et al., 1993; Wright et al., 2014).  
Few years after penicillin started being used as the antimicrobial of choice for 
the treatment of pneumococcal infections, other antimicrobials effective against 
pneumococcus started being discovered. Chloramphenicol was discovered in 1947 
and erythromycin in 1949. Aureomycin was discovered in 1948 and soon after, in 1952, 
tetracycline was synthesized from aureomycin. The use of co-trimoxazole 
(sulfamethoxazole-trimethoprim) occurred later, at the end of the 1960s, while the 
first to fourth generations of fluoroquinolones were developed from late 1970s to late 
1990s (Wright et al., 2014). 
Resistant pneumococci for all the aforementioned antibiotics emerged some 
years after their discovery and use. Resistant strains were in general sporadic during 
the early 1970s, but became widespread during the 1980s (Klugman, 1990). In the case 
of penicillin, resistance was demonstrated in the laboratory soon after its extensive 
use, in the 1940s, but pneumococci remained clinically susceptible to penicillin 
during the following two decades. The first report of tolerance to penicillin came from 
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Boston, in 1965, although it did not draw attention at the time. Later, in 1967, 
Hansman and Bullen reported a resistant isolate from Australia. This was followed 
shortly after by new cases, again from Australia and also from Papua New Guinea 
(McGee et al., 2015). Additional reports arose from the USA in 1974, from South Africa 
in 1977 and from Spain in 1979 (Liñares et al., 2010; McGee et al., 2015). In 1978, 1/3 of 
57 isolates causing severe infections in Papua New Guinea were penicillin-non-
susceptible (Gratten et al., 1980). In the late 1980s, the fraction of penicillin non-
susceptible isolates reached > 40% in Spain (Fenoll et al., 1991) and 70% in Hungary 
(Marton et al., 1991).  
The first report of erythromycin resistant pneumococci is contemporaneous to 
that of penicillin non-susceptibility (Kislak, 1967). Similarly to penicillin, macrolide 
resistant pneumococci became globally dispersed with continued use of this class of 
antibiotics. In the period 2001-2004, erythromycin resistant rates were reported to 
range from 15% in Latin America to 80% in the Far East from (Felmingham et al., 
2007).  
Resistance to tetracycline was detected even before the report of penicillin non-
susceptibility (Turner, 1963), while the first reports of chloramphenicol resistance in 
pneumococci occurred in the 1970s (Dang-Van et al., 1978). The emergence 
pneumococci resistant to co-trimoxazole occurred soon after the availability of this 
antibiotic, in 1972 (Howe and Wilson, 1972). This later drug has been globally used 
due to its low cost and effectiveness. Therefore, resistance to co-trimoxazole escalated 
greatly in many parts of the globe, reaching 50% and > 60% pneumococci in Africa 
and Asia, respectively (McGee et al., 2015). Like the other classes of antibiotics, 
resistance to fluoroquinolones did not take too long to emerge (Goldstein and Acar., 
1996). 
 
Mechanisms of Resistance   
The mechanisms of action of the different antibiotics are diverse, as well as the 
adaptations of pneumococci to them. β-lactams bind to pneumococcal proteins that 
are involved in the synthesis of the pneumococcal cell wall, the penicillin-binding 
proteins (PBPs), inhibiting pneumococcal growth.  There are six types of PBPs in 
pneumococci: PBPs 1a, 1b, 2a, 2b, 2x and 3 (Hakenbeck et al., 1986). The mechanisms 
General Introduction 
19 
 
of resistance to β-lactams vary according to the antibiotic, but usually encompass 
altered pbp genes encoding PBP2x, PBP2b or PBP1a (McGee et al., 2015). 
Erythromycin prevents protein synthesis due to its binding to the 23S ribosomal 
RNA. Resistance to this antibiotic can occur by two different mechanisms: target 
modification and drug efflux. The mechanism of target modification consists in most 
cases in the methylation of the 23S ribosomal RNA, weakening the affinity of the 
antibiotic for this structure. This modification results in high-level resistance to 
macrolides, lincosamides and streptogramins (MLSB phenotype) (Roberts et al., 
1999).  In most cases the methylase is encoded in ermB gene and much less frequently 
in the erm(TR) gene. Other modifications of the target 23S RNA result from point 
mutations (Davies et al., 2005). The mechanism of drug efflux consists on the 
expression of efflux pumps that confer low to moderate resistance to macrolides (14- 
and 15-member), but not to lincosamides or streptogramin (M phenotype). The efflux 
pumps are encoded in mef genes, in the great majority of cases, mefA and mefE. The 
M phenotype has been the most commonly found in Canada, the USA and some 
countries from Europe and Asia (McGee et al., 2015). Additionally, some isolates can 
present both mechanisms of macrolide resistance (Felmingham et al., 2007). 
Tetracycline targets the 30S ribosome subunit, preventing binding of the tRNA. 
Resistance to this drug is mediated by the binding of TetM or TetO proteins to the 
ribosome and the consequent hampering of the association between the 
antimicrobial and its target (Widdowson et al., 1996). The tetM gene is more common 
that the tetO gene (McGee et al., 2015) and is usually carried in transposons that can 
also harbor the ermB gene (Amezaga et al., 2002).  
Chloramphenicol targets the enzyme peptidyl transferase, therefore inhibiting 
bacterial protein synthesis.  Resistance to this antimicrobial is due to the acetylation 
of the drug by an acyltransferase encoded in the cat gene (Charpentier and 
Tuomanen, 2000).  
Co-trimoxazole interferes with the biosynthesis of folic acid (Charpentier and 
Tuomanen, 2000). Resistance to trimethoprim is the result of modifications in the 
protein dihydrofolate reductase (Adrian and Klugman, 1997), while resistance to 
sulfonamides results from changes in the protein dihydropteroate synthase 
(Padayachee and Klugman, 1999). 
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Fluoroquinolones target DNA gyrase and topoisomerase, which are needed for 
DNA supercoiling and relaxation. Resistance to this class is the result of mutations in 
the genes encoding the DNA gyrase or topoisomerase or of the action of drug efflux 
pumps (McGee et al., 2015). 
 
Pneumococcal Vaccines 
Vaccination against S. pneumoniae is the best tool to prevent pneumococcal 
disease, but this measure should be combined with other preventive strategies, such 
as exclusive breastfeeding during the first 6 months of age, anti-influenza vaccination 
and control of risk factors for pneumococcal disease (e.g. tobacco smoke; diabetes 
mellitus and HIV infection) (WHO, 2012; Goldblatt and O’Brien, 2015). 
The history of pneumococcal vaccination is almost as old as the history of 
pneumococci, with pneumococcal vaccines being already marketed in the beginning 
of the 20th century. The first was a whole-cell vaccine licensed in the USA in 1909, 
even before a clinical trial. The first trial of a pneumococcal vaccine was conducted 
in 1911, by Sir Almroth Wright. It was a whole-cell vaccine of unspecified serotypes 
given to South African gold miners, which reduced the rate of pneumonia during a 
short period of time. In the 1940s, Colin MacLeod and Michael Heidelberger headed 
a clinical trial of a pneumococcal polysaccharide vaccine (PPV) targeting four 
pneumococcal serotypes. This was followed by the licensing in 1947 of two hexavalent 
PPVs targeting two different groups of serotypes, one for children and the other for 
adults. However, vaccine adherence was limited due to the preference of clinicians 
for antimicrobial treatment.  Attention was again given to pneumococcal vaccines 
when Robert Austrian realized that case-fatality rates of pneumococcal disease were 
still significant despite the availability of antimicrobial treatment (Grabenstein and 
Klugman, 2012). In 1977, a 14-valent polysaccharide vaccine was licensed, and in 1983, 
the formulation was extended to encompass a total of 23 polysaccharides (de Paz, 
2015).  
PPV23 is still in use today, but since plain polysaccharide-based vaccines are not 
protective in children < 2 years, a different type of pneumococcal vaccine was 
developed specifically for this age group. In this new type of pneumococcal vaccine, 
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the polysaccharides are conjugated to carrier proteins, eliciting a different immune 
response. The development of pneumococcal conjugate vaccines (PCVs) followed the 
previous knowledge obtained with the development of a successful conjugate vaccine 
against Haemophilus influenzae type b (Adams et al., 1993).  
Even though both PPVs and PCVs rely on the polysaccharides included in their 
formulations to trigger an immune response that is specific to these antigens 
(Durando et al., 2013), strictly polysaccharide-based vaccines trigger a T cell-
independent immune response, not fully functional in young children, while PCVs 
trigger a T cell-dependent immune response, already functional in infants (Pollard et 
al., 2009). PPVs stimulate B-cell responses by cross-linking the B-cell receptors. The 
B cells differentiate into plasmocytes, but this process does not promote proliferation 
of serotype-specific B cells nor the formation of serotype-specific memory B-cells. In 
contrast, when polysaccharides are conjugated with carrier proteins, the 
polysaccharides bind B cells and the proteins are processed within the B cells. The 
resulting peptides are presented to helper T cells, which are primed by antigen-
presenting cells that also processed the carrier proteins. This T cell-dependent 
response leads to the formation of antibodies that are highly specific and functional, 
and an anamnestic response is generated with subsequent doses of the vaccine 
(Durando et al., 2013). Three different pneumococcal conjugate vaccines were 
licensed since the beginning of the 21st century, PCV7, PCV10 and PCV13, targeting 7, 
10 and 13 serotypes, respectively (Ramirez, 2014). Table I.1 shows the main features of 
PPV23 and of the three PCVs. 
 
Table I.1 Main features of PPV23, PCV7, PCV10 and PCV13. 
Vaccine Targeted Serotypes Manufacturer/ Trade Name Year of Licensure 
PPV23 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 
9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 
23F and 33F 
Merck & Co / PneumovaxTM 23 
Lederle Laboratories (Pnu-ImuneTM 23) 
Sanofi Pasteur / Pneumo 23TM 
1983 (USA) 
1983 (USA) 
1987 (Europe) 
PCV7 4, 6B, 9V, 14, 18C, 19F, 23F Wyeth (now Pfizer) / Prevnar
TM or 
PrevenarTM  
2000 (USA) 
2001 (Europe) 
PCV10 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F GlaxoSmithKline / Synflorix
TM 2009 (Europe) 
PCV13 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 
Wyeth (now Pfizer) / PrevnarTM 13 or 
PrevenarTM 13 2010 (Europe; USA) 
Based on data from Grabenstein and Klugman (2012) and de Paz et al. (2015). 
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23-Valent Pneumococcal Polysaccharide Vaccine 
Before the availability of PCVs for childhood vaccination, the serotypes included 
in PPV23 accounted for 85-90% of adult IPD in the USA and other industrialized 
countries. Also promising was the fact that this vaccine targeted several serotypes 
frequently associated with antimicrobial resistance (WHO, 2008). However, the 
efficacy and effectiveness of PPV23 is not well defined and has been under strong 
debate in the last decades (Huss et al., 2009; Trück et al., 2012; Moberley et al., 2013). 
Recognizing the inconsistency in the results of randomized control trials and 
observational studies, the World Health Organization (WHO) stated in its 2008 
position paper that the net result of the available studies suggested protection against 
IPD among healthy young adults and, in a lower extent, among adults ≥ 65 years 
(WHO, 2008).  
In general, PPV23 is believed to prevent IPD but to be less effective in the 
prevention of non-invasive infections, such as non-invasive pneumococcal 
pneumonia (Goldblatt and O’Brien, 2015). However, it remains baffling why countries 
with high PPV23 uptake (~ 70%) and strong surveillance systems for IPD, such as the 
USA and the UK, are not showing decreases in IPD due to the serotypes targeted 
exclusively by this vaccine (Sings, 2017). Another concern of PPV23 vaccination is 
hyporesponsiveness with subsequent doses of the vaccine (Sings, 2017). Therefore, 
revaccination with PPV23 is usually not recommended (Centers for Disease Control 
and Prevention, 2010; Tomczyk et al., 2014).  
The controversy around the efficacy and effectiveness of PPV23 has resulted in 
a great variety of national recommendations in Europe (Fedson et al., 2011). In 
Portugal, PPV23 is available since 1996 (Horácio et al., 2012), but its uptake among 
adults ≥ 65 years was estimated to be < 10% in one study (Sousa et al., 2009). This 
situation may be related with the fact that in our country national recommendations 
for the use of PPV23 have been restricted to specific risk groups only (Direcção-Geral 
da Saúde, 2005; Direcção-Geral da Saúde, 2010; Direção-Geral da Saúde, 2015b; 
Direção-Geral da Saúde, 2015c). 
 
7-Valent Pneumococcal Conjugate Vaccine 
PCV7, which is composed of the polysaccharides of seven serotypes (Table I.1) 
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conjugated to the carrier protein CRM197 (cross reactive material 197, non-toxic 
mutant of diphtheria toxin), was the first pneumococcal conjugate vaccine to become 
available in the market. This vaccine, also known as Prevenar™, was licensed in the 
USA in February 2000 and in Europe in February 2001. PCV7 was available for use 
until its replacement by the homologue vaccine, PCV13, targeting six additional 
serotypes (Table I.1). PCV7 was licensed in almost 100 countries and included in 
several national immunization programs (NIPs) (Durando et al., 2013).  
The introduction of PCV7 into the NIP of many Western European countries 
occurred mainly from 2006 to 2008 (Tin Tin Htar et al., 2015). Portugal was one of the 
few countries from Western Europe not including PCV7 into its NIP (Durando et al., 
2013). In Portugal, the vaccine was available through the private market since June 
2001 and the initially low vaccine uptake increased throughout the years. In a birth 
cohort of 2001, the percentage of children with three doses in the first year of life was 
23.7%, while in a 2005 birth cohort, was 51.2% (Aguiar et al., 2008a). By 2008, 75% of 
children with an indication for PCV7 had received the vaccine (Horácio et al., 2012).  
PCV7 schedules varied by country. Common regimens were 3+1, 2+1 and 3+0 
(Durando et al., 2013). In Portugal, the recommendation was the 3+1 schedule, to be 
given at 2, 4, 6 and 18 months of age or 3, 5, 7 and 18 months of age (Aguiar et al., 
2008a).  
The use of PCV7 led to important changes in the dynamics of pneumococcal 
infections. Several countries reported decreases in the incidence of total IPD in 
children (Feikin, et al., 2013). In the USA, where PCV7 serotypes accounted for the 
great majority of IPD, the incidence of total IPD in children < 5 years decreased by 
76%, from 98.7 cases per 100,000 population in the pre-PCV7 period, to 23.6 cases per 
100,000 population in the post-PCV7 period. After 7 years of PCV7 use, a 100% 
reduction of PCV7-type IPD was noted in children in this country (Pilishvili et al., 
2010). The incidence of total IPD also declined in children in Europe from the pre-
PCV7 period to the post-PCV7 period. Examples are the decreases noted in Norway 
(77/100,000 to 20/100,000) (Steens et al., 2013), Denmark (55.1/100,000 to 
25.9/100,000) (Harboe et al., 2014) and France (30.3/100,000 to 24.6/100,000) 
(Lepoutre et al., 2015). These decreases were due to declines in the incidence of IPD 
due to PCV7 serotypes, which became very low or null in children in those countries. 
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Remarkably, reduction of vaccine-type IPD was not only felt among vaccinated 
children, but also across the surrounding non-vaccinated population, including 
adults. This phenomenon, known as “herd protection” occurs with the elimination of 
vaccine serotypes from the nasopharynx of vaccinated children and the interruption 
of their transmission to close contacts (Moore and Whitney, 2015). In the USA, the 
incidence of IPD due to PCV7 serotypes decreased among adults within the first few 
years of PCV7 use in children. In this country, among adults aged ≥ 65 years, IPD 
caused by PCV7 serotypes declined from 33 in 100,000 population in 1998-1999 to 24 
in 100,000 population in 2001 (Whitney et al., 2003). Herd protection was also noticed 
among adults from Europe. For example, in Denmark, among adults ≥ 65 years, the 
incidence of IPD due to PCV7 serotypes declined from 27.1 cases per 100,000 
population in the pre-PCV7 period to 14 cases per 100,000 population, in the post-
PCV7 period (Harboe et al., 2014). The UK (Miller et al., 2011b), France (Lepoutre et 
al., 2015) and Norway (Steens et al., 2013) also registered declines in IPD due to PCV7 
serotypes in adults. In Portugal, PCV7 serotypes were not highly prevalent in adult 
IPD in the pre-PCV7 period (30.5% in 1999-2003), but they still declined in proportion 
after PCV7 introduction (16.6% in 2005) (Aguiar et al., 2008a).   
Unfortunately, if on the one hand reductions of PCV7 serotypes in carriage of 
vaccinated children has resulted in decreases of IPD due to these serotypes across the 
entire population, on the other, the niche left available was promptly occupied by 
non-PCV7 serotypes (Frazão et al., 2005), resulting in serotype replacement in 
carriage and disease (Feikin, et al., 2013). In fact, the substitution of vaccine serotypes 
by non-vaccine serotypes in carriage had been detected in clinical trials conducted 
before PCV7 availability, making serotype replacement in disease an existing fear 
(Obaro et al., 1996). Since not all pneumococcal serotypes have a high invasive disease 
potential (Sá-Leão et al., 2011), the magnitude of serotype replacement in disease was 
generally lower than that reported for carriage (Weinberger et al., 2011). The net result 
of serotype replacement in disease varied by geographical region. Most countries 
reported an overall decrease of IPD incidence, while a few, such as Spain and the UK, 
reported an overall increase of IPD in some age groups (Weinberger et al., 2011). In 
the post-PCV7 period, non-PCV7 serotypes 7F and 19A were frequently reported as 
emerging serotypes in IPD (Moore and Whitney, 2015; Tin Tin Htar et al., 2015).  
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The hypothesis of an “ecological niche left open” is the most accepted 
explanation for the increase of non-PCV7 serotypes in carriage and disease. However, 
other situations may have helped in the emergence of non-vaccine types (NVTs) in 
disease in the post-PCV7 period, such as secular trends of particular serotypes, 
incorrect antimicrobial drug use and capsular switching (Moore and Whitney, 2015). 
Periodic changes in the incidence of IPD due to particular serotypes have been 
documented and this may be a confounding factor in surveillance studies assessing 
vaccine impact in IPD (Fenoll et al., 2009; Harboe et al., 2010). Inappropriate 
antimicrobial drug use is suspected to have played a role in the emergence of non-
PCV7 serotypes in the post-PCV7 period, since serotype 19A is highly associated with 
antimicrobial resistance. Moreover, this serotype increased not only in countries 
using PCV7 (Aguiar et al., 2008a; Pilishvili et al., 2010; Miller et al., 2011b), but also in 
those not adopting the vaccine (Choi et al., 2008), strengthening the idea that PCV7 
pressure was not the sole reason behind the increase of non-PCV7 serotypes in the 
post-PCV7 period. Capsular switching occurs naturally in pneumococci (Coffey et al., 
1991; Coffey et al., 1998) and there was a concern that clones expressing PCV7 
serotypes would change their capsules with serotypes not targeted by PCV7, resulting 
in vaccine escape. This indeed happened in some cases (Brueggemann et al., 2007), 
but it still did not account for all the increase of non-PCV7 serotypes in disease in the 
post-PCV7 period.     
An additional theory was raised to explain the increase of non-PCV7 serotypes 
in carriage. According to this theory, the decrease in prevalence of PCV7 serotypes 
among vaccinated children resulted in the “unmasking” of non-PCV7 serotypes, 
already present in carriage but in lower proportions (Lipsitch, 2001). Since co-
colonization exists (Valente et al., 2016), this hypothesis is possible. However, this 
situation can only be a minor contributor to serotype replacement in carriage for 
several reasons: first, it would imply higher frequencies of co-colonization than those 
generally reported (Valente et al., 2016); second, co-colonization would have to be 
caused in a frequent basis by both PCV7 and non-PCV7 serotypes; and third, it does 
not explain the increase of non-PCV7 serotypes in disease (Weinberger et al., 2011). 
Given that five of the seven serotypes targeted by PCV7 are associated with 
antimicrobial resistance (Dagan and Klugman, 2008), a decrease in antimicrobial 
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resistance rates was expected in countries using PCV7. A decrease in penicillin non-
susceptibility was frequently reported among isolates responsible for IPD in children 
(Aguiar et al., 2010a; Pilishvili et al., 2010; Pérez-Trallero et al., 2009), but this was not 
reproduced in all regions for adults (Horácio et al., 2012; Pérez-Trallero et al., 2009). 
The increase of serotype 19A was the main barrier to the expected reduction in 
antimicrobial resistance after PCV7 availability (Dagan and Klugman, 2008). 
Following PCV7 use in children, some studies from the USA showed an overall 
decline in mortality (Tsigrelis et al., 2008; Pulido and Sorvillo, 2010), while another 
found a reduction in the incidence of death, but an increase in case-fatality rates 
(Lexau et al., 2005). A study from Spain showed overall unaltered case fatality rates 
(15% vs 17%) (Burgos et al., 2013), but found that IPD was associated with higher rates 
of septic shock in the post-PCV7 period (19% vs 31%). 
The serotypes targeted by PCV7 were chosen based on their high frequency in 
pediatric IPD in North America. In the pre-PCV7 period, these serotypes accounted 
for ~ 80% of IPD in the USA and Canada. However, PCV7 serotypes represented much 
smaller fractions of IPD in children in other continents. For example, these serotypes 
accounted for < 60% of IPD in Europe, ~ 50% in Latin America, and only ~ 30% in 
Asia (Hausdorff et al., 2000). Additionally, serotype replacement lowered the 
potential coverage of PCV7 in several countries (Tin Tin Htar et al., 2015). Therefore, 
the introduction of PCV10 and PCV13 (Table I.1), targeting previously frequent or later 
emerging serotypes, was an important mark in the history of pneumococcal disease 
prevention.  
 
10 and 13-Valent Pneumococcal Conjugate Vaccines 
PCV10, also known as 10-valent pneumococcal non-typeable Haemophilus 
influenzae protein D-conjugate vaccine, PHiD-CV or Synflorix™ uses three different 
protein carriers: serotype 18C is conjugated to the tetanus toxoid, serotype 19F is 
conjugated to the diphtheria toxoid and the remaining 8 serotypes are conjugated to 
a recombinant version of protein D of NTHi (Dagan and Frasch, 2009). PCV13, also 
known as Prevenar 13™, similarly to PCV7, has all its polysaccharides conjugated to 
CRM197. The European Commission granted a marketing authorization for PCV10 on 
March 2009, and for PCV13, on December 2009 (Aguiar et al., 2010a). In the USA, 
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PCV13 received approval for marketing on February 2010 (Aguiar et al., 2010a), while 
PCV10 was not licensed (Ramirez, 2014).  
In the USA, PCV13 was licensed with the same schedule as PCV7, which enabled 
a rapid switch from PCV7 to PCV13 and a high uptake of PCV13 following its 
availability (Moore and Whitney, 2015). In Western Europe, several countries adopted 
the vaccines into their NIPs almost immediately after the licensing of the new PCVs, 
most of them to substitute the already included PCV7 (Tin Tin Htar et al., 2015). Most 
of these countries adopted PCV13 (e.g. Italy, France, Norway and the UK), while a few 
chosen PCV10 (e.g. Finland and the Netherlands) or both vaccines (e.g. Germany and 
Sweden) (Tin Tin Htar et al., 2015). Portugal included PCV13 into the NIP of children 
only in June 2015, with a 2+1 schedule at 2, 4 and 12 months of age (Direção Geral da 
Saúde, 2015a). Before that, both PCV10 and PCV13 were available for children through 
the private market. However, PCV13 was the most frequently prescribed PCV since its 
availability, with estimates of 63% coverage in 2012 (Aguiar et al., 2014). Before the 
inclusion of PCV13 in the NIP of children in Portugal, this vaccine was also the 
recommended PCV for children and adolescents belonging to risk groups for IPD. In 
these cases, PCV13 was administered for free (Direcção Geral da Saúde, 2010). 
Similarly to PCV7, the use of the new PCVs has resulted in changes in the 
incidence of IPD in children and adults in numerous sites. In the USA, the incidence 
of total IPD declined in all age groups when compared with the incidence expected if 
PCV7 was still in use in children. In this country, declines in total IPD were of 64% in 
children < 5 years, 53% in children 5-17 years and 12% to 32% among adults, according 
to the age group. In the USA, the declines in total IPD were mainly promoted by 
decreases of serotypes 19A and 7F (Moore et al., 2015). Among countries from Western 
Europe, initial results were diverse, but in several places adopting PCV13 into their 
NIPs, a decline in incidence of overall IPD was noted for children and adults. 
Examples of such places are Norway (Steens et al., 2013), Denmark (Harboe et al., 
2014), France (Lepoutre et al., 2015) and the UK (Waight et al., 2015). In Switzerland, 
where PCV13 was included in the NIP, a decrease in incidence of total IPD occurred 
for children by 2012, but not for adults. Similarly, in Finland, where PCV10 was the 
adopted vaccine, a decrease in incidence of total IPD was only noted among children, 
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while in adults > 64 years the incidence of total IPD remained stable (Tin Tin Htar et 
al., 2015).  
The herd protection noticed in adults suggests an effect of PCV13 in carriage, as 
was reported in some studies (Gladstone et al., 2015; Steens et al., 2015). However, 
more time will be needed to evaluate the ultimate impact of PCVs on serotype 
replacement in carriage and disease. For now, some serotypes have been reported to 
be emerging as causes of disease. Examples are serotypes 8, 15A, 22F and 24F in 
countries using PCV13 and serotypes 3 and 19A in countries using PCV10 (Tin Tin Htar 
et al., 2015). Fortunately, in countries where PCV13 was the adopted vaccine, no 19A-
like serotype has been shown to be emerging in the post-PCV13 period (Tin Tin Htar 
et al., 2015). 
 
Adult Vaccination with PCV13 
PPV23 was for several years the only vaccine available for the prevention of adult 
IPD, but this situation changed in late 2011. In October 2011, PCV13 was licensed in 
Europe for the prevention of IPD in adults ≥ 50 years and on December 2011, this 
vaccine was licensed in the USA for the prevention of IPD and pneumonia in adults ≥ 
50 years (Durando et al., 2013). In 2013, the European indications were expanded to 
include all adults ≥ 18 years and in 2015, indications expanded again to include not 
only the prevention of IPD but also pneumonia. In the USA, PCV13 indication was 
extended for adults ≥ 18 years in 2016 (Sings, 2017).  
Following the indications of PCV13 use in adults, many national 
recommendations for vaccination of adults with PCV13 started to emerge (Castiglia, 
2014). In 2012, the US CDC Advisory Committee on Immunization Practices (ACIP) 
recommended PCV13 for adults ≥ 19 years having immunocompromising conditions 
and other risk factors for IPD (Sings, 2017). Later, in 2014, ACIP updated its 
recommendations to include all adults ≥ 65 yrs, immunocompromised or not 
(Tomczyk et al., 2014). This later recommendation was based on results of a large 
randomized placebo-controlled trial that became available in 2014. This study took 
place in the Netherlands and was called the Community-Acquired Pneumonia 
immunization Trial in Adults (CAPiTA) (Bonten et al., 2015). The CAPiTA study 
included 85,000 adults ≥ 65 years and aimed to evaluate the efficacy of PCV13 in the 
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prevention of vaccine-type pneumococcal CAP and vaccine-type pneumococcal IPD. 
Results from this study showed that PCV13 was 75% effective in the prevention of 
PCV13-type IPD and 45% effective against PCV13-type NIPP. ACIP recommendations 
were also based in the remaining burden of disease caused by PCV13 serotypes in 
adults after some years of PCV13 use in children. With the continued use of PCV13 in 
children and adults, the incidence of pneumococcal disease due to these serotypes is 
expected to decrease in all age groups. Therefore, ACIP recommendations were 
planned to be revised in 2018 (Tomczyk et al., 2014). In Europe, national 
recommendations for adult vaccination with PCV13 are highly diverse, with some 
countries having age-based recommendations and others, risk-based 
recommendations (Castiglia et al., 2014; Sings, 2017). The preferred vaccine (PCV13 or 
PPV23) also changes with country (Plosker, 2015). In Portugal, the sequential 
vaccination with PCV13 and PPV23 is recommended for specific risk groups only 
(Direção-Geral da Saúde, 2015b). 
Since childhood immunization with PCVs confer herd protection to the non-
vaccinated population, the need for adult vaccination with PCV13 has been 
questioned (Musher and Rodriguez-Barradas, 2015). Several studies showed that 
PCV13 is cost effective in adults (Dirmesropian et al., 2015). However, a recent cost-
effectiveness study from England, performed after the availability of the results from 
the CAPiTA study, concluded that vaccinating immunocompetent adults aged ≥ 65 
yrs with PCV13 was efficacious, but not cost-effective (van Hoek and Miller, 2016). 
 
Worldwide Availability of Pneumococcal Conjugate Vaccines 
The WHO recommends PCVs to be part of routine childhood immunization 
programs, especially in countries with high infant mortality rates (WHO, 2012). Until 
2010, PCVs were mainly available in high income countries, but this scenario changed 
in that year, with the support of Gavi, the Vaccine Alliance, and the agreement of 
PCVs manufactures to supply their vaccines at reduced prices in low income countries 
(Rodgers and Klugman, 2016). As of November 2016, a total of 139 countries (72%) 
have included PCV10 or PCV13 into their routine immunization programs. However, 
middle income countries, which have less support, are struggling to include or to 
maintain PCVs into their NIPs (IVAC, 2017).  
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Studies evaluating the impact of the PCVs in developing regions have shown 
high effectiveness both in the targeted population and in the remaining non-targeted 
population (herd protection). For example, South Africa adopted PCV13 with a 2+1 
schedule and showed reductions in IPD in the post-vaccine period in children and 
adults, independently of HIV status. An important additional benefit was a reduction 
in antimicrobial resistance (von Gottberg et al., 2014). Kenya adopted PCV10 with a 
3+0 schedule and showed a decline of 30% in the incidence of total IPD in children < 
5 years (Rodgers and Klugman, 2016). Besides the positive effect against IPD, other 
studies showed that overall pneumonia hospitalizations also decreased with the use 
of PCV10 (Afonso et al., 2013) or PCV13 (Becker-Dreps et al., 2014).  
 
Future of Pneumococcal Vaccines 
The availability of PCVs has resulted in major health benefits throughout the 
World. However, these vaccines may not be the ultimate solution for the prevention 
of pneumococcal disease. First, there is always a possibility of serotype replacement 
in disease. In fact, the emergence of serotypes not targeted by the vaccines may even 
occur without PCVs pressure, meaning that static formulations would not succeed in 
these situations. The overall impact of PCVs has so far been beneficial, but several 
NVTs have been shown to have a high invasive disease potential (Sá-Leão et al., 2011) 
being, therefore, candidates to increase as causes of disease in the future (Ramirez et 
al., 2015). Second, PCVs are complex to produce and relatively expensive. Therefore, 
low and middle-income countries will struggle to include PCV10 or PCV13 into their 
NIPs without financial support (Rodgers and Klugman, 2016). Third, non-PCV13 
serotypes may have a significant role in the future, since risk groups for IPD are 
increasing. Concerning this last point, while the younger fraction of the population is 
growing in developing countries, the older fraction of the population is increasing in 
developed countries. Regarding older adults, the WHO estimated that individuals ≥ 
60 years will reach 2 billion by 2050 (http://www.who.int/ageing/en/). In the USA, 
hospitalizations due to pneumococcal pneumonia are expected to increase 96% 
between 2004 and 2040, and without any intervention, the total cost of pneumococcal 
pneumonia in the USA is estimated to increase $2.5 billion annually (Wroe et al., 
2012).  
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To overcome the limitations of the currently licensed pneumococcal vaccines, 
several pharmaceutical companies are working on the development of a new type of 
pneumococcal vaccine. One approach under test is the development of a vaccine 
targeting surface epitopes that are expressed by all pneumococci. Examples of 
pneumococcal proteins that are being considered to be part of these new vaccines are 
pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC) and 
pneumolysin (Ply). Another strategy is to combine a common pneumococcal protein 
with a PCV. Additionally, the development of inactivated whole cell preparations is a 
possibility and this path is likely to be a globally affordable strategy (Alderson, 2016). 
Another hypothesis is to increase the valency of the existing PCVs. A 15-valent PCV is 
under evaluation and includes all serotypes of PCV13 plus serotypes 22F and 33F 
(Skinner et al., 2011). The development of PCVs targeting the most common serotypes 
occurring specifically in low income countries is another strategy being pursued. One 
aim of this later approach is to reduce the overall price associated with the production 
and distribution of PCVs in these regions (Alderson, 2016). 
Until a new pneumococcal vaccine is available, or the current vaccine 
indications are changed, PCVs will remain in use in most countries. The pressure 
imposed by pneumococcal vaccination and the use of antibiotics will continue to 
impact on the dynamics of pneumococci and therefore, it is important to maintain 
epidemiological surveillance of pneumococcal infections. Such surveillance activities 
can help to understand if vaccine policies adopted by each country remain up to date 
and may give important insights concerning the next path to follow in the prevention 
of pneumococcal disease. 
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AIMS OF THE THESIS 
The availability of pneumococcal conjugate vaccines in the 2000s decade 
prompted an increased need for epidemiological studies in the countries adopting 
these vaccines. PCV7 became available in Portugal in June 2001, followed by PCV10 in 
mid-2009 and PCV13 in early-2010. Contrasting with other countries that 
implemented universal vaccination of children shortly after or few years after the 
availability of PCVs, in Portugal, only in 2015 was a PCV (PCV13) included in the 
national immunization program of children. Until then, PCVs were given through the 
private market, with a modest but increasing uptake. The main aim of this thesis work 
was to study the characteristics of pneumococci causing disease in adults in Portugal 
during the period of PCVs use in children outside the national immunization 
program. The pneumococcal isolates analyzed in this thesis were recovered from 
adults with invasive pneumococcal disease or non-invasive pneumococcal 
pneumonia. 
Two studies are presented in chapter II of this thesis (Horácio et al., 2013; 
Horácio et al., 2016b). In these studies, we determined the serotype and antimicrobial 
susceptibility of pneumococcal isolates causing invasive disease in adults in Portugal 
in two different periods - 2009-2011 and 2012-2014 – to continue the epidemiological 
surveillance study initiated in the laboratory in 1999. We aimed to document new 
changes in the serotype distribution of isolates responsible for adult IPD and to see 
how these changes related with the private use PCVs in children. PCV13 became 
available for adults in the beginning of 2012 and therefore, we also aimed to evaluate 
the potential coverage of this vaccine in adult IPD. The management of 
pneumococcal infections depends on antibiotic therapy and since antimicrobial 
resistance has an association with the serotype, another goal was to evaluate if there 
were significant changes in antimicrobial susceptibility of pneumococci causing adult 
IPD in this period. 
In chapter III, only one study is presented (Horácio et al., 2016a). In this study, 
isolates causing adult IPD in Portugal between 2008 and 2011 were analyzed regarding 
their MLST-defined clonal composition and prevalence of pilus islands 1 and 2. The 
main aim of this study was to analyze the clonal structure of pneumococci responsible 
for adult IPD in Portugal in the late post-PCV7 period and early post-PCV10/PCV13 
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period to better understand the changes occurring in adult IPD during the time of 
private PCVs use in children. For that purpose, we searched specifically for changes 
in the prevalence of genetic lineages within each serotype and for evidence of capsular 
switching. Pilus-like structures are virulence factors of pneumococci that contribute 
to pneumococcal adhesion to host cells (Moschioni et al., 2010; Bagnoli et al., 2008). 
It is noteworthy that most of the serotypes targeted by the PCVs available to date 
present these structures, possibly indicating a role of pili in the success of these 
serotypes. Decreases in the proportion of the serotypes targeted by PCVs likely 
resulted in decreases in the prevalence of pili, but one study reported a re-emergence 
of PI-1 among non-vaccine serotypes after several years of PCV7 use (Regev-Yochay 
et al., 2010). Therefore, another goal of the study presented in chapter III was to 
evaluate how the presence and type of pili related with pneumococcal serotypes and 
genotypes responsible for adult IPD and how the use of PCVs in children may have 
affected the prevalence of pilus islands 1 and 2 among the isolates causing adult IPD.  
Chapter IV is composed of two studies (Horácio et al., 2014; Horácio et al., 2018). 
In these studies, we evaluated the serotype distribution and antimicrobial 
susceptibility of isolates causing adult non-invasive pneumococcal pneumonia in 
Portugal in the periods 1999-2011 and 2012-2015, respectively. The aims were similar 
to those of chapter II for adult IPD. That is, we aimed to characterize changes in the 
serotype distribution and antimicrobial susceptibility of isolates responsible for adult 
NIPP and to see if the changes detected were possibly the result of the use of 
PCV10/PCV13 in children. The period chosen for analysis also included the years of 
PCV7 use in children and therefore another goal was to evaluate the possible impact 
of childhood vaccination with PCV7 in adult NIPP. Results from the two studies of 
chapter IV were compared with contemporary results of adult IPD to evaluate if adult 
IPD data could be used to infer adult NIPP data. 
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RATIONALE 
The study of IPD is important, not only due to the current burden of these 
infections, but also because isolation of pneumococci from a normally sterile site 
unambiguously indicates pneumococcal disease. Therefore, changes in the serotype 
distribution of the pneumococci causing IPD can be used to evaluate the potential 
impact of pneumococcal vaccines in IPD.  
The two studies presented in this chapter describe the serotype and 
antimicrobial susceptibility of isolates causing IPD in adults (≥ 18 years) in Portugal 
in two different periods – 2009-2011 and 2012-2014. They continue the epidemiological 
study initiated in the laboratory in 1999. Concerning previous studies, results mainly 
preceding PCV7 availability (1999-2002) were reported in Serrano et al. (2004), data 
from the early post-PCV7 period (2003-2005) was presented in Aguiar et al. (2008a) 
and results from the late post-PCV7 period (2006-2008) were reported in Horácio et 
al. (2012).  
In summary, the study of Serrano et al. (2004) showed that in 1999-2002 PCV7 
serotypes were much less represented among invasive isolates collected from older 
children and adults (6-60 yrs: 33.0% and ≥ 60 yrs: 35.1%) than among isolates collected 
from younger children (< 2 yrs: 63.2% and 2-6 yrs: 60.0%). The most frequent 
serotypes in this period among individuals aged ≥ 60 years were serotypes 3, 14, 1, 8 
and 4. Almost 30% of the isolates recovered from patients ≥ 6 years in 1999-2002 were 
resistant to at least one class of antibiotics (Serrano et al., 2004). 
The study of Aguiar et al. (2008a) gave the first evidence that childhood 
vaccination with PCV7 outside the national immunization program and with a 
modest uptake (e.g. ~ 43% in 2004) was likely changing the serotype distribution of 
pneumococci responsible for adult IPD in Portugal. PCV7 was introduced in 2001 and 
after 2003 there was a 28% decline in the conditional relative risk that adult IPD was 
caused by a PCV7 serotype. However, when comparing periods 1999-2003 and 2004-
2005, they found an increase in the conditional relative risk of serotypes 19A and 7F 
and a rise in the fraction of isolates that were resistant to erythromycin, tetracycline 
and simultaneously non-susceptible to penicillin and erythromycin.  
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The study of Horácio et al. (2012) reinforced the major findings of the previous 
work. In this study, the period 1999-2003 was considered a pre-PCV7 period in adults 
because the initial uptake of PCV7 was too low to be relevant and because the stronger 
changes in the serotype distribution of adult IPD isolates occurred from 2004 
onwards. In this study, we found that the proportion of PCV7 serotypes in adult IPD 
declined from 30% in 1999-2003 to 16% in 2008. From 2004 to 2008, serotypes 1, 7F 
and 19A increased in adult IPD. The most frequent serotypes in 2006-2008 were 
serotypes 3, 1, 7F, 19A and 14. In addition, the proportion of isolates resistant to 
erythromycin increased again in adult IPD (from 14.4% in 2004-2005 to 18.3% in 2006-
2008, p = 0.029). 
The studies presented in the current chapter reports on the serotype and 
antimicrobial susceptibility of the isolates causing adult IPD in a time of PCV10 and 
PCV13 private use in Portugal (Horácio et al., 2013; Horácio et al., 2016b). PCV10 
became available for children in mid-2009 and PCV13 in the beginning of 2010. The 
first study presented in this chapter (Horácio et al., 2013) evaluates isolates causing 
adult IPD mostly in a period of transition from PCV7 to PCV10 and PCV13. PCV13 
became the most frequently used PCV in Portugal following its availability for 
children (Aguiar et al., 2014). Therefore, the second study of this chapter (Horácio et 
al., 2016b) aimed to evaluate the possible impact of the relatively moderate uptake of 
PCV13 in children (~ 63% in 2012) in adult IPD. 
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The following study was performed by Andreia N. Horácio, Jorge Diamantino-
Miranda, Sandra I. Aguiar, Mário Ramirez, José Melo-Cristino and the Portuguese 
Group for the Study of Streptococcal Infections. Andreia N. Horácio participated in 
the experimental work by serotyping and performing antimicrobial resistant tests to 
part of the isolates, performed great part of the statistical analysis and wrote the first 
version of the “Results” section of the manuscript. The 2009 data were previously 
included in the studies of two master thesis (one from Andreia N. Horácio and the 
other from Jorge Diamantino-Miranda). 
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THE MAJORITY OF ADULT PNEUMOCOCCAL INVASIVE INFECTIONS IN 
PORTUGAL ARE STILL POTENTIALLY VACCINE PREVENTABLE IN SPITE OF 
SIGNIFICANT DECLINES OF SEROTYPES 1 AND 51 
Andreia N. Horácio, Jorge Diamantino-Miranda, Sandra I. Aguiar, Mário Ramirez, José Melo-
Cristino, the Portuguese Group for the Study of Streptococcal Infections 
Faculty of Medicine, Instituto de Microbiologia, Instituto de Medicina Molecular, University 
of Lisbon, Lisbon, Portugal 
 
Abstract 
In Portugal, pneumococcal conjugate vaccines have been administered to 
children outside of the national immunization plan since 2001. We determined the 
serotype and antimicrobial susceptibility of 1265 isolates responsible for adult invasive 
pneumococcal infections (IPD) between 2009 and 2011 and compared the results with 
previously published data from 1999 to 2008. Serotypes 3 (12.6%), 7F (10.0%), 19A 
(9.1%), 14 (8.4%), 1 (6.9%) and 8 (6.2%) were the most frequent and together 
accounted for 53.2% of adult IPD. Serotypes 1 and 5 declined significantly while 
serotype 34, not included in any vaccine, increased. Taken together, the serotypes 
included in the 13-valent conjugate vaccine (PCV13) peaked among adult IPD isolates 
in 2008 (70.2%) and declined since then reaching 53.5% in 2011. The decline in the 
serotypes included in the 23-valent polysaccharide vaccine since 2007 was also 
significant but much more modest with 79.2% of the isolates causing IPD in 2011 
expressing these serotypes. Since the changes in serotypes causing IPD in adults 
coincided with the 10-valent and PCV13 introduction in children, it is unlikely that 
vaccination triggered these changes although it may have accelerated them. The 
proportion of IPD caused by serotypes included in the 7-valent conjugate vaccine 
remained stable (19.0%). Both penicillin non-susceptibility and erythromycin 
resistance increased in the study period, with serotypes 14 and 19A accounting for the 
majority of resistant isolates. 
                                                     
1 A facsimile of this publication can be found at the “Publications” section of this thesis. 
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Introduction 
Streptococcus pneumoniae (pneumococcus) remains a significant cause of 
morbidity and mortality throughout the world affecting disproportionally the 
extremes of life. Prevention of these infections in persons ≥ 2 years belonging to risk 
groups and particularly among adults ≥ 65 years has relied on a vaccine including 23 
of the 94 capsular polysaccharides known in pneumococci. Although older age is a 
recognized risk factor for pneumococcal disease, in Europe different countries have 
distinct recommendations regarding the use of the 23-valent polysaccharide vaccine 
(PPV23), ranging from the absence of national guidelines, to recommendations of 
universal or risk group vaccination starting at 60 or 65 years (Michel et al., 2010). 
Perhaps because of an ongoing debate on PPV23 efficacy (Grabenstein, 2012; Paradiso, 
2012; Truck et al., 2012), in most European countries there is a low overall uptake of 
PPV23 (Fedson et al., 2011). In Portugal PPV23 uptake is at the lower end of the 
spectrum with estimates that approximately 10% of adults ≥ 65 years are vaccinated 
(Horácio et al., 2012). 
The remarkable efficacy of the seven-valent conjugate vaccine (PCV7) against 
the serotypes included in its formulation resulted in a sharp decline in the proportion 
of invasive pneumococcal infections (IPD) caused by these serotypes not only in 
vaccinated children (Aguiar et al., 2010a; Bettinger et al., 2010; Pilishvili et al., 2010; 
Rodenburg et al., 2010; Miller et al., 2011b; Ingels et al., 2012) but also across the entire 
population (Horácio et al., 2012). This ‘‘herd effect’’ is attributed to the reduced 
transmission of these serotypes from children to adults. In Europe, although there 
were epidemiological changes in the serotypes causing IPD in the non-vaccinated 
population in all countries where the vaccine was administered, the large reduction 
in the overall number of invasive infections in adults observed in the USA was not 
replicated in countries such as Spain, England and Wales and the Netherlands (Pérez-
Trallero et al., 2009; Rodenburg et al., 2010; Miller et al., 2011b) where significant 
increases in non-vaccine serotypes (NVT) occurred. 
Since the PCV7 serotypes represented a significant fraction of resistant isolates, 
vaccination was also anticipated to affect resistance. However, the effect of PCV7 on 
antibiotic resistance in Europe was variable. While a decrease in penicillin non-
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susceptibility was noted in all countries among isolates responsible for pediatric IPD 
in the post-PCV7 period (Aguiar et al., 2008a; Pérez-Trallero et al., 2009; Aguiar et al., 
2010a), such decline was not apparent in adults in Portugal and Spain (Aguiar et al., 
2008a; Pérez-Trallero et al., 2009; Horácio et al., 2012). 
Serotype 19A has consistently been identified as a dominant non-vaccine 
serotype but other emerging non-vaccine serotypes differ between geographic 
locations and also between age groups (Aguiar et al., 2008a; Aguiar et al., 2010a; 
Bettinger et al., 2010; Pilishvili et al., 2010; Horácio et al., 2012). Even within serotype 
19A, different genetic lineages emerge in different geographic locations (Aguiar et al., 
2010b). These data highlight the importance of the characteristics of the local 
pneumococcal population and of local selective forces in conditioning the outcomes 
of vaccination (Rosen et al., 2011).  
On the other hand, it is known that serotypes responsible for IPD may have 
significant temporal variations in the same geographic region as documented in Spain 
and Denmark (Fenoll et al., 2009; Harboe et al., 2010), even with limited antibiotic 
selective pressure and in the absence of PCV use. In addition, the divergent 
prevalence of the various serotypes in different geographic regions also conditions 
the potential benefits of vaccination. A much lower prevalence of serotype 1 IPD is 
documented in the USA than elsewhere (Aguiar et al., 2008a; Fenoll et al., 2009; 
Pilishvili et al., 2010; Horácio et al., 2012; Muhammad et al., 2013; Regev-Yochay et al., 
2013). Although serotype 1 is frequently associated with outbreaks and significant 
yearly variations of the proportion of IPD caused by this serotype are documented, a 
considerable fraction of IPD was consistently caused by this serotype in the last 
decades in Europe (Fenoll et al., 2009; Harboe et al., 2010).  
Two new pneumococcal conjugate vaccine (PCV) formulations are now 
commercially available and used in children. A 10-valent formulation (PCV10) 
including, in addition to the PCV7 serotypes, serotypes 1, 5 and 7F and a 13-valent 
conjugate vaccine (PCV13), including all PCV10 serotypes plus serotypes 3, 6A and 
19A. The introduction of these vaccines into clinical practice has the potential to once 
again change the characteristics of pediatric IPD, with initial data showing the 
capacity of PCV13 to blunt or even reverse the rise of some of the most successful 
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serotypes that have emerged as causes of pediatric IPD since the introduction of PCV7 
(Miller et al., 2011a; Kaplan et al., 2013; Picazo et al., 2013). 
PCV13 was recently licensed for use in adults ≥ 50 years and this was soon 
followed by a recommendation in the USA for its use in adults with 
immunocompromising conditions (Centers for Disease Control and Prevention, 
2012). Approval of PCV13 for adults was based on immunogenicity studies and the 
results of a large study that is currently underway in the Netherlands (Hak et al., 2008) 
comparing it to placebo for the prevention of vaccine-serotype community acquired 
pneumonia in adults are expected to become available in late 2013. The observed 
benefits of conjugate vaccines in children launched a discussion about the potential 
benefits of vaccinating the adult population with these vaccines instead of PPV23 
(Musher et al., 2011; Grabenstein, 2012; Paradiso, 2012; Truck et al., 2012). 
Independently of the immunological arguments, the potential benefits of adult 
vaccination with either PCV13 or PPV23 are a moving target since secular trends in 
pneumococcal serotypes and the herd effect provided by PCV7, and now also hoped 
for the use of PCV13 in children, would be expected to reduce the importance of the 
serotypes included in conjugate vaccines in adult IPD. 
In Portugal PCVs were not included in the National Immunization Plan but 
there has been a steady increase in PCV7 uptake since 2001, reaching 75% of children 
≤ 2 yrs in 2008 (Aguiar et al., 2008a). The expanded valency PCVs for childhood 
vaccination – PCV10 and PCV13 – became available in mid-2009 and early-2010, 
respectively. In previous studies, we showed that significant changes in the serotypes 
causing IPD in children followed PCV7 availability (Aguiar et al., 2008a; Aguiar et al., 
2010a) and that there was evidence for a herd effect in the adult population (Aguiar 
et al., 2008a; Horácio et al., 2012). This study aimed at documenting the continued 
changes on serotype distribution and antimicrobial resistance in different adult 
groups and evaluating the proportion of potentially vaccine preventable adult IPD in 
Portugal immediately prior to the approval in January 2012 of PCV13 use in adults > 
50 yrs. 
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Materials and Methods 
Ethics Statement 
Case reporting and isolate collection were considered to be surveillance 
activities and were exempt from evaluation by the Review Board of the Faculdade de 
Medicina da Universidade de Lisboa. 
 
Bacterial Isolates 
Since 1999, the Portuguese Group for the Study of Streptococcal Infections has 
monitored pneumococci causing invasive infections in Portugal. This is a laboratory-
based surveillance system, in which 30 microbiology laboratories throughout 
Portugal are asked to identify all isolates responsible for IPD and to send them to a 
central laboratory for characterization. A case of invasive disease is defined by an 
isolate of S. pneumoniae recovered from a normally sterile body site such as blood or 
CSF. Although the laboratories were contacted periodically to submit the isolates to 
the central laboratory, no audit was performed to ensure compliance, which may be 
variable in this type of study. Isolates recovered up to 2008 were previously 
characterized (Serrano et al., 2004; Aguiar et al., 2008a; Horácio et al., 2012). Only 
isolates recovered from adult invasive infections, i.e. recovered from patients ≥ 18 yrs, 
between 2009 and 2011 were included in the present study. One isolate from each 
patient in each year was considered. All strains were identified as S. pneumoniae by 
colony morphology and hemolysis on blood agar plates, optochin susceptibility and 
bile solubility. 
 
Serotyping and Antimicrobial Susceptibility Testing 
Serotyping was performed by the standard capsular reaction test using the 
chessboard system and specific sera (Statens Serum Institut, Copenhagen, Denmark). 
Serotypes were grouped into conjugate vaccine serotypes, i.e., those included in 
PCV13 (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F) and that comprise all 
the serotypes found in the lower valency vaccines, those included in PPV23 (all 
serotypes included in PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 
20, 22F and 33F), and non-vaccine serotypes (NVT). Etest strips (AB Biodisk, Solna, 
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Sweden) were used to determine the MICs for penicillin and cefotaxime. In 2008, the 
CLSI changed the recommended breakpoints used to interpret MIC values. Unless 
otherwise stated we have used the CLSI-recommended breakpoints prior to 2008 
(Clinical and Laboratory Standards Institute, 2007) as epidemiological breakpoints 
that allow the comparison with previous studies. According to these 
recommendations, intermediate level penicillin resistance was defined as MIC 0.12–
1.0 µg/ml and high level resistance as MIC ≥ 2.0 µg/ml. Isolates that fell into either of 
these classes were designated penicillin non-susceptible. Susceptibility to cefotaxime 
was defined as MIC ≤ 1.0 µg/ml for non-meningitis cases and an MIC ≤ 0.5 µg/ml for 
meningitis cases. 
Isolates were further characterized by determining their susceptibility to 
erythromycin, clindamycin, vancomycin, linezolid, tetracycline, levofloxacin, 
trimethroprim-sulfamethoxazole and chloramphenicol by the Kirby-Bauer disk 
diffusion technique, according to the CLSI recommendations and interpretative 
criteria (Clinical and Laboratory Standards Institute, 2011). 
Macrolide resistance phenotypes were identified using a double disc test with 
erythromycin and clindamycin according to a previously published procedure (Melo-
Cristino et al., 2003). Simultaneous resistance to erythromycin and clindamycin 
defines the MLSB phenotype (resistance to macrolides, lincosamides and 
streptogramin B) while non-susceptibility only to erythromycin indicates the M 
phenotype. 
The prevalence of the various serotypes was compared with already published 
data from 1999–2008 (Serrano et al., 2004; Aguiar et al., 2008a; Horácio et al., 2012). 
We established previously that no significant changes in serotype distribution 
occurred until 2003 in adult IPD and have therefore considered 1999–2003 as the pre-
vaccine period (Aguiar et al., 2008a). 
 
Statistical Analysis 
Simpson’s index of diversity (SID) and respective 95% confidence intervals 
(CI95%) was used to measure the population diversity (Carriço et al., 2006). Adjusted 
Wallace (AW) coefficients were used to compare two sets of partitions (Severiano et 
al., 2011). The calculation of these indices was done using the online tool 
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www.comparingpartitions.info. Differences were evaluated by the Fisher exact test 
and the Cochran-Armitage test was used for trends with the false discovery rate (FDR) 
correction for multiple testing (Benjamini and Hochberg, 1995). A p < 0.05 was 
considered significant for all tests. 
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Results 
Isolate Collection 
Between 2009 and 2011 a total of 1265 isolates were recovered from normally 
sterile sites: 448 in 2009, 404 in 2010 and 413 in 2011. Isolates were recovered from 
blood (n = 1121, 88.6%), CSF (n = 97, 7.7%), pleural fluid (n = 30, 2.4%), peritoneal fluid 
(n = 10, 0.8%) and other normally sterile sites (n = 7, 0.5%). Regarding age 
distribution, 353 isolates (27.9%) were recovered from patients 18–49 yrs, 272 (21.5%) 
from patients 50–64 yrs and 640 (50.6%) from patients ≥ 65 yrs. 
The 1265 isolates recovered in 2009–2011 are in line with the 1100 isolates 
recovered in 2006–2008 and reported previously (Horácio et al., 2012). This suggests 
that the surveillance network is stable and that no major changes are affecting IPD 
reporting in the two periods. However, although unlikely, we cannot completely 
exclude the possibility that there was an increase in reporting that may have 
compensated for a potential decrease in IPD incidence. 
 
Serotype Distribution 
We detected 50 different capsular types among the 1265 isolates. The most 
frequent, that accounted for 53.2% of all adult IPD, were serotypes 3 (n = 160, 12.6%), 
7F (n = 126, 10.0%), 19A (n = 115, 9.1%), 14 (n = 106, 8.4%), 1 (n = 87, 6.9%) and 8 (n = 
79, 6.2%). During the study period (2009–2011), the only significant changes found in 
individual serotype prevalence after FDR correction were of serotype 1, that decreased 
from 10.7% to 4.1% (Cochran-Armitage test of trend p < 0.001), serotype 5, that 
decreased from 2.0% to 0% (Cochran-Armitage test of trend p = 0.003) and serotype 
34, that did not cause any invasive infections in 2009 and 2010 but was detected in 
1.9% of the isolates causing IPD in 2011 (Cochran-Armitage test of trend p < 0.001). 
Figure IIa.1 shows the evolution of vaccine preventable IPD between 1999 and 
2011. For the period 1999–2003, defined previously as the pre-PCV7 period (Aguiar et 
al., 2008a), the results were averaged over the entire period. After the significant 
decline of IPD caused by PCV7 serotypes between 2004 and 2005, from 30.8% to 16.5% 
(p < 0.001), a steady and low prevalence was seen until 2011. As previously documented 
(Horácio et al., 2012), in spite of the decrease of PCV7 serotypes, the increase in 
serotypes 1, 19A and 7F resulted in an overall increase in PCV13 serotypes in the post-
  
 
 
Figure IIa.1 Proportion of isolates expressing serotypes included in pneumococcal vaccines causing invasive infections in adults in Portugal (1999–2011). The data up to 2008 were 
presented previously (Serrano et al., 2004; Aguiar et al., 2008a; Horácio et al., 2012). The period of 1999–2003, previously identified as the pre-PCV7 period (Aguiar et al., 2008a) was analyzed 
together. 
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PCV7 period, from 61.9% in 1999–2003 to 70.2% in 2008 (Cochran-Armitage test of 
trend p = 0.014). However, 2008 was an inflection point (Fig. IIa.1) and the proportion 
of isolates presenting PCV13 serotypes started to decline from then onwards such that 
in 2011 only 53.5% of the isolates presented PCV13 serotypes (from 2008 to 2011, 
Cochran-Armitage test of trend p < 0.001). This change was mainly driven by a 
decrease in prevalence of serotypes 1 and 5 from 13.5% and 2.9% in 2008 to 4.1% and 
0% in 2011, respectively (Cochran-Armitage test of trend p < 0.001 for both, significant 
after FDR) (Table SIIa.1). 
The proportion of PPV23 serotypes also increased slightly but non-significantly 
up to 2007. From 2007 onwards there was a slight but significant decrease in the 
proportion of IPD caused by PPV23 serotypes, from 85.0% in 2007 to 79.2% in 2011 
(Cochran-Armitage test of trend p = 0.018). Initially this decline occurred in spite of 
the increase in PCV13 serotypes that peaked in 2008. Later, the decline of PCV13 
serotypes was opposed by an important increase in the proportion of IPD caused by 
the additional serotypes found in PPV23 but absent from PCV13, from 13.7% in 2008 
to 25.9% in 2011 (Cochran-Armitage test of trend p < 0.001). When looking 
individually at these serotypes, although several increased in frequency, only serotype 
8 increased significantly from 3.7% in 2008 to 8.0% in 2011 (Cochran-Armitage test of 
trend p < 0.002, significant after FDR).  
Figure IIa.2 shows the distribution of the individual serotypes included in the 
conjugate vaccines, stratified by the age group of the patients. Figure IIa.3 shows the 
distribution of the additional serotypes found in PPV23 that are not included in the 
conjugate vaccines. 
To analyze the serotype diversity within each age group, SIDs were calculated. 
The serotypes of the isolates causing invasive infections in any of the age groups 
considered were highly diverse (18–49 yrs [SID: 0.939, CI95%: 0.930–0.947]; 50–64 yrs 
[SID: 0.949, CI95%: 0.941–0.958]; ≥ 65 yrs [SID: 0.934, CI95%: 0.926–0.943]). The only 
significant difference was a higher diversity of serotypes in the 50–64 yrs age group 
relative to ≥ 65 yrs age group (p = 0.013). A similar analysis was performed for 
determining the serotype diversity in each study year but no significant changes 
occurred between 2009 and 2011 nor were changes in diversity noted between the 
2004–2008 period and 2009–2011 (data not shown).
  
 
 
Figure IIa.2 Number of isolates expressing serotypes included in conjugate vaccines causing invasive infections in Portugal (2009–2011). The number of isolates expressing each serotype in each of 
the age groups considered is indicated. Isolates recovered from patients 18 to 49 yrs are indicated by black triangles. Isolates recovered from patients 50 to 64 yrs are indicated by open squares. Isolates 
recovered from patients ≥ 65 yrs are indicated by open circles. Isolates presenting both erythromycin resistance and penicillin non-susceptibility (EPNSP) are represented by closed black bars. Penicillin non-
susceptible isolates (PNSP) are indicated by dark hatched bars. Erythromycin resistant pneumococci (ERP) are indicated by light hatched bars. Isolates susceptible to both penicillin and erythromycin are 
represented by white open bars. The serotypes included in each of the conjugate vaccines are indicated by the arrows. NVT – non-vaccine serotypes, i.e., serotypes not included in any of the currently available 
vaccines (PCV13 and PPV23). Twenty-eight NVT were detected representing 236 isolates as follows: 6C (n = 36); 23A (n = 20); 12B (n = 19); 16F (n = 18); 23B and 33A (n = 16 each); 15A and 29 (n = 15 each); 
24F (n = 13); non-typable (n = 10); 31, 34 and 35F (n = 8 each); 7C, 25A and 35B (n = 5 each); 21 (n = 4); 18A (n = 3); 13 and 17A (n = 2 each); 7A, 11C, 15F, 24A, 25F, 28A, 28F and 37 (n = 1 each). 
  
 
 
Figure IIa.3 Number of isolates expressing serotypes present in the 23-valent polysaccharide vaccine but not included in conjugate vaccines causing invasive infections in Portugal 
(2009–2011). See the legend of Figure IIa.1. Out of the 11 serotypes present in the 23-valent polysaccharide vaccine PPV23 but absent from the 13-valent conjugate vaccine PCV13, serotype 2 
was not found in our collection. 
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Although the frequency of each serotype varies according to the age groups 
considered, only for serotypes 1, 3, 8 and 19A were these differences significant. While 
the frequency of serotype 1 decreases with age (18–49 yrs – 11.0%, 50–64 yrs – 7.7%, ≥ 
65 yrs – 4.2%; Cochran-Armitage test of trend p < 0.001), the frequency of serotype 3 
increases with age (18–49 yrs – 7.6%, 50–64 yrs – 10.7%, ≥ 65 yrs – 16.3%; Cochran-
Armitage test of trend p < 0.001). For serotypes 8 and 19A a trend with age was not 
evident. However, serotype 8 was more frequent in the youngest group (18–49 yrs –
10.5%) than in either of the oldest age groups (50–64 yrs – 4.8%, p = 0.011 and ≥ 65 – 
4.5%, p < 0.001), and serotype 19A showed a higher prevalence in older adults (≥ 65 
yrs; 10.5%) than in younger adults (18–49 yrs; 5.9%, p = 0.019). Taking together the 
three years of the study (2009–2011), the proportion of IPD caused by the serotypes 
included in both conjugate vaccines and in PPV23 was roughly the same in all age 
groups considered (Table IIa.1). 
 
Table IIa.1 Isolates expressing serotypes included in pneumococcal 
vaccines (2009-2011). 
    
No. isolates (%) 
18-49 yrs 50-64 yrs ≥65 yrs 
  2009 24 (18.2) 21 (22.8) 49 (21.9) 
PCV7 2010 22 (19.6) 20 (24.7) 30 (14.2) 
  2011 24 (22.0) 21 (21.2) 29 (14.1) 
  2009 80 (60.6) 63 (68.5) 150 (67.0) 
PCV13 2010 65 (58.0) 48 (59.3) 125 (59.2) 
  2011 64 (58.7) 56 (56.6) 101 (49.3) 
  2009 104 (78.8) 78 (84.8) 187 (83.5) 
PPV23 2010 97 (86.6) 66 (81.5) 159 (75.4) 
  2011 96 (88.1) 77 (77.8) 154 (75.1) 
 
When analyzing individual serotypes with three or more CSF isolates, a positive 
association with CSF was found for serotypes 6B (p = 0.002), 16F (p = 0.009) and 19F 
(p = 0.002), all significant after FDR (Table IIa.S2). 
 
Antimicrobial Susceptibility 
Resistance to the tested antimicrobials is summarized in Table IIa.2 and Figures 
IIa.2 and IIa.3. Overall 266 isolates (21.0%) were penicillin non-susceptible 
pneumococci (PNSP) – 205 (16.2%) expressed low level resistance (MIC = 0.12–1.0) and 
61 (4.8%) high level resistance (MIC ≥ 2 µg/ml). 
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Table IIa.2 Antimicrobial resistance of the isolates 
responsible for invasive infections in adults (2009-2011). 
  No. resistant isolates (%)a 
 18-49 yrs 50-64 yrs ≥65 yrs 
  (n=353) (n=272) (n=640) 
PEN 62 (17.6) 58 (21.3) 146 (22.8) 
MIC90 1 1 1 
MIC50 0.023 0.023 0.023 
CTX 14 (4.0) 12 (4.4) 24 (3.8) 
MIC90 0.75 0.75 0.75 
MIC50 0.023 0.023 0.023 
LEV 0 (0) 0 (0) 2 (0.3) 
ERY 53 (15.0) 58 (21.3) 134 (20.9) 
CLI 40 (11.3) 51 (18.8) 108 (16.9) 
CHL 7 (2.0) 11 (4.0) 11 (1.7) 
SXT 68 (19.3) 62 (22.8) 117 (18.3) 
TET 49 (13.9) 51 (18.8) 118 (18.4) 
aPEN – penicillin; CTX – cefotaxime; LEV – levofloxacin; ERY – 
erythromycin; CLI – clindamycin; CHL – chloramphenicol; 
SXT – trimethoprim/sulphamethoxazole; TET – tetracycline. 
All isolates were susceptible to vancomycin and linezolid.  
 
Considering current CLSI breakpoints for parenteral penicillin where 
susceptibility is defined as MIC < 0.06 µg/ml for meningitis cases (Clinical and 
Laboratory Standards Institute, 2011), 17 isolates (17.5%) from CSF would have been 
considered resistant and 27 isolates (2.3%) from non-meningitis cases would have 
been considered non-susceptible – 24 (2.1%) intermediately resistant and 3 (0.3%) 
fully resistant. Erythromycin resistant pneumococci (ERP) accounted for 19.4% of the 
isolates (n = 245), of which 194 isolates (79.2%) expressed the MLSB phenotype and 51 
(20.8%) the M phenotype. All isolates were susceptible to vancomycin and linezolid. 
The simultaneous expression of erythromycin resistance and penicillin non-
susceptibility (EPNSP) was found in 13.0% of the isolates. 
Resistance to penicillin, erythromycin and clindamycin increased with the age 
group considered (Table IIa.2). While the increase in erythromycin and clindamycin 
were statistically supported (Cochram-Armitage test of trend, p = 0.035 and p = 0.039, 
respectively) the increase in penicillin non-susceptibility was not (p = 0.057). For the 
other tested antimicrobials no significant differences were noted. The proportions of 
PNSP and ERP in 2009–2011 were higher than those previously reported (Figure 
SIIa.1). The proportion of PNSP increased from being previously stable (from an 
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average value of 16.7% in 1999–2008 to 21.0% in 2009–2011, p = 0.002). On the other 
hand, there was a consistent increase in the proportion of ERP since PCV7 
introduction (from 1999–2003 to 2011, Cochran-Armitage test of trend p < 0.001). 
Although the overall proportion of ERP has been increasing, when analyzing changes 
within the study period a significant decrease was noted from 2010 to 2011, from 23.8% 
to 15.7% (p = 0.005). Similarly, the proportion of PNSP also decreased from 23.8% in 
2010 to 19.6% in 2011, but this change was not statistically significant (p = 0.174). 
The correlation between serotype and antimicrobial resistance was high. The 
AW for serotype and penicillin non-susceptibility was 0.539 (CI95% 0.476–0.601), 
higher than the AW for serotype and erythromycin resistance (0.403, CI95% 0.336–
0.470). Together, serotypes 19A and 14 contributed greatly to penicillin non-
susceptibility (59.0%) and to erythromycin resistance (53.1%) (Fig. IIa.2). Serotypes 
included in PCV7 represented 47.4%, 36.7% and 35.8% of PNSP, ERP and EPNSP, 
respectively, while serotypes included in PCV13 constituted 76.7%, 71.4% and 72.1%, 
respectively. Considering the serotypes included in PPV23, only a modest increase 
relative to the PCV13 serotypes is noted (80.2%, 75.1% and 74.5%, of PNSP, ERP and 
EPNSP, respectively) since most of the remaining resistant isolates express NVTs (Fig. 
IIa.3). Among the EPNSP expressing NVTs, serotypes 6C (45.2%) and 15A (28.6%) 
were dominant. 
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Discussion 
The effect of childhood vaccination in the distribution of IPD serotypes in adults 
was always found to be delayed in relation to the effects seen in children in the 
countries where the vaccine is available (Aguiar et al., 2008a; Miller et al., 2011b; 
Demczuk et al., 2012). Given this prior experience with PCV7, the introduction of 
PCV13 in childhood vaccination in early 2010 in Portugal would only be expected to 
have an effect in the distribution of serotypes causing IPD in adults around 2011. If 
one considers the serotypes common to PCV10, then the introduction of PCV10 in 
childhood vaccination in mid-2009 would raise the possibility that an effect on these 
serotypes could occur earlier. However, the significant increase in adult IPD in the 
post-PCV7 period of serotypes 1, 7F (common to both PCVs) and 19A (exclusively 
found in PCV13) peaked in 2008 (Horácio et al., 2012). While serotypes 7F and 19A 
remained stable from then onwards, the number of serotype 1 isolates started to 
decline in 2009 (Table IIa.S1). This was accompanied by a significant reduction of 
serotype 5 and a strong reduction of serotype 6A (not included in PCV10) in the same 
period, that were responsible for the overall fall in PCV13 serotypes (Fig. IIa.1). The 
fact that the decline started in 2009, before PCV13 introduction and shortly after 
PCV10 became available, strongly argues that the changes seen here were not 
triggered by the use of PCVs, although they may have been accelerated by PCV use. 
Serotype 3 remains the most prevalent serotype in adult IPD after PCV7 
introduction and continued to be significantly associated with older adults (Horácio 
et al., 2012). Similarly, serotype 7F remains the second most frequently identified 
serotype. Although serotypes 3 and 7F were not as frequent, these were also important 
among IPD in children (Aguiar et al., 2010a) and were commonly found among 
patients with pleural parapneumonic effusion of all ages in the same period 
(unpublished data), attesting to their virulence. In spite of their continued 
dominance, both serotype 3 and 7F isolates remain mostly susceptible to all tested 
antimicrobials (Fig. IIa.2), as previously described in Portugal and elsewhere (Serrano 
et al., 2005; Fenoll et al., 2009). 
The increase in serotype 19A as a cause of IPD in both children (Aguiar et al., 
2010a) and adults (Horácio et al., 2012) plateaued in the study period in adults with 
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the overall proportion of IPD isolates expressing this serotype remaining stable at 
around 9%. Serotype 19A as a whole, did not have an enhanced propensity to cause 
invasive infections (Sá-Leão et al., 2011), but particular lineages within this serotype 
were found to have different preferences in their association with the human host 
(Aguiar et al., 2010b). In Portugal it was shown that the lineage that was expanding 
was associated with antimicrobial resistance (Aguiar et al., 2010b), as was also seen 
here (Fig. IIa.2). While no association with particular adult age groups was seen 
previously for serotype 19A IPD, this serotype was now significantly associated with 
older adults (≥ 65 yrs) rather than younger adults (18–49 yrs). This could be driven in 
part by a higher antimicrobial consumption in this age group, a trend that may be 
emerging in developed countries (Haeseker et al., 2012). However, in Norway the 
post-PCV7 rise of serotype 19A was mostly dominated by a penicillin susceptible clone 
(Vestrheim et al., 2012), suggesting that selection for antimicrobial resistance alone 
cannot explain the post-PCV7 rise of this serotype. 
Despite 10 years of PCV7 use in children, serotype 14 was still responsible for a 
significant fraction of IPD in all adult age groups (Fig. IIa.2) in contrast to what 
happens elsewhere, where more significant reductions of serotype 14 in adult IPD 
followed PCV7 use in children (Miller et al., 2011b; Demczuk et al., 2012). Serotype 14 
isolates were mostly resistant to either erythromycin or penicillin or both (101/106, 
95%) (Fig. IIa.2). A high proportion of penicillin non-susceptibility, erythromycin 
resistance and erythromycin and penicillin non-susceptibility has been a 
characteristic of serotype 14 isolates since before PCV7 introduction (Serrano et al., 
2004; Serrano et al., 2005; Aguiar et al., 2008a), a feature that was accentuated in the 
post-PCV7 period in both pediatric and adult IPD (Aguiar et al., 2010a; Horácio et al., 
2012). 
Serotype 1 traditionally accounts for a higher proportion of pediatric IPD in 
Europe than in North America. In Portugal serotype 1 was the second most important 
serotype in adult IPD between 2006–2008 (Horácio et al., 2012). In neighboring Spain, 
outside the Madrid area where PCV7 was available but not included in the national 
immunization plan similar to Portugal, an increased importance of serotype 1 in IPD 
both in the group targeted for PCV7 vaccination as well as in older children and adults 
was also documented (Marimón et al., 2009). The decline in the importance of 
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serotype 1 as a cause of IPD with age in adults reported previously (Horácio et al., 
2012) was also seen in this period. However, serotype 1 dropped from the second most 
frequent overall cause of IPD in adults to fifth. As discussed above, the trigger of this 
decline cannot be solely attributed to a possible herd effect of PCV use in children 
since it started before vaccination of children with the expanded valency PCVs that 
include this serotype. Since serotype 1 remains mostly susceptible to antimicrobials 
(Fig. IIa.2), the continued pressure of antimicrobial use could be invoked to explain 
this reduction. However, this does not seem plausible since serotypes 3, 4 and 7F, all 
also included in PCV13 and mostly susceptible to antimicrobials similarly to serotype 
1 isolates, remain important and stable serotypes in IPD in adults in Portugal in the 
post-PCV7 period. Serotypes 1 and 7F were found to have an enhanced invasive 
disease potential (Sá-Leão et al., 2011) and were thus candidates to increase in 
prevalence in IPD in the post-PCV7 period, as indeed happened (Horácio et al., 2012). 
The decline in serotype 1 could be due to unexplained temporal trends that have been 
known to affect this serotype (Fenoll et al., 2009; Harboe et al., 2010). These temporal 
trends may have subsequently been accelerated by PCV use. 
Two other serotypes with enhanced invasive disease potential – serotypes 5 and 
8 (Sá-Leão et al., 2011) – showed opposite trends. Serotype 5 was shown to cause 
outbreaks in open communities (Vanderkooi et al., 2011) and a significant increase in 
cases had been noted in 2008, although we have no evidence that these cases 
correspond to an outbreak. The subsequent decline of serotype 5 isolates could then 
be the natural dynamics of a putative outbreak. The suggestion that PCV use could 
have contributed to the decline of serotype 5 is supported by the observation that 2011 
is the only year since surveillance started in 1999 when no isolates expressing serotype 
5 were detected among IPD cases in adults. Serotype 8 on the other hand is a non- 
PCV serotype that has been increasing since 2008 and that is now the sixth most 
frequent serotype in IPD in adults (Fig. IIa.3). Serotype 34 is a NVT that increased in 
the study period, although it is responsible for a modest number of cases. Although 
this serotype as a whole was associated with carriage, different lineages expressing 
this serotype showed distinct capacities to cause invasive disease (Sá-Leão et al., 2011). 
It is therefore possible that its increase in IPD documented here is driven by a limited 
expansion of particularly virulent lineages. The other non-PCV serotypes that are 
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among the ten most frequently found in adult IPD (Fig. IIa.3) have all increased in 
frequency, although this was not statistically supported, and included the PPV23 
serotypes 22F, 11A and 9N and the NVT serotype 6C. The latter was also notable for 
being frequently resistant to both erythromycin and penicillin. Serotypes 6C and 22F 
were also found among the most frequent in adult IPD in Canada in 2010 (Demczuk 
et al., 2012). Since these are not covered by currently available PCVs, these serotypes 
may emerge as important causes of adult IPD in the post-PCV era. 
In spite of the large reduction in the number of PCV7 serotypes, the five 
serotypes included in this vaccine and that were traditionally associated with 
resistance (6B, 9V, 14, 19F and 23F), still accounted for a significant fraction of isolates 
resistant to either erythromycin, penicillin or both (45%), and this proportion 
declined only slightly from what was seen in 2006–2008 (47%) (Horácio et al., 2012). 
Both penicillin and erythromycin non-susceptibility, that is concentrated in the 
serotypes included in PCVs, has risen in adult IPD. The emergence of multiresistant 
serotype 19A isolates in the post-PCV7 period in adult IPD played a major role in 
preventing the decline of resistance in IPD in Portugal by compensating the decline 
of resistant isolates expressing PCV7 serotypes. The significant decrease of 
erythromycin resistance noted in 2011 may signal a change in this trend, but there 
were multiple serotypes responsible for this decline and no significant concentration 
in PCV13 serotypes was noted. 
In contrast to our expectations, the use of PCV7 and now of PCV13 has not 
resulted in further declines of the PCV7 serotypes as causes of adult IPD. The 
continued importance of these serotypes is in contrast to the massive declines that 
lead to the almost elimination of PCV7 serotypes as causes of adult IPD in the USA 
(Pilishvili et al., 2010; Rosen et al., 2011). The reasons behind this difference are 
possibly multifactorial and may include: 1) differences in the transmission dynamics 
of these serotypes in the USA and Portugal; 2) differences in the clonal composition 
or in the selective pressures exerted upon the pneumococcal populations; 3) a 
relatively slow uptake of PCV7 in Portugal when compared to the USA; and 4) a lower 
coverage of PCV7 vaccination in children in Portugal. Although we cannot formally 
exclude the first two possibilities, we believe that their impact would be transient 
since the pneumococcal population would adapt to these new circumstances. On the 
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other hand, the later two possibilities are particularly interesting and suggest that in 
order to obtain the full public health benefits of vaccinating children with PCV13, one 
should aim at the rapid introduction of the vaccine and at vaccination coverage higher 
than the 75% currently achieved in Portugal. The proportion of PCV7 serotypes has 
shown little change since 2005, when the proportion of PCV7 serotypes causing IPD 
in adults declined from pre-PCV7 levels to its current values. It is therefore likely that 
the stability of PCV7 serotypes in the intervening six years corresponds to a new 
steady-state related to the lower vaccination coverage of children in Portugal relative 
to that in the USA or England and Wales (Miller et al., 2011b; Muhammad et al., 2013). 
The recent replacement with the 13-valent formulation for the vaccination of 
children in Portugal, as has happened in many countries, may equally lead to herd 
effects in the additional serotypes included in this vaccine. The approval for the use 
of PCV13 in adults raises the possibility that adult vaccination may not only reduce 
IPD due to vaccine serotypes in vaccinees but also lead to reduced carriage of the 
serotypes included in the vaccine, as was seen in children, further compounding the 
herd effect noted from childhood vaccination. However, even without adult 
vaccination, continued use of conjugate vaccines in children and the herd effects they 
produce together with sustained high antimicrobial usage, are likely to drive 
alterations in the serotypes causing adult IPD that will influence the fraction of 
potentially vaccine preventable disease in this age group. 
Our study was not designed to allow the estimate of the incidence of IPD and it 
therefore does not evaluate potential changes in incidence with time and in particular 
since PCV7 introduction. However, the design based on the reporting of all laboratory 
confirmed IPD cases with isolation of the etiological agent within the surveillance 
network, the large number of isolates studied, the wide coverage of the country by 
the network and the stable number of isolates reported in each year, guarantees that 
the data accurately represents IPD in Portugal and can be used to evaluate changes 
in the relative importance of the different serotypes. PPV23 availability since 1996 had 
only minor effects on the proportion of adult IPD caused by PPV23 serotypes but due 
to its limited use in the country (Horácio et al., 2012) maybe none should be expected. 
The proportion of infections potentially covered by PPV23 in Portugal remained 
always above 80% since surveillance was started in 1999, except in 2011 when it 
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dropped slightly below that level (Fig. IIa.1). This occurred despite significant 
serotype changes in this period. In contrast, the fraction of adult IPD potentially 
preventable by PCV13 that had increased diminished in recent years reaching 53.5% 
in 2011 and may be even lower in patients with co-morbidities (Grau et al., 2012). 
PCV13 use could still potentially prevent more than half of adult IPD in Portugal at 
the time it was licensed for use in adults > 50 yrs. The dynamics of the serotypes 
causing IPD in adults justify the continued surveillance of these infections in order to 
evaluate the potential coverage afforded by each of the two currently available 
vaccines with an adult indication. 
IPD – Serotypes and Antimicrobial Susceptibility 
 
63 
 
Acknowledgements 
Members of the Portuguese Group for the Study of Streptococcal Infections are: 
Teresa Vaz, Marília Gião, Rui Ferreira (Centro Hospitalar do Barlavento Algarvio), 
Ana Buschy Fonseca (Hospital de Cascais), Henrique Oliveira (Centro Hospitalar de 
Coimbra), Ana Cristina Silva, Hermínia Costa (Centro Hospitalar de Entre Douro e 
Vouga), Margarida Pinto, Odete Chantre, João Marques, Isabel Peres, Isabel Daniel, 
Ema Canas, Teresa Ferreira, Cristina Marcelo (Centro Hospitalar de Lisboa Central), 
Lurdes Monteiro, Luís Marques Lito (Centro Hospitalar Lisboa Norte), Filomena 
Martins, Maria Ana Pessanha, Elsa Goncalves, Teresa Morais, Teresa Marques (Centro 
Hospitalar Lisboa Ocidental), Paulo Lopes, Luísa Felício, Angelina Lameirão (Centro 
Hospitalar de Vila Nova de Gaia/ Espinho), Ana Paula Mota Vieira, Margarida Tomaz 
(Centro Hospitalar do Alto Ave), Rosa Bento (Centro Hospitalar do Baixo Alentejo), 
Maria Helena Ramos, Ana Paula Castro (Centro Hospitalar do Porto), Fernando 
Fonseca (Centro Hospitalar da Póvoa do Varzim/Vila do Conde), Ana Paula Castro, 
(Hospital de Vila Real), Graça Ribeiro, Rui Tomé, Celeste Pontes (Hospitais da 
Universidade de Coimbra), Nuno Canhoto, Teresa Afonso (Hospital Central do 
Funchal), Teresa Pina, Helena Peres (Hospital Curry Cabral, Lisboa), Ilse Fontes, 
Paulo Martinho (Hospital de Santa Luzia, Elvas), Ana Domingos, Gina Marrão, José 
Grossinho (Hospital de Santo André, Leiria), Manuela Ribeiro (Hospital de São João, 
Porto), Alberta Faustino, Adelaide Alves (Hospital de Braga), Maria Paula Pinheiro, 
R. Semedo (Hospital Dr. José Maria Grande, Portalegre), Adriana Coutinho (Hospital 
do Espirito Santo, Évora), Luísa Cabral, Olga Neto (Hospital dos SAMS, Lisboa), Luísa 
Sancho (Hospital Dr. Fernando da Fonseca, Amadora/Sintra), José Diogo, Ana 
Rodrigues, Isabel Nascimento (Hospital Garcia de Orta, Almada), Elmano 
Ramalheira, Fernanda Bessa (Hospital Infante D. Pedro, Aveiro), Isabel Marques, José 
Miguel Ribeiro (Hospital de São Teotónio, Viseu), Maria Antónia Read, Valquíria 
Alves (Hospital Pedro Hispano, Matosinhos), Engrácia Raposo, Maria Lurdes 
Magalhães, Helena Rochas, Anabela Silva (Instituto Nacional de Saúde Ricardo Jorge, 
Porto), Margarida Rodrigues (Hospital Reynaldo dos Santos, Vila Franca de Xira). 
 
 
Chapter II 
 
64 
 
Funding  
A.N. Horácio, J. Diamantino-Miranda and S.I. Aguiar were supported by grants 
SFRH/BD/81205/2011, SFRH/BD/81766/2011, SFRH/BPD/78376/2011, respectively, 
from Fundação para a Ciência e Tecnologia, Portugal. This work was partially 
supported by Fundação para a Ciência e Tecnologia, Portugal (PTDC/ 
DTPEPI/1759/2012) and unrestricted research grants from Pfizer and Glaxo 
SmithKline. The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript. 
 
Author Contributions 
Conceived and designed the experiments: MR and JM-C. Performed the 
experiments: ANH, JD-M and SIA. Analyzed the data: ANH, MR and JM-C. 
Contributed with reagents, materials and analysis tools: PGSSI. Wrote the paper: 
ANH, MR and JM-C. 
IPD – Serotypes and Antimicrobial Susceptibility 
 
65 
 
Supporting Information 
Table IIa.S1 Number of isolates expressing serotypes included in the 13-
valent conjugate vaccine but not included in the 7-valent conjugate 
vaccine causing invasive infections in Portugal (2008-2011). 
Serotype No. isolates in each year (%) 
2008 2009 2010 2011 
1 55 (13.4) 48 (10.7) 22 (5.4) 17 (4.1) 
3 51 (12.5) 53 (11.8) 59 (14.6) 48 (11.6) 
5 12 (2.9) 9 (2.0) 4 (1.0) 0 (0) 
6A 6 (1.5) 8 (1.8) 2 (0.5) 1 (0.2) 
7F 48 (11.7) 48 (10.7) 35 (8.7) 43 (10.4) 
19A 48 (11.7) 33 (7.4) 44 (10.9) 38 (9.2) 
 
 
Table IIa.S2 Capsular types of the isolates recovered from CSF 
between 2009 and 2011. 
  No. isolates    
Serotype CSF non-CSF OR (CI95%) 
3 9 151 0.69 (0.30-1.41) 
19A 9 106 1.02 (0.44-2.11) 
19F 7 19 4.69 (1.62-12.05) 
6B 6 13 5.84 (1.78-16.95) 
11A 5 34 1.81 (0.54-4.81) 
16F 5 13 4.82 (1.32-14.80) 
7F 5 121 0.47 (0.15-1.17) 
22F 4 51 0.94 (0.24-2.65) 
33A 4 12 4.14 (0.95-14.00) 
1 3 84 0.41 (0.08-1.29) 
14 3 103 0.33 (0.07-1.02) 
10A 3 18 2.04 (0.38-7.17) 
a Odds ratio (OR) and 95% confidence intervals (CI95%) are shown 
for serotypes that were represented by at least 3 isolates.  b In bold are 
the serotypes with significant p-values after FDR correction. 
 
  
 
 
Figure SIIa.1 Proportion of penicillin non-susceptible pneumococci (PNSP) and erythromycin resistant pneumococci (ERP) (1999-2011). The period 1999-2003, previously identified as 
the pre-PCV7 period, was analyzed together. 
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SEROTYPE 3 REMAINS THE LEADING CAUSE OF INVASIVE PNEUMOCOCCAL 
DISEASE IN ADULTS IN PORTUGAL (2012–2014) DESPITE CONTINUED 
REDUCTIONS IN OTHER 13-VALENT CONJUGATE VACCINE SEROTYPES1
Andreia N. Horácio, Catarina Silva-Costa, Joana P. Lopes, Mário Ramirez, José Melo-Cristino 
and the Portuguese Group for the Study of Streptococcal Infections 
Faculty of Medicine, Instituto de Microbiologia, Instituto de Medicina Molecular, University 
of Lisbon, Lisbon, Portugal 
 
Abstract 
Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 
7-valent vaccine (PCV7) as the leading pneumococcal vaccine used in children 
through the private sector. Although, neither of the PCVs were used significantly in 
adults, changes in adult invasive pneumococcal disease (IPD) were expected due to 
herd protection. We characterized n = 1163 isolates recovered from IPD in adults in 
2012–2014 with the goal of documenting possible changes in serotype prevalence and 
antimicrobial resistance. Among the 54 different serotypes detected, the most 
frequent, accounting for half of all IPD, were serotypes: 3 (14%), 8 (11%), 19A (7%), 22F 
(7%), 14 (6%), and 7F (5%). The proportion of IPD caused by PCV7 serotypes remained 
stable during the study period (14%), but was smaller than in the previous period (19% 
in 2009–2011, p = 0.003). The proportion of IPD caused by PCV13 serotypes decreased 
from 51% in 2012 to 38% in 2014 (p < 0.001), mainly due to decreases in serotypes 7F 
and 19A. However, PCV13 serotype 3 remained relatively stable and the most frequent 
cause of adult IPD. Non-PCV13 serotypes continued the increase initiated in the late 
post-PCV7 period, with serotypes 8 and 22F being the most important emerging 
serotypes. Serotype 15A increased in 2012–2014 (0.7% to 3.5%, p = 0.011) and was 
strongly associated with antimicrobial resistance. However, the decreases in resistant 
isolates among serotypes 14 and 19A led to an overall decrease in penicillin non-
susceptibility (from 17 to 13%, p = 0.174) and erythromycin resistance (from 19 to 13%, 
p = 0.034). Introduction of PCV13 in the NIP for children, as well as its availability for 
adults may further alter the serotypes causing IPD in adults in Portugal and lead to 
changes in the proportion of resistant isolates. 
                                                     
1 A facsimile of this publication can be found at the “Publications” section of this thesis. 
Chapter II 
 
70 
 
IPD – Serotypes and Antimicrobial Susceptibility 
 
71 
 
Introduction 
Two types of pneumococcal vaccines are licensed to prevent invasive 
pneumococcal disease (IPD), both targeting a restricted number of serotypes out of 
the 94 serotypes currently recognized in Streptococcus pneumoniae: strictly 
polysaccharide based vaccines and polysaccharide-protein conjugate based vaccines 
(PCVs) (Ramirez, 2014). The first licensed pneumococcal conjugate vaccine was the 
7-valent pneumococcal conjugate vaccine (PCV7), which targets serotypes 4, 6B, 9V, 
14, 18C, 19F, and 23F. PCV7 became available for children in the USA in 2000 and in 
Europe in 2001. Two additional conjugate vaccines became available more recently: a 
10-valent vaccine (PCV10), which includes PCV7 serotypes and serotypes 1, 5, and 7F; 
and a 13-valent vaccine (PCV13), which includes PCV10 serotypes and serotypes 3, 6A, 
and 19A. PCVs proved to be highly effective in reducing the number of IPD episodes 
caused by vaccine serotypes (Pilishvili et al., 2010; Aguiar et al., 2014). Moreover, a 
decrease in IPD caused by PCV serotypes was also noted in non-vaccinated 
individuals (a phenomenon termed herd protection) (Horácio et al., 2013; Moore et 
al., 2015). However, use of PCVs was also accompanied by replacement of vaccine 
serotypes by non-vaccine types (NVTs) as causes of IPD, both in vaccinated children 
and in non-vaccinated adults. The overall impact of this phenomenon varied greatly 
around the world (Pérez-Trallero et al., 2009; Guevara et al., 2014; Harboe et al., 2014; 
Moore et al., 2015; Waight et al., 2015). The switch to the higher valency vaccines 
PCV10 and PCV13 also affected emerging serotypes. For instance, serotypes 7F and 
19A were reported as emerging in IPD in the post-PCV7 period (Aguiar et al., 2010a; 
Steens et al., 2013; Guevara et al., 2014; Harboe et al., 2014; Waight et al., 2015) but 
several studies have already shown that they decrease following PCV13 use (Aguiar et 
al., 2014; Moore et al., 2015; Waight et al., 2015). A 23-valent strictly polysaccharide 
vaccine (PPV23) includes 12 of the serotypes found in PCV13 (except6A) and serotypes 
2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F. This vaccine has been used for two 
decades in older children and adults and has proven efficacy in the prevention of IPD 
(Moberley et al., 2013).  
PCV7, PCV10 and PCV13 became available in Portugal in late-2001, mid-2009 and 
in early-2010, respectively. However, in contrast to many European countries, in 
Portugal PCV7 was not included in the national immunization program (NIP) and the 
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uptake of PCV7 in children increased gradually over time, reaching 75% in 2008 
(Aguiar et al., 2008a). PCV13 replaced PCV7 since its availability and has been the 
most widely used pneumococcal vaccine since then, with estimates of 63% coverage 
in 2012 (Aguiar et al., 2014). PCV13 received an indication for adults ≥ 50 years in 2012 
and in 2013 its indication was extended to all ages, but use of these vaccines in adults 
in Portugal was believed to be low until 2014. PCV13 was introduced into the NIP for 
children in 2015, being given free of charge to all children born from January 2015 
onwards, with a 2+1 schedule (Direção Geral de Saúde, 2015a). PPV23 is also available 
in Portugal since 1996, but its uptake among adults is estimated to below (∼ 10%) 
(Horácio et al., 2012). Since 2015, guidelines from the national health authorities 
recommend vaccinating adults in particular risk groups with both PCV13 and PPV23 
(Direção Geral de Saúde, 2015b). However, these groups will constitute a minority of 
the overall population and there are no guidelines recommending vaccinating adults 
more broadly with any of the pneumococcal vaccines.  
In spite of the gradual increase in PCV uptake in children and the relatively 
modest coverage, we found significant changes in serotype distribution and 
antimicrobial susceptibility of pneumococci causing adult IPD that could be 
attributed at least in part to herd protection. The proportion of adult IPD caused by 
PCV13 serotypes was highest in 2008 (70%), but a gradual decrease took place until 
2011, when only 54% of the isolates causing adult IPD expressed PCV13 serotypes 
(Horácio et al., 2012 and 2013). In the present study we continued monitoring 
potential changes in serotype distribution and antimicrobial susceptibility of isolates 
causing adult IPD after PCV13 received an adult indication and before the 
introduction of PCV13 in the NIP for children. 
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Materials and Methods 
Ethics Statement 
Case reporting and isolate collection were considered to be surveillance 
activities and were exempt from evaluation by the Review Board of the Faculdade de 
Medicina of Universidade de Lisboa. The data and isolates were de-identified so that 
these were irretrievably unlinked to an identifiable person. 
 
Bacterial Isolates  
Invasive pneumococcal infections have been monitored in Portugal since 1999 
by the Portuguese Group for the Study of Streptococcal Infections (Serrano et al., 
2004). This is a laboratory-based surveillance system, in which 31 microbiology 
laboratories throughout Portugal are asked to identify all isolates responsible for IPD 
and to send them to a central laboratory for characterization. Although, the 
laboratories were contacted periodically to submit the isolates to the central 
laboratory, no audit was performed to ensure compliance, which may be variable in 
this type of study. A case of IPD was defined by the isolation of pneumococci from a 
normally sterile fluid, such as blood, pleural fluid or cerebral spinal fluid (CSF). The 
isolates included in the study were recovered from adult patients (≥ 18 years) with 
IPD between January 2012 and December 2014. Only one isolate from each patient in 
each year was included in the study. All isolates were identified as pneumococci by 
colony morphology, hemolysis on blood agar plates, optochin susceptibility and bile 
solubility. 
 
Serotyping and Antimicrobial Susceptibility Testing  
Serotypes were determined by the standard capsular reaction test using the 
chessboard system and specific sera (Sørensen, 1993) (Statens Serum Institut, 
Copenhagen, Denmark). Serotypes were classified into vaccine serotypes, i.e., those 
included in PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), in PCV10 (all PCV7 serotypes 
plus serotypes 1, 5, and 7F), in PCV13 (all PCV10 serotypes plus 3, 6A, and 19A) or in 
PPV23 (all PCV13 serotypes, except serotype 6A and serotypes 2, 8, 9N, 10A, 11A, 12F, 
15B, 17F, 20, 22F, and 33F) and non-vaccine serotypes (NVT). Given the high frequency 
of spontaneous switching between serotypes 15B and 15C we have opted to group 
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isolates with these serotypes into a single group. Due to difficulties in phenotypically 
distinguishing isolates of serotype 25A and serogroup 38 these were also grouped 
together into the 25A/38. Minimal inhibitory concentrations (MICs) for penicillin and 
cefotaxime were determined using Etest strips (Biomérieux, Marcy l’Étoile, France). 
In 2008, the CLSI changed the recommended breakpoints used to interpret MIC 
values. Unless otherwise stated we have used the CLSI-recommended breakpoints 
prior to 2008 (Clinical and Laboratory Standards Institute, 2007) as epidemiological 
breakpoints that allow the comparison with previous studies. Isolates were further 
characterized by determining their susceptibility to erythromycin, clindamycin, 
vancomycin, linezolid, tetracycline, levofloxacin, trimethroprim-sulfamethoxazole 
and chloramphenicol by the Kirby-Bauer disk diffusion technique, according to the 
CLSI recommendations and interpretative criteria (Clinical and Laboratory Standards 
Institute, 2014). Macrolide resistance phenotypes were identified using a double disc 
test with erythromycin and clindamycin, as previously described (Melo-Cristino et 
al., 2003). Simultaneous resistance to erythromycin and clindamycin defines the 
MLSB phenotype (resistance to macrolides, lincosamides and streptogramin B) while 
non-susceptibility only to erythromycin indicates the M phenotype. 
 
Statistical Analysis 
Simpson’s index of diversity (SID) and respective 95% confidence intervals 
(CI95%) was used to measure the population diversity (Carriço et al., 2006). Adjusted 
Wallace (AW) coefficients were used to compare two sets of partitions (Severiano et 
al., 2011). These indices were calculated using the online tool available at 
http://www.comparingpartitions.info. Differences were evaluated by the Fisher exact 
test and the Cochran-Armitage test (CA) was used for trends with the false discovery 
rate (FDR) correction for multiple testing (Benjamini and Hochberg, 1995). A p < 0.05 
was considered significant for all tests. 
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Results 
Isolate Collection  
A total of 1163 isolates were collected from adults with invasive pneumococcal 
disease between 2012 and 2014: 404 in 2012, 383 in 2013 and 376 in 2014. The majority 
were recovered from blood (n = 1066, 91.7%) and the remaining from CSF (n = 59, 
5.1%), pleural fluid (n = 26, 2.2%), peritoneal fluid (n = 9, 0.8%) and other normally 
sterile sites (n = 3, 0.3%). 
 
Serotype Distribution 
Between 2012 and 2014, a total of 54 different serotypes were identified. The most 
frequent, which accounted for half of the isolates were serotypes 3 (n = 161, 13.8%), 8 
(n = 123, 10.6%), 19A (n = 84, 7.2%), 22F (n = 79, 6.8%), 14 (n = 73, 6.3%), and 7F (n = 
61, 5.2%). Figures IIb.1–IIb.3 represent the number of isolates expressing serotypes 
included in PCVs, the additional serotypes found in PPV23, and the number of isolates 
expressing NVTs stratified by age group. Serotype diversity was high (2012–2014 SID 
= 0.944, CI95%: 0.939–0.949). Although, diversity was > 0.93 in all the studied years, 
there was a small but significant increase in serotype diversity between 2012 (SID = 
0.935, CI95%: 0.924–0.945) and 2013 (SID = 0.950, CI95%: 0.942–0.958) (p = 0.019). 
Serotype distribution varied according to age group but serotype diversity was not 
different in the three age groups considered (18–49 years, SID = 0.948, CI95%: 0.938–
0.958; 50–64 years, SID = 0.945, CI95%: 0.933–0.957; ≥ 65 years, SID = 0.939, CI95%: 
0.931–0.946). Only for serotype 1 were the differences in age distribution statistically 
supported after FDR correction with the proportion of serotype 1 decreasing with age 
(accounting for 6.5, 2.6, and 0.6% of the isolates recovered from patients aged 18–49 
years, 50–64 years and ≥ 65 years, respectively, CA p < 0.001). In contrast, the 
proportion of IPD caused by the group of additional serotypes found only in PCV13 
(3, 6A, and 19A) increases with age (15.2% in 18–49 years, 19.9% in 50–64 years and 
24.7% in ≥ 65years, CA p = 0.002, significant after FDR). 
When considering serotypes presenting three or more CSF isolates, we found a 
positive association with CSF for serotypes 19F (p = 0.006) and 23B (p = 0.005), both 
  
 
 
Figure IIb.1 Serotypes of isolates causing invasive pneumococcal disease in adult patients (≥18 years) in Portugal, 2012–2014. The number of isolates expressing each serotype in each of the age groups 
considered is indicated. Isolates recovered from patients 18–49 years are indicated by black triangles, from patients 50–64 years by open squares, and from patients ≥65 years by open circles. Isolates presenting 
both erythromycin resistance and penicillin non-susceptibility (EPNSP) are represented by black bars. Penicillin non-susceptible isolates (PNSP) are indicated by dark hatched bars. Erythromycin resistant 
pneumococci (ERP) are indicated by light hatched bars. Isolates susceptible to both penicillin and erythromycin are represented by white bars. The serotypes included in the seven-valent conjugate vaccine 
(PCV7) and in the 13-valent conjugate vaccine (PCV13) are indicated by the arrows. NVT, non-vaccine serotypes; PPV23, 23-valent polysaccharide vaccine. 
  
 
 
Figure IIb.2 Isolates expressing serotypes present in PPV23 but not included in conjugate vaccines causing invasive pneumococcal disease in adult patients (≥18 years) in Portugal, 
2012–2014. See legend of Figure IIb.1 Out of the 11 serotypes present in PPV23 but absent from PCV13, serotype 2 was not found in our collection. 
 
  
 
 
Figure IIb.3 Isolates expressing serotypes not included in any pneumococcal vaccine causing invasive pneumococcal disease in adult patients (≥18 years) in Portugal, 2012–2014. See 
legend of Figure IIb.1. NT, non-typable. Isolates expressing serotype 25A and 38 could not be distinguished phenotypically and are represented together. Only serotypes including n > 3 isolates 
are discriminated. 
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significant after FDR correction (Table IIb.S1). No significant associations with 
serotype were found for isolates recovered from pleural fluid.  
Figure IIb.4 shows the proportion of potentially vaccine preventable IPD during 
the study period and, for comparison purposes, also from 2008 to 2011 since important 
changes in serotype distribution initiated in this period (Horácio et al., 2013). 
Considering the current study period only (2012–2014), the overall proportion of IPD 
caused by PCV7 serotypes remained stable, while there was a decrease in the 
proportion of IPD caused by the additional serotypes found in both PCV10 and PCV13 
(serotypes 1, 5, 7F; from 11.1 to 4.8%, p = 0.001, significant after FDR) and in PCV13 only 
(serotypes 3, 6A, and 19A; from 26.5 to 19.9%, p = 0.024, significant after FDR).This 
resulted in the overall decrease in the proportion of IPD caused by PCV13 serotypes 
from 51.2% in 2012 to 38.0% in 2014 (p < 0.001, significant after FDR). The proportion 
of IPD caused by PPV23 serotypes and NVTs did not suffer significant changes during 
the study period (Figure IIb.4). However, the proportion of IPD caused by the 
additional serotypes found only in PPV23 (PPV23 add) significantly increased, from 
27.2 to 38.0% (p = 0.001, significant after FDR). 
When considering the evolution of potentially vaccine preventable IPD in the 
entire period from 2008 to 2014, there was a decrease in the overall proportion of IPD 
caused by PCV13 serotypes, although this was temporarily interrupted in 2012, mainly 
due to a slight increase of serotype 3 (see below).  
Table IIb.1 shows the evolution of individual serotypes causing adult IPD from 
2008 to 2014. When looking for trends in the proportion of individual serotypes 
during the current study period (2012–2014), the only significant change that was 
supported after FDR correction was the decrease in serotype 7F (from 8.2% in 2012 to 
4.7% in 2013 and 2.7% in 2014, CA p < 0.001). No significant changes in the proportion 
of individual serotypes were detected during the study period when stratifying by age 
group (data not shown). 
When considering together data from 2008 to 2014 there were changes 
(significant after FDR) in the proportion of individual serotypes. There were decreases 
in the proportion of IPD caused by serotypes: 1 (from 13.4 to 1.9%, CA p < 0.001), 5 
(from 2.9 to 0.3%, CA p < 0.001), 9V (from 3.4 to 0.3%, CA p < 0.001) and 19A (from 
11.7 to 5.6%, CA p = 0.005). In contrast, there were increases in the proportion of IPD  
  
 
 
Figure IIb.4 Proportion of isolates expressing serotypes included in pneumococcal vaccines causing invasive pneumococcal disease in adult patients (≥18 years) in Portugal, 2008–2014. 
The data up to 2011 were presented previously (Horácio et al., 2012, 2013). 
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Table IIb.1 Serotypes of the isolates responsible for invasive pneumococcal disease in adult patients 
(≥18 years), 2008–2014. 
 Serotype 
No. of isolates (%) CAa CA 
2008 2009 2010 2011 2012 2013 2014 2012-14 2008-14 
PCV13          
1 55 (13.4) 48 (10.7) 22 (5.4) 17 (4.1) 12 (3.0) 7 (1.8) 7 (1.9) 0.289 <0.001 
3 51 (12.5) 53 (11.8) 59 (14.6) 48 (11.6) 66 (16.3) 45 (11.7) 50 (13.3) 0.209 0.613 
4 10 (2.4) 12 (2.7) 17 (4.2) 14 (3.4) 6 (1.5) 8 (2.1) 9 (2.4) 0.360 0.352 
5 12 (2.9) 9 (2.0) 4 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 0.211 <0.001 
6A 6 (1.5) 8 (1.8) 2 (0.5) 1 (0.2) 2 (0.5) 1 (0.3) 4 (1.1) 0.315 0.062 
6B 1 (0.2) 7 (1.6) 3 (0.7) 9 (2.2) 5 (1.2) 5 (1.3) 5 (1.3) 0.909 0.272 
7F 48 (11.7) 48 (10.7) 35 (8.7) 43 (10.4) 33 (8.2) 18 (4.7) 10 (2.7) <0.001 <0.001 
9V 14 (3.4) 7 (1.6) 8 (2.0) 5 (1.2) 4 (1.0) 4 (1.0) 1 (0.3) 0.255 <0.001 
14 29 (7.1) 45 (10.0) 30 (7.4) 31 (7.5) 29 (7.2) 26 (6.8) 18 (4.8) 0.172 0.045 
18C 0 (0) 6 (1.3) 1 (0.2) 1 (0.2) 1 (0.2) 4 (1.0) 2 (0.5) 0.588 0.676 
19A 48 (11.7) 33 (7.4) 44 (10.9) 38 (9.2) 39 (9.7) 24 (6.3) 21 (5.6) 0.027 0.005 
19F 7 (1.7) 13 (2.9) 8 (2.0) 5 (1.2) 9 (2.2) 12 (3.1) 6 (1.6) 0.576 0.956 
23F 6 (1.5) 4 (0.9) 5 (1.2) 9 (2.2) 1 (0.2) 3 (0.8) 9 (2.4) 0.005 0.618 
PPV23                 
8 15 (3.7) 19 (4.2) 27 (6.7) 33 (8.0) 34 (8.4) 43 (11.2) 46 (12.2) 0.081 <0.001 
9N 10 (2.4) 12 (2.7) 13 (3.2) 11 (2.7) 8 (2.0) 13 (3.4) 18 (4.8) 0.030 0.122 
10A 3 (0.7) 8 (1.8) 7 (1.7) 6 (1.5) 2 (0.5) 8 (2.1) 8 (2.1) 0.062 0.294 
11A 7 (1.7) 13 (2.9) 10 (2.5) 16 (3.9) 16 (4.0) 18 (4.7) 15 (4.0) 0.974 0.012 
12F 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)  - 0.334 
15B/C 8 (2.0) 4 (0.9) 3 (0.7) 8 (1.9) 5 (1.2) 9 (2.3) 8 (2.1) 0.353 0.096 
17F 3 (0.7) 2 (0.4) 4 (1.0) 4 (1.0) 5 (1.2) 2 (0.5) 2 (0.5) 0.255 0.981 
20 4 (1.0) 8 (1.8) 5 (1.2) 7 (1.7) 14 (3.5) 11 (2.9) 14 (3.7) 0.851 0.001 
22F 10 (2.4) 17 (3.8) 16 (4.0) 22 (5.3) 25 (6.2) 23 (6.0) 31 (8.2) 0.261 <0.001 
33F 0 (0) 0 (0) 1 (0.2) 0 (0) 1 (0.2) 1 (0.3) 1 (0.3) 0.959 0.180 
NVTb          
6C 4 (1.0) 13 (2.9) 13 (3.2) 10 (2.4) 8 (2.0) 14 (3.7) 6 (1.6) 0.757 0.600 
15A 4 (1.0) 5 (1.1) 5 (1.2) 5 (1.2) 3 (0.7) 11 (2.9) 13 (3.5) 0.011 0.002 
23A 6 (1.5) 8 (1.8) 8 (2.0) 4 (1.0) 9 (2.2) 8 (2.1) 9 (2.4) 0.879 0.317 
16F 3 (0.7) 8 (1.8) 3 (0.7) 7 (1.7) 13 (3.2) 3 (0.8) 7 (1.9) 0.161 0.234 
24F 3 (0.7) 6 (1.3) 5 (1.2) 2 (0.5) 5 (1.2) 9 (2.3) 9 (2.4) 0.241 0.027 
12B 10 (2.4) 5 (1.1) 3 (0.7) 11 (2.7) 6 (1.5) 8 (2.1) 4 (1.1) 0.649 0.700 
35B 2 (0.5) 5 (1.1) 10 (2.5) 5 (1.2) 6 (1.5) 4 (1.0) 8 (2.1) 0.480 0.222 
35F 2 (0.5) 3 (0.7) 2 (0.5) 3 (0.7) 7 (1.7) 4 (1.0) 2 (0.5) 0.110 0.350 
23B 4 (1.0) 3 (0.7) 7 (1.7) 6 (1.5) 4 (1.0) 5 (1.3) 3 (0.8) 0.801 0.958 
31 2 (0.5) 2 (0.4) 1 (0.2) 5 (1.2) 5 (1.2) 2 (0.5) 4 (1.6) 0.786 0.197 
NT 0 (0) 3 (0.7) 4 (1.0) 3 (0.7) 1 (0.2) 3 (0.8) 6 (1.6) 0.042 0.060 
33A 1 (0.2) 4 (0.9) 8 (2.0) 4 (1.0) 2 (0.5) 5 (1.3) 2 (0.5) 0.930 0.913 
25A/38 2 (0.5) 3 (0.7) 0 (0) 2 (0.5) 3 (0.7) 3 (0.8) 2 (0.5) 0.726 0.583 
29 0 (0) 0 (0) 0 (0) 0 (0) 4 (1.0) 2 (0.5) 2 (0.5) 0.433 0.009 
34 2 (0.5) 0 (0) 0 (0) 8 (1.9) 3 (0.7) 1 (0.3) 4 (1.0) 0.607 0.148 
7C 2 (0.5) 2 (0.4) 2 (0.5) 1 (0.2) 1 (0.2) 4 (1.0) 1 (0.3) 0.944 0.907 
18A 6 (1.5) 0 (0) 1 (0.2) 2 (0.5) 0 (0) 3 (0.8) 0 (0) 0.959 0.080 
21 3 (0.7) 0 (0) 0 (0) 4 (1.0) 0 (0) 0 (0) 0 (0)  - 0.108 
Othersc  8 (2.0) 1 (0.2) 8 (2.0) 3 (0.7) 7 (1.7) 9 (2.3) 8 (2.1)  -  - 
Total 409 448 404 413 404 383 376  -  - 
aCA, Cochran Armitage test of trend. In bold are the serotypes with significant p-values (p < 0.05) after FDR 
correction. bNVT, non-vaccine serotypes. cOnly serotypes detected in ≥3 isolates in at least one year are 
shown; the remaining are represented in “Others.” 
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caused by PPV23 serotypes: 8 (from 3.7 to 12.2%, CA p < 0.001), 22F (from 2.4 to 8.2%, 
CA p < 0.001) and 20 (from 1.0 to 3.7%, CA p = 0.001); and an increase of the NVT 15A 
(from 1.0 to 3.5%, CA p = 0.002). Even though these changes were statistically 
supported when analyzing data from 2008 to 2014, in the case of serotypes 19A and 
15A, the more disparate values were only detected from 2013 onwards, while for 
serotype 20, this occurred from 2012 onwards. 
Table IIb.2 shows the evolution of IPD serotypes during the study period (2012–
2014) according to vaccine serotypes and stratified by age group. Recapitulating what 
was seen when considering all age groups together (Figure IIb.4), a decrease in the 
overall proportion of IPD caused by PCV13 serotypes was detected in the three age 
groups considered; however, only for individuals ≥ 65 years was this statistically 
supported (Table IIb.2). Moreover, only for this age group was the decrease in the 
additional serotypes found in both PCV10 and PCV13 (serotypes 1, 5 and 7F) 
statistically supported after FDR correction (Table IIb.2). 
  
Table IIb.2 Number of isolates responsible for invasive pneumococcal disease in adult 
patients (≥18 years), according to vaccine serotype groups and age groups, 2012–2014 
  
  
Serotype 
Groups 
No. isolates (%) 
C. A.a 
2012 2013 2014 
18-49  
years 
PCV7b 18 (21.4) 12 (15.0) 8 (11.9) 0.112 
1, 5 and 7F 15 (17.9) 10 (12.5) 8 (11.9) 0.286 
3, 6A and 19A 12 (14.3) 12 (15.0) 11 (16.4) 0.719 
PCV13c 45 (53.6) 34 (42.5) 27 (40.3) 0.094 
PPV23 addd 26 (31.0) 29 (36.3) 24 (35.8) 0.511 
NVTse 13 (15.5) 17 (21.3) 16 (23.9) 0.191 
50-64 
years 
PCV7b 7 (9.2) 14 (13.9) 15 (16.7) 0.164 
1, 5 and 7F 10 (13.2) 6 (5.9) 4 (4.4) 0.037 
3, 6A and 19A 20 (26.3) 19 (18.8) 14 (15.6) 0.087 
PCV13c 37 (48.7) 39 (38.6) 33 (36.7) 0.124 
PPV23 addd 17 (22.4) 34 (33.7) 37 (41.1) 0.011 
NVTse 22 (28.9) 28 (27.7) 20 (22.2) 0.316 
≥65 
years 
PCV7b 30 (12.3) 36 (17.8) 27 (12.3) 0.947 
1, 5 and 7F 20 (8.2) 9 (4.5) 6 (2.7) 0.008 
3, 6A and 19A 75 (30.7) 39 (19.3) 50 (22.8) 0.042 
PCV13c 125 (51.2) 84 (41.6) 83 (37.9) 0.004 
PPV23 addd 67 (27.5) 65 (32.2) 82 (37.4) 0.022 
NVTs 52 (21.3) 53 (26.2) 54 (24.7) 0.384 
aCA, Cochran Armitage test of trend. In bold are the serotype groups with significant pvalues 
(p < 0.05) after FDR correction. bPCV7, serotypes included in the 7-valent pneumococcal 
conjugate vaccine. cPCV13, serotypes included in the 13-valent pneumococcal conjugate 
vaccine. dPPV23 add, the additional 11 serotypes present in the 23-valent pneumococcal 
polysaccharide vaccine but absent from the 13-valent pneumococcal conjugate vaccine. 
eNVTs, serotypes not included in any of the currently available pneumococcal vaccines. 
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When analyzing the evolution of each serotype from 2008 to 2014 stratifying by 
age group, only serotype 1 decreased in all age groups considered (CA p < 0.001 for 
each, significant after FDR correction), while the increase of serotype 8 was significant 
only in the two older groups (≥ 50 years) (CA p < 0.001 for both, significant after FDR 
correction), and the changes in serotypes 5, 7F, 19A, 20, and 22F were statistically 
supported only in individuals ≥ 65 years (CA p < 0.001 for serotypes 5 and 7F, CA p = 
0.007 for serotype 19A, CA p = 0.003 for serotype 20 and CA p = 0.001 for serotype 22F, 
all significant after FDR correction). 
 
Antimicrobial Susceptibility  
Resistance to the antimicrobials tested is summarized in Table IIb.3. A total of 
n = 179 isolates (15.4%) were classified as penicillin non-susceptible pneumococci 
(PNSP): n = 160 (89.4%) presenting low level resistance and n = 19 (10.6%), high level 
resistance. Considering current CLSI breakpoints for penicillin, n = 12/59 CSF isolates 
(20.3%) would have been considered resistant and only n = 5/1104 non-CSF isolates 
(0.5%) would have been considered intermediately resistant. A total of n = 198 isolates 
(17.0%) were classified as erythromycin resistant pneumococci (ERP). Of these, n = 
159 presented the MLSB phenotype, while the remaining (n = 39, 19.7%) presented the 
M phenotype. Isolates simultaneously non-susceptible to penicillin and erythromycin 
(EPNSP) accounted for 10.4% of the collection (n = 121). Antimicrobial resistance did 
not change significantly between age groups. In 2012–2014, there was a significant 
decrease in antimicrobial resistance for several antimicrobials — erythromycin 
resistance decreased from 18.8 to 13.0% (CA p = 0.034), clindamycin resistance 
decreased from 16.1 to 10.4% (CA p = 0.022) and tetracycline resistance decreased from 
13.4 to 7.7% (CA p = 0.010). Although, not statistically supported, there was also a 
decrease in penicillin non-susceptibility, from 16.8% in 2012 to 13.3% in 2014 (CA p = 
0.174). 
There was some correlation between serotype and antimicrobial resistance 
(Figures IIb.1–IIb.3). The AW for serotype and PNSP was 0.569 (CI95%: 0.507–0.631) 
and the AW for serotype and ERP was 0.527 (CI95%: 0.458–0.596). Serotypes 14 and 
19A were the most frequent serotypes among PNSP and ERP. Serotype 14 accounted 
for 35.2% of PNSP and 22.2% of ERP while serotype 19A occurred in 21.2% of PNSP 
Chapter II 
 
84 
 
and 21.2% of ERP. Taken together, PCV7 serotypes accounted for 48.6% of PNSP, 
37.9% of ERP and 40.5% of EPNSP. Considering the PCV13 serotypes, these 
constituted 71.5, 61.1, and 67.8% of PNSP, ERP and EPNSP, respectively. The 
additional serotypes found in PPV23 but not in PCV13 accounted for only 2.8, 6.6, and 
1.7% of PNSP, ERP and EPNSP, respectively. The proportion of resistant isolates was 
higher among isolates expressing NVTs: 25.7, 32.3, and 30.6% of PNSP, ERP and 
EPNSP, respectively (Figures IIb.1–IIb.3). The most frequent NVTs among PNSP and 
ERP were serotypes 6C and 15A, which together accounted for 19.0% of PNSP and 
18.2% of ERP (Figure II.3b). 
 
Table IIb.3 Antimicrobial resistance of the isolates responsible for invasive 
pneumococcal disease in adult patients (≥18 years) in Portugal, 2012–2014. 
  No. resistant isolates (%) 
 18-49 years (n=231) 50-64 years (n=267) ≥65 years (n=665) 
PEN 40 (17.3) 32 (12.0) 107 (16.1) 
MIC90 0.38 0.125 0.25 
MIC50 0.016 0.012 0.016 
CTX 4 (1.7) 3 (1.1) 6 (0.9) 
MIC90 0.25 0.19 0.25 
MIC50 0.016 0.016 0.016 
LEV 0 (0) 1 (0.4) 6 (0.9) 
ERY 34 (14.7) 37 (13.9) 127 (19.1) 
CLI 31 (13.4) 30 (11.2) 100 (15.0) 
CHL 5 (2.2) 6 (2.2) 8 (1.2) 
SXT 30 (13.0) 39 (14.6) 93 (14.0) 
TET 23 (10.0) 21 (7.9) 79 (11.9) 
PEN, penicillin; CTX, cefotaxime; LEV, levofloxacin; ERY, erythromycin; CLI, 
clindamycin; CHL, chloramphenicol; SXT, trimethoprim/sulphamethoxazole; 
TET, tetracycline. All isolates were susceptible to vancomycin and linezolid 
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Discussion 
The decrease in PCV13 serotypes observed previously (Horácio et al., 2012 and 
2013) continued during the present study period resulting in only 38.0% of the isolates 
collected in 2014 expressing PCV13 serotypes (Figure IIb.4). However, different 
serotypes underlie the changes in 2008–2011 and 2012–2014.  
The timeframes of the decreases seen for serotypes 7F and 19A are consistent 
with a possible herd protection of childhood vaccination with the most recently 
introduced PCVs. Similar decreases in serotypes 7F and 19A as causes of adult IPD 
followed the use of PCV13 in children in the USA (Moore et al., 2015) and in several 
European countries (Steens et al., 2013; Guevara et al., 2014; Harboe et al., 2014; 
Waight et al., 2015). Decreases in the incidence of IPD caused by these two serotypes 
were also documented among children in Portugal (Aguiar et al., 2014). In Portugal 
the decrease in serotype 7F preceded that of serotype 19A in adult IPD. This could 
have been attributed to the use of PCV10 in children, since PCV10 includes serotype 
7F but not serotype 19A. Moreover, this vaccine was introduced in Portugal months 
earlier than PCV13. However, in children, serotype 19A decreased as a cause of IPD 
before an effect of PCV13 was expected and before any decrease in serotype 7F (Aguiar 
et al., 2014). This points to the importance of other factors besides vaccination in 
triggering changes in serotype prevalence and suggest that the initial changes seen in 
serotype 7F IPD in adults are the result of secular trends.  
In contrast to these serotypes, there was no overall reduction of serotype 3. 
These results are concordant with other studies that failed to show a consistent 
reduction of serotype 3 among adult IPD after the use of PCV13 in children (Steens et 
al., 2013; Harboe et al., 2014; Moore et al., 2015; Waight et al., 2015) and with a study 
that demonstrated a low and non-significant effectiveness of PCV13 against serotype 
3 IPD in children (Andrews et al., 2014).  
The proposed higher efficacy of PCV13 against serotype 19F (Dagan et al., 2013) 
cannot explain the decrease in proportion of PCV7 serotypes, since serotype 19F was 
uncommon in our collection and no significant decrease was seen between the two 
periods (Table IIb.1).The reduction of the overall proportion of IPD caused by PCV7 
serotypes was instead related with decreases in serotypes 4, 9V and 14 (Table IIb.1). 
Among these, serotype 4 exhibited the most significant decrease. Since the most 
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significant decrease of serotype 14 IPD was detected in 2014, it remains uncertain if it 
will be sustained in the following years. Serotype 14 has been the most frequent PCV7 
serotype causing adult IPD in Portugal, both before and after PCV7 use in children. 
This could be associated with particular characteristics of the highly successful and 
resistant clone Spain14-ST156, to which this serotype was found to be associated 
(Horácio et al., 2016a). High antimicrobial consumption in our country could also 
contribute significantly to maintain resistant clones such as this one in circulation.  
The non-PCV serotypes that increased the most since the late-post PCV7 period 
were those found in PPV23, especially serotypes 8, 22F, and 20 (ranked by frequency); 
but also the non-PPV23 serotype 15A (Table IIb.1). Serotypes 15A and 22F were found 
in carriage in adults in Portugal (Almeida et al., 2014), while serotypes 8 and 20 were 
not found in carriage in adults and were shown to have a high invasive disease 
potential (Sá-Leão et al., 2011). Serotype 8 was the second most frequent cause of IPD 
during the current study period and in 2013 and 2014 was the most frequent cause of 
IPD among younger adults (18–49 years). Serotype 8 increased in importance as a 
cause of IPD in other countries, being the most frequent cause of IPD in patients aged 
> 5 years in England and Wales after the introduction of PCV13 (Waight et al., 2015) 
and also important in adult IPD elsewhere (Guevara et al., 2014; Regev-Yochay et al., 
2015). Serotype 22F became the second most frequent cause of IPD in adults aged ≥ 
65 years in 2013 and 2014. In the USA, this serotype was the most common cause of 
adult IPD in the post-PCV13 period (Moore et al., 2015). An increase of serotype 22F 
after PCV13 use was also reported in Canada (Demczuk et al., 2013) and in some 
European countries (Steens et al., 2013; Lepoutre et al., 2015). Serotype 20 increased 
more modestly and only among individuals aged ≥ 65 years. An increase of this 
serotype was also noted in Canada, although mostly among individuals aged 15–49 
years (Demczuk et al., 2013). Taken together, these observations indicate that, 
although there may be some regional differences, there are serotypes that seem to be 
consistently emerging in different geographic locations in the post-PCV13 period. 
These may reflect circulating serotypes in asymptomatic carriers but also serotypes 
with an enhanced invasive disease potential. 
In 2014, the last year of the study, serotype 15A surpassed serotype 19A and 14 to 
become the most frequent serotype among ERP and was the second most frequent 
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serotype among PNSP behind serotype 14. The overall decreases observed in PNSP 
and ERP were not only due to decreases in the total number of isolates expressing 
serotypes 14 and 19A, which were not compensated by the increase in serotype 15A 
(Table IIb.1), but also to an unexpected decrease in the proportion of resistant isolates 
within serotypes 14 and 19A. While 72% of serotype 14 and 64% of serotype 19A were 
ERP in 2012, only 44% of serotype 14 and 33% of serotype 19A were ERP in 2014 (p = 
0.071 and p = 0.031, respectively). Similarly, there was a decrease in the proportion of 
PNSP among serotype 19A, from 59% in 2012 to 24% in 2014 (p = 0.014).  
Our surveillance system is exclusively laboratory based and lacks compliance 
audits, so our study was not designed to estimate the incidence of adult IPD. 
However, we did note a slight decrease in the number of isolates sent to us in 2013 
and 2014 (Figure IIb.4). This could reflect a net reduction of adult IPD following PCV13 
use in children, as reported by others (Guevara et al., 2014; Harboe et al., 2014; 
Lepoutre et al., 2015; Moore et al., 2015; Regev-Yochay et al., 2015) and seen with IPD 
in children in Portugal (Aguiar et al., 2014). Alternatively, this could reflect lower 
reporting by participating laboratories. We also noted a marked decrease in the 
number of isolates recovered from younger patients relative to either of the older age 
groups when comparing 2009–2011 to 2012–2014 (p < 0.001) (Figure IIb.1) (Horácio et 
al., 2013). Even if the decrease in number of isolates is attributed to lower reporting, 
we have no reason to believe that this would affect preferentially a particular age 
group. We also have no indication of changes in clinical practice (such as blood 
culturing practices), which could influence these results. We therefore believe that 
the most likely explanation is a true reduction in incidence of IPD in 18–49 years old 
individuals, in agreement with a study from the UK that found that this group was 
the one where the decrease in IPD incidence was more pronounced and followed 
more closely PCV13 use in children (Waight et al., 2015).  
As discussed above, our study was not designed to allow the estimate of the 
incidence of IPD and it therefore does not evaluate potential changes in incidence 
with time. Specifically, although we include the majority of medical centers in 
Portugal our surveillance is not comprehensive and we did not perform audits to 
ensure that participating centers reported all cases, namely we did not include cases 
for which no viable pneumococcal isolate was received for characterization. However, 
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the design based on the reporting of all isolates causing IPD within the surveillance 
network, the large number of isolates studied, the wide coverage of the country by 
the network and the stable number of reporting centers, guarantees that the data 
accurately represents IPD in Portugal and can be used to evaluate changes in the 
relative importance of the different serotypes.  
In spite of relatively modest vaccine coverage (63% in 2012), there were major 
changes in the serotype distribution of the pneumococcal population responsible for 
adult IPD in Portugal following the use of PCVs in children consistent with herd 
protection. These changes have contributed also to significant reductions in 
antimicrobial resistance. The recent inclusion of PCV13 in the NIP for children in 
Portugal may have an even greater impact on IPD in adults. This remarkable effect of 
PCVs in protecting non-vaccinated individuals may question the need of using PCV13 
directly in vaccinating adults. Still, data from 2014 indicates that the overall 
proportion of adult IPD caused by PCV13 serotypes remained significant (38%) and 
that isolates expressing PPV23 serotypes accounted for 75% of all IPD. Taken together 
this suggests a key role of vaccination in any effective management strategy of IPD. 
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Table IIb.S1: Capsular types of the isolates recovered from 
CSF in adult patients (≥18 yrs), Portugal, 2012-2014. 
  No. Isolates   
Serotype CSF non-CSF OR (CI95%) 
3 12 149 1.20 (0.56-2.30) 
19F 6 21 4.45 (1.41-12.04) 
11A 4 45 1.30 (0.33-3.76) 
23B 4 8 7.60 (1.62-29.47) 
8 3 120 0.33 (0.06-1.03) 
16F 3 20 2.22 (0.41-7.82) 
24F 3 20 2.22 (0.41-7.82) 
Others 24 466 0.56 (0.32-0.99) 
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RATIONALE 
In the studies presented in the previous chapter we found significant changes in 
the serotype distribution of isolates responsible for adult IPD in Portugal, both in the 
post-PCV7 period and in the early post-PCV10/PCV13 period. If there were changes in 
the serotypes associated with adult IPD, there must have been changes in the genetic 
lineages associated with adult IPD also. In the study presented in this chapter 
(Horácio et al., 2016a) we aimed to identify the genetic lineages responsible for adult 
IPD in Portugal. The period analyzed (2008-2011) included the late-post PCV7 period 
and the first years of PCV10/PCV13 use in children. We also evaluated the prevalence 
of pilus islands in this collection of isolates.  
The study composing this chapter continues two other published studies from 
the laboratory – the study of Serrano et al. (2005) and the study of Aguiar et al. 
(2008b). The study of Serrano et al. (2005) evaluated the genetic lineages of invasive 
pneumococci before the widespread use of PCV7 in children (1999-2002). They 
detected a stable clonal structure and found most lineages were represented in all 
years of the study period. The clonal diversity within each serotype varied, with some 
serotypes being highly diverse in their clonal structure, while others were represented 
by only few genetic lineages. Representatives of some of the internationally 
disseminated clones of that time were detected in the collection. In the study of 
Aguiar et al. (2008b) the prevalence of PI-1 was determined. They found that only a 
small proportion of isolates (27%) were positive for the rlrA gene and that the 
presence of PI-1 was a clonal property of pneumococci, despite a strong correlation 
with serotype. 
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The following study was performed by Andreia N. Horácio, Catarina Silva-Costa, 
Jorge Diamantino-Miranda, Joana P. Lopes, Mário Ramirez, José Melo-Cristino and 
the Portuguese Group for the Study of Streptococcal Infections. Andreia N. Horácio 
performed a significant part of the experimental work, analyzed the data and wrote 
the first versions of the manuscript. Part of the 2008 and 2009 data were previously 
included in the studies of two master thesis (one of them from Andreia N. Horácio 
and the other from Jorge Diamantino-Miranda). 
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POPULATION STRUCTURE OF STREPTOCOCCUS PNEUMONIAE CAUSING 
INVASIVE DISEASE IN ADULTS IN PORTUGAL BEFORE PCV13 AVAILABILITY 
FOR ADULTS: 2008-20111
Andreia N. Horácio, Catarina Silva-Costa, Jorge Diamantino-Miranda, Joana P. Lopes, Mário 
Ramirez, José Melo-Cristino and the Portuguese Group for the Study of Streptococcal 
Infections 
Faculty of Medicine, Instituto de Microbiologia, Instituto de Medicina Molecular, University 
of Lisbon, Lisbon, Portugal 
 
Abstract 
Among the 1660 isolates recovered from invasive pneumococcal disease (IPD) 
in adults (≥ 18yrs) in 2008–2011, a random sample of ≥ 50% of each serotype (n = 871) 
was chosen for MLST analysis and evaluation for the presence and type of pilus islands 
(PIs). The genetic diversity was high with 206 different sequence types (STs) detected, 
but it varied significantly between serotypes. The different STs represented 80 clonal 
complexes (CCs) according to goeBURST with the six more frequent accounting for 
more than half (50.6%) of the isolates — CC156 (serotypes 14, 9V and 23F), CC191 
(serotype 7F), CC180 (serotype 3), CC306 (serotype 1), CC62 (serotypes 8 and 11A) and 
CC230 (serotype 19A). Most of the isolates (n = 587, 67.3%) were related to 29 
Pneumococcal Molecular Epidemiology Network recognized clones. The overall 
proportion of isolates positive for any of the PIs was small (31.9%) and declined 
gradually during the study period (26.6% in 2011), mostly due to the significant 
decline of serotype 1 which is associated with PI-2.  The changes in serotypes that 
occurred in adult IPD after the introduction of the seven-valent pneumococcal 
conjugate vaccine (PCV7) for children were mostly due to the expansion of previously 
circulating clones, while capsular switching was infrequent and not related to vaccine 
use. The reduction of IPD caused by PCV7 serotypes in the years following PCV7 
implementation did not result in a decline of antimicrobial resistance in part due to 
the selection of resistant genotypes among serotypes 14 and 19A. 
                                                     
1 A facsimile of this publication can be found at the “Publications” section of this thesis. 
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Introduction 
The 7-valent conjugate vaccine (PCV7) was available for children through the 
private sector in Portugal from 2001 onwards until it was replaced in the beginning of 
2010 by the 13-valent conjugate vaccine (PCV13). In 2012, PCV13 received approval for 
use also in adults > 50 years of age with an extension being made to all ages in 2013. 
Additionally, PCV13 entered the Portuguese National Immunization Program (NIP) 
in June 2015 for children born from January 2015 onwards. Two other vaccines, the 23-
valent pneumococcal polysaccharide vaccine (PPV23) and the 10-valent conjugate 
vaccine (PCV10), have also been available in Portugal since 1996 and 2009, 
respectively, but with a low uptake (Horácio et al., 2012). 
Among the more than 90 different pneumococcal serotypes identified, only a 
few cause the majority of IPD. While for some serotypes the capsular polysaccharide 
is the dominant determinant of invasiveness, for others distinct genotypes show 
important differences in invasiveness (Sá-Leão et al., 2011). Additionally, there are 
other features that are strongly associated with genotype independently of serotype, 
such as antimicrobial susceptibility and the presence and type of pilus islands (Aguiar 
et al., 2008b and 2010b). With the availability of pneumococcal conjugate vaccines 
that efficiently target particular serotypes, important changes have been reported 
regarding not only serotype but also genotype distributions of pneumococci causing 
IPD (Beall et al., 2006; Aguiar et al., 2010a; Bettinger et al., 2010; Pilishvili et al., 2010; 
Rodenburg et al., 2010). Interestingly, while non-vaccine serotypes have emerged as a 
cause of IPD, in some cases distinct clones expressing the same serotype have risen 
in frequency in different geographic regions (Pai et al., 2005; Serrano et al., 2005).  
While numerous studies have addressed the serotype distribution of IPD, 
information regarding the clonal composition of pneumococcal populations has been 
scarcer. In a previous study we defined the clonal composition of pneumococci 
causing IPD in both children and adults in the pre-PCV7 period (Serrano et al., 2005). 
In a subsequent study we documented major changes in the potential coverage of 
PCV13 starting in 2009, due to decreases in prevalence of serotypes 1 and 5 (Horácio 
et al., 2013). In the present study we aimed to characterize the clonal composition of 
pneumococci causing adult IPD in Portugal between 2008 and 2011, a period 
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characterized by extensive use of PCV7 and the adoption of PCV13 in children and 
prior to the use of PCV13 in adults. 
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Materials and Methods 
Bacterial Isolates 
The isolates included in this study were recovered from adult patients (≥ 18 yrs) 
with invasive pneumococcal disease between 2008 and 2011 and were characterized 
in previous studies regarding serotype distribution and antimicrobial susceptibility 
(Horácio et al., 2012 and 2013). A case of invasive disease was defined by the recovery 
of pneumococci from a normally sterile source, such as blood or cerebral spinal fluid 
(CSF). Serotypes were grouped into conjugate vaccine serotypes, i.e., those included 
in PCV13 (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F) that comprise all 
serotypes found in lower valency vaccines (PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F; and 
PCV10: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F), those included in PPV23 (all serotypes 
included in PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 
33F), and non-vaccine serotypes (NVT). The isolates that were not typable with any 
of the complete set of sera available from the Staten Serum Institute (Copenhagen, 
Denmark) were considered non-typable (NT). Given the high frequency of 
spontaneous switching between serotypes 15B and 15C we opted to include strains 
with these serotypes into a single group. Due to the difficulty in distinguishing a set 
of isolates that were positive for both serotypes 25A and 38 we opted to include strains 
with these serotypes into a single group. 
From a total of 1660 isolates recovered, a random sample of ≥ 50% of the isolates 
(n = 871) from each serotype and from each year was chosen to be characterized by 
MLST and tested for the presence of the pilus islands. Briefly, among the 1660 isolates, 
there were 52 different serotypes, with the 10 most frequent being serotypes 3 (13.0%), 
7F (10.0%), 19A (9.8%), 1 (8.5%), 14 (8.1%), 8 (5.7%), 22F (3.9%), 4 (3.2%), 9N (2.8%) 
and 11A (2.8%). However, the 10 most frequent serotypes were different in each of the 
age groups. In the 18–49 yr olds (n = 472) these were serotypes 1 (14.0%), 7F (11%), 8 
(9.1%), 14 (8.7%), 3 (7.6%), 19A (6.1%), 9N (4.2%), 4 (3.8%), 22F (3.2%), 11A (2.8%). In 
the 50–64 yr olds (n = 358) these were serotypes 3 (12%), 19A (10.3%), 1 (9.5%), 7F 
(9.2%), 14 (6.1%), 4 (5.0%), 8 (4.5%), 11A (3.4%), 22F (3.4%), 9V (2.8%). In the 65 yr 
olds (n = 830) these were serotypes 3 (15.8%), 19A (11.6%), 7F (10.2%), 14 (8.7%), 1 
(4.9%), 22F (4.6%), 8 (4.2%), 6C (3.0%), 11A (2.5%), 9N (2.3%). Overall, the 
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proportions of PCV7, PCV13 and PPV23 serotypes were 18.4%, 61.9% and 79.4%, 
respectively. Non-susceptibility to penicillin, defined as either intermediate level 
penicillin resistance (MIC 0.12–1.0 μg/ml) or high level resistance (MIC ≥ 2.0 μg/ml) 
as discussed previously (Horácio et al., 2012 and 2013), was found in 330 isolates 
(19.9%), while 315 isolates (19.0%) were resistant to erythromycin. The age and sex of 
the patients and the source of the isolates randomly chosen for further study was 
similar to that of the 1660 isolates. In the genotyped group the age distribution was 
as follows: 28.5% of the isolates were from individuals 18–49 yrs, 21.2% from 50–64 yrs 
and 50.3% from ≥ 65 yrs. The majority of the isolates were collected from blood 
(87.9%), 8.4% from CSF, 2.5% from pleural fluid and 1.2% from other normally sterile 
sources. 
 
MLST 
MLST was performed as described previously (Enright and Spratt, 1998). The 
DNA sequences were analyzed using Bionumerics software (Applied-Maths, Sint-
Martens-Laten, Belgium) and the alleles and sequence types were assigned according 
to the pneumococcal MLST database available at http://pubmlst.org/spneumoniae/. 
The goeBURST algorithm (Francisco et al., 2009) implemented in the PHYLOViZ 
software (Francisco et al., 2012) was used to establish relationships between STs. 
Clonal complexes were defined at the single-locus-variant (SLV) and double-locus-
variant (DLV) levels. 
 
Detection of Pilus Islands 
The presence of pilus islets (PI) was evaluated by PCR. Briefly, for PI-1 in the 
absence of the pilus islet, a product of 1-3Kb was expected using primers PFL-up and 
P-dn flanking the islet (Aguiar et al., 2008b). In strains yielding no PCR product, the 
rlrA gene was detected using primers RLRA-up and RLRA-dn. A similar approach was 
followed to detect the presence of PI-2 (Aguiar et al., 2012). 
 
Statistical Analysis 
Sample diversity was evaluated using the Simpson’s index of diversity (SID) and 
the respective 95% confidence intervals (CI95%) (Carriço et al., 2006). To compare 
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two sets of partitions the Adjusted Wallace (AW) coefficients were calculated 
(Severiano et al., 2011) using the online tool available at 
http://www.comparingpartitions.info. Differences were evaluated by the Fisher exact 
test with the false discovery rate (FDR) correction for multiple testing (Benjamini and 
Hochberg, 1995) and the Cochran-Armitage test was used for trends. A p < 0.05 was 
considered significant for all tests. 
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Results 
Sequence Type Distribution and Relationship with Serotype 
The 871 isolates analyzed by MLST presented 206 different STs (SID = 0.971, 
CI95%: 0.967–0.976) grouping into 80 CCs (SID = 0.948, CI95%: 0.942–0.953) 
according to goeBURST analysis, when including all STs deposited in the database. 
The 14 most frequent STs, which accounted for more than half of the genotyped 
isolates (50.6%) were, in decreasing order, ST191 (9.9%), ST306 (7.0%), ST180 (6.9%), 
ST53 (4.5%), ST156 (4.0%), ST276 (3.6%), ST433 (3.2%), ST66 (2.8%), ST408 (1.7%), 
ST232 (1.7%), ST260 (1.5%), ST143 (1.4%), ST179 (1.3%) and ST289 (1.3%).  
Twenty new allelic combinations and 19 new alleles were identified. The new 
allelic combinations were identified as STs: 6176, 6177, 6180, 6181, 6182, 6973, 8866, 
9955, 9956, 9957, 9958, 9960, 9963, 9966, 9969, 9970, 9971, 9979, 9982 and 9986. The 
novel alleles identified were designated 200, 307 and 309 for aroE, 429, 636 and 637 
for ddl, 294, 295, 428 and 430 for gdh, 437 and 438 for gki, 273 for recP and 588, 589, 
590, 592, 593 and 605 for xpt. 
There was a strong correlation between CC and the vaccine serotype groups 
(AW = 0.810, CI95%: 0.763–0.857), with the six most prevalent CCs being mainly 
composed of isolates presenting vaccine serotypes (95.5%). Table III.1 shows the age 
distribution and serotypes of the most frequent STs found in the 22 major CCs (n ≥ 10 
isolates), together accounting for 83.7% of the genotyped isolates. The major CC 
(CC156, n = 101) included mostly isolates expressing PCV7 serotypes, namely 14, 9V 
and 23F, while four of the remaining five most frequent CCs were mainly composed 
of isolates presenting the additional serotypes found in PCV13 (mainly 7F, 3, 1 and 
19A). The other most frequent lineage, CC62, consisted mostly of isolates expressing 
serotypes included only in PPV23 (serotypes 8 and 11A). The age distribution and 
serotypes of the STs found in CCs with < 10 isolates are shown in III.S1 Table. 
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Table III.1 Age distribution and the serotypes of the most frequent STs found in the 22 major CCs (n≥10 
isolates) identified by goeBURST. 
CC  (n) ST  Total no. of isolates Dominant serotype (n) Other serotypes  [18-49] [50-64] >=65 
156 (101) 
156  35 13 5 17 14 (31) 9V (3), 10A (1)  
143  12 2 2 8 14 (12)  - 
338  10 3 1 6 23F (7) 23A (2), 19F (1) 
162  6 2 1 3 9V (4) 19F (1), 24A (1) 
2944  5 0 3 2 14 (5)  - 
Othersa  33 8 6 19 9V (10) 14 (8), 6B (5), 6C (3), 23F (3), 35F (2), 17F (1), 17A (1) 
191 (88) 191  86 30 14 39 7F (83)  NT
c (2), 7A (1) 
Othersa  2 0 2 0 7F (2)  - 
180 (68) 180  60 8 17 35 3 (60)  - Othersa  8 2 1 5 3 (8)  - 
306 (68) 306  61 26 14 21 1 (61)  - 
 350  5 1 2 2 1(5)  - 
 Othersa  2 2 0 0 1(2)  - 
62 (67) 
53  39 15 8 16 8 (37) NT (2) 
408  15 6 4 5 11A (14) 11C (1) 
62  7 1 2 4 11A (7)  - 
Othersa  6 3 0 3 8 (2), 11A (2) 18C (1), 22F (1) 
230 (47) 
276  31 3 7 21 19A (31)  - 
230  6 1 1 4 24F (4) 19A (2) 
Othersa  10 4 3 3 19A (8) 10A (1), 24F (1) 
81 (30) 66  24 12 3 9 9N (23) NT (1) Othersa  6 1 0 5 24F (4) 4 (2) 
433 (29) 433  28 4 5 19 22F (28)  -  Othersa  1 0 0 1 22F (1)  -  
439 (25) 
439  7 0 3 4 23B (7)  - 
42  5 1 3 1 23A (4) 6A (1) 
Othersa  13 3 2 8 23A (7) 23B (3), 23F (3) 
15 (24) 
9  8 3 0 5 14 (8)  
1201  7 3 0 4 19A (4) 7C (3) 
Othersa  9 1 2 6 14 (5) 34 (2), 6B (1), 7C (1) 
177 (24) 
179  11 4 4 3 19F (11)  - 
Othersa  13 3 5 5 19A (5) 19F (3), 21 (3), 15A (1), 15 B/C (1) 
199 (21) 
416  8 1 2 5 19A (8)  - 
411  7 1 2 4 15B/C (7)  - 
199  6 2 2 2 19A (3) 15B/C (2), 18C (1) 
378 (19) 232  15 3 5 7 3 (15)  - Othersa  4 2 0 2 3 (4)  - 
113 (16) 
123  5 1 0 4 17F (5)  - 
1766  5 2 0 3 31 (5)  - 
Othersa  6 1 2 3 22F (3) 17F (1), 18C (1), 31 (1) 
460 (16) 97  10 2 3 5 10A (10)  - Othersa  6 3 1 2 6A (4) 10A (1), 35F (1) 
260 (15) 260  13 2 3 8 3 (13)  - Othersa  2 1 0 1 3 (2)  - 
218 (13) 218  10 3 2 5 12B (10)  - Othersa  3 1 1 1 12B (2) 12F (1) 
289 (13) 289  11 5 2 4 5 (11)  - Othersa  2 1 0 1 5 (2)  - 
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Table III.1 (continued) 
CC (n) ST Total no. of isolates Dominant serotype (n) Other serotypes 
[18-49] [50-64] >=65 
30 (11) 30 10 2 2 6 16F (10)  - 
 Othersa 1 0 0 1 16F (1)  - 
63 (11) 63 8 3 0 5 15A (7) 15F (1) Othersa 3 0 1 2 3 (1), 7F (1), 15A (1)  - 
315 (11) 386 7 1 1 5 6C (6) 6B (1) 
 Othersa 4 0 1 3 6C (3) 6B (1) 
404 (10) 404 9 5 0 4 8 (9)  - 
 Othersa 1 1 0 0 8 (1)  - 
a Sequence types that accounted for less than 5 isolates each were grouped together in “Others”. b NT-
non typable. 
 
 
Figure III.1 shows the STs expressing each of the 13 serotypes included in PCV13 
and Figure III.2 the STs expressing each of the 10 most frequent serotypes found 
among those not included in any of the conjugate vaccines. The STs found in the 
remaining serotypes are indicated in III.S2 Table. The genetic diversity varied greatly 
with serotype, with serotypes, 4, 6A, 6B, 9V, 18C, 19A, 20 and 23A being highly diverse 
(SID > 0.8) and serotypes 1, 5, 7F, 9N and 22F displaying very limited diversity (SID < 
0.3). In general, there was a predominance of high genetic diversity among PCV13 
serotypes and low genetic diversity among the 10 most frequent non-PCV13 serotypes. 
For serotypes 9V, 14 and 23A, the wide variety of STs did not result in a high diversity 
of CCs, with a maximum of two CCs being detected in each. The genetic diversity of 
each serotype was independent of the serotype’s frequency. Examples of this are the 
low frequency serotypes 6B and 18C that presented a high genetic diversity and no 
dominant ST. 
A total of 587 isolates (67.3%) presented STs related to 29 of the 43 clones 
recognized by the Pneumococcal Molecular Epidemiology Network (PMEN) (McGee 
et al., 2001), sharing at least five MLST alleles with these clones (357 isolates had the 
same ST, 133 were SLVs and 97 were DLVs). When considering these isolates the 
predominant clones were Netherlands7F-191 (n = 88), Spain9V-156 (n = 71), 
Netherlands3-180 (n = 68), Netherlands8-53 (n = 63), Sweden1-306 (n = 63), 
Denmark14-230 (n = 47), Tennessee14-67 (n = 24), Tennessee23F-37 (n = 24) and 
Netherlands15B-199 (n = 21) (Figs III.1 and III.2 and III.S2 Table). Additionally, another 
63 isolates were included in the same CCs of other four PMEN clones.  
 
  
 
 
Figure III.1 Distribution of STs according to serotype of the isolates causing adult IPD in 2008–2011 and expressing serotypes included in the conjugate vaccines. The STs that were 
considered by goeBURST as founders of a CC are indicated by “f”. The STs that matched the STs of PMEN clones are indicated by “p”. Marked either with “*” or “†” are STs belonging to the 
same CC in each serotype. The respective SID values are indicated on top of the bars and in parenthesis are the respective confidence intervals. In grey are represented the isolates included in STs 
with < 3 isolates. These were: serotype 4 – ST801 (n = 2) and STs 244, 246, 259 and 1866 (n = 1, each); serotype 6B – ST 176 (n = 2), STs 138, 273, 386, 473, 1518, 6175, 9957, 9970, 9986 and 
10051 (n = 1, each); serotype 9V –STs 280 and 10044 (n = 2, each) and STs 239, 1762 and 10054 (n = 1, each); serotype 14 – ST15 (n=2) and STs 2511, 2616, 4573, 4576 and 10041 (n = 1, each); 
serotype 18C – STs 102, 113, 199, 1233 and 10033 (n = 1, each); serotype 19F –ST 177 (n = 2), STs 89, 162, 271, 338 and 391 (n = 1, each); serotype 23F – ST 10039 (n = 2) and STs 1135 and 
9579 (n = 1, each); serotype 1 –STs 217, 228, 1233, 3081 and 4578 (n = 1, each); serotype 3 – ST 1220 (n=2) and STs 505, 1230, 6014, 9162 and 10038 (n = 1, each); serotype 5 – STs 280 and 
10044 (n = 2, each), STs 239, 1762 and 10054 (n = 1, each); serotype 6A –ST 1876 (n=2) and STs 42, 460 and 10055 (n = 1, each); serotype 7F – STs 1062, 1589 and 3130 (n = 1, each) and 
serotype 19A – STs 230, 242, 320, 2013 and 6174 (n = 2, each) and STs 241, 878, 2102, 2669, 2732, 4197, 4847, 6178, 6973, 9963 and 10042 (n = 1, each). 
  
 
 
Figure III.2 Distribution of STs according to serotype of the isolates causing adult IPD in 2008–2011 and expressing the 10 most frequent serotypes not included in any of the conjugate 
vaccines. The respective SID values are shown on top of the bars and in parenthesis are the respective confidence intervals. In grey are represented the isolates included in STs with < 3 isolates. 
These were: serotype 8 – ST 1012 (n = 2) and ST 9969 (n = 1); serotype 22F – STs 10053 and 10220 (n = 1, each); serotype 9N – ST 3982 (n = 1); serotype 11A – STs 9955, 9960 and 10052 (n 
= 1, each); serotype 6C – STs 1150, 1692 and 3396 (n = 2, each) and STs 1390, 1715, 2667 and 4310 (n = 1, each); serotype 12B – ST 6180 (n = 2); serotype 10A – STs 156, 816 and 3135 (n = 
1, each); serotype 20 – STs 1483, 1871, 7221, 9958 and 10047 (n = 1, each); serotype 23A – ST 338 (n = 2) and STs 190, 311, 438, 6177, 7960, 8866 and 10048 (n = 1, each); serotype 16F – STs 
570 and 5902 (n = 1, each). 
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The correlation between ST and serotype was high (AW = 0.942, CI95%: 0.912–
0.973), but there were STs that presented more than one serotype (Table III.1 and 
III.S1 and III.S2 Tables). The serotype distribution along the studied years for the STs 
expressing more than one serotype is shown in Table III.2. 
 
Variation of STs with Time 
When analyzing the evolution of STs between 2008 and 2011 we identified some 
fluctuations, although the majority reflected changes in serotype prevalence 
occurring in this period. However, while for ST306 (serotype 1) there was a decline, 
significant after correcting for multiple testing (from 11.0% to 2.8%, Cochran-
Armitage test of trend p = 0.014), for the  other STs the changes were only significant 
before FDR correction. The STs for which there was a significant p-value in the 
Cochran-Armitage test for trends but unsupported after FDR correction were: ST53 
(serotype 8), that increased from 3.3% to 6.5% (p = 0.043); ST289 (serotype 5), that 
accounted for 2.4% of IPD in 2008 and 0% in 2011 (p = 0.020); ST717 (serotypes 33A 
and 33F) that increased from 0% to 1.4% (p = 0.048); and STs 193 (serotype 19A) and 
409 (serotype 14) that were only detected in 2008 (1.9% and 1.4%, respectively; p = 
0.001 and p = 0.020, respectively). Regarding changes in CCs with time, these reflected 
the changes identified in STs, with only CC306 declining significantly after FDR 
correction (from 12.9% to 2.8%, Cochran-Armitage test of trend p = 0.001). 
 
Relationship of STs with Patient Age and Isolate Source 
When grouping the isolates according to the three patient age groups – 18–49 
yrs, 50–64 yrs and ≥ 65 yrs — only CC5902 showed a statistically significant 
association with age. The seven isolates belonging to this CC were all recovered from 
individuals with 18–49 yrs (p = 0.011, significant after FDR correction, III.S1 Table).  
When testing for associations between STs and CCs and isolate source, the only 
significant association found was between CC460 and CSF, with 6 out of 16 isolates 
being collected from CSF (p = 0.012, significant after FDR correction). 
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Table III.2 Serotype distribution for the STs expressing more than one serotype between 2008–
2011. 
  Serotype (n) 
STa (n) 2008 2009 2010 2011 
156 (35) 14 (6), 9V (1) 14 (12), 9V (1) 14 (7), 10A (1) 14 (6), 9V (1) 
338 (10)  - 23F (3) 23F (2), 23A (1), 19F (1) 23F (2), 23A (1) 
717 (9)  - 33A (1) 33A (4), 33F (1) 33A (2), 3 (1) 
63 (8) 15A (2) 15A (3) 15A (2), 15F (1)  -  
386 (7)  - 6C (2) 6C (2)  6C (2), 6B (1)  
1201 (7) 19A (2), 7C (1) 19A (1), 7C (1) 19A (1), 7C (1)  - 
162 (6) 9V (3), 19F (1)  - 9V (1) 24A (1) 
199 (6) 15B/C (1) 15B/C (1), 19A (2), 18C (1)  - 19A (1) 
230 (6) 24F (2)  - 24F (2), 19A (1) 19A (1) 
42 (5) 6A (1) 23A (2) 23A (2)  - 
241 (5) 18A (3)  - 18A (1), 19A (1)  - 
a Only the sequence types that presented ≥ 5 isolates are shown. 
 
Presence of Pilus Islands 
A total of 278 isolates, representing 31.9% of the genotyped collection, carried at 
least one PI. Among these, 107 (38.5%) had only PI-1, 165 (59.4%) only PI-2 and 6 
(2.2%) presented the two PIs simultaneously. While the proportion of PI-1 positive 
isolates remained stable between 2008 and 2011 (from 10.0% to 11.6%, Cochran-
Armitage test of trend p = 0.857), there was a significant decline of PI-2 carrying 
isolates (from 24.8% to 15.8%, Cochran-Armitage test of trend (p = 0.007). This also 
resulted in an overall increase in the proportion of isolates lacking any of the pilus 
islands, from 63.8% in 2008 to 72.6% in 2011 (p = 0.013). 
 The presence and variants of the PIs were more strongly associated with ST 
(AW = 0.950, CI95%: 0.933–0.967) than with serotype (AW = 0.711, CI95%: 0.651–
0.771). The STs that were significantly associated with PI-1 and PI-2 are shown in Table 
III.3. All isolates included in CC320 (n = 3) and CC2669 (n = 3) presented the two PIs 
simultaneously. 
Among the 105 isolates presenting only PI-1, 87.9% expressed PCV7 serotypes, 
namely serotypes 14 (n = 49), 4 (n = 15), 19F (n = 13), 9V (n = 11) and 6B (n = 6). The 
remaining isolates were from serotypes 19A (n = 9) and 7F, 24A and 35B (n = 1, each). 
PI-2 positive isolates were from serotypes 7F (n = 85), 1 (n = 68), 11A (5), 19A (n = 2), 
3, 7A and 31 (n = 1, each) and NT (n = 2). The isolates presenting simultaneously the 
two types of PIs were from serotypes 19A (n = 5) and 19F (n = 1). 
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Table III.3 Sequence types that were associated with pilus island 1 (PI-1) and pilus island 2 
(PI-2). 
Type of Pilus ST Yes No ORa (95% CI) p-valueb 
Pilus 1 
156 26 9 24.68 (10.79-61.89) <0.001 
143 12 0 Inf (20.32-Inf) <0.001 
179 10 1 72.89 (10.18-3133.46) <0.001 
416 8 0 Inf (12.04-Inf) <0.001 
162 6 0 Inf (8.16-Inf) <0.001 
205 6 0 Inf (8.16-Inf) <0.001 
2944 5 0 Inf (6.30-Inf) <0.001 
1221 5 0 Inf (6.30-Inf) <0.001 
4575 3 0 Inf (2.8-Inf) 0.002 
838 3 0 Inf (2.8-Inf) 0.002 
191 0 86 0 (0-0.27) <0.001 
306 0 61 0 (0-0.39) <0.001 
180 0 60 0 (0-0.40) <0.001 
Pilus 2 
191 86 0 Inf (181.20-Inf) <0.001 
306 61 0 Inf (99.04-Inf) <0.001 
350 5 0 Inf (3.81-Inf) <0.001 
180 0 60 0 (0-0.24) <0.001 
53 0 39 0 (0-0.39) <0.001 
156 0 35 0 (0-0.44) <0.001 
aOR — Odds ratio. bOnly significant values after FDR correction are shown. 
 
No associations between isolate source and type of PI were detected. Still, there 
was a low proportion of PI-2 positive isolates among isolates recovered from the CSF, 
with only 6 of the 73 CSF isolates presenting PI-2, and while 7 of the 15 isolates 
recovered from pleural fluid carried PI-2, none carried PI-1. 
 
Antimicrobial Resistance 
Similarly to pilus islands, resistance to antimicrobials was more strongly 
associated with ST than with serotype. The AW for ST or serotype and penicillin 
susceptibility was, respectively, 0.785 (CI95%: 0.729–0.841) and 0.389 (CI95%: 0.326–
0.452), while the AW for ST or serotype and erythromycin susceptibility was, 
respectively, 0.711 (CI95%: 0.598–0.824) and 0.315 (CI95%:0.217–0.413). The sequence 
types that were associated with penicillin non-susceptible pneumococci (PNSP) and 
erythromycin resistant pneumococci (ERP) are presented in Table III.4. 
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Table III.4 Sequence types that were positively associated with penicillin non-susceptibility, 
erythromycin resistance and erythromycin and penicillin non-susceptibility simultaneously. 
Antimicrobial 
resistancea ST Yes No ORb (95% CI) p-valuec 
Penicillin MIC 
range (µg/ml) 
PNSP 
156 34 1 153.83 (25.29-6036.47) <0.001 0.5-3 
276 31 0 Inf (34.58-Inf) <0.001 0.19-3 
143 12 0 Inf (10.84-Inf) <0.001 0.75-3 
338 10 0 Inf (8.65-Inf) <0.001 0.064-0.19 
63 8 0 Inf (6.52-Inf) <0.001 0.094-1 
386 7 0 Inf (5.48-Inf) <0.001 0.064-0.19 
179 7 4 6.69 (1.68-31.50) <0.001 0.047-2 
230 6 0 Inf (4.45-Inf) <0.001 0.38-0.75 
2944 5 0 Inf (3.45-Inf) <0.001 2-8 
ERP 
276 30 1 150.50 (24.56-5946.55) <0.001 0.19-3 
179 11 0 Inf (10.96-Inf) <0.001 0.047-2 
143 10 2 21.90 (4.60-206.95) <0.001 0.75-3 
717 9 0 Inf (8.52-Inf) <0.001 0.008-0.032 
9 8 0 Inf (7.32-Inf) <0.001 0.016-0.064 
63 8 0 Inf (7.32-Inf) <0.001 0.094-1 
386 7 0 Inf (6.15-Inf) <0.001 0.064-0.19 
350 5 0 Inf (3.87-Inf) <0.001 0.004-0.023 
230 5 1 21.27 (2.36-1006.44) 0.001 0.38-0.75 
EPNSP 
276 30 1 274.20 (44.39-10466.80) <0.001 0.19-3 
143 10 2 36.81 (7.69-350.14) <0.001 0.75-3 
63 8 0 Inf (12.17-Inf) <0.001 0.064-0.19 
386 7 0 Inf (10.19-Inf) <0.001 0.064-0.19 
179 7 4 12.52 (3.12-59.31) <0.001 0.047-2 
230 5 1 35.15 (3.88-1669.53) <0.001 0.38-0.75 
4575 3 0 Inf (2.83-Inf) 0.002 2-3 
aPNSP—Penicillin non-susceptible pneumococci, ERP—Erythromycin resistant pneumococci, 
EPNSP—Erythromycin and penicillin non-susceptible pneumococci. bOR—odds ratio. INF—infinite. 
cOnly significant values after FDR correction are shown. 
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Discussion 
In spite of several years of PCV7 use in children, the most frequent CC was CC156 
(11.6%, Table III.1), a lineage that expressed mainly PCV7 serotypes (89.1%) and which 
was also the most frequent in IPD in the pre-PCV7 period (Serrano et al., 2005). We 
had previously shown that the serotype distribution of pneumococci causing adult 
IPD had changed significantly in the post-PCV7 period, with the proportion of PCV7 
serotypes declining to values below 20% (Aguiar et al., 2008a; Horácio et al., 2012; 
Horácio et al., 2013). Adult vaccination with anti-pneumococcal vaccines was low to 
negligible and prior work indicated that these changes were due to a combination of 
secular trends and herd effect from children vaccination, which although occurring 
through the private market reached a coverage of 75% of children ≤ 2 yrs in 2008 
(Aguiar et al., 2008a; Horácio et al., 2012; Horácio et al., 2013). Due to these changes 
one could expect that CC156 would also decrease (this CC accounted for 21.7% of all 
IPD in 1999–2003 (Serrano et al., 2005)) and potentially lose its dominance. During 
the study period CC156 accounted for an approximately constant proportion of the 
characterized isolates in each year (varying slightly between 5.5% and 7.0%). The 
observed persistence of this CC may be explained by three different factors: 1) while 
it is true that PCV7 serotypes have declined in importance, it is also true that they 
still account for approximately one fifth of adult IPD and 57% of the isolates 
expressing PCV7 serotypes in 2008–2011 belonged to this CC; 2) this CC is strongly 
associated with antimicrobial resistance, with n = 70/101 isolates being resistant to at 
least two different classes of antibiotics; and 3) the genomic diversity of CC156 is high, 
with one study reporting the presence of 10 unrelated genetic subgroups (Moschioni 
et al., 2013), suggesting that this CC may be particularly suited to adapt to different 
selective pressures. Regarding the last point, in our study we found representatives of 
three different clones recognized by the PMEN included in CC156: Spain9V-156, 
Colombia23F-338 and Greece6B-273 (McGee et al., 2001). 
 Overall, the clones recognized by the PMEN were strongly represented in our 
collection with up to 67.3% of the isolates being at most DLVs of one of the 29 
different PMEN clones identified. Among the 22 major CCs occurring in the study 
period (Table III.1), only six did not include a PMEN clone: CC433, CC378, CC460, 
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CC260, CC30 and CC404. The most frequent of these, CC433 (mainly ST433, Table 
III.1), was the eighth most frequent CC, included mostly isolates susceptible to 
antimicrobials, and is now an important cause of IPD worldwide (Ardanuy et al., 
2009; Pichon et al., 2013; Golden et al., 2015; Metcalf et al., 2016; Nakano et al., 2016). 
The eight more frequent CCs (Table III.1) were mainly composed of isolates 
expressing one of the top 10 serotypes causing adult IPD in 2008–2011, excluding 
serotype 4 that presented a high genetic diversity and no dominant CC (Fig. III.1). In 
fact, the clonal composition of the 10 most frequent serotypes causing adult IPD in 
Portugal in 2008–2011 (Figs III.1 and III.2) presented both similarities and differences 
with other geographic regions in similar periods, with most matching results coming 
from countries in Europe and the Americas, especially for serotypes 3 (Netherlands3-
180), 7F (Netherlands7F-191), 22F (ST433) and 9N (ST66) (Ardanuy et al., 2009; 
Muñoz-Almagro et al., 2011; Yildirim et al., 2012; Pichon et al., 2013; Caierão et al., 2014; 
Golden et al., 2015; Metcalf et al., 2016). Most of these lineages, with the exception of 
ST66, were also dominant among isolates expressing the same serotypes and causing 
IPD in children in Japan (Nakano et al., 2016). Among the isolates expressing 
serotypes 19F and 23F, the lineages that dominated in the present study where either 
absent or represented a minority of the isolates of the same serotype in the recent 
studies from the United States and Japan (Metcalf et al., 2016; Nakano et al., 2016), 
indicating the persistence of different lineages expressing PCV7 serotypes in different 
countries. Serotype 19A, which increased as a cause of IPD after PCV7 implementation 
in several countries, was associated in Portugal with the expansion of the PMEN clone 
Denmark14-230 while in the USA and Asia it was associated with the emergence of 
the PMEN clone Taiwan19F-236, as previously described (Aguiar et al., 2010b). 
Serotype 1 was mostly represented by the Sweden1-306 European clone (Brueggemann 
and Spratt, 2003). However, we detected for the first time in Portugal two serotype 1 
isolates belonging to the hypervirulent PMEN clone Sweden1-217 (STs 217 and 3081), 
which has been responsible for epidemics with high mortality in Africa 
(Brueggemann and Spratt, 2003; Harvey et al., 2011). The detection of these genotypes 
in Portugal is not surprising, since they were found in neighboring Spain (Muñoz-
Almagro et al., 2011) and Portugal has a significant community of citizens of African 
descent. Still, the two isolates detected were collected in 2011, the last year of the study 
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period, so it will be important to monitor the potential emergence of this genotype as 
a cause of adult IPD in Portugal. Serotypes 14 and 8 were found mainly among 
representatives of Spain9V-156 and Netherlands8-53, respectively, similarly to Spain 
(Muñoz-Almagro et al., 2011). Serotype 11A was found mainly among representatives 
of ST408 in our study, while the most common lineage in both Spain and the USA 
was its SLV, ST62 (Muñoz-Almagro et al., 2011; Metcalf et al., 2016). For serotype 4, in 
spite of the higher diversity some similarity was also found with Spain, with Sweden4-
205 and ST246 being common to the two collections of isolates (Muñoz-Almagro et 
al., 2011). 
When comparing our results with those from a recent carriage study in adults 
in Portugal (Almeida et al., 2014) in addition to the difference in serotype distribution 
due to the recognized differences in invasiveness of the various serotypes (Sá-Leão et 
al., 2011), there was also a marked difference between the clonal compositions of 
serotype 19A, since the majority of isolates expressing this serotype among 
asymptomatic carriers represented ST1201 (CC15), while in our study the most 
frequent was ST276, indicating possible differences in virulence between these two 
serotype 19A lineages. 
After the introduction of PCV7, several studies documented a general decrease 
in IPD incidence. However, the benefits of vaccination were also partly overcome by 
increases in incidence of non-vaccine serotypes (Aguiar et al., 2010a; Pilishvili et al., 
2010; Aguiar et al., 2014; Waight et al., 2015). This could occur through the persistence 
of a successful lineage now expressing a different serotype not covered by the 
conjugate vaccines, a phenomenon described as capsular switching. Among our 
collection a notable case of possible capsular switching was the detection of five 
isolates related to the PMEN clone Denmark14-230 (ST230, n = 4 and ST4253, n = 1) 
expressing the non-PCV13 serotype 24F (Table III.2). This combination has already 
been reported in Portugal in colonized children (Simões et al., 2011), in Italy (Pantosti 
et al., 2002), Spain and other European countries (http://pubmlst.org/). In Portugal, 
in the pre-PCV7 period, serotype 24F was predominantly CC81 and mostly susceptible 
to antimicrobials. In 2008–2011, among the nine isolates genotyped, four represented 
CC81 and were mainly antimicrobial susceptible as before, while five represented 
CC230 and were EPNSP. The detection of this genotype expressing serotype 24F in 
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Portugal is of concern since ST276, an SLV of ST230, was behind the expansion of 
serotype 19A as a cause of IPD in Portugal in the post-PCV7 era (Aguiar et al., 2010b). 
Among other possible capsular switches detected in our collection (Table III.2), most 
reflected the occasional detection of a single isolate of a different serotype, suggesting 
that even if these result from capsular switching they did not persist in the population 
at a significant frequency. Taken together this data indicates that capsular switching 
in our collection was infrequent and cannot be attributed to vaccine pressure, in 
agreement with other studies (Ramirez and Tomasz, 1999; Wyres et al., 2013). 
However, even though these events were rare they can be important since the 
uncommon combinations may proliferate in the future if the conditions become 
favorable maintaining successful clones in circulation. 
Clonal expansion of previously less frequent lineages was a major contributor to 
the expansion of non-PCV7 serotypes, since the 22 most frequent CCs occurring in 
2008–2011 (Table III.1) were already in circulation in 1999–2003 (Serrano et al., 2005). 
When comparing these two periods the most relevant changes were the expansion of 
CC191 (serotype 7F) and CC439 (serotypes 23B and 23A) and the decline of CC260 and 
CC458 (both associated with serotype 3), CC1381 (serotype 18C) and that of CC156 
discussed above. The variations in frequency of CC191, CC439 and CC1381 followed the 
changes occurring in the respective serotypes. Regarding the clonal composition of 
serotype 3, we found that the decrease in CC260 and CC458 was accompanied by an 
expansion of CC180 among serotype 3 isolates, explaining the relative stability of this 
serotype among IPD in adults (Horácio et al., 2013), with CC180 accounting for 40% 
of serotype 3 IPD in 1999–2003 but for 64% in 2008–2011. Given that isolates belonging 
to CC180, CC260 or CC458 were mostly susceptible to all tested antimicrobials and 
that only one isolate from CC180 and another from CC458 carried a PI, this different 
behavior in time cannot be attributed to differences in these characteristics. 
The presence and type of the PIs was more strongly associated with genotype 
than with serotype, as previously reported (Aguiar et al., 2008b). The genotypes that 
carried PIs in our study (Table III.3) were essentially the same reported recently in 
USA (Metcalf et al., 2016), although the proportions of these genotypes differed 
considerably between the two studies. The proportion of PI-1 carrying isolates 
increased in the post-PCV7 period in the USA associated with the emergence of the 
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non-PCV7 serotypes 19A and 35B (Regev-Yochay et al., 2010). Although serotype 19A 
also increased in Portugal, the genotype behind this increase does not carry a PI 
(ST276) and an actual decrease of PI-1 positive isolates occurred when compared to 
the pre-PCV7 period, when 24% of the adult isolates presented PI-1 (Aguiar et al., 
2008b). The proportion of isolates presenting only PI-2 declined during the study 
period, from 25% in 2008 to 15% in 2011. This was expected since serotype 1 isolates 
are significantly associated with PI-2 and these decreased as a cause of adult IPD 
during the study period (Horácio et al., 2013). Since PCV13 also includes serotype 7F, 
which in Portugal was strongly associated with PI-2, continued use of PCV13 may 
further reduce the proportion of isolates carrying PI-2. In 2011, the proportion of 
isolates carrying any of the PIs was down to 26.6% of the isolates. As suggested for 
isolates causing IPD in children (Aguiar et al., 2012), continued PCV13 use has the 
potential to virtually eliminate PI carrying isolates. 
Antimicrobial resistance is not a crucial pre-requisite for the success of 
serotypes in IPD, as demonstrated by serotypes 1, 3 and 7F that were frequent in the 
post-PCV7 period and are mostly susceptible to antimicrobials. Still, the presence of 
resistant clones may help the persistence of serotypes targeted by vaccines, as was 
possibly the case with serotypes 14 and 19A. The highest proportions of penicillin and 
erythromycin resistance among adult IPD since the beginning of epidemiological 
surveillance were registered in 2010, although these declined again in 2011 (Horácio et 
al., 2013). Between 2008 and 2009, when only the increase in PNSP was significant, 
this was due to an increase in PNSP expressing serotypes 14 and 19A. In contrast, 
between 2009 and 2010, the increase in both PNSP and ERP was due to an increase in 
genetically unrelated resistant isolates expressing different serotypes. Since the 
number of isolates collected yearly between 2008 and 2011 did not suffer significant 
fluctuations, two possibilities could explain the initial increase in PNSP isolates 
expressing serotypes 14 and 19A: 1) an increase in the overall proportions of serotypes 
14 and 19A, including PNSP STs or 2) an increase in the proportion of PNSP STs within 
each of these serotypes, with a concomitant decrease of susceptible STs. Regarding 
serotype 14 isolates, which increased slightly during the study period, these were by 
2008 almost equally distributed into only two CCs: CC15, which includes ST409 and 
that is almost entirely penicillin susceptible, and CC156, in which all serotype 14 
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isolates were PNSP. From 2009 onwards, CC156 became the dominant lineage, 
accounting for over 90% of the isolates expressing serotype 14, a change that was not 
only due to a decline in frequency of CC15 but also to a slight overall increase in 
frequency of CC156 among all adult IPD isolates. Among serotype 19A isolates, the 
increase in proportion of PNSP between 2008 and 2009 was due to the disappearance 
of ST193, which was fully susceptible to penicillin, and to an increase of ST276, which 
represented solely PNSP isolates (Table III.4). Although PNSP and ERP returned in 
2011 to values similar to those found prior to 2010, this was due to a decrease in 
frequency of resistant isolates representing multiple STs and expressing different 
serotypes, while the emerging clones (CC156 among serotype 14 and ST276 among 
serotype 19A) persisted as important causes of adult IPD. Continued surveillance of 
resistant isolates should focus particularly on the evolution of serotype 24F since ≥ 
50% of the isolates expressing this serotype in our study were associated with the 
PMEN clone Denmark14-230 (III.S2 Table) which was a major clone in the expansion 
of serotype 19A in the post-PCV7 period in Portugal. 
The significant differences in genetic variation, as documented here by MLST, 
within the various serotypes remain unexplained and should be the object of future 
study. We have shown that the changes in serotypes occurring during the study 
period have been driven mostly by the expansion of previously circulating clones or 
to declines in the majority of the lineages expressing a given serotype. However, in 
some serotypes, such as 14 and 19A, changes in serotype frequency were driven mostly 
by changes in particular lineages. In the case of serotype 3, although its proportion 
remained constant with time, there were significant changes in the dominant 
lineages. These observations raise the possibility that lineage-specific properties may 
condition the dynamics of particular serotypes. Serotype switching played a minor 
role in this population but may be an important source of new variants that may 
increase in the post PCVs period. Taken together, these observations reinforce the 
importance of determining the clonal lineages of pneumococci to better understand 
the changes in the bacterial population occurring following the use of PCVs. 
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Supporting Information 
 Table III.S1 Age distribution and serotypes of the STs found in CCs with less than 10 isolates. 
CC 
(no.isolates) 
ST  
(no. Isolates) 
 no. of isolates per age group 
Serotypes (no.isolates) [18-49] [50-64] >=65 
717 (9) 717 (9) 0 3 6 33A (7), 33F (1), 3 (1) 
994/6158 (9) 994  (7) 1 1 5 19A (7) 4197 (2) 0 0 2 19A (2) 
235 (8) 
235 (5) 2 1 2 20 (5) 
1483 (1) 0 1 0 20 (1) 
7221 (1) 0 0 1 20 (1) 
10047 (1) 0 0 1 20 (1) 
395 (7) 395 (5) 2 1 2 6C (5) 1692 (2) 0 0 2 6C (2) 
205 (6) 205 (6) 4 0 2 4 (6) 
5902 (6) 
1222 (4) 4 0 0 4 (4) 
801 (2) 2 0 0 4 (2) 
5902 (1) 1 0 0 16F (1) 
241 (5) 241 (5) 2 0 3 18A (4), 19A (1) 
473 (5) 
1876 (2) 0 1 1 6A (2) 
473 (1) 0 0 1 6B (1) 
1135 (1) 0 0 1 23B (1) 
10055 (1) 1 0 0 6A (1) 
1221 (5) 1221 (5) 2 2 1 4 (5) 
393 (4) 393 (4) 0 0 4 25A (4) 
989 (4) 989 (4) 1 2 1 12B (4) 
1816 (4) 1342 (3) 1 0 2 29 (3) 2567 (1) 0 0 1 29 (1) 
320 (3) 320 (2) 0 1 1 19A (2) 271 (1) 0 0 1 19F (1) 
1026 (3) 1026 (3) 1 1 1 20 (3) 
1046 (3) 1046 (2) 1 0 1 34 (2) 8967 (1) 0 0 1 34 (1) 
1652/6956 (3) 1652 (3) 0 3 0 4 (3) 
2669 (3) 2669 (2) 0 1 1 19A (2) 2102 (1) 0 0 1 19A (1) 
2690 (3) 2690 (3) 0 0 3 35B (3) 
198 (2) 198 (1) 0 0 1 35B (1) 3329 (1) 1 0 0 35B (1) 
217 (2) 217 (1) 1 0 0 1 (1) 3081 (1) 0 1 0 1 (1) 
242 (2) 242 (2) 0 0 2 19A (2) 
452 (2) 452 (1) 0 1 0 35B (1) 9979 (1) 0 1 0 29 (1) 
546 (2) 494 (2) 0 1 1 28A (2) 
1381 (2) 1233 (2) 2 0 0 1 (1), 18C (1)  
2021 (2) 1116 (1) 1 0 0 3 (1) 1126 (1) 0 1 0 39 (1) 
2599 (2) 2599 (2) 1 0 1 17A (2) 
9958 (2) 9958 (2) 1 0 1 18A (1), 20 (1) 
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Table III.S1 (continued). 
CC 
(no.isolates) 
ST  
(no.isolates) 
no. of isolates per age group 
Serotypes (no.isolates) [18-49] [50-64] >=65 
1368 (2) 1368 (2) 0 1 1 35F (2) 
100 (2) 100 (2) 0 0 2 33A (1), 33F (1) 
70 (1) 70 (1) 1 0 0 13 (1) 
87 (1) 89 (1) 0 1 0 19F (1) 
102 (1) 102 (1) 1 0 0 18C (1) 
259 (1) 259 (1) 0 1 0 4  (1) 
343 (1) 10049 (1) 0 0 1 15A (1) 
432 (1) 432 (1) 1 0 0 21 (1) 
458 (1) 458 (1) 0 1 0 3 (1) 
558 (1) 558 (1) 0 1 0 35B (1) 
901 (1) 901 (1) 0 1 0 13 (1) 
1010 (1) 9955 (1) 0 0 1 11A (1) 
1025 (1) 1025 (1) 0 0 1 15B/C (1) 
1151 (1) 2732 (1) 0 0 1 19A (1) 
1390 (1) 1390 (1) 0 0 1 6C (1) 
1866 (1) 1866 (1) 0 0 1 4 (1) 
1884 (1) 478 (1) 1 0 0 NT (1) 
2658 (1) 2658 (1) 0 0 1 13 (1) 
3214 (1) 3214 (1) 0 0 1 35F (1) 
3982 (1) 3982 (1) 0 0 1 9N (1) 
6182 (1) 6182 (1) 0 0 1 36 (1) 
7069 (1) 7069 (1) 0 0 1 15A (1) 
8153 (1) 5823 (1) 0 1 0 28F (1) 
9957 (1) 9957 (1) 0 1 0 6B (1) 
9970 (1) 9970 (1) 0 1 0 6B (1) 
10043 (1) 10043 (1) 1 0 0 29  (1) 
10051 (1) 10051 (1) 0 0 1 6B (1) 
1083/7843 (1) 1083 (1) 1 0 0 25F (1) 
1715/1640 (1) 1715 (1) 1 0 0 6C (1) 
6973/2668 (1) 6973 (1) 0 1 0 19A (1) 
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Table III.S2 Distribution of STs according to serotype of the 
isolates (n≤11) causing adult IPD in 2008-2011 and expressing 
serotypes not included in any of the conjugate vaccines. 
Serotype (no. isolates) ST (no. isolates) 
15A (11) 
63 (7) 
1228 (1) 
3130 (1) 
7069 (1) 
10049 (1) 
15B/C (11) 
199 (2) 
411 (7) 
1025 (1) 
3863 (1) 
23B (11) 
439 (7) 
1135 (1) 
9579 (1) 
10039 (2) 
24F (9) 
72 (4) 
230 (4) 
4253 (1) 
29 (8) 
198 (1) 
558 (1) 
1342 (3) 
2567 (1) 
9979 (1) 
10043 (1) 
33A (8) 100 (1) 717 (7) 
17F (7) 
123 (5) 
6179 (1) 
9966 (1) 
31 (6) 1766 (5) 1994 (1) 
35F (6) 
1366 (2) 
1368 (2) 
3214 (1) 
4849 (1) 
Non-typable (6) 
53 (2) 
66 (1) 
191 (2) 
478 (1) 
1046 (2) 
2001 (2) 
8967 (1) 
34 (5) 
1046 (2) 
2001 (2) 
8967 (1) 
 
 
 
 
Chapter III 
126 
 
 
Table III.S2 (continued). 
Serotype (no. Isolates) ST (no. Isolates) 
35B (5) 
452 (1) 
2690 (3) 
3329 (1) 
18A (5) 241 (4) 9958 (1) 
18C (5) 
102 (1) 
113 (1) 
199 (1) 
1233 (1) 
10033 (1) 
7C (4) 1201 (3) 9956 (1) 
25A (4) 393 (4) 
21 (4) 432 (1) 1877 (3) 
17A (3) 392 (1) 2599 (2) 
13 (3) 
70 (1) 
901 (1) 
2658 (1) 
28A (2) 494 (2) 
33F (2) 100 (1) 717 (1) 
15F (1) 63 (1) 
36 (1) 6182 (1) 
11C (1) 408 (1) 
25F (1) 1083 (1) 
24A (1) 162 (1) 
28F (1) 5823 (1) 
39 (1) 1126 (1) 
12F (1) 220 (1) 
7A (1) 191 (1) 
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RATIONALE 
In the studies presented in previous chapters we analyzed pneumococci 
responsible for invasive disease in adults. Now, in the two studies included in the 
present chapter (Horácio et al., 2014; Horácio et al., 2018) we focused our attentions 
on pneumococci causing non-invasive pneumonia in adults. The importance of NIPP 
is unquestionable. NIPP is the most common cause of hospitalization and death due 
to a pneumococcal disease in adults and this is largely due to the high incidence and 
relatively high severity of this disease. There were no previous publications from the 
laboratory evaluating isolates causing adult NIPP in Portugal and therefore the 
studies presented in this chapter evaluate adult NIPP isolates recovered since 1999. 
The first study includes a random sample of 100 isolates per year from a collection of 
adult NIPP isolates recovered from 1999 to 2011 (Horácio et al., 2014), while the second 
study includes all adult NIPP isolates collected from 2012 to 2015 (Horácio et al., 2018). 
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The following study was performed by Andreia N. Horácio, Joana P. Lopes, 
Mário Ramirez, José Melo-Cristino and the Portuguese Group for the Study of 
Streptococcal Infections. Andreia N. Horácio performed a significant part of the 
experimental work, most of the statistical analysis and wrote the first version of the 
manuscript. 
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NON-INVASIVE PNEUMOCOCCAL PNEUMONIA IN PORTUGAL — SEROTYPE 
DISTRIBUTION AND ANTIMICROBIAL RESISTANCE1
Andreia N. Horácio, Joana P. Lopes, Mário Ramirez, José Melo-Cristino and the Portuguese 
Group for the Study of Streptococcal Infections 
Faculty of Medicine, Instituto de Microbiologia, Instituto de Medicina Molecular, University 
of Lisbon, Lisbon, Portugal 
 
Abstract 
There is limited information on the serotypes causing non-invasive 
pneumococcal pneumonia (NIPP). Our aim was to characterize pneumococci causing 
NIPP in adults to determine recent changes in serotype prevalence, the potential 
coverage of pneumococcal vaccines and changes in antimicrobial resistance. 
Serotypes and antimicrobial susceptibility profiles of a sample of 1300 isolates 
recovered from adult patients (≥ 18 yrs) between 1999 and 2011 (13 years) were 
determined. Serotype 3 was the most frequent cause of NIPP accounting for 18% of 
the isolates. The other most common serotypes were 11A (7%), 19F (7%), 19A (5%), 14 
(4%), 22F (4%), 23F (4%) and 9N (4%). Between 1999 and 2011, there were significant 
changes in the proportion of isolates expressing vaccine serotypes, with a steady 
decline of the serotypes included in the 7-valent conjugate vaccine from 31% (1999–
2003) to 11% (2011) (p < 0.001). Taking together the most recent study years (2009–
2011), the potential coverage of the 13-valent conjugate vaccine was 44% and of the 23-
valent polysaccharide vaccine was 66%. While erythromycin resistance increased 
from 8% in 1999–2003 to 18% in 2011 (p < 0.001), no significant trend was identified 
for penicillin non-susceptibility, which had an average value of 18.5%. The serotype 
distribution found in this study for NIPP was very different from the one previously 
described for IPD, with only two serotypes in common to the ones responsible for half 
of each presentation in 2009–2011 – serotypes 3 and 19A. In spite of these differences, 
the overall prevalence of resistant isolates was similar in NIPP and in IPD. 
                                                     
1 A facsimile of this publication can be found at the “Publications” section of this thesis. 
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Introduction 
Pneumonia is a common infection that causes high rates of morbidity and 
mortality worldwide. Streptococcus pneumoniae (pneumococcus) is thought to be the 
major cause of pneumonia, responsible for up to half of all cases (Polverino et al., 
2013). Only a small fraction of pneumococcal pneumonias are bacteremic, with non-
invasive pneumococcal pneumonia (NIPP) estimated to be three to ten times more 
frequent than invasive pneumococcal pneumonia (Said et al., 2013; Rodrigo et al., 
2014). While bacteremic pneumonia is a more severe form of pneumonia, it is less 
clear if bacteremia can be considered an independent predictor of mortality (Cillóniz 
and Torres, 2012; Benfield et al., 2013). In adults, bacteremic pneumonia accounts for 
most of the cases of invasive pneumococcal disease (IPD). While the serotype 
distribution of IPD and NIPP have been sometimes assumed to be the same (Smith 
et al., 2012), it is becoming increasingly clear that this is not so (Benfield et al., 2013; 
Sherwin et al., 2013). This observation is in agreement with the recognition that some 
serotypes, and even different genetic lineages expressing the same serotype, may have 
different invasive disease potentials (Sá-Leão et al., 2011), leading to the expectation 
that less invasive serotypes would be more abundantly represented in NIPP than in 
IPD. 
In developed countries, pneumonia is believed to be a major cause of morbidity 
among older adults, and, together with influenza, is the leading cause of death from 
infectious disease in the US considering the entire population (Heron, 2013). Until 
recently, the only available vaccine for adults was the 23-valent polysaccharide 
vaccine (PPV23) that, while potentially effective in preventing IPD, may be less 
efficacious against NIPP (Grabenstein, 2012; Trück et al., 2012). Possibly due to the 
ongoing debate on the usefulness of PPV23 vaccination, in the majority of the 
European countries, including Portugal, there has been a low uptake of this vaccine 
(Fedson et al., 2011; Horácio et al., 2012). On the other hand, the 7-valent conjugate 
vaccine (PCV7) was introduced in many European countries for vaccinating children, 
rapidly reaching high coverages in the targeted age groups. PCV7 was available in 
Portugal for vaccination of children between 2001 and 2009 and, although not part of 
the national immunization program, its uptake was estimated to have grown 
continuously, albeit slower that in countries where it was part of the national 
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immunization program (Aguiar et al., 2008a). Changes in the serotype distribution of 
isolates causing IPD, compatible with an effect of PCV7 occurred in both children and 
adults in Portugal and elsewhere (Aguiar et al., 2008a; Aguiar et al., 2010a; Horácio et 
al., 2012; Steens et al., 2013; Regev-Yochay et al., 2014), the latter potentially resulting 
from a herd effect. The 10-valent (PCV10) and the 13-valent conjugate vaccines 
(PCV13) became available in Portugal in 2009 and in 2010, respectively. In September 
2011, PCV13 received the European Medicines Agency approval for use in adults ≥ 50 
yrs and in July 2013 was approved for adults ≥ 18 yrs, for the prevention of IPD. 
Currently PCV13 is approved for all ages from 6 weeks up and there is now initial 
evidence of its efficacy against pneumococcal pneumonia in adults caused by the 
serotypes included in the vaccine (Bonten et al., 2014).  
The aim of this study was to determine the serotype distribution and 
antimicrobial resistance of pneumococci causing NIPP in adults in Portugal during a 
13-year period, when the three conjugate vaccines were available for children, and to 
compare these data to the information available for IPD published previously 
(Horácio et al., 2013). 
NIPP – Serotypes and Antimicrobial Susceptibility 
 
137 
 
Materials and Methods 
Ethics Statement 
Case reporting and isolate collection were considered to be surveillance 
activities and were exempt from evaluation by the Review Board of the Faculdade de 
Medicina da Universidade de Lisboa. The data and isolates were de-identified so that 
these were irretrievably unlinked to an identifiable person.  
 
Bacterial Isolates 
Isolates were provided by a laboratory-based surveillance system that includes 
30 microbiology laboratories throughout Portugal. These were asked to identify and 
send to our laboratory all pneumococci causing infections. Although the laboratories 
were contacted periodically to submit the isolates to the central laboratory, no audit 
was performed to ensure compliance, which may be variable in this type of study. 
After arrival, all isolates were confirmed as S. pneumoniae by colony morphology and 
hemolysis on blood agar plates, optochin susceptibility and bile solubility.  
The isolates included in this study were recovered from adult patients (≥ 18 yrs) 
with a clinical diagnosis of pneumonia between 1999 and 2011. A total of 1300 isolates, 
100 isolates randomly chosen from among the isolates received in each of the 13 years 
of the study were included. The total number of isolates submitted to the central 
laboratory in each year was 161 in 1999, 184 in 2000, 319 in 2001, 282 in 2002, 265 in 
2003, 341 in 2004, 338 in 2005, 392 in 2006, 525 in 2007, 601 in 2008, 473 in 2009, 519 
in 2010 and 445 in 2011. We believe this reflects increasing compliance with the 
surveillance activities with time. Only isolates recovered from sputum, bronchial 
secretions or bronchoalveolar lavage were considered. Isolates were not included 
when pneumococci were simultaneously isolated from blood or another usually 
sterile product, and when other potential bacterial pathogens besides pneumococci 
were detected in the sample (such as Haemophilus influenzae that was frequently 
detected). Only one isolate from each patient in each year was considered. Among 
the 1300 isolates selected, 103 (7.9%) were isolates from bronchoalveolar lavage fluid. 
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Serotyping and Antimicrobial Susceptibility Testing  
Serotyping was performed by the standard capsular reaction test using the 
chessboard system and specific sera (Statens Serum Institut, Copenhagen, Denmark). 
Serotypes were grouped into conjugate vaccine serotypes, i.e., those included in 
PCV13 (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F) that comprise all the 
serotypes found in the lower valency vaccines (PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F; and 
PCV10: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F), those included in PPV23 (all serotypes 
included in PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 
33F), and non-vaccine serotypes (NVT). The isolates that were not typable with any 
of the complete set of sera were considered non-typable (NT). 
Minimum inhibitory concentrations (MICs) for penicillin and cefotaxime were 
determined using Etest strips (Biomérieux, Marcy-L’Etoile, France). The results were 
interpreted using the Clinical and Laboratory Standards Institute (CLSI) 
recommended breakpoints prior to 2008 (Clinical and Laboratory Standards 
Institute, 2007), as these allows the comparison with previously published data. 
According to these criteria, intermediate level penicillin resistance is defined as MIC 
0.12–1.0 µg/ml and high level resistance as MIC ≥ 2.0 µg/ml. Isolates that fell into 
either one of these classes were designated penicillin non-susceptible. Susceptibility 
to cefotaxime was defined as MIC ≤ 1.0 µg/ml. The Kirby-Bauer disk diffusion assay 
was used to determine susceptibility to levofloxacin, erythromycin, clindamycin, 
chloramphenicol, trimethoprim/sulphamethoxazole, tetracycline, vancomycin and 
linezolid, according to the CLSI recommendations and interpretative criteria (Clinical 
and Laboratory Standards Institute, 2013). Macrolide resistance phenotypes were 
identified using a double disc test with erythromycin and clindamycin, as previously 
described (Melo-Cristino et al., 2003). The MLSB phenotype (resistance to macrolides, 
lincosamides and streptogramin B) was defined as the simultaneous resistance to 
erythromycin and clindamycin, while the M phenotype (resistance to macrolides) was 
defined as non-susceptibility only to erythromycin. 
 
Statistical Analysis 
Sample diversity was measured using Simpson’s index of diversity (SID) and the 
respective 95% confidence intervals (CI95%) (Carriço et al., 2006). To compare two 
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sets of partitions the Adjusted Wallace (AW) coefficients were calculated (Severiano 
et al., 2011) using the online tool available at www.comparingpartitions.info. 
Differences were evaluated by the Fisher exact test with the false discovery rate (FDR) 
correction for multiple testing (Benjamini and Hochberg, 1995) or the Chi-squared 
test, and the Cochran-Armitage test was used for trends. A p < 0.05 was considered 
significant for all tests. 
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Results 
Serotype Distribution 
Serotype diversity was high [SID: 0.941, CI95%: 0.935–0.948], with 57 different 
serotypes detected among the 1300 isolates. The most frequent serotypes, which 
accounted for more than half of the isolates, were serotypes: 3 (17.8%), 11A (6.7%), 19F 
(6.7%), 19A (5.2%), 14 (4.1%), 22F (4.1%), 23F (3.8%) and 9N (3.5%). Serotype 
distribution in each of the studied years is represented in Figure IVa.1. We chose to 
represent an average of the yearly values between 1999 and 2003, because it was 
shown previously that this period corresponded to the years before an effect of 
children vaccination with PCV7 was noted in the distribution of adult IPD serotypes 
(Aguiar et al., 2008a). The yearly distribution of the 10 overall most frequent serotypes 
between 1999 and 2003 is represented in Figure IVa.S1. In spite of yearly variations, 
serotype diversity was high in all studied years with the lowest SID detected in 2008 
[SID: 0.901, CI95%: 0.857–0.945] and the highest value found in both 2004 and 2009 
[SID: 0.957, CI95%: 0.840–0.973]. 
The change in distribution of vaccine types along the study years is shown in 
Figure IVa.2 and Figure IVa.S2. The serotypes included in PCV7 declined gradually 
from 31% in 1999–2003 to 11% in 2011 (Cochran-Armitage test of trend p < 0.001). 
Among the PCV7 serotypes, those that contributed mostly to this decline were 
serotypes 6B (from 4.6% to 0%, Cochran-Armitage test of trend p < 0.001), 9V (from 
3.2% to 0%, Cochran-Armitage test of trend p < 0.001) and 23F (from 6.6% to 1.0%, 
Cochran-Armitage test of trend p < 0.001). Despite fluctuations throughout the study 
period in the number of isolates representing PCV13 and PPV23 serotypes, no 
consistent trend was noted. However, a decline of the isolates expressing serotypes 
included in these vaccines, and a consequent increase in the prevalence of NVTs, can 
be distinguished between 2008 and 2009. This can be attributed to a fall in serotype 
3, from 28% to 9%, between these two years (p < 0.001, Figure IVa.1). Although in 
subsequent years the proportion of isolates expressing serotype 3 returned to values 
similar to those found previously (Figure IVa.1), this did was not reflected in an 
increase in the proportion of isolates expressing PCV13 serotypes, which remained 
close to 43% (Figure IVa.2). In contrast, the decline in the proportion of isolates 
expressing PPV23 serotypes noted in 2009 was not sustained, with the increases in  
  
 
 
Figure IVa.1 Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia in adults in Portugal (1999–2011). Only the overall 10 most frequent serotypes are shown. 
The other serotypes found between 1999 and 2011 were serotypes 6B, 7F and 15A (n = 32, each), 23B (n = 30), 15B (n = 28), 10A (n = 27), 9V and non-typable (n = 26, each), 23A (n = 24), 1 (n 
= 22), 8 (n = 20), 16F (n = 19), 29 (n = 18), 4 (n = 17), 31 (n = 16), 34 (n = 15), 18C (n = 14), 17F and 33A (n = 13, each), 21 and 35F (n = 11, each), 15C and 35C (n = 10, each), 20 (n = 9), 12B 
and 17A (n = 8, each), 13, 25F and 25A/38 (n = 7, each), 7C and 28A (n = 5, each), 5 (n = 4), 11F, 18A and 19C (n = 3, each), 12A, 12F, 35A, 35B, 38 (n = 2, each) and 9L, 10F, 15F, 16A, 19B, 
33F, 39 and 42 (n = 1, each). The value shown for 1999–2003 refers to the yearly average of the 500 isolates studied that were isolated in these 5 years. This period was analyzed together since 
previously published IPD data indicated that these corresponded to a pre-PCV7 serotype distribution.  
  
 
 
Figure IVa.2 Proportion of isolates expressing serotypes included in pneumococcal vaccines causing non-invasive pneumococcal pneumonia in adults in Portugal (1999–2011). The value 
shown for 1999–2003 refers to the yearly average of the 500 isolates studied that were isolated in these 5 years. This period was analyzed together since previously published IPD data indicated 
that these corresponded to a pre-PCV7 serotype distribution. 
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the following years bringing this value back into the range found in the previous 
decade (Figure IVa.2). 
The distribution of the 10 most frequent serotypes found between 1999 and 2011, 
stratified by age group, is shown in table IVa.S1. The serotype distribution is similar 
for each of the age groups considered (p = 0.398) and no significant associations, after 
correction for FDR, could be found between specific serotypes and age groups. When 
considering only the three last years of the study, corresponding to the years 
immediately prior to PCV13 receiving approval for use in adults (2009–2011), the 
overall proportion of isolates expressing serotypes included in the various vaccines 
were 10.3% for PCV7, 43.7% for PCV13 and 66.0% for PPV23. There was also no 
correlation between the proportion of isolates causing NIPP included in the vaccines 
and the different age groups (table IVa.S2). 
 
Antimicrobial susceptibility 
The proportion of isolates resistant to the tested antimicrobials between 1999 
and 2011 is summarized in table IVa.1. Penicillin non-susceptible pneumococci (PNSP) 
accounted for 18.5% of the isolates (n = 241). Among these, 211 isolates (16.2%) 
expressed low level resistance (MIC = 0.12–1 µg/mL) and 30 isolates (2.3%) high level 
resistance (MIC ≥ 2 µg/mL). Considering the current CLSI guidelines for parenteral 
penicillin in non-meningitis cases, where high level is defined as MIC≥8 µg/mL and 
intermediate resistance as MIC ≥ 2 µg/mL (Clinical and Laboratory Standards 
Institute, 2013), only 16 strains (1.2%) would have been considered non-susceptible to 
penicillin, with only one of these expressing high level resistance. 
Erythromycin resistant pneumococci (ERP) accounted for 16.3% of the isolates 
(n = 212), with 84.0% (n = 178) of these expressing the MLSB phenotype and 16.0% (n 
= 34) the M phenotype. A total of 9.8% (n = 127) of the isolates were simultaneously 
non-susceptible to penicillin and resistant to erythromycin (EPNSP).  
Resistance to levofloxacin was low overall (1.3%, n = 17), but higher in the older 
age groups than in the youngest group (Table IVa.1, 18–49 yrs versus 50–64 yrs, p = 
0.014 and 18–49 yrs versus ≥ 65 yrs, p = 0.012). No other significant associations with 
age were found for the other antimicrobials tested. All isolates were susceptible to 
vancomycin and linezolid. The proportion of erythromycin and clindamycin resistant 
Chapter IV 
 
144 
 
isolates increased between 1999–2003 and 2011. Erythromycin resistance increased 
from 8.0% to 18.0% (Cochran-Armitage test of trend p < 0.001) and clindamycin 
resistance increased from 7.0% to 15.0% (Cochran-Armitage test of trend p = 0.004). 
No other significant changes were noted for the other antimicrobials tested. 
 
Table IVa.1 Antimicrobial resistance of the isolates responsible for non-invasive 
pneumococcal pneumonia in adults in Portugal, stratified by age groups (1999–2011). 
  
  
No. resistant isolates (%)ª   
[18-49] yrs [50-64] yrs ≥65 yrs Total  
(n = 481) (n = 293) (n = 526) (n = 1300) 
PEN 95 (19.8) 57 (19.5) 89 (16.9) 241 (18.5) 
MIC90 0.25 0.38 0.25  - 
MIC50 0.023 0.023 0.023  - 
CTX 4 (0.8) 3 (1.0) 2 (0.4) 9 (0.7) 
MIC90 0.19 0.125 0.094  - 
MIC50 0.012 0.012 0.012  - 
LEV 1 (0.2) 6 (2.0) 10 (1.9) 17 (1.3) 
ERY 76 (15.8) 54 (18.4) 82 (15.6) 212 (16.3) 
CLI 66 (13.7) 44 (15.0) 68 (12.9) 178 (13.7) 
CHL 17 (3.5) 12 (4.1) 22 (4.2) 51 (3.9) 
SXT 89 (18.9) 46 (15.7) 84 (16.0) 219 (16.8) 
TET 61 (12.7) 42 (14.3) 63 (12.0) 166 (12.8) 
aPEN – penicillin; CTX – cefotaxime; LEV – levofloxacin; ERY – erythromycin; CLI 
– clindamycin; CHL – chloramphenicol; SXT – trimethoprim/sulphamethoxazole; 
TET – tetracycline. All isolates were susceptible to vancomycin and linezolid. 
bNon-susceptibitily to penicillin was determined using the CLSI breakpoints prior 
to 2008. 
 
There was an association between serotype and antimicrobial resistance. The 
AW for serotype and PNSP was 0.588 (CI95%: 0.541–0.634) and the AW for serotype 
and ERP was 0.489 (CI95%: 0.419–0.558). Table IVa.2 shows the serotypes that 
presented at least 10 PNSP and ERP isolates, respectively. Among the major serotypes 
expressed by PNSP, only serotype 19F was not significantly associated with PNSP. 
Among the major serotypes expressed by ERP, only serotypes 23F and 6C were not 
significantly associated with ERP. The PCV7, PCV13 and PPV23 serotypes accounted 
for 56.0%, 70.5% and 69.7% of PNSP, respectively, and 42.9%, 60.8% and 66.5% of 
ERP, respectively. 
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Table IVa.2 Serotype distribution of PNSP and ERP causing non-invasive pneumococcal 
pneumonia in adults in Portugal (1999–2011). 
  Serotypea No. of resistant isolates (%) OR (CI95%) p-valueb 
PEN 
23F 39 (16.2) 12.6 (6.2-27.7) <0.001 
14 37 (15.4) 8.1 (4.3-15.9) <0.001 
19A 28 (11.6) 2.3 (1.3-3.9) 0.002 
15A 27 (11.2) 18.2 (6.8-61.3) <0.001 
19F 27 (11.2) 1.4 (0.8-2.3) 0.193 
9V 23 (9.5) 25.5 (7.6-133.7) <0.001 
6C 18 (7.5) 3.0 (1.5-6.2) 0.001 
Others c 42 (17.4)  -  - 
ERY 
19F 37 (17.5) 3.4 (2.1-5.4) <0.001 
19A 31 (14.6) 3.7 (2.2-6.4) <0.001 
15A 28 (13.2) 31.9 (11.0-126.2) <0.001 
14 21 (9.9) 2.8 (1.5-5.1) <0.001 
6B 15 (7.1) 3.7 (1.7-8.0) <0.001 
23F 14 (6.6) 1.6 (0.8-3.1) 0.151 
33A 10 (4.7) 13.8 (3.5-79.0) <0.001 
6C 10 (4.7) 1.5 (0.6-3.3) 0.296 
NTd 10 (4.7) 2.6 (1.0-6.1) 0.025 
Otherse 36 (17.0)  -  - 
aOnly the serotypes that presented at least 10 non-susceptible isolates are shown. bSignificant P-
values after FDR correction are highlighted in bold. cOther serotypes found among PNSP: 6B (n=8), 
non-typable (n=7), 6A and 29 (n=5, each), 23B and 24F (n=3, each), 7C (n=2), 1, 3, 4, 11A, 15B, 15F, 
22F, 23A, 35A (n=1, each). dNT – non typable. eOther serotypes found among ERP: 9V and 11A (n=4, 
each), 3, 15B, 22F, 23A, 24F (n=3, each), 6A (n=2), 1, 7F, 8, 9N, 15F, 16F, 17F, 23B, 29, 33F and 35F (n=1, 
each). 
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Discussion 
Serotype 3 was the most important serotype in NIPP in adults in Portugal. This 
serotype was the most frequently detected in all studied years, with the exception of 
2009, when it ranked third (Figure IVa.1). A predominance of serotype 3 was also 
found in two studies that focused on the serotype distribution of pneumococcal 
pneumonia isolates (Domenech et al., 2011; Benfield et al., 2013), and this serotype was 
among the most frequent in two recent studies using urinary antigen detection assays 
to diagnose pneumococcal pneumonia (Huijts et al., 2013; Sherwin et al., 2013), 
although these last studies included both NIPP and bacteremic pneumonia. In 
Portugal, serotype 3 is not only a leading cause of NIPP but also of IPD, as can be seen 
in Figure IVa.S3, showing the distribution of the most frequently detected serotypes 
immediately prior to the licensure of PCV13 for adult immunization (2009–2011).  
Although both IPD and NIPP were characterized by a high serotype diversity 
(for NIPP SID = 0.943, CI95%: 0.932–0.955; and for IPD SID = 0.942, CI95%: 0.937–
0.946; considering 2009–2011), the actual serotype distribution is quite different 
(Figures IVa.3, Figure IVa.S3 and Table IVa.S3). Among the most frequent serotypes, 
accounting for half of the characterized isolates in 2009–2011, only two serotypes were 
common to both NIPP and IPD, which were serotypes 3 and 19A (Figure IVa.S3). 
When comparing the serotype distribution, serotypes 6A, 11A, 15C, 19F and 23B were 
significantly more abundant among NIPP isolates, whereas serotypes 1, 4,7F and 14 
were significantly more abundant among IPD isolates (Figure IVa.3 and Table IVa.S3). 
These four serotypes, together with serotype 3, were already shown to have an 
enhanced invasive disease potential in a study evaluating the serotypes and clones 
circulating in Portugal (Sá-Leão et al., 2011). On the other hand, serotypes 6A, 11A and 
19F were associated with carriage, suggesting their lower invasive disease potential, 
consistent with the association with NIPP determined here (Figure IVa.3 and Table 
IVa.S3). 
A recent study described the serotype distribution among isolates recovered in 
2011 causing bacteremic and non-bacteremic pneumonia in adults in Denmark 
(Benfield et al., 2013). When considering only the isolates recovered in 2009–2011 in 
Portugal, the serotype distribution is, perhaps surprisingly, remarkably similar in 
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Figure IVa.3 Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia and invasive 
pneumococcal disease in adults in Portugal (2009–2011). Data from IPD were published previously (Horácio et al., 
2013). Serotypes associated with NIPP or IPD are marked by asterisks. The odds ratio was used to measure the association 
between serotype and disease presentation and only significant values (P < 0.05) after FDR correction are indicated. The P 
values for the serotypes associated with NIPP were: P = 0.001 for 19F, P = 0.007 for 6A, P = 0.004 for 11A, P = 0.001 for 
15C, P < 0.001 for 23B. The P values for the serotypes associated with IPD were: P = 0.007 for 4, P < 0.001 for 14, P < 
0.001 for 1 and P < 0.001 for 7F. 
 
both studies. Among the differences are the more significant fractions of non-typable 
isolates among NIPP and of serotype 1 isolates in bacteremic pneumonia in Denmark 
relative to Portugal. 
Serotype 1 was always an important serotype among isolates causing IPD in both 
children and adults in Portugal, but its significance has declined in recent years 
(Aguiar et al., 2010a; Horácio et al., 2012; Horácio et al., 2013; Aguiar et al., 2014). This 
change cannot be attributed entirely to the use of higher valency vaccines, such as 
PCV13, although vaccination was potentially a contributing factor (Horácio et al., 
2013; Aguiar et al., 2014). Another important difference is the persistence of serotype 
14 isolates among both NIPP and IPD in Portugal, in contrast to Denmark where this 
serotype was found at a lower frequency (Benfield et al., 2013). Serotype 14 was already 
included in PCV7, and continued vaccine use could be expected to significantly 
reduce its prevalence. A lower and more protracted vaccine uptake in Portugal 
compared to Denmark, together with a higher antibiotic consumption, could 
contribute to the differences observed between the two countries. 
In previous studies, we showed that immunization of children with PCV7 
resulted in the decline of PCV7 serotypes as causes of adult IPD (Horácio et al., 2012; 
Horácio et al., 2013). In the present study, we show that a decline of PCV7 serotypes 
also occurred among isolates causing NIPP in adults. However, while in IPD this 
decline was abrupt, occurring between 2004 and 2005, in NIPP this decline was 
gradual and occurred over the entire post-PCV7 period (Figure IVa.2 and Figure 
IVa.S2). The proportion of isolates expressing PCV7 serotypes in the most recent years 
of the study was different between NIPP and IPD (10.3% versus 19.0% in 2009–2011, p 
< 0.001, Figure IVa.3). 
Taken together, the isolates expressing PCV13 serotypes also declined in IPD and 
in NIPP, a change that was observed from 2008 onwards for both disease 
presentations. However, again there were important differences. While in IPD this 
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decline occurred from 2008 to 2011 and was mostly due to decreases in serotypes 1 and 
5, in NIPP this decline occurred between 2008 and 2009 and was predominantly 
caused by a decrease in serotype 3. In neither case can we attribute these changes to 
the introduction of PCV13 in Portugal, since this vaccine only became available for 
children in the beginning of 2010 and received an indication for adults in the 
beginning of 2012. In NIPP, one possible explanation for the change observed could 
be the H1N1pdm09 pandemic that occurred between 2009 and 2010. Individuals 
infected by influenza are at high risk of developing secondary bacterial infections, 
especially with pneumococci (Smith et al., 2013). Consistent with the hypothesis that 
influenza allowed the emergence of multiple serotypes as causes of NIPP, the decrease 
of serotype 3 from 2008 to 2009 was accompanied by an increase in serotype diversity.  
Another remarkable difference between NIPP and IPD is the proportion of 
isolates that expresses serotypes included in the available vaccine formulations with 
an adult indication. When analyzing data from 2009 to 2011, we found that the 
number of IPD cases that could have been potentially prevented by PCV13 and PPV23 
was 59%, and 80%, respectively (Horácio et al., 2013), while the proportion of isolates 
expressing these serotypes was only 44% and 66%, respectively, among our collection 
of NIPP isolates. The higher proportion of vaccine types among IPD isolates was also 
documented in Denmark (Benfield et al., 2013). The efficacy of the conjugate vaccines 
is well established and adults could now benefit directly from PCV13 use. However, 
according to our sample more than half of NIPP cases could not have been prevented 
by vaccination with PCV13. 
In the present study we could not find any significant associations between 
serotypes and age groups. This is in contrast to our previous studies with invasive 
isolates, where serotypes 3 and 19A were associated with older patients and serotypes 
1 and 8 were associated with younger patients (Horácio et al., 2013). However, if we 
do not consider the correction for multiple testing, serotype 3 was more frequent in 
older adults than in the youngest (14% in 18–49 yrs versus 20% in ≥ 50 yrs, p = 0.005, 
Table IVa.S1). The lack of association for the other three serotypes with age is likely 
the result of their small numbers in our NIPP sample, particularly in what concerns 
serotypes 1 and 8. 
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A high proportion of the resistant isolates recovered between 1999 and 2011 are 
of serotypes included in PCV7 (Table IVa.2), accounting for 56% of PNSP and 43% of 
ERP in the entire study period. Unlike what could have been expected, the 
introduction of PCV7 in Portugal did not reduce the proportion of resistant isolates, 
neither in NIPP nor in IPD (Aguiar et al., 2008a; Horácio et al., 2013). Actually, for 
both presentations there was an increase in ERP between 1999 and 2011, and for IPD 
there was also an increase in PNSP. However, when we considered the most recent 
data (2009 to 2011) we found that only 22% of PNSP and 26% of ERP causing NIPP, 
represented serotypes included in PCV7. This means that resistant isolates expressing 
serotypes that are not included in PCV7 have emerged and expanded in the post-
PCV7 period.  
When considering the entire study period, antimicrobial resistance among NIPP 
isolates was similar to the values reported recently for IPD (Horácio et al., 2013) (Table 
IVa.1). Given the association between serotype and antimicrobial resistance, and the 
different serotype distributions between NIPP and IPD, how can we explain the 
similar overall resistance? For the most part, the explanation can be found in the more 
gradual decrease of resistant PCV7 serotypes, albeit to a lower level, in NIPP when 
compared to IPD. This was accompanied by the rise of a different set of serotypes 
including resistant isolates that are not included in PCV7, resulting in similar overall 
resistance levels. Resistance among NIPP isolates is partly due to the proliferation of 
resistant serotype 19A isolates, probably representing a lineage which has been 
expanding as a cause of IPD in children and adults (Horácio et al., 2013; Aguiar et al., 
2010b), and that became the single most important serotype among PNSP and ERP in 
the last three years of the study. This was accompanied by increases in serotypes 
including resistant isolates not represented in PCV13, such as serotypes 6C, 15A, 29, 
33A, as well as non-typable isolates, each including n > 5 PNSP or ERP during the 
entire study period (table IVa.2). 
The major limitation of this study is that we do not know if blood cultures were 
performed for all patients, and so we cannot exclude the possibility that some of the 
isolates attributed to NIPP were in fact reflecting cases of invasive disease. However, 
the distinct serotype distribution between IPD and NIPP and the similar distribution 
found in this study and among isolates causing NIPP in Denmark in a similar period 
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(Benfield et al., 2013), in spite of the different epidemiological contexts, strongly 
argues against a significant bias in our sample. Another possible confounder could be 
that a fraction of our isolates are reflecting colonization and not infection. Again we 
consider this unlikely. The fluids included are not present in healthy subjects (sputum 
and bronchial secretions) or are not obtained unless there is a strong suspicion of 
pneumonia (bronchoalveolar lavage). The participating laboratories used criteria to 
exclude low quality samples, which would be more likely to reflect upper airway 
microbiota. Finally, adult colonization is known to be rare (Almeida et al., 2014) and 
would be therefore unlikely to account for a significant fraction of the isolates. Taken 
together, these arguments support a role for the pneumococci analyzed in infection 
and not asymptomatic colonization. The decision to collect specimens for 
microbiological analysis was the responsibility of the attending physician that did not 
receive specific guidelines. We are not aware of significant changes in practice during 
the study period, although differences between the participating centers may exist. 
However, since these are expected to be minor and stable during the study period we 
do not feel these constitute a significant source of bias. 
In this study, we found a different serotype distribution and dynamics in NIPP 
and IPD in the same population. This was highlighted by the fact that the potential 
coverage of the currently available pneumococcal vaccines with an adult indication is 
lower in NIPP than in IPD. The distinct dynamics of NIPP, the availability of PCV13 
for adults together with the issues raised regarding the efficacy of PPV23 in the 
context of NIPP, and the fact that NIPP is a frequent cause of morbidity and mortality 
among adults, all underscore the relevance of considering the use of PCV13 in adults. 
However, the expected herd protection conferred by vaccinating children with PCV13 
could reduce the benefits of direct adult vaccination. We documented here ongoing 
changes in the serotypes causing NIPP that are potentially due to long-term PCV7 
use, but there is uncertainty regarding the ultimate reduction in vaccine serotypes 
one can expect from this effect, as well as regarding the kinetics of such a decline. 
Continued surveillance is essential to evaluate the changing potential benefits of 
direct adult vaccination. 
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Figure IVa.S1 Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia in adults in 
Portugal (1999–2003). 
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Figure IVa.S2 Proportion of isolates expressing serotypes included in pneumococcal vaccines causing non-invasive 
pneumococcal pneumonia in adults in Portugal (1999–2003). 
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Figure IVa.S3 Proportion of isolates of each of the serotypes that together were responsible for half of non-invasive 
pneumococcal pneumonia isolates and half of invasive pneumococcal disease cases in adults in Portugal (2009–2011). 
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Table IVa.S1 Serotype distribution of the 10 most common serotypes 
responsible for non-invasive pneumococcal pneumonia in adults in 
Portugal, stratified by age groups (1999-2011). 
  No. isolates (%)     
 [18-49] yrs [50-64] yrs ≥65 yrs 
  (n=481) (n=293) (n=526) 
3 67 (13.9) 63 (21.5) 101 (19.2) 
11A 29 (6.0) 16 (5.5) 42 (8.0) 
19F 36 (7.5) 16 (5.5) 35 (6.7) 
19A 25 (5.2) 15 (5.1) 28 (5.3) 
14 20 (4.2) 13 (4.4) 20 (3.8) 
22F 18 (3.7) 9 (3.1) 26 (4.9) 
23F 17 (3.5) 10 (3.4) 23 (4.4) 
9N 21 (4.4) 6 (2.0) 19 (3.6) 
6C 16 (3.3) 8 (2.7) 13 (2.5) 
6A 10 (2.1) 10 (3.4) 15 (2.9) 
Other 222 (46.2) 127 (43.3) 204 (38.8) 
 
 
Table IVa.S2 Isolates expressing vaccine serotypes responsible 
for non-invasive pneumococcal pneumonia in adults in 
Portugal, stratified by age groups (2009-2011). 
  No. isolates (%)  
  [18-49] yrs [50-64] yrs ≥65 yrs 
PCV7 9 (12.0) 10 (12.2) 12 (8.4) 
PCV13 34 (45.3) 39 (47.6) 58 (40.6) 
PPV23 45 (60.0) 57 (69.5) 96 (67.1) 
 
 
Table IVa.S3 Serotype distribution of the 10 overall most common serotypes in NIPP and 
in IPD (2009-2011). 
  NIPP   IPD* 
Serotype† n (%) Cumulative n (%) Serotype n (%) Cumulative n (%) 
3 49 (16.3) 49 (16.3) 3 160 (12.6) 160 (12.6) 
19A 24 (8.0) 73 (24.3) 7F 126 (10.0) 286 (22.6) 
11A 21 (7.0) 94 (31.3) 19A 115 (9.1) 401 (31.7) 
6C 17 (5.7) 111 (37.0) 14 106 (8.4) 507 (40.1) 
19F 17 (5.7) 128 (42.7) 1 87 (6.9) 594 (47.0) 
22F 16 (5.3) 144 (48.0) 8 79 (6.2) 673 (53.2) 
23B 14 (4.7) 158 (52.7) 22F 55 (4.3) 728 (57.5) 
9N 12 (4.0) 170 (56.7) 4 43 (3.4) 771 (60.9) 
7F 10 (3.3) 180 (60.0) 11A 39 (3.1) 810 (64.0) 
8 10 (3.3) 190 (63.3) 6C 36 (2.8) 846 (66.0) 
*Information published previously (19). †Serotypes in bold were associated with NIPP or IPD (p 
< 0.05).
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the isolates, performed most of the statistical analysis and wrote the first version of 
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CONJUGATE VACCINE SEROTYPES PERSIST AS MAJOR CAUSES OF NON-
INVASIVE PNEUMOCOCCAL PNEUMONIA IN PORTUGAL DESPITE 
DECLINES IN SEROTYPES 3 AND 19A (2012-2015)1
Andreia N. Horácio, Catarina Silva-Costa, Elísia Lopes, Mário Ramirez, José Melo-Cristino 
and the Portuguese Group for the Study of Streptococcal Infections 
Faculty of Medicine, Instituto de Microbiologia, Instituto de Medicina Molecular, University 
of Lisbon, Lisbon, Portugal 
 
Abstract 
Non-invasive pneumococcal pneumonia (NIPP) is a frequent cause of morbidity 
and mortality worldwide. The 13-valent pneumococcal conjugate vaccine (PCV13) was 
included in the national immunization program of children living in Portugal in 2015. 
Until then, PCV7 (since late 2001) and PCV13 (since early 2010) were given through 
the private market. We determined the serotype distribution and antimicrobial 
susceptibility of isolates causing adult NIPP in 2012-2015 and compared the results 
with previously published data (2007-2011).  
There were 50 serotypes among the 1435 isolates. The most common were 
serotypes: 3 (14%), 11A (8%), 19F (6%), 23A (5%), 6C (5%), 19A (4%), 23B (4%), 9N (4%) 
and non-typable isolates (4%). When considering data since the availability of PCV13 
for children in the private market, the proportion of PCV13 serotypes declined from 
44.0% in 2010 to 29.7% in 2015 (p < 0.001), mainly due to early decreases in the 
proportions of serotypes 3 and 19A. In contrast, during the same period, PCV7 
serotypes (11.9% in 2012-2015) and the serotypes exclusive of the 23-valent 
polysaccharide vaccine (26.0% in 2012-2015), remained relatively stable, while non-
vaccine types increased from 27.0% in 2010 to 41.9% in 2015 (p < 0.001). According to 
the Clinical and Laboratory Standards Institute (CLSI) breakpoints, penicillin non-
susceptible (PNSP) and erythromycin resistant isolates accounted for 1% and 21.7%, 
respectively, of the isolates recovered in 2012-2015, with no significant changes seen 
since 2007. Comparison of NIPP serotypes with contemporary invasive disease 
serotypes identified associations of 19 serotypes with either disease presentation. The 
introduction of PCV13 in the national immunization program for children from 2015 
                                                     
1 A facsimile of this publication can be found at the “Publications” section of this thesis. 
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onwards may lead to reductions in the proportion of NIPP due to vaccine serotypes 
but continued NIPP surveillance is essential due to a different serotype distribution 
from invasive disease. 
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Introduction 
Pneumococcal pneumonia is among the most frequent causes of death due to 
infection worldwide, particularly among young children and older adults (GBD 2015 
Mortality and Causes of Death Collaborators, 2016). Non-invasive pneumococcal 
pneumonia (NIPP) is three to ten times more frequent than bacteremic pneumonia 
(Said et al., 2013), but studies evaluating NIPP are less abundant than those evaluating 
invasive pneumococcal disease (IPD). 
After the introduction of pneumococcal conjugate vaccines (PCVs) for children, 
several studies reported a reduction of IPD in children (Pilishvili et al., 2010; Aguiar 
et al. 2014). Given that young children are the main reservoirs and transmitters of 
pneumococcus in the community and because the PCVs reduce pneumococcal 
colonization, several studies also reported reductions of IPD due to vaccine serotypes 
in the non-vaccinated population (Horácio et al., 2013; Moore et al., 2015; Waight et 
al., 2015; Horácio et al., 2016b). 
Despite the lower number of studies, there is also evidence of herd protection 
in adult NIPP (Mendes et al., 2015; Rodrigo et al., 2015; Pletz et al., 2016; Georgalis et 
al., 2017). One study from the Netherlands suggested that, based on the similarity of 
vaccine serotype trends between NIPP and IPD, their national IPD data could be used 
to extrapolate the trends of NIPP (van Werkhoven et al., 2016). However, there are 
also reasons to question predictions of NIPP trends from IPD data in all settings. 
Perhaps the most significant is that serotype distribution and the proportion of 
disease that is due to vaccine serotypes differs geographically and between IPD and 
NIPP (Benfield et al., 2013; Horácio et al., 2014). Moreover, vaccine serotypes are free 
to circulate in unvaccinated people so that, especially in countries where the PCVs 
are not included in national immunization programs, these can persist as causes of 
disease, both of NIPP and IPD. 
In Portugal, PCVs were available outside the national immunization program 
for pediatric use until mid-2015. The first PCV to become available was the 7-valent 
formulation (PCV7), in late-2001. Although the cost of vaccination was fully 
supported by the parents, the initially modest uptake of PCV7 increased steadily, 
reaching 75% in 2008 (Aguiar et al., 2008a). A 13-valent formulation (PCV13) replaced 
PCV7 in early-2010 but uptake declined, although it stayed above 60% (Silva-Costa et 
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al., 2018). In June 2015, PCV13 was included in the national immunization program to 
be given free of charge to all children born from January 2015 onwards, with a 2+1 
schedule (Silva-Costa et al., 2018). Besides children, sequential vaccination with 
PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPV23) is 
recommended since 2015 by the national health authorities, but only for specific risk 
groups (Direção Geral da Saúde, 2015b). In addition, two Portuguese medical societies 
(respiratory society and general practitioner society) have issued recommendations 
for the sequential vaccination with PCV13 and PPV23 of all immunocompetent adults 
≥ 65 years (Frões et al., 2014; Costa et al., 2016). Still, pneumococcal vaccine uptake in 
adults is generally believed to be low, with a study finding that < 9% of all adults ≥ 65 
years had received PPV23 (Sousa et al., 2009; Fedson et al., 2011).  
In a previous study we analyzed the distribution of serotypes in a randomly 
selected sample of 100 isolates/year collected from adult NIPP between 1999 and 2011 
(Horácio et al., 2014). In the present study we aimed to gain further insights regarding 
vaccine serotype trends in adult NIPP in the years that followed. We characterized 
isolates causing adult NIPP throughout Portugal from 2012 to 2015 for serotype 
distribution and antimicrobial susceptibility. We also wanted to compare the NIPP 
data with contemporary adult IPD data obtained by the same network. 
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Materials and Methods 
Ethics Statement 
The study was approved by the Institutional Review Board of the Centro 
Académico de Medicina de Lisboa. These were considered surveillance activities and 
were exempt from informed consent. All methods were performed in accordance with 
the relevant guidelines and regulations. The data and isolates were de-identified so 
that these were irretrievably unlinked to an identifiable person. 
 
Bacterial Isolates 
Isolates were provided by a laboratory-based surveillance system that includes 
30 microbiology laboratories throughout Portugal. These were asked to submit all 
consecutively collected pneumococci causing infections to the central laboratory. 
Although the laboratories were contacted periodically to submit the isolates to the 
central laboratory, no audit was performed to ensure compliance, which may be 
variable in this type of study. The identification of all isolates as Streptococcus 
pneumoniae was confirmed by colony morphology and hemolysis on blood agar 
plates, optochin susceptibility and bile solubility. 
The isolates included in this study were recovered from sputum, bronchial 
secretions or bronchoalveolar lavage of adult patients (≥ 18 yrs) with a presumptive 
diagnosis of pneumonia between 2012 and 2015. Isolates were not included when 
pneumococci were simultaneously isolated from blood or another usually sterile 
product, and when other potential bacterial pathogens besides pneumococci were 
detected in the sample (such as Haemophilus influenzae, which was also frequently 
detected). Only one isolate from each patient in each year was considered. 
 
Serotyping and Antimicrobial Susceptibility Testing 
Serotyping was performed by the standard capsular reaction test using the 
chessboard system and specific sera (Statens Serum Institut, Copenhagen, Denmark) 
(Sørensen, 1993). Serotypes were classified into vaccine serotypes, i.e., those included 
in PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), in PCV13 (all PCV7 serotypes and the 
additional serotypes present only in PCV13, addPCV13: 1, 3, 5, 6A, 7F and 19A), in 
PPV23 (all PCV13 serotypes, except serotype 6A, and the additional serotypes present 
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only in PPV23, addPPV23: 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F) and non-
vaccine serotypes (NVT, including all other serotypes). Given the high frequency of 
spontaneous switching between serotypes 15B and 15C we have opted to group isolates 
with these serotypes into a single group. Due to difficulties in phenotypically 
distinguishing isolates of serotype 25A and serogroup 38 and of serogroup 29 and 
serotype 35B these were also grouped together into the 25A/38 and 29/35B groups. 
The isolates that were not typable with any of the complete set of sera were 
considered non-typable (NT). 
Minimum inhibitory concentrations (MICs) for penicillin and cefotaxime were 
determined using Etest strips (Biomérieux, Marcy-L’Etoile, France). Unless otherwise 
stated, the results were interpreted using the Clinical and Laboratory Standards 
Institute (CLSI) recommended breakpoints prior to 2008 (Clinical and Laboratory 
Standards Institute, 2007), corresponding to the current breakpoints of oral penicillin 
V allowing comparison with previously published data. According to these criteria, 
intermediate resistance to penicillin is defined as MIC 0.12–1.0 µg/ml and high-level 
resistance as MIC ≥ 2.0 µg/ml. Isolates that fell into either one of these classes were 
designated penicillin non-susceptible (PNSP). The interpretation according to the 
current CLSI guidelines was also performed (Clinical and Laboratory Standards 
Institute, 2015). According to these criteria, for non-meningitis cases, intermediate 
resistance to penicillin is defined as MIC between 2–8 μg/ml and high-level resistance 
as MIC > 8 μg/ml. Susceptibility to cefotaxime was defined as MIC ≤ 1.0 µg/ml. The 
Kirby-Bauer disk diffusion assay was used to determine susceptibility to levofloxacin, 
erythromycin, clindamycin, chloramphenicol, trimethoprim/sulfamethoxazole, 
tetracycline, vancomycin and linezolid, according to the CLSI recommendations and 
interpretative criteria (Clinical and Laboratory Standards Institute, 2015). Macrolide 
resistance phenotypes were identified using a double disc test with erythromycin and 
clindamycin, as previously described (Horácio et al., 2014). The MLSB phenotype 
(resistance to macrolides, lincosamides and streptogramin B) was defined as the 
simultaneous resistance to erythromycin and clindamycin, while the M phenotype 
(resistance to macrolides) was defined as non-susceptibility only to erythromycin. 
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Statistical Analysis 
Sample diversity was measured using Simpson’s index of diversity (SID) and the 
respective 95% confidence intervals (CI95%) (Carriço et al., 2006). To compare two 
sets of partitions the Adjusted Wallace (AW) coefficients were calculated (Carriço et 
al., 2006) using the online tool available at www.comparingpartitions.info. 
Differences were evaluated by the Fisher exact test with the false discovery rate (FDR) 
correction for multiple testing (Benjamini and Hochberg, 1995) or the Chi-squared 
test, and the Cochran-Armitage test was used for trends. A p < 0.05 was considered 
significant for all tests. 
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Results 
Serotype Distribution 
A total of 1435 isolates were collected from adults with non-invasive 
pneumococcal pneumonia: n = 368 in 2012, n = 319 in 2013, n = 311 in 2014 and n = 437 
in 2015. Stratifying by age group, 339 isolates (23.6%) were recovered from patients 
18–49 years old, 382 (26.6%) from patients 50–64 years old and 714 (49.8%) from 
patients ≥ 65 years old. Most of the isolates were recovered from sputum (n = 787, 
54.8%), 531 (37.0%) were recovered from bronchial secretions and 117 (8.2%) were 
recovered from bronchoalveolar lavage fluid. A total of 50 different serotypes were 
detected. The most frequent serotypes, which accounted for 52% of the isolates, were 
serotypes 3 (n = 196, 13.7%), 11A (n = 120, 8.4%), 19F (n = 85, 5.9%), 23A (n = 67, 4.7%), 
6C (n = 64, 4.5%), 19A (n = 58, 4.0%), 23B (n = 56, 3.9%), 9N (n = 52, 3.6%) and NT 
isolates (n = 50, 3.5%).  
The IVb.S1 Fig represent the number of isolates expressing serotypes included 
in PCVs, the addPPV23, and the number of isolates expressing NVTs, respectively, 
stratified by age group. Serotype diversity was high – SID = 0.952, CI95%: 0.948–0.956 
– with no difference between SIDs of different years.  No individual serotype (n > 15 
isolates) showed differences in age distribution, statistically supported after FDR 
correction. 
Fig IVb.1 shows the proportion of potentially vaccine preventable NIPP during 
the study period and, for comparison purposes, also the previously published data 
from 2007-2011, since these years represent the late post-PCV7 period (2007-2009) 
and the first two years of PCV13 use in children (2010-2011) (Horácio et al., 2014). 
Considering the evolution during the current study period only (2012–2015), there was 
a decline in the proportion of NIPP caused by PCV13 serotypes, from 34.5% in 2012 to 
29.7% in 2015, but this was not statistically supported (p = 0.090). This decline was 
associated with slight and non-significant decreases in both the proportion of NIPP 
caused by PCV7 serotypes (from 13.6% to 11.0%, p = 0.177) and addPCV13 (from 20.9% 
to 18.8%, p = 0.377). In contrast, there was a non-significant increase in the proportion 
of NIPP caused by addPPV23 (from 24.7% in 2012 to 28.4% in 2015, p = 0.325), while 
the proportion of NIPP caused by NVTs remained relatively stable from 2012 to 2015
Figure IVb.1 Proportion of isolates expressing serotypes included in each of the pneumococcal vaccines causing non-invasive pneumococcal pneumonia in adult patients (≥18 years) in 
Portugal, 2007–2015. The data up to 2011 were presented previously (Horácio et al., 2014). 
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(40.8% vs 41.9%, respectively, p = 0.460). 
We then evaluated possible serotype trends since 2010 when PCV13 started 
being used in children through the private market. The overall proportion of PCV13 
serotypes declined from 44.0% in 2010 to 29.7% in 2015 (p < 0.001), while that of 
addPCV13 decreased from 36.0% in 2010 to 18.8% in 2015 (p < 0.001). This was 
accompanied by an increase of  NVTs from 27.0% in 2010 to 41.9% in 2015 (p = 0.002). 
The PCV7 and addPPV23 serotypes remained relatively stable 
Table IVb.1 shows the evolution of the individual serotypes causing NIPP in 
adults during the current study period (2012-2015).  
Table IVb.1 Serotypes of the isolates responsible for non-invasive 
pneumococcal pneumonia in adult patients (≥18 years), 2012–2015. 
Serotype No. of isolates (%) CA 
a 
2012 2013 2014 2015 2012-2015 
PCV13 
1 2 (0.5) 0 (0) 0 (0) 1 (0.2) 0.399 
3 48 (13.0) 54 (16.9) 41 (13.2) 53 (12.1) 0.408 
4 1 (0.3) 1 (0.3) 2 (0.6) 3 (0.7) 0.329 
5 0 (0) 0 (0) 0 (0) 0 (0)  - 
6A 5 (1.4) 7 (2.2) 6 (1.9) 9 (2.1) 0.547 
6B 7 (1.9) 4 (1.3) 4 (1.3) 6 (1.4) 0.578 
7F 5 (1.4) 4 (1.3) 4 (1.3) 5 (1.1) 0.800 
9V 0 (0) 5 (1.6) 0 (0) 0 (0) 0.275 
14 12 (3.3) 6 (1.9) 6 (1.9) 10 (2.3) 0.426 
18C 4 (1.1) 1 (0.3) 1 (0.3) 1 (0.2) 0.106 
19A 17 (4.6) 9 (2.8) 18 (5.8) 14 (3.2) 0.645 
19F 22 (6.0) 22 (6.9) 15 (4.8) 26 (5.9) 0.746 
23F 4 (1.1) 2 (0.6) 4 (1.3) 2 (0.5) 0.483 
PPV23 only 
8 7 (1.9) 10 (3.1) 6 (1.9) 16 (3.7) 0.222 
9N 11 (3.0) 13 (4.1) 16 (5.1) 12 (2.7) 0.942 
10A 11 (3.0) 6 (1.9) 5 (1.6) 10 (2.3) 0.519 
11A 29 (7.9) 29 (9.1) 22 (7.1) 40 (9.2) 0.703 
12F 0 (0) 0 (0) 0 (0) 0 (0)  - 
15B/C 6 (1.6) 11 (3.4) 7 (2.3) 10 (2.3) 0.807 
17F 8 (2.2) 4 (1.3) 8 (2.6) 4 (0.9) 0.319 
20 5 (1.4) 5 (1.6) 6 (1.9) 8 (1.8) 0.557 
22F 14 (3.8) 8 (2.5) 6 (1.9) 21 (4.8) 0.448 
33F 0 (0) 0 (0) 2 (0.6) 3 (0.7) 0.048 
NVT b 
6C 19 (5.2) 16 (5.0) 7 (2.3) 22 (5.0) 0.627 
23A 24 (6.5) 12 (3.8) 14 (4.5) 17 (3.9) 0.130 
23B 15 (4.1) 8 (2.5) 15 (4.8) 18 (4.1) 0.631 
NT 9 (2.4) 8 (2.5) 16 (5.1) 17 (3.9) 0.123 
15A 10 (2.7) 9 (2.8) 8 (2.6) 16 (3.7) 0.465 
31 15 (4.1) 7 (2.2) 14 (4.5) 12 (2.7) 0.587 
16F 7 (1.9) 10 (3.1) 3 (1.0) 20 (4.6) 0.070 
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Table IVb.1 (continued). 
Serotype No. of isolates (%) CA 
a 
2012 2013 2014 2015 2012-2015 
NVTb 
29/35B 12 (3.3) 6 (1.9) 6 (1.9) 10 (2.3) 0.426 
35F 5 (1.4) 3 (0.9) 6 (1.9) 14 (3.2) 0.033 
34 3 (0.8) 8 (2.5) 5 (1.6) 8 (1.8) 0.445 
21 3 (0.8) 6 (1.9) 7 (2.3) 8 (1.8) 0.265 
24F 4 (1.1) 2 (0.6) 6 (1.9) 10 (2.3) 0.082 
33A 6 (1.6) 1 (0.3) 5 (1.6) 0 (0) 0.052 
25A/38 7 (1.9) 2 (0.6) 0 (0) 0 (0) 0.001 
35A 2 (0.5) 3 (0.9) 4 (1.3) 2 (0.5) 0.946 
7C 2 (0.5) 2 (0.6) 6 (1.9) 1 (0.2) 0.946 
13 2 (0.5) 3 (0.9) 1 (0.3) 1 (0.2) 0.333 
37 1 (0.3) 4 (1.3) 1 (0.3) 3 (0.7) 0.802 
Others c 4 (1.1) 8 (2.5) 8 (2.6) 4 (0.9)  - 
Total 368 319 311 437  - 
aCA, Cochran Armitage test of trend. In bold is the only serotype with 
significant p-value (p < 0.05) after FDR correction. bNVT, non-vaccine 
serotypes, i.e., serotypes not included in any of the currently available 
pneumococcal vaccines. cOnly serotypes detected in ≥3 isolates in at least 
one year are shown; the remaining are grouped together under “Others.” 
Only serotype 25A/38 significantly changed its proportion after FDR correction 
(from 1.9% in 2012 to 0.0% in 2015, p = 0.001). When considering the evolution of 
individual serotypes since 2007 (Table IVb.1 and Table IVb.S1), only four serotypes 
significantly changed their proportion after FDR correction (Fig IVb.S2), which were 
serotypes 3 (declined from 22.0% in 2007 to 12.1% in 2015, p < 0.001), 19A (declined 
from 6.0% in 2007 to 3.2% in 2015, p = 0.003), 7F (declined from 3.0% in 2007 to 1.1% 
in 2015, p = 0.004) and 35F (increased from 0% in 2007 to 3.2% in 2015, p = 0.003). The 
declines in proportion of serotypes 3 and 19A showed important yearly fluctuations 
and these were also found for several other serotypes (Table IVb.1 and Table IVb.S1). 
When analyzing the evolution of individual vaccine serotypes and of vaccine 
serotype groups in 2012-2015 stratified by age group (Table IVb.2), there were no 
significant changes after FDR correction. When considering data since 2007, only for 
serotype 3 and for adults aged ≥ 65 years old did the change remain statistically 
supported after FDR correction (serotype 3 declined from 27.5% in 2007 to 11.1% in 
2015, p < 0.001). 
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Table IVb.2 Number of isolates responsible for non-invasive pneumococcal 
pneumonia in adult patients (≥18 years), according to vaccine serotype groups 
and age groups, 2012–2015. 
 Serotype Groupsb No. isolates (%) C. A.a
2012 2013 2014 2015 
18-49 yrs
PCV7 12 (12.9) 11 (16.4) 8 (10.3) 16 (15.8) 0.782 
1, 5 and 7F 1 (1.1) 1 (1.5) 2 (2.6) 1 (1.0) 0.926 
3, 6A and 19A 19 (20.4) 11 (16.4) 10 (12.8) 20 (19.8) 0.800 
PCV13 32 (34.4) 23 (34.3) 20 (25.6) 37 (36.6) 0.983 
PPV23 add 25 (26.9) 15 (22.4) 28 (35.9) 30 (29.7) 0.417 
NVTs 36 (38.7) 29 (43.3) 30 (38.5) 34 (33.7) 0.385 
50-64 yrs
PCV7 12 (14.1) 7 (8.4) 7 (7.4) 8 (6.7) 0.328 
1, 5 and 7F 3 (3.5) 0 (0) 1 (1.1) 1 (0.8) 0.656 
3, 6A and 19A 15 (17.6) 23 (27.7) 23 (24.2) 19 (16.0) 0.095 
PCV13 30 (35.3) 30 (36.1) 31 (32.6) 28 (23.5) 0.026 
PPV23 add 45 (18.8) 50 (27.7) 53 (24.2) 65 (32.8) 0.082 
NVTs 39 (45.9) 30 (36.1) 41 (24.2) 52 (32.8) 0.531 
≥65 yrs 
PCV7 26 (13.7) 23 (13.6) 17 (12.3) 24 (11.1) 0.381 
1, 5 and 7F 3 (1.6) 3 (1.8) 1 (0.7) 4 (1.8) 0.976 
3, 6A and 19A 36 (18.9) 36 (21.3) 32 (23.2) 37 (17.1) 0.665 
PCV13 65 (34.2) 62 (36.7) 50 (36.2) 65 (30.0) 0.332 
PPV23 add 50 (26.3) 48 (28.4) 27 (19.6) 55 (25.3) 0.078 
NVTs 75 (39.5) 59 (34.9) 61 (44.2) 97 (44.7) 0.125 
aCA, Cochran Armitage test of trend. bPCV7, serotypes included in the 7-valent 
pneumococcal conjugate vaccine. PCV13, serotypes included in the 13-valent 
pneumococcal conjugate vaccine. addPPV23, the additional 11 serotypes present in the 
23-valent pneumococcal polysaccharide vaccine but absent from PCV13. NVTs,
serotypes not included in any of the currently available pneumococcal vaccines.
Antimicrobial Susceptibility 
Susceptibility to the tested antimicrobials between 2012 and 2015 stratified by 
the age groups considered is summarized in Table IVb.3. When considering all 
isolates, a total of n = 258 isolates (18.0%) were classified as PNSP of which n = 229 
(88.8%) expressed low-level resistance and n = 29 (11.2%), high-level resistance. 
According to the current CLSI guidelines for parental penicillin in non-meningitis 
cases (Clinical and Laboratory Standards Institute, 2015), only n = 15 isolates (1.0%) 
would have been considered PNSP, with only 2 of these expressing high-level 
resistance. A total of n = 311 isolates (21.7%) were classified as erythromycin resistant 
pneumococci (ERP). Of these, n = 246 isolates (79.1%) expressed the MLSB phenotype, 
while the remaining (n = 65, 20.9%) presented the M phenotype. A total of 12.3% (n = 
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176) of the isolates were simultaneously non-susceptible to penicillin and resistant to
erythromycin (EPNSP).
There were no significant variations in antimicrobial resistance during the 
current study period (2012-2015), nor were there significant changes in antimicrobial 
resistance when considering NIPP from 2007 (Horácio et al., 2014). Although with 
moderate overall AW values [the AW for serotype to PNSP was 0.441 (CI95%: 0.386-
0.496) and the AW for serotype to ERP was 0.443 (CI95%: 0362-0.524)], there was an 
association between certain serotypes and antimicrobial resistance (Fig IVb.S1). The 
serotypes that were positively associated with PNSP after FDR correction were 
serotypes 6C, 14, 15A, 19F, 19A and 23F. Among these, serotypes 19F (15.5%), 14 (12.4%), 
6C (12.0%) and 19A (11.6%) accounted for half of all PNSP. The serotypes which were 
positively associated with ERP after FDR correction were serotypes 6B, 6C, 14, 15A,19F, 
19A, 33A and 35A, of which serotypes 19F (20.3%), 19A (10.6%), 6C (9.6%) and 15A 
(8.0%) accounted for half of all ERP. The PCV7, PCV13 and PPV23 serotypes 
accounted for 33.7%, 47.3% and 53.5% of PNSP, respectively, and 33.4%, 49.5% and 
54.3% of ERP, respectively. 
Table IVb.3 Antimicrobial resistance of the isolates responsible for non-invasive 
pneumococcal pneumonia in adult patients (≥18 years) in Portugal, 2012–2015. 
No. resistant isolates (%)a 
18-49 years (n = 339) 50-64 years (n = 382) ≥65 years (n = 714)
PENb 57 (16.8) 70 (18.3) 131 (18.3) 
MIC90 0.19 0.19 0.38 
MIC50 0.012 0.012 0.012 
CTX 7 (2.1) 7 (1.8) 4 (0.6) 
MIC90 0.25 0.25 0.38 
MIC50 0.015 0.016 0.016 
LEV 2 (0.6) 3 (0.8) 16 (2.2) 
ERY 73 (21.5) 70 (18.3) 168 (23.5) 
CLI 56 (16.5) 58 (15.2) 136 (19.0) 
CHL 7 (2.1) 7 (1.8) 4 (0.6) 
SXT 57 (16.8) 66 (17.3) 104 (14.6) 
TET 59 (17.4) 55 (14.4) 115 (16.1) 
aPEN, penicillin; CTX, cefotaxime; LEV, levofloxacin; ERY, erythromycin; CLI, 
clindamycin; CHL, chloramphenicol; SXT, trimethoprim/sulfamethoxazole; 
TET, tetracycline. All isolates were susceptible to vancomycin and linezolid. 
bNon-susceptibitily to penicillin was determined using the CLSI breakpoints 
prior to 2008 (Clinical and Laboratory Standards Institute, 2007). 
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Discussion 
The present study documented a decline of PCV13 serotypes in adult NIPP in 
the post-PCV13 period. This occurred mostly in 2011-2012 but continued, albeit more 
moderately, in recent years, from 44.0% in 2010 to 29.7% in 2015. It was also noted 
that during 2007-2015 there were several important yearly fluctuations in the 
proportion of individual serotypes, both among PCV13 and non-PCV13 serotypes 
(Table IVb.1 and Table IVb.S1). This suggests that variations of the PCV13 serotypes in 
the post-PCV13 period in adult NIPP could be the result of, not only the herd 
protection conferred by childhood vaccination with PCV13, but also of temporal 
trends, which had been documented in adult NIPP in Portugal previously (Horácio et 
al., 2014). 
The evolution of PCV13 serotypes in adult NIPP from 2010 onwards (when PCV13 
was being used for children vaccination in the private market) was different from the 
one previously found for adult IPD in Portugal in a similar period (Horácio et al., 
2016b). While in NIPP the sharpest decrease in addPCV13 serotypes in the post-PCV13 
period occurred from 2011 to 2012, in IPD this occurred only from 2012 to 2013. 
Although the decrease of addPCV13 serotypes in adult NIPP may have been also 
influenced by temporal trends, the sustained lower values found from 2013 onwards 
suggest an important contribution of herd protection resulting from PCV13 childhood 
vaccination. 
Serotypes 3 and 19A had a major influence in the decrease of PCV13 serotypes in 
adult NIPP in the post-PCV13 period (2010-2015), although these changes were also 
most significant in the first years (Table IVb.1 and Table IVb.S1). Similarly, in adult 
IPD two serotypes accounted for most of the decline in the prevalence of PCV13 
serotypes in the post-PCV13 period, but in this case these were serotypes 7F and 19A 
(Horácio et al., 2016b). In contrast with the declines of serotypes 3 and 19A in adult 
NIPP, the decreases of serotypes 7F and 19Ain adult IPD were more pronounced and 
sustained.  
Serotype 3 has been the dominant serotype in adult NIPP and IPD in Portugal, 
both before and after the introduction of PCV13 for children (Horácio et al., 2014; 
Horácio et al., 2016b). The decline in serotype 3 in NIPP is surprising because this 
serotype did not show major changes in adult IPD in the post-PCV13 period in 
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Portugal (Horácio et al., 2016b) nor in other countries (Steens et al., 2013; Harboe et 
al., 2014; Moore et al., 2015; Waight et al., 2015; Ladhani et al., 2018). However, 
reductions in incidence of serotype 3 NIPP was reported in other studies, including a 
study from England (Rodrigo et al., 2015). The reduced efficacy of PCV13 in preventing 
pediatric complicated pneumonias caused by serotype 3 (Silva-Costa et al., 2018) and 
the use of PCV13 outside of the national immunization program with somewhat 
modest uptake, raise the possibility of continued circulation of this serotype in 
carriage, potentially explaining its persistence in disease. Since serotype 3 is 
heterogeneous in its invasive disease potential, meaning that there are different 
clones expressing this serotype that differ in their capacity to cause invasive disease 
(Sá-Leão et al., 2011), it is possible that more invasive clones of serotype 3 have 
increased post-PCV use for reasons that remain unknown. In adult IPD, there was an 
expansion of the multilocus sequence type clonal complex CC180 among isolates 
expressing serotype 3 (Horácio et al., 2016a), prior to the use of PCV13 in children, but 
no information is available in the post-vaccine period. 
Serotype 19A emerged in Portugal in the late post-PCV7 period, to become one 
of the most important serotypes in both adult NIPP (Horácio et al., 2014) and IPD 
(Horácio et al., 2012; Horácio et al., 2013; Horácio et al., 2016b). A decrease of serotype 
19A in adult IPD and in NIPP in the post-PCV13 period was documented not only for 
Portugal but for other countries (Mendes et al., 2015; Moore et al., 2015; Rodrigo et al., 
2015; Waight et al., 2015; Ladhani et al., 2018). Given the compelling evidence of herd 
protection in adult IPD resulting from PCV13 use in children in serotype 19A, the lack 
of a more significant reduction of serotype 19A in adult NIPP in the post-PCV13 period 
could be due to a particular propensity of this serotype to cause NIPP. A clearer 
picture of the impact of PCV13 use in children in reducing the importance of serotypes 
3 and 19A in adult NIPP may only be provided by further studies following the 
epidemiology of adult NIPP after the inclusion of PCV13 in the national immunization 
plan. 
A decrease in serotype 7F was also detected but its contribution to the reduction 
of PCV13 serotypes in NIPP was minor since this serotype was an uncommon cause of 
NIPP in the pre-PCV13 period. 
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Contrasting with the declining trend of PCV13 serotypes, no significant trend 
was seen for PCV7 serotypes in adult NIPP and this was mostly due to the persistence 
of serotype 19F, which occurred in 49% of the isolates expressing a PCV7 serotype in 
2012-2015. Despite being targeted by all PCVs available to date, serotype 19F remained 
common in nasopharyngeal carriage of children in Portugal in the late post-PCV7 
period (Horácio et al., 2012) and in the post-PCV13 period (Rodrigues et al., 2013) 
including among vaccinated children. The inability of the PCVs to eliminate this 
serotype from carriage in children, at least in a non-universal coverage scenario, 
together with its likely intrinsic propensity to cause NIPP rather than IPD (Horácio 
et al., 2014) as was also shown here, may have contributed to why this serotype 
remained the third most frequent cause of adult NIPP in the post-PCV13 period in 
Portugal. 
The decrease of PCV13 serotypes in the post-PCV13 period was accompanied by 
an increase in the proportion of NVTs, while the addPPV23 serotypes remained 
relatively stable. However, among the NVTs, only one serotype was clearly emerging 
(serotype 35F) and only in the last year of the study period. Most of the remaining 
increase in NVTs was based in increases in the proportion of serotypes 16F, 24F and 
NTs (Table IVb.1 and Table IVb.S1), which were not significant if considered 
independently. This contrasts with results from adult IPD, in which there were several 
non-PCV13 emerging serotypes (serotypes 8, 22F, 20 and 15A), most of them included 
in PPV23 (Horácio et al., 2016b).  These differences are not surprising, since isolates 
responsible for adult NIPP and adult IPD are known to have different serotype 
distributions (Benfield et al., 2013; Horácio et al., 2014). 
When comparing the serotype distribution of the isolates causing adult NIPP in 
2012-2014 n 2012–2014 with the serotype distribution of isolates causing adult IPD in 
the same period (Table IVb.S2), serotypes 11A, 19F, 23A, 23B, 31, NT, 17F, 6A, 21 and 37 
(ranked by their frequency in NIPP) were significantly associated with NIPP, while 
serotypes 8, 19A, 22F, 14, 7F, 20, 1, 4 and 12B (ranked by their frequency in IPD) were 
significantly associated with IPD. Most of these associations had been already 
recognized in the pre-PCV13 period (Horácio et al., 2014), while the new associations 
in adult IPD reflect mainly the emerging serotypes in the post-PCV13 period. 
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While antimicrobial resistance declined in adult IPD in the post-PCV13 period, 
no decline was found for adult NIPP in this study. In NIPP, the small decrease in 
proportion of the mostly antimicrobial resistant serotype 19A isolates, was balanced 
by an increase of NT isolates, which were also associated with antimicrobial 
resistance. NTs were found to be frequent colonizers of the nasopharynx of children 
in the post-PCV13 period (Rodrigues et al., 2013) and were more frequently found in 
NIPP than in IPD (Table IVb.S2). The stability of PCV7 serotypes in the post-PCV13 
period also helped maintaining antimicrobial resistance rates in adult NIPP (Horácio 
et al., 2014).  
The study presented has the limitations discussed previously (Horácio et al., 
2014). These include the possibility that some of the isolates we identified as being 
responsible for NIPP were in fact causing bacteremic pneumonia or reflected 
colonization and not disease. Despite the general recommendation that both blood 
and respiratory tract samples should be collected for the etiologic diagnosis of 
pneumonia, we cannot guarantee that this was done in all cases. However, we 
consider these to account, at most, for a small fraction of the isolates and therefore 
not to introduce a significant bias. Moreover, the distinct serotype distribution found 
in this study for IPD and NIPP, strongly argues against this possibility. Since our study 
is laboratory-based, it was not designed to collect information important to assess the 
severity of the infections caused by the different serotypes (e.g. hospitalization, ICU 
admission, 30-day mortality). However, this does not compromise our approach of 
comparing the serotype distribution of IPD and NIPP cases. Our temporal analyses 
were based on previously published data reporting the characteristics of a random 
sample of 100 isolates per year (Horácio et al., 2014). Since not all available isolates 
before 2012 were characterized, it is possible that some of the changes in the serotype 
distribution occurring from 2011 to 2012 are due to this sampling process. 
In this study it was found that the overall proportion of PCV13 serotypes 
decreased only moderately in adult NIPP in the post-PCV13 period. In 2015, 30% of 
NIPP was due to PCV13 serotypes and 28% was due to the addPPV23 serotypes, 
highlighting the potential role of vaccination in disease prevention. However, the 
inclusion of PCV13 in the national immunization program for children in 2015 and the 
anticipated declines in at least some of the PCV13 serotypes due to herd effect, raise 
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important issues regarding the cost-effectiveness of a universal adult vaccination 
program. However, because the magnitude and timeframe of this herd effect remains 
poorly defined, particularly in NIPP, further surveillance is essential to document 
future trends in pneumococcal serotype prevalence in adult NIPP, as these seem to 
differ from adult IPD. 
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Fig IVb.S1. Number of isolates expressing each serotype causing non-invasive pneumococcal pneumonia in adult patients (≥18 yrs), Portugal, 2012-2015. The number of isolates expressing 
each serotype in each of the age groups considered is indicated. Isolates recovered from patients 18-49 years are indicated by black triangles. Isolates recovered from patients 50-64 years are 
indicated by open squares. Isolates recovered from patients ≥ 65years are indicated by open circles. Isolates presenting both erythromycin resistance and penicillin non-susceptibility (EPNSP) are 
represented by closed black bars. Penicillin non-susceptible isolates (PNSP) are indicated by dark hatched bars. Erythromycin resistant pneumococci (ERP) are indicated by light hatched bars. 
Isolates susceptible to both penicillin and erythromycin are represented by white open bars. Panel A - Serotypes included in conjugate vaccines. The serotypes included in the seven-valent conjugate 
vaccine (PCV7) and in the 13-valent conjugate vaccine (PCV13) are indicated by the arrows. NVT, non-vaccine serotypes; addPPV23, the additional serotypes included in the 23-valent 
polysaccharide vaccine but not included in PCV13. Panel B - Additional serotypes included in the 23-valent polysaccharide vaccine but not included in the 13-valent conjugate vaccine. Out of the 
11 addPPV23 serotypes only serotype 2 was not found in our collection. Panel C - Serotypes not included in any pneumococcal vaccine. NT, non-typable. Isolates expressing serotypes 25A and 
38 and serotypes 29 and 35B could not be distinguished phenotypically and are represented together. Only serotypes including n>3 isolates are discriminated, all remaining serotypes are grouped 
together under the “Others” category grouping isolates of serotypes: 10B, 12B, 17A, 18A (n=3 each); 10F, 11F, 11B and 47F (n=2 each) and 28A, 35C, 36 and 42 (n=1 each).
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Table IVb.S1: Serotypes of the isolates responsible for non-invasive 
pneumococcal pneumonia in adult patients (≥18 years), 2007–2011. These data 
were presented previously (Horácio et al., 2014). 
Serotypea No. of isolates  CA
b 
2007 2008 2009 2010 2011 2007-2015 
PCV13       
1 0 0 3 2 1 0.039 
3 22 28 9 22 18 <0.001 
4 1 0 0 1 1 0.776 
5 0 0 2 0 0 0.041 
6A 3 3 2 4 3 0.342 
6B 3 1 0 1 0 0.926 
7F 3 4 4 4 2 0.004 
9V 3 0 0 0 0 0.048 
14 4 3 4 2 3 0.172 
18C 0 2 0 0 0 0.435 
19A 6 9 11 4 9 0.003 
19F 6 3 7 4 6 0.682 
23F 3 4 1 0 1 0.011 
PPV23 
only           
8 3 0 3 2 5 0.316 
9N 1 0 4 6 2 0.184 
10A 2 0 2 1 1 0.394 
11A 9 8 4 10 7 0.582 
12F 0 0 0 0 1 0.555 
15B/C 1 2 4 3 3 0.864 
17F 1 2 0 0 3 0.734 
20 0 1 1 0 2 0.087 
22F 6 3 3 7 6 0.398 
33F 0 0 0 0 0 0.035 
NVT        
6C 2 4 10 5 2 0.786 
23A 3 4 3 1 2 0.440 
23B 2 2 4 3 7 0.308 
NT 1 3 2 1 2 0.021 
15A 2 3 4 2 4 0.632 
31 2 1 1 1 0 0.063 
16F 2 2 2 3 0 0.097 
29/35B 2 1 2 4 2 0.974 
35F 0 0 1 1 1 0.003 
34 0 0 0 1 2 0.023 
21 0 0 1 1 0 0.015 
24F 2 0 2 0 0 0.133 
33A 0 1 2 1 1 0.373 
25A/38 1 2 1 0 0 0.024 
35A 0 1 0 0 0 0.305 
7C 0 0 0 0 0 0.102 
13 1 0 0 1 1 0.600 
37 0 0 0 0 0  0.102 
Othersc 3 3 1 2 2  - 
Total 100 100 100 100 100  - 
aNVT, non-vaccine serotypes, i.e., serotypes not included in any of the currently available 
pneumococcal vaccines. bCA, Cochran Armitage test of trend. In bold are the serotypes 
with significant p-value (p < 0.05) after FDR correction. cOnly serotypes detected in ≥3 
isolates or in at least 2 years are shown; the remaining are grouped together under “Others.” 
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Table IVb.S2: Serotype distribution of the isolates causing non-invasive 
pneumococcal pneumonia and invasive pneumococcal disease in adults 
in Portugal (2012–2014). 
Serotype n (%) OR b CI95% p value c 
  NIPP (n=998) IPD (n=1163) a       
3 143 (14.3) 161 (13.8) 1.1 (0.8-1.3) 0.757 
11A 80 (8.0) 49 (4.2) 2.0 (1.4-2.9) <0.001 
19F 59 (5.9) 27 (2.3) 2.6 (1.6-4.4) <0.001 
23A 50 (5.0) 26 (2.2) 2.3 (1.4-3.9) 0.001 
19A 44 (4.4) 84 (7.2) 0.6 (0.4-0.9) 0.006 
6C 42 (4.2) 28 (2.4) 1.8 (1.1-3.0) 0.020 
9N 40 (4.0) 39 (3.4) 1.2 (0.7-1.9) 0.424 
23B 38 (3.8) 12 (1.0) 3.8 (1.9-8.0) <0.001 
31 36 (3.6) 11 (0.9) 3.9 (1.9-8.6) <0.001 
NT 33 (3.3) 10 (0.9) 3.9 (1.9-9.0) <0.001 
22F 28 (2.8) 79 (6.8) 0.4 (0.2-0.6) <0.001 
15A 27 (2.7) 27 (2.3) 1.2 (0.7-2.1) 0.583 
14 24 (2.4) 73 (6.3) 0.4 (0.2-0.6) <0.001 
15B/C 24 (2.4) 22 (1.9) 1.3 (0.7-2.4) 0.456 
29/35B 24 (2.4) 26 (2.1) 1.1 (0.6-2.0) 0.886 
8 23 (2.3) 123 (10.6) 0.2 (0.1-0.3) <0.001 
10A 22 (2.2) 18 (1.5) 1.4 (0.7-2.9) 0.267 
16F 20 (2.0) 23 (2.0) 1.0 (0.5-1.9) 1 
17F 20 (2.0) 9 (0.8) 2.6 (1.1-6.6) 0.015 
6A 18 (1.8) 7 (0.6) 3.0 (1.2-8.6) 0.014 
20 16 (1.6) 39 (3.4) 0.5 (0.2-0.9) 0.009 
21 16 (1.6) 0 (0) Inf (4.5-inf) <0.001 
34 16 (1.6) 8 (0.7) 2.4 (0.9-6.4) 0.062 
6B 15 (1.5) 15 (1.3) 1.2 (0.5-2.6) 0.715 
35F 14 (1.4) 13 (1.1) 1.3 (0.5-2.9) 0.566 
7F 13 (1.3) 61 (5.2) 0.2 (0.1-0.4) <0.001 
24F 12 (1.2) 23 (2.0) 0.6 (0.3-1.3) 0.173 
33A 12 (1.2) 9 (0.8) 1.6 (0.6-4.2) 0.381 
7C 10 (1.0) 6 (0.5) 2.0 (0.6-6.6) 0.215 
23F 10 (1.0) 13 (1.1) 0.9 (0.3-2.2) 0.836 
25A/38 9 (0.9) 8 (0.7) 1.3 (0.4-3.9) 0.631 
35A 9 (0.9) 2 (0.2) 5.3 (1.1-50.3) 0.029 
13 6 (0.6) 2 (0.2) 3.5 (0.6-35.6) 0.155 
18C 6 (0.6) 7 (0.6) 1.0 (0.3-3.5) 1 
37 6 (0.6) 0 (0) Inf (1.4-inf) 0.010 
9V 5 (0.5) 9 (0.8) 0.6 (0.2-2.2) 0.593 
4 4 (0.4) 23 (2.0) 0.2 (0.1-0.6) 0.001 
12B 3 (0.3) 18 (1.5) 0.2 (0-0.7) 0.003 
17A 3 (0.3) 0 (0) Inf (0.5-inf) 0.098 
1 2 (0.2) 26 (2.2) 0.1 (0-0.4) <0.001 
10B 2 (0.2) 0 (0) Inf (0.2-inf) 0.213 
10F 2 (0.2) 1 (0.1) 2.3 (0.1-137.7) 0.599 
11B 2 (0.2) 2 (0.2) 1.2 (0.1-16.1) 1 
18A 2 (0.2) 3 (0.3) 0.8 (0.1-6.8) 1 
33F 2 (0.2) 3 (0.3) 0.8 (0.1-6.8) 1 
47F 2 (0.2) 1 (0.1) 2.3 (0.1-137.7) 0.599 
28A 1 (0.1) 1 (0.1) 1.2 (0-91.5) 1 
35C 1 (0.1) 0 (0) Inf (0-inf) 0.462 
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Table IVb.S2 (continued). 
Serotype n (%) OR b CI95% p value c 
  NIPP (n=998) IPD (n=1163) a       
36 1 (0.1) 0 (0) Inf (0-inf) 0.462 
42 1 (0.1) 0 (0) Inf (0-inf) 0.462 
5 0 (0) 1 (0.1) 0 (0-45.4) 1 
6D 0 (0) 1 (0.1) 0 (0-45.4) 1 
12A 0 (0) 2 (0.2) 0 (0-6.2) 0.503 
16A 0 (0) 2 (0.2) 0 (0-6.2) 0.503 
18F 0 (0) 2 (0.2) 0 (0-6.2) 0.503 
19B 0 (0) 1 (0.1) 0 (0-45.4) 1 
22A 0 (0) 1 (0.1) 0 (0-45.4) 1 
24A 0 (0) 2 (0.2) 0 (0-6.2) 0.502 
24B 0 (0) 1 (0.1) 0 (0-45.4) 1 
33B 0 (0) 2 (0.2) 0 (0-6.2) 0.503 
39 0 (0) 1 (0.1) 0 (0-45.4) 1 
aIPD - invasive pneumococcal disease. NIPP – non-invasive pneumococcal 
pneumonia. Data from IPD were published previously (Horácio et al., 
2016b). bOdds ratios and 95% confidence intervals (CI95%) were used to 
measure the association between serotype and disease presentation. cIn bold 
are significant p-values (p < 0.05) after FDR correction.
  
 
 
  
Figure IVb.S2 Proportion of isolates expressing serotypes that changed in proportion after FDR correction causing non-invasive pneumococcal pneumonia in adult patients (≥18 years) 
in Portugal, 2007–2015. The data up to 2011 were presented previously (Horácio et al., 2014). 
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The high morbidity and mortality associated with pneumococcal infections 
boosted a search for vaccines that could prevent these infections in individuals at high 
risk for pneumococcal disease. PCV7, which was the first licensed pneumococcal 
vaccine to be effective in young children, became available in the beginning of the 
21st century and had a tremendous impact on the epidemiology of pneumococci 
causing disease in children (Vestrheim et al., 2008; Rückinger et al., 2009; Pilishvili et 
al., 2010; Steens et al., 2013). Remarkably, the use of PCV7 in children protected not 
only vaccinated children, but also the surrounding non-vaccinated population, with 
several studies showing that vaccinating children with PCV7 resulted in marked 
decreases of PCV7-type IPD in adults (e.g. Lexau et al., 2005; Miller et al., 2011b; 
Harboe et al., 2014). However, at the same time, there were also increases in the 
incidence of non-PCV7-type IPD in children and adults (Lepoutre et al., 2008; Miller 
et al., 2011b; Weinberger et al., 2011; Feikin et al., 2013). This situation reduced the 
benefits of childhood vaccination with PCV7 and led to the development of broader 
PCVs capable of preventing IPD due to the emerging serotypes. PCV13 replaced PCV7 
in the USA and in several countries in Europe. Similarly to PCV7, the use of PCV13 in 
children was followed by decreases in the incidence of vaccine-type IPD in children 
and adults (Moore et al., 2015; Tin Tin Htar et al., 2015).  
Portugal was for several years in a particular position given that PCVs were used 
privately in children from June 2001 to June 2015, leading to an uptake below that 
reached in most other countries adopting PCVs (Aguiar et al., 2008a; Tin Tin Htar et 
al., 2015; Horácio et al., 2016b). The work presented in this thesis aimed to 
characterize possible effects of having vaccinated children with PCVs outside the 
national immunization program on the characteristics of pneumococci causing 
disease in adults. For that purpose, the serotype and antimicrobial susceptibility of 
isolates causing adult IPD (Horácio et al., 2013; Horácio et al., 2016b) or adult NIPP 
(Horácio et al., 2014; Horácio et al., 2018) were determined. For the isolates collected 
from adult IPD, the clonal structure and prevalence of the pilus islands 1 and 2 were 
also assessed (Horácio et al., 2016a). 
 
Chapter V 
 
192 
 
Invasive Pneumococcal Disease 
Evolution of Vaccine Serotypes in Adult IPD 
The studies of adult IPD presented in this thesis continued an epidemiological 
surveillance study initiated in 1999. Figure V.S1 shows the evolution of vaccine 
serotypes in adult IPD in Portugal in the broad period 1999-2014. Previous studies 
from this epidemiological surveillance network evaluated the possible impact of the 
private use of PCV7 in children on adult IPD and found that even a low PCV7 uptake 
in children possibly caused some degree of herd protection in adults against PCV7-
type IPD (Aguiar et al., 2008a; Horácio et al., 2012). The proportion of PCV7 serotypes 
in adult IPD declined from 30.8% in 2004 to 16.6% in 2005 (p < 0.001), one year after 
the first changes occurring in IPD in children that were compatible with the use of 
PCV7 (Aguiar et al., 2008a). However, even with the significant decline of PCV7 
serotypes in adult IPD, PCV7 serotypes still accounted for > 15% of adult IPD in the 
post-PCV7 period in Portugal (Horácio et al., 2012). These serotypes also persisted as 
a cause of IPD in children in Portugal (Aguiar et al., 2010a). This remaining burden of 
PCV7 serotypes in IPD in children and adults in the post-PCV7 period contrasted with 
the reality in the USA, where PCV7 serotypes declined more markedly (Pilishvili et 
al., 2010). This difference between Portugal and the USA was probably associated with 
the slow uptake and lower coverage of PCV7 in children in Portugal.  
Another important change accompanying the use of PCVs in children was the 
significant increase of non-PCV7 type IPD (Lepoutre et al., 2008; Muñoz-Almagro et 
al., 2008; Pérez-Trallero et al., 2009; Miller et al., 2011b). Previous data from Portugal 
(Aguiar et al., 2008a; Horácio et al., 2012) found significant increases in the proportion 
of particular non-PCV7 serotypes in adult IPD in the post-PCV7 period. The serotypes 
that increased the most in adult IPD in the post-PCV7 period were serotypes 1, 7F and 
19A (Aguiar et al., 2008a; Horácio et al., 2012), which are included in PCV13. 
When PCV13 replaced PCV7 in children in Portugal it became important to 
characterize the potential herd protection of this new vaccine regarding the PCV7 
serotypes, which are common to both PCV7 and PCV13, and the additional serotypes 
included in PCV13. These aims were considered in the studies presented in chapter II 
of this thesis (Horácio et al., 2013; Horácio et al., 2016b).  
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Regarding PCV7 serotypes, we found an additional decline in the proportion of 
these serotypes in adult IPD between the periods 2009-2011 and 2012-2014 (Horácio, 
et al., 2016b) (Figure V.S1). This additional decline of PCV7 serotypes in adult IPD 
might have been due to a higher effectiveness of PCV13 in comparison with PCV7 in 
the elimination in children of the serotypes that are common to both vaccines, with 
this reflecting in stronger herd protection in adults, or perhaps it was simply the result 
of the continued use of PCVs in children in the country. 
Concerning the additional serotypes of PCV13, we found important declines in 
their proportion in adult IPD in the post-PCV13 period (Figure V.S1) (Horácio et al., 
2016b). However, while the decreases of some of the additional PCV13 serotypes were 
consistent with herd protection caused by childhood vaccination with PCV13, other 
serotypes started to decrease in adult IPD too soon to represent herd protection due 
to the use of PCV13 in children (Horácio et al., 2013). This was the case of serotypes 1 
and 5 that significantly decreased in adult IPD from 2008 onwards. Given that PCV10 
became available for children in Portugal only in mid-2009 and PCV13 only in early-
2010, the lower values found for these two serotypes in adult IPD in 2009 and 2010 
could not have been associated with childhood vaccination with these two vaccines. 
In addition, it is known that herd protection takes some time to establish (Aguiar et 
al., 2008a; Miller et al., 2011a), which means that only data from 2011-2012 onwards 
would represent with more certainty possible herd protection due the use of PCV13 
in children in adult IPD. Serotype 1 is associated with secular trends with long term 
fluctuations (Fenoll et al., 2009; Harboe et al., 2010) and serotype 5 was found to be 
responsible for outbreaks (Vanderkooi et al., 2011). Therefore, the significant 
decreases of serotypes 1 and 5 in adult IPD from 2008 to 2011 may be related with these 
features (Horácio et al., 2013). 
The declines in the PCV13 additional serotypes that we believe were consistent 
with the use of PCV13 in children in Portugal were those found for serotypes 7F and 
19A (Horácio et al., 2016b). This is because these two serotypes declined significantly 
in adult IPD when a herd effect was expected. In addition, serotypes 7F and 19A also 
decreased as causes of IPD in children and adults in several other countries following 
the use of PCV13 in children (Harboe et al., 2014; Moore et al., 2015; Waight et al., 
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2015). Moreover, in countries only using PCV10, serotype 19A did not declined in IPD 
in the post-PCV10 period (Tin Tin Htar et al., 2015). 
In studies evaluating proportions and not incidences, such as those presented 
in this thesis, decreases in the overall proportion of PCV13 serotypes are naturally 
compensated by increases of the same magnitude in the overall proportion of non-
PCV13 serotypes. However, among the two groups of non-PCV13 serotypes considered 
in our studies – PPV23 additional serotypes and non-vaccine types – it was the group 
of PPV23 additional serotypes that accounted for most of the increase found from 
2008 to 2014 (Figure V.S1) (Horácio et al., 2013; Horácio et al., 2016b). Additionally, 
among all the usually detected non-PCV13 serotypes in adult IPD, only some 
serotypes increased significantly. These were, in decreasing frequency, serotypes 8, 
22F, 20 and 15A, which also increased in other countries from Europe and North 
America in a similar period (e.g. Demczuk et al., 2013; Moore et al., 2015; Waight et 
al., 2015). Importantly, in Portugal, these serotypes increased not only in proportion 
but also in absolute numbers. This situation was noteworthy at least in the last two 
years studied (2013 and 2014), because the increases in these four serotypes were 
opposed to declines in the total number of isolates recovered from adult IPD in each 
year (Horácio et al., 2016b). Hence, another finding of the studies presented in this 
thesis (Horácio et al., 2013; Horácio et al., 2016b) was that particular non-PCV13 
serotypes emerged as causes of adult IPD in Portugal during the 2008-2014 period. 
In conclusion, in the studies presented in chapter II of this thesis (Horácio et 
al., 2013; Horácio et al., 2016b) we found that, as what happened with PCV7 in 
Portugal, even a relatively moderate uptake of PCV13 in children likely resulted in 
some degree of herd protection in adults against PCV13-type IPD. Nevertheless, the 
increase of non-PCV13 serotypes in adult IPD is concerning. The evolution of these 
non-PCV13 serotypes should be monitored in future surveillance studies. 
 
Serotype Distribution and Characteristics of the Most Frequent Serotypes 
Causing Adult IPD 
The relative proportion of each serotype causing adult IPD between 2009 and 
2014 was detailed in the studies presented in chapter II of this thesis (Horácio et al., 
2013; Horácio et al., 2016b). We found a high diversity of serotypes, as demonstrated 
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by the high SIDs (≥ 0.93) and the ≥ 50 different serotypes identified in each year. 
However, similarly to what was found before with data collected from 1999 to 2008 
(Serrano et al., 2004; Aguiar et al., 2008b; Horácio et al., 2012), only a limited number 
of serotypes were highly frequent and accounted for the majority of adult IPD.  
When considering together all adult IPD isolates recovered from 1999 to 2014, 
the 10 most frequent serotypes, which accounted for 65.5% of the entire collection of 
adult IPD isolates (n = 3019 / 4610) were, in decreasing frequency, serotypes 3, 7F, 19A, 
14, 1, 8, 22F, 4, 11A and 9N. Figure V.S2 shows the distribution of these 10 serotypes 
according to different periods of the broad period 1999-2014. Despite yearly 
fluctuations in the representation of the individual serotypes in adult IPD, together 
these 10 serotypes accounted for at least 60% of the isolates recovered in each period. 
It is known that only a limited number of serotypes cause the majority of IPD 
globally (WHO, 2008; Johnson et al., 2010) and in agreement with this knowledge, 
the 10 most frequent serotypes occurring in adult IPD in Portugal in 1999-2014 were 
also identified as highly prevalent in adult IPD in other countries (Demczuk et al., 
2012; Steens et al., 2013). However, there were still important differences between the 
serotype distribution of adult IPD in Portugal and the serotype distribution of adult 
IPD in other countries. For example, serotype 12F was a common cause of adult IPD 
in the USA and in Israel in the post-PCV13 period (Moore et al., 2015; Regev-Yochay 
et al., 2015), but was rarely found in our collection of adult IPD isolates in a similar 
period (Horácio et al., 2016b). In addition, even though some serotypes may be 
equally prevalent between countries, they may still have different clonal structures. 
One example is the case of serotype 19A that increased in the post-PCV7 period in 
several countries, including in Portugal, due to the expansion of different genetic 
lineages (Aguiar et al., 2010b). 
The polysaccharide capsule is the major determinant of pneumococcal 
invasiveness since acapsular isolates are barely found causing invasive disease 
(Horácio et al., 2016b). However, for some serotypes not all genetic lineages are 
equally represented in disease (Serrano et al., 2005; Beall et al., 2006; Horácio et al., 
2016a). This highlights the importance of other factors, besides the capsule, for the 
outcome of human-pneumococcal interaction. It is thought it is the combination of 
the polysaccharide capsule and the array of virulence factors of a given pneumococcal 
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strain that influences its ability to cause disease. Factors associated with the host 
immune system also condition the interaction of pneumococci with humans, as 
shown by the existence of several risk groups for pneumococcal infection (Kyaw et 
al., 2005; Goldblatt and O’Brien, 2015; Torres et al., 2015). The studies presented in 
this thesis did not aim to evaluate the reasons underpinning the success of the most 
frequent serotypes occurring in adult IPD in Portugal, but we still evaluated the 
correlation of all serotypes with some properties, namely patient’s age, antimicrobial 
susceptibility, presence and type of pneumococcal pilus islands and MLST-defined 
genotypes (Horácio et al., 2013; Horácio et al., 2016a; Horácio et al., 2016b).  
Serotype 3 was the most common serotype causing adult IPD in Portugal in the 
broad period 1999-2014 (Fig. V.S2). In fact, this serotype was the most frequent 
serotype in all studied periods included in this broad period, except in 1999-2003, 
when it occurred immediately after serotype 14. Serotype 3 is targeted by PCV13, but 
it did not decline in proportion in adult IPD in the post-PCV13 period (Horácio et al., 
2016b). By the time we have written the second manuscript of chapter II, the available 
literature also reported a lack of a consistent reduction of serotype 3 in adult IPD in 
the post-PCV13 period (e.g. Steens et al., 2013; Harboe et al., 2014; Moore et al., 2015; 
Waight et al., 2015). However, a later published study from Israel (Regev-Yochay et 
al., 2017), which analyzed adult IPD isolates after ~ 5 years of PCV13 use in the national 
immunization program of children, showed a small but consistent decline in the 
incidence of serotype 3 IPD. In addition, this serotype declined in adult NIPP in the 
post-PCV13 period in Portugal (Horácio et al., 2018) and elsewhere (Rodrigo et al., 
2015). Perhaps a continued use of PCV13 in children is needed before consistent 
results emerge regarding the ability of PCV13 use in children to eliminate serotype 3 
in adult IPD.  
Serotype 3 was described in one study to resemble “opportunistic pathogens” in 
that it caused IPD mostly in patients with underlying disease (Sjöström et al., 2006). 
Even though in two of our studies (Horácio et al., 2012; Horácio et al., 2013) serotype 
3 showed an association with elderly patients, it was still common in the younger age 
group. This means the debilitated health state of the elderly cannot by itself explain 
the high prevalence of serotype 3 in adult IPD in Portugal. Instead, specific 
characteristics of the isolates expressing serotype 3 must also have been important for 
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its high prevalence among adults of all ages. Serotype 3 was not associated with 
antimicrobial resistance during the broad period 1999-2014 and so its high frequency 
as a cause of adult IPD was not related with this feature. Even though the 
polysaccharide capsule of serotype 3 isolates may have played a role in the success of 
this serotype in adult IPD, we found that not all genetic lineages expressing serotype 
3 were equally prevalent in 2008-2011 (Horácio et al., 2016a). In this period (2008-2011), 
all except one isolate expressing serotype 3 lacked the two pilus islands, meaning that 
the presence of pili 1 and 2 did not influence the different prevalence of the distinct 
genetic lineages associated with serotype 3 in adult IPD. In 2008-2011, CC180 was the 
dominant clonal cluster among serotype 3 isolates and we found this CC was selected 
in relation to two other clonal clusters, which were CC260 and CC458, when 
comparing data from periods 1999-2002 and 2008-2011 (Horácio et al., 2016a). A 
dominance of CC180 among isolates expressing serotype 3 has also been reported in 
other countries (Beall et al., 2006; Muñoz-Almagro et al., 2011). Therefore, it is 
possible that CC180 presents some traits justifying its high prevalence in adult IPD 
and dominance in relation to other genetic lineages associated with serotype 3. This 
could be the object of future research. 
Serotype 14 was the fourth most frequent serotype causing adult IPD in 1999-
2014 (Fig. V.S2). This serotype is targeted by all the PCVs available to date and 
probably due to indirect protection caused by PCV7 use in children declined in 
proportion in adult IPD in the post-PCV7 period (Aguiar et al., 2008a). Even though 
this decline was significant, serotype 14 remained an important cause of IPD in adults 
in the post-PCV7 period. In fact, the prevalence of serotype 14 remained relatively 
constant following the decline, with only an additional small decrease in 2014 
(Horácio et al., 2016b). Other countries reported stronger decreases of serotype 14 in 
adult IPD following PCV7 use in children (Miller et al., 2011b; Demczuk et al., 2012), 
but vaccine coverage was higher in those places. Therefore, the use of PCV13 in the 
national immunization program of children since June 2015 possibly resulted in a 
more marked decline of serotype 14 in adult IPD in Portugal from 2015 onwards. 
Serotype 14 was strongly associated with antimicrobial resistance throughout 
the 1999-2014 period (Aguiar et al., 2008a, Horácio et al., 2012; Horácio et al., 2013; 
Horácio et al., 2016b) and with the presence of pilus island 1 in the 2008-2011 period 
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(Horácio et al., 2016a). However, the two clonal clusters expressing serotype 14 in 
2008-2011, which were CC156 and CC15, were differently correlated with these two 
characteristics (Horácio et al., 2016a). While all isolates expressing serotype 14 and 
belonging to CC156 were PNSP (in fact, < 50% of these isolates were EPNSP) and 
presented PI-1, all serotype 14 isolates from CC15 were ERP and did not present any of 
the pilus islands. From 2008 to 2009, CC156 expanded within serotype 14, while CC15 
reduced. Therefore, CC156 intrinsic properties may have promoted the expansion of 
CC156 as a cause of adult IPD in 2009. One of the consequences of the growth of 
CC156 was an overall increase in penicillin-non-susceptibility from 2008 to 2009. 
However, we found that erythromycin resistance decreased within serotype 14 from 
2012 to 2014. The solid association of CC15 with erythromycin resistance in the 2008-
2011 period suggests this later change in resistance within serotype 14 was linked to 
additional shrinking of CC15. Further studies are needed to explore this idea since 
erythromycin resistance also existed among CC156 isolates expressing serotype 14 
(Horácio et al., 2016a).  
Serotype 4 was the eighth most frequent serotype causing adult IPD in 1999-
2014 (Fig. V.S2) and, as serotype 14, declined significantly in adult IPD following the 
use of PCV7 in children in Portugal (Aguiar et al., 2008a). Serotype 4 was the second 
most frequent PCV7 serotype in all studied periods of the broad period 1999-2014, 
following always serotype 14. The only exception was the 2012-2014 period, when this 
serotype was also surpassed by PCV7 serotype 19F (Horácio et al., 2016b). Almost all 
isolates expressing serotype 4 were susceptible to the antibiotics tested, a factor that 
may have helped in the strong decline of serotype 4 in the post-PCV7 period (Aguiar 
et al., 2008a; Horácio et al., 2012; Horácio et al., 2013). The most important findings 
regarding the clonal structure of serotype 4 in 2008-2011 were: its high genetic 
diversity with no dominant genotype; the association of some genetic lineages 
expressing serotype 4 with pilus island 1 (e.g. CC205 and CC1221); and the association 
of one clonal cluster, which was CC5902 (ST1222 and ST801), with the younger age 
group (Horácio et al., 2016a). Since we did not detect any genotype selection within 
serotype 4 and because there was no dominant genetic lineage among serotype 4 
isolates in the 2008-2011 period it is difficult to suggest a role for the different genetic 
lineages associated with this serotype on the relatively high prevalence of serotype 4 
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in adult IPD in Portugal. Perhaps in the case of serotype 4, the polysaccharide capsule 
was the most important determinant of invasiveness.  
Serotype 1, which ranked fifth in the list of the 10 most common serotypes in 
adult IPD in 1999-2014 (Fig. V.S2), was particularly frequent in adult IPD from 1999 
to 2008 (Aguiar et al., 2008a; Horácio et al., 2012). A high prevalence of serotype 1 was 
also detected in other European countries in a similar period (Fenoll et al., 2009; 
Harboe et al., 2010). In our studies, serotype 1 was mostly susceptible to the 
antibiotics, was significantly associated with the younger age groups (Horácio et al., 
2013; Horácio et al., 2016b) and presented very low genetic diversity (Horácio et al., 
2016a). The dominant clonal cluster was CC306, which was positively associated with 
pilus island 2 (Horácio et al., 2016a). One study found that isolates from ST306 were 
highly prevalent as a cause of IPD but rarely carried asymptomatically, suggesting 
high invasive disease potential for this genetic lineage (Sá-Leão et al., 2011). The high 
invasiveness of serotype 1 and its preference for the younger adult age groups supports 
the idea that serotype 1 isolates act as primary pathogens in Portugal. In our country, 
serotype 1 has been associated with empyema (Aguiar et al., 2010a), attesting also to 
its virulence. The fact that younger patients usually have less comorbidities than older 
patients may explain why infections due to isolates of ST306 rarely result in death of 
the patient (Harvey et al., 2011). Infections due to other genetic lineages associated 
with serotype 1, such as CC217, were however associated with high mortality in Africa 
(Harvey et al., 2011). We found that two of our serotype 1 isolates collected from adult 
IPD in 2011 were of CC217 (Horácio et al., 2016a). This would be a major concern if 
there were no effective vaccines today for the prevention of serotype 1 infections. Even 
so, the evolution of serotype 1 isolates in Portugal should be monitored in future 
studies. 
Serotypes 7F and 19A, which were, respectively, the second and third most 
common serotypes causing adult IPD in 1999-2014 (Fig. V.S2), exhibited similar trends 
throughout this broad period. In summary, both serotypes expanded in the post-
PCV7 period (Aguiar et al., 2008a; Horácio et al., 2012) and declined in the post-PCV13 
period (Horácio et al., 2016b). However, the characteristics associated with serotypes 
7F and 19A differed in several ways. Serotype 7F isolates, resembling serotype 1 isolates 
instead, were in our studies highly susceptible to the antibiotics tested (e.g. Horácio 
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et al., 2013), were associated with pilus island 2 and with only one CC, namely CC191 
(Horácio et al., 2016a), which was found in one study to be highly invasive (Sá-Leão 
et al., 2011). However, in contrast to serotype 1, no association with age was found for 
serotype 7F in our studies (Horácio et al., 2013; Horácio et al., 2016b). Serotype 19A, 
on the other hand, shared several traits with serotype 14. In 2008-2011, serotype 19A 
isolates presented high genetic diversity and the different genetic lineages expressing 
this serotype were also differently associated with antimicrobial resistance and pili 
(Horácio et al., 2016a). In addition, our data suggested genotype selection within 
serotype 19A (Horácio et al., 2016a). The dominant clonal cluster among serotype 19A 
isolates in 2008-2011, which was CC230, was mostly composed by EPNSP and did not 
present pilus islands, while the second most frequent clonal cluster among serotype 
19A isolates, which was CC199, presented pilus island 1 and was mostly susceptible to 
the antibiotics tested. From 2008 to 2009, CC230 expanded among serotype 19A 
isolates despite a decrease in the total number of isolates expressing this serotype. 
This expansion of CC230 led to an increase in penicillin-non-susceptibility within 
serotype 19A in this period (Horácio et al., 2016a). However, we also noted that from 
2012 to 2014 the proportion of ERP and PNSP decreased within serotype 19A (Horácio 
et al., 2016b). Therefore, changes in the genetic lineages expressing serotype 19A may 
have occurred in this period and deserve further evaluation.  
Serotypes 8 and 22F, which were, respectively, the sixth and seventh more 
common serotypes causing adult IPD in the broad period 1999-2014 (Fig. V.S2), 
significantly increased in adult IPD since the late post-PCV7 period (Horácio et al., 
2013; Horácio et al., 2016b). These two serotypes shared some characteristics, such as 
their association with antimicrobial susceptibility in all studied periods (e.g. Horácio 
et al., 2013; Horácio et al., 2016b) and the fact that at least in the 2008-2011 period both 
serotypes presented low genetic diversity and lacked the two pilus islands (Horácio 
et al., 2016a). However, serotype 8 was found to be associated with the younger age 
group in 2009-2011 (Horácio et al., 2013), while no association with age was detected 
for serotype 22F. Additionally, representatives of the dominant clonal cluster among 
serotype 8 isolates, which was CC62 (ST53), were found in one study to be highly 
invasive, while representatives of the most important clonal cluster among serotype 
22F isolates, which was CC433, were found to be equally prevalent in IPD and carriage 
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(Sá-Leão et al., 2011). These last two characteristics of serotype 8 were shared with 
serotype 1 instead, as discussed above. The increase of serotype 8 as a cause of adult 
IPD in the post-PCV7 period was more notorious than that of serotype 22F, and in 
2013 and 2014, serotype 8 became the second most common cause of adult IPD in 
Portugal (Horácio et al., 2016b). Importantly, of these two serotypes, only serotype 
22F is covered by the 15-valent PCV that is under evaluation (Skinner et al., 2011). The 
strong increase of serotype 8 in adult IPD in the post-PCV7 and post-PCV13 period 
stresses the need to continue following IPD due to this serotype. 
Serotypes 9N and 11A, which were, respectively, the ninth and tenth most 
frequent serotypes causing adult IPD in 1999-2014 (Fig. V.S2), were consistently 
recovered from adult IPD throughout the entire study period (1999-2014). These two 
serotypes shared some characteristics, such as antimicrobial susceptibility and the 
absence of pilus islands. Serotype 9N presented very low genetic diversity and had all 
but one isolate included in the same clonal cluster, which was CC81.  Similarly, and 
despite the higher genetic diversity of serotype 11A, all except one isolate expressing 
serotype 11A were included in only one clonal cluster, which was CC62 (Horácio et al., 
2013; Horácio et al., 2016a; Horácio et al., 2016b).  
In summary, only a limited number of serotypes caused the majority of adult 
IPD in Portugal during the broad period 1999-2014, suggesting that these serotypes 
may have some properties contributing to their high frequency in adult IPD. The 10 
most common serotypes in adult IPD in 1999-2014 associated differently with the 
three age groups considered, with antimicrobial resistance and with pili, and while 
some of these serotypes presented a complex non-static clonal structure, others 
presented low genetic diversity. The reasons behind the high frequency of these 10 
serotypes as a cause of adult IPD in Portugal were therefore possibly multifactorial 
and this could be the object of future research. 
 
Overall Genetic Diversity in Adult IPD 
The study of MLST presented in chapter III of this thesis (Horácio et al., 2016a) 
was important to better understand the diversity of isolates occurring within each 
serotype and to evaluate the stability of the genetic lineages. We opted to determine 
the genetic lineages of all serotypes causing adult IPD in 2008-2011 (i.e. 52 different 
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serotypes), as this would give us a clearer view of the pneumococcal population 
causing adult IPD in Portugal in this period and how it adapted during the time of 
private PCVs use in children. The period chosen for analysis corresponds to the last 
two years of PCV7 private use in children in Portugal (2008 and 2009) and the first 
two years of PCV13 private use in children in the country (2010 and 2011). These results 
were compared with previously published data from the same network (Serrano et 
al., 2005).  
In summary, we found the isolates responsible for adult IPD in 2008-2011 
presented high genetic diversity (SID = 0.971, CI95%: 0.967–0.976), with 206 different 
STs being detected among the sample of 871 isolates (Horácio et al., 2016a). These STs 
distributed into 80 different clonal clusters, according to goeBURST analysis 
(Francisco et al., 2009). Despite this high diversity of STs and CCs, only 14 STs and 6 
CCs accounted for half of the isolates analysed. The more frequent clonal clusters 
were mainly composed of isolates expressing vaccine serotypes, which was not 
surprising due to the high frequency of these serotypes in 2008-2011. The major clonal 
cluster was CC156, which was mostly composed of isolates expressing PCV7 serotypes 
(namely serotypes 14, 9V and 23F). Several of the genetic lineages found to be causing 
IPD in adults in Portugal were also detected as causes of IPD in other countries (e.g. 
Muñoz-Almagro, et al., 2011; Pichon et al., 2013; Caierão et al., 2014; Metcalf et al., 
2016). 
As already discussed, there were important changes in the serotype distribution 
of adult IPD isolates during the time of PCVs use in children, including in the 2008-
2011 period (Horácio et al., 2012; Horácio et al., 2013). We found the changes in the 
serotype distribution occurring in adult IPD in Portugal in this period were 
accompanied by decreases and expansions in the proportions of the associated 
genetic lineages. The most important of these changes was the significant decline of 
CC306, which accompanied the decline of its associated serotype (serotype 1), from 
2008 onwards (Horácio et al., 2013).  
Another goal of the study presented in chapter III of this thesis (Horácio et al., 
2016a) was to evaluate the importance of capsular switching among the isolates 
collected from adult IPD. Capsular switching is known to occur in pneumococci and 
a concern exists that successful lineages expressing vaccine serotypes may change 
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their capsules to non-vaccine serotypes and escape vaccine control, as reported before 
(Brueggemann et al., 2007). Increases of non-vaccine serotypes after the availability 
of PCVs may be associated with these events and therefore, need to be evaluated. Our 
data suggested capsular switching was rare among the isolates causing adult IPD in 
2008-2011. Worth of attention was only a case of a possible capsular switching from 
the PCV13 serotype 19A to the NVT 24F. We saw that in the pre-PCV7 period, serotype 
24F was mainly CC81, while in the 2008-2011 period among the nine 24F isolates 
genotyped, four were CC81 and five were CC230. This finding is relevant because 
ST276, which is an SLV of ST230, led to the expansion of serotype 19A in the post-
PCV7 period in Portugal and this genetic lineage is associated with antimicrobial 
resistance (Aguiar et al., 2010b). This combination was also detected in other 
countries (Pantosti et al., 2002; Simões et al., 2011) and hence, close attention should 
be paid to its evolution in the future. 
In what concerns the overall prevalence of pilus islands 1 and 2 among the 
isolates causing adult IPD in 2008-2011, we found that almost 1/3 of the isolates (32%) 
presented a pilus island (Horácio et al., 2016a). As expected (Aguiar et al., 2008b), 
there was an association between the presence and type of pilus islands with serotype, 
and an even stronger association between the presence and type of pilus islands with 
genotype. PI-1 was mainly found among isolates expressing PCV7 serotypes, while PI-
2 among isolates expressing the additional serotypes covered by PCV13. The 
additional serotypes of PCV13 were common causes of adult IPD in 2008-2011 and this 
explains the higher frequency of PI-2 positive isolates (19%) over PI-1 positive isolates 
(12%), found in this pneumococcal collection. The decrease in proportion of serotype 
1 in adult IPD in 2008-2011 led to a significant decline in proportion of invasive isolates 
bearing PI-2 (from 25% in 2008 to 16% in 2011, p = 0.007). Contrasting with results 
from one study showing the re-emergence of pneumococcal isolates bearing PI-1 in a 
population of children in Massachusetts (Regev-Yochay et al., 2010), our data suggests 
that in Portugal there was no re-emergence of PI-1 in pneumococci causing adult IPD 
after the continued use of PCVs in children. The overall prevalence of the PIs in adult 
IPD may be even smaller in 2012-2014, due to the significant decline of serotype 7F in 
the post-PCV13 period (Horácio et al., 2016b), which was also associated with PI-2 
(Horácio et al., 2016a).  
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Overall Antimicrobial Susceptibility in Adult IPD 
Since five of the seven serotypes targeted by PCV7 have been associated with 
antimicrobial resistance (Dagan and Klugman, 2008), the use of PCV7 in children was 
expected to reduce invasive disease caused by antimicrobial resistant pneumococci. 
However, the emergence of the resistant serotype 19A in the post-PCV7 period 
prevented this from happening in some countries, especially in adults (Horácio et al., 
2012; Pérez-Trallero et al., 2009). PCV13 targets serotype 19A and since no serotype-
like 19A seems to have emerged in the post-PCV13 period in countries using PCV13 
(Tin Tin Htar et al., 2015), a decrease in the representation of antimicrobial resistant 
isolates in IPD can, once again, be expected.   
In the studies of chapter II of this thesis (Horácio et al., 2013; Horácio et al., 
2016b), all isolates collected from adult IPD from 2009 to 2014 were tested for 
susceptibility to several classes of antibiotics, continuing the epidemiological 
surveillance initiated in 1999 (Serrano et al., 2004; Aguiar et al., 2008a; Horácio et al., 
2012). The classes of antibiotics used for testing the isolates were chosen according to 
their clinical or epidemiological relevance.  
When considering the broad period 1999-2014 (Serrano et al., 2004; Aguiar et 
al., 2008a; Horácio et al., 2012; Horácio et al., 2013; Horácio et al., 2016b), all adult IPD 
isolates were found to be susceptible to vancomycin and linezolid. Resistance to 
levofloxacin was extremely rare and the great majority of isolates were susceptible to 
cefotaxime and chloramphenicol. For the remaining antibiotics tested, resistance was 
higher and varied in time.  
β-lactams and macrolides have been widely used in the empirical treatment of 
pneumonia globally (Goldblatt and O’Brien, 2015). The proportions of penicillin-non 
susceptible pneumococci and erythromycin resistant pneumococci occurring in adult 
IPD in Portugal in the broad period 1999-2014, and according to the CLSI breakpoints 
prior to 2008, are represented in Figure V.S3. Previous studies from Portugal reported 
an increase in the proportion of ERP in adult IPD in the time of PCV7 use in children 
(i.e., from 1999-2003 to 2008, ERP increased in adult IPD from 10% to 17%) (Aguiar et 
al., 2008b; Horácio et al., 2012). We found there were new increases in the proportion 
of ERP in adult IPD until 2010, with this resulting in almost ¼ of adult IPD isolates 
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being ERP in 2010 (Horácio et al., 2013). Concerning the proportion of PNSP in adult 
IPD, no significant change was found from 1999 to 2008 in previous studies (Aguiar 
et al., 2008; Horácio et al., 2012). However, we found there was an increase of PNSP 
in adult IPD from 2008 to 2010 (from 16% to 24%). The trends found from 1999 to 2010 
for ERP and PNSP in adult IPD in Portugal were not only associated with the 
emergence of serotype 19A in this period, but also with the persistence of PCV7 
serotypes in adult IPD, as discussed above (Aguiar et al., 2008; Horácio et al., 2012).  
When adding data from 2012 to 2014 (Horácio et al., 2016b), we found that in 
this period, both the representation of PNSP and ERP declined in adult IPD, though 
not continuously for ERP (Figure V.S3). These declines of PNSP and ERP in adult IPD 
were in part promoted by decreases in the number of isolates expressing serotypes 14 
and 19A in this period (Horácio et al., 2016b) and in part promoted by decreases of 
PNSP and ERP even within serotypes 14 and 19A (Horácio et al., 2016b). These 
decreases were unexpected, but positive. Among the emerging serotypes in the post-
PCV13 period, only one serotype was associated with antimicrobial resistance – 
serotype 15A. The increase of this serotype in adult IPD was much moderate than that 
noticed before for serotype 19A in the post-PCV7 period (Aguiar et al., 2008a), which 
agrees with the idea that no serotype-like 19A have emerged in the post-PCV13 period 
(Tin Tin Htar et al., 2015). Given that serotypes 14 and 19A still contributed to 
antimicrobial resistance in the last year of the study (i.e. 2014), the inclusion of PCV13 
in the national immunization program of children, since June 2015, is expected to 
further reduce the prevalence of resistant isolates in adult IPD. 
In the studies presented in chapter II of this thesis (Horácio et al., 2013; Horácio 
et al., 2016b) we decided to use the CLSI breakpoints for penicillin prior to 2008 
throughout the entire study period (1999-2014) to better understand the changes 
occurring in pneumococci causing invasive disease in adults. However, we also 
reported the results considering the current cut-off values (Clinical and Laboratory 
Standards Institute, 2015). According to the current breakpoints, the great majority 
of isolates recovered from non-meningitis cases in 2009-2014 were classified as 
susceptible to penicillin (0.5% of resistance in 2012-2014) (Horácio et al., 2013; Horácio 
et al., 2016b). This result agrees with international and national guidelines suggesting 
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the use of β-lactams for the empirical treatment of pneumonia (Direção Geral da 
Saúde, 2011; Goldblatt and O’Brien, 2015). 
 
Non-invasive Pneumococcal Pneumonia 
Evolution of Vaccine Serotypes in Adult NIPP  
Non-invasive pneumococcal pneumonia is estimated to be much more frequent 
than invasive pneumococcal pneumonia (Said et al., 2013) and to account for a 
significant fraction of pneumococcal associated deaths (Cillóniz and Torres, 2012). 
However, several factors, such as the challenges associated with the etiological 
diagnosis of NIPP (Goldblatt and O’Brien, 2015), complicate appropriate 
epidemiological surveillance of these infections, with this situation reflecting in a 
limited number of NIPP studies. The last two studies presented in this thesis (Horácio 
et al., 2014; Horácio et al., 2018) were dedicated to the analysis of pneumococci 
causing adult NIPP in Portugal. Similarly to what we have done in the studies of adult 
IPD (Horácio et al., 2013; Horácio et al., 2016b), we aimed to evaluate the 
characteristics of pneumococci causing non-invasive pneumococcal pneumonia in 
adults in Portugal and how these characteristics changed in time with the private use 
of PCVs in children. For that purpose, we analysed isolates collected from adult NIPP 
between 1999 and 2015. We also compared adult NIPP data with adult IPD data to 
evaluate if adult IPD data could be used to extrapolate information of adult NIPP, as 
suggested elsewhere (van Werhoven et al., 2016).   
We found that childhood private vaccination with PCVs in Portugal possibly 
caused herd effects not only on pneumococci responsible for adult IPD, but also on 
pneumococci responsible for adult NIPP. However, the overall proportion of vaccine 
serotypes was usually lower in adult NIPP than in adult IPD, and the serotypes that 
changed the most in the post-PCVs period in adult NIPP did not match entirely with 
those that changed the most in adult IPD in a similar period. In addition, adult NIPP 
and adult IPD presented different serotype distributions, with several serotypes being 
associated with either disease presentation (Horácio et al., 2014; Horácio et al., 2018). 
There were changes in the serotype distribution in adult NIPP in the 1999-2015 
period that suggested herd protection in adults due to the use of PCVs in children. 
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Figure V.S4 shows the evolution of vaccine serotypes in adult NIPP in the broad 
period 1999-2015. Concerning the representation of PCV7 serotypes in adult NIPP, the 
proportion of these serotypes declined gradually in adult NIPP in the post-PCV7 
period (Horácio et al., 2014) and then remained slightly above 10% from 2008 to 2015 
(Horácio et al., 2018). This suggests that PCV7 and PCV13 use in children in Portugal 
protected adults from PCV7-type NIPP. However, and as what happened in adult IPD, 
PCV7 serotypes did not disappear as causes of adult NIPP in Portugal (Figure V.S4). 
As discussed above for adult IPD, this situation may be the result of the use of PCVs 
outside the national immunization program of children until June 2015.  
Regarding the additional serotypes of PCV13, we found a significant decline in 
their proportion after the availability of PCV13 for private use in children (declined 
from 36% in 2010 to 19% in 2015, p < 0.001; Figure V.S4) (Horácio et al., 2018). The 
PCV13 serotypes that decrease the most were serotypes 3 and 19A. The decrease of 
serotype 3 in adult NIPP was surprising since this serotype did not show a consistent 
decline in adult IPD in Portugal (Horácio et al., 2016b) nor in other countries (e.g. 
Steens et al., 2013; Harboe et al., 2014; Moore et al., 2015; Waight et al., 2015) in the 
early post-PCV13 period, as discussed above. However, a decrease in the incidence of 
NIPP associated with serotype 3 was reported elsewhere (Rodrigo et al., 2015). Perhaps 
a decline of serotype 3 in adult IPD in Portugal will occur now that PCV13 is 
implemented in the national immunization program of children. In what concerns 
the decline of serotype 19A in adult NIPP it was much less pronounced than that 
registered for adult IPD in the post-PCV13 period (Horácio et al., 2018). Due to the 
strong evidence of herd protection resulting from childhood vaccination against 
serotype 19A in adult IPD (Tin Tin Htar et al., 2015), it is possible that the universal 
vaccination of children with PCV13, now implemented in Portugal, may also cause a 
stronger decrease of serotype 19A in adult NIPP. The evolution of serotypes 3 and 19A 
as a cause of disease in adults in Portugal should be monitored. 
As discussed above for adult IPD, in studies evaluating proportions and not 
incidences, such as those presented in this thesis, declines in the global proportion of 
PCV13 serotypes are consequently compensated by increases in the remaining groups 
of serotypes. However, among the two other groups considered in our studies (i.e. 
PPV23 additional serotype and NVTs), only NVTs increased significantly in adult 
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NIPP in the post-PCV13 period (Figure V.S4). This contrasted with results from adult 
IPD, for which the decrease in the global proportion of PCV13 serotypes was 
accompanied by an increase in the overall proportion of PPV23 additional serotypes 
(Horácio et al., 2016b). While the overall increase of PPV23 additional serotypes in 
adult IPD was mainly promoted by important increases of particular serotypes, with 
this suggesting the existence of emerging serotypes in adult IPD, the same did not 
happen in adult NIPP, since none of the NVTs showed a remarkable increase in adult 
NIPP in the post-PCV13 period (Horácio et al., 2018).  
In conclusion, in the studies presented in chapter IV of this thesis (Horácio et 
al., 2014; Horácio et al., 2008) we found that even a relatively moderate uptake of 
PCV7 and PCV13 in children possibly caused herd protection in adults against 
vaccine-type NIPP. However, PCV13 serotypes persisted as causes of adult NIPP 
following the private use of PCV13 in the country, highlighting the importance of the 
implementation of PCV13 in the national immunization program of children to 
reduce the circulation of these serotypes. Fortunately, none of the serotypes not 
covered by PCV13 seemed to have emerged in adult NIPP in the post-PCV13 period. 
Since the evolution of vaccine serotypes in adult NIPP in the post-PCVs period 
differed from that reported for adult IPD, studies focusing specifically on adult NIPP 
are also needed. 
  
Serotype Distribution in Adult NIPP 
The relative proportion of each serotype causing adult NIPP in 1999-2015 was 
detailed in the studies presented in chapter IV of this thesis (Horácio et al., 2014; 
Horácio et al., 2018). As what was found for adult IPD, there was high diversity of 
serotypes among the isolates collected from adult NIPP in Portugal. In the first study 
period (1999-2011), 57 different serotypes were detected as causes of adult NIPP and 
SID values ranged from 0.901 to 0.957 in each year, while in the second study period 
(2012-2015), 50 different serotypes were detected as causes of adult NIPP and SID 
values ranged from 0.944 to 0.955 in each year. Despite the high diversity of serotypes, 
some serotypes were more frequently detected than others. The 10 most common 
serotypes causing adult NIPP when considering the whole study period together 
(1999-2015) were, in decreasing frequency, serotypes 3, 11A, 19F, 19A, 22F, 6C, 9N, 23A, 
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14 and 23B. Their proportions, according to the different periods within the broad 
period 1999-2015, are represented in Figure V.S5. These 10 serotypes were found in 
54.7% of the adult NIPP collection (n = 1497 / 2735), a value that is much lower than 
that found above for adult IPD (65.5%), when performing a similar analysis. The next 
more frequent serotypes in adult NIPP in the broad period 1999-2015 were serotypes 
15A, 15B/C, 31 and NTs, with each accounting for 2.3% to 2.8% of the 2735 isolates. 
Among the 10 most frequent serotypes causing adult NIPP in 1999-2015 (Figure 
V.S5), six serotypes were also amongst the 10 most frequent serotypes causing adult 
IPD during the period 1999-2014 (Figure V.S2), namely serotypes 3, 11A, 19A, 22F, 9N 
and 14. However, when comparing similar periods for adult IPD and adult NIPP, we 
found serotype 11A to be significantly more represented in adult NIPP than in adult 
IPD and serotypes 19A, 22F and 14 to be significantly more represented in adult IPD 
than in adult NIPP (Horácio et al., 2014; Horácio et al., 2018). In addition, several other 
serotypes from the list of the most frequent serotypes in adult NIPP and adult IPD 
showed an association with one or the other disease presentation (i.e. serotypes 19F, 
23A and 23B with adult NIPP and serotypes 7F, 1, 8 and 4 with adult IPD) (Horácio et 
al., 2014; Horácio et al., 2018). Serotypes 11A, 19F, 23A and 23B were found to be 
associated with carriage instead of IPD in a study evaluating the invasiveness of the 
genetic lineages circulating in Portugal (Sá-Leão et al., 2011). The suggestion of a low 
invasiveness for these four serotypes (Sá-Leão et al., 2011) agrees with their association 
with adult NIPP instead of adult IPD found in our studies.  
The different serotype distributions of adult NIPP and adult IPD resulted in a 
different representation of the serotypes included in PCVs in the two collection of 
isolates. For example, for both adult IPD and adult NIPP the highest representation 
of PCV13 serotypes occurred in 2008, but while the value reached for adult IPD was 
70%, for adult NIPP it was only 57% (Figures V.S2 and V.S5). We did not evaluate the 
genetic lineages of the isolates responsible for adult NIPP in Portugal for any of the 
studied periods, but the different serotype distributions found between adult NIPP 
and adult IPD suggests their genetic lineages may also not match entirely if such 
analysis is performed. For the future it will be important to characterize the 
population structure of pneumococci responsible for adult NIPP, since this may give 
a clear view of the differences between pneumococci responsible for adult NIPP and 
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adult IPD. In addition, it may also contribute to understand the reasons behind the 
high frequency of particular serotypes in adult NIPP.  
Since we did not determine the population structure, nor the distribution of pili, 
for the isolates collected from adult NIPP and because no significant associations 
were found between the different serotypes detected in adult NIPP with the three age 
groups considered in the studies presented in this thesis, it is difficult to discuss on 
the relative importance of the pneumococcal capsule versus other pneumococcal 
features for the high representation of these 10 serotypes in adult NIPP, as was done 
above for adult IPD.  
One important finding of the studies presented in chapter IV (Horácio et al., 
2014; Horácio et al., 2018) was the realization that serotype 3 was not only the most 
common cause of adult IPD (Horácio et al., 2013; Horácio et al., 2016b), but also of 
adult NIPP in Portugal in the time of childhood vaccination with PCVs through the 
private market. Serotype 3 was also reported has highly prevalent in NIPP in other 
regions (Domenech et al., 2011; Benfield et al., 2013; Mendes et al., 2015), stressing out 
its international significance. It is noteworthy that despite the significant decline 
from 2007 to 2015 in the proportion of serotype 3 in adult NIPP in Portugal, this 
serotype was still the most frequent serotype in the last years studied (i.e. 2014 and 
2015). The importance of serotype 3 as a cause of disease in adults and the fact that 
isolates expressing this serotype have been found to be genetically diverse, with 
distinct genetic lineages differently associated with carriage or invasive disease (Sá-
Leão et al., 2011), makes this serotype an appealing serotype to study by WGS 
(Croucher et al., 2013). WGS may also help to identify genetic factors involved in the 
development of non-invasive pneumonia or invasive disease, and this may be an 
interesting line of investigation for the future.  
  
Overall Antimicrobial Susceptibility in Adult NIPP 
All adult NIPP isolates included in the studies presented in chapter IV of this 
thesis (Horácio et al., 2014; Horácio et al., 2018) were tested for several classes of 
antibiotics, similarly to what was performed for adult IPD isolates (Horácio et al., 
2013; Horácio et al., 2016b). As also found for adult IPD, all adult NIPP isolates were 
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susceptible to vancomycin and linezolid. Non-susceptible isolates to levofloxacin, 
cefotaxime and chloramphenicol were also rare in adult NIPP.  
The proportions of PNSP and ERP in adult NIPP in the broad period 1999-2015 
and using the 2007 CLSI criteria are shown in Figure V.S6 (Clinical and Laboratory 
Standards Institute, 2007). In general, antimicrobial resistance among adult NIPP 
isolates were not that different from that reported for adult IPD in the post-PCV7 
period and the use of PCV7 in children also did not reflect in a decrease in the 
proportion of PNSP or ERP in adult NIPP in the post-PCV7 period. Concerning the 
evolution of the proportion of PNSP in adult NIPP in the post-PCV7 period, no 
significant trend was observed over the years, only non-significant fluctuations 
throughout the entire study period. In contrast, the proportion of ERP increased in 
adult NIPP in the post-PCV7 period (from 12.4% in 1999-2003 to 27% in 2009). The 
emergence of serotype 19A and the persistence of PCV7 serotypes in adult NIPP 
contributed to the results found (Horácio et al., 2014), as what happened for adult 
IPD (Horácio et al., 2013).  
However, while in the post-PCV13 period there was a decline of PNSP and ERP 
in adult IPD (Horácio et al., 2016b), the same was not replicated in adult NIPP 
(Horácio et al., 2018). This was mainly due to the higher representation of serotype 
19F and NTs in adult NIPP, which are associated with antimicrobial resistance, and to 
the lower decline of serotype 19A in adult NIPP. 
Using current CLSI breakpoints (Clinical and Laboratory Standards Institute, 
2015), penicillin non-susceptibility was rare among the isolates causing adult NIPP 
(1% in 2012-2015). Therefore, not only our adult IPD data but also our adult NIPP data 
agree with the empirical treatment of pneumonias recommended in Portugal 
(Direção Geral da Saúde, 2011). 
One of the advantages of the etiological diagnosis of pneumonia by bacterial 
culture over urine antigen detection assays is the fact that the first enables to 
determine antimicrobial susceptibility profiles of pneumococci. Our studies suggest 
that not even a different serotype distribution between adult NIPP and adult IPD can 
reveal if antimicrobial resistance between adult NIPP and adult IPD will also differ.  
In conclusion, only in adult IPD were there decreases in the representation of 
antimicrobial resistant isolates in the post-PCV13 period. The increasing importance 
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of NTs in adult NIPP in Portugal, which are associated with antimicrobial resistance 
and which cannot be covered by pneumococcal vaccines based only on 
polysaccharides, is of concern, and should be followed.  
 
Concluding Remarks and Future Perspectives 
In 2015, a total of 6126 people died with pneumonia (ICD-10: J12-J18) in Portugal, 
with most of these deaths (n = 5840) occurring in adults ≥ 65 yrs (INE, 2015). For 
unknown reasons, mortality rates due to pneumonia are more pronounced in 
Portugal than in many other countries from Europe. For example, in 2013, Portugal 
occupied the second highest position among 23 European countries in a study 
evaluating mortality rates due to pneumonia (Direção-Geral da Saúde, 2015d). Since 
S. pneumoniae is frequently reported as the most common cause of bacterial 
pneumonia (e.g. Torres et al., 2014; GBD 2015 Mortality and Causes of Death 
Collaborators, 2016), one can presume that a significant fraction of pneumonia-
associated deaths in Portugal is due to this microorganism. Despite this uncertainty, 
the large number of pneumococcal isolates recovered from adults with invasive 
disease or non-invasive pneumonia in each year by this epidemiological surveillance 
network (e.g. Horácio et al., 2016b; Horácio et al., 2018), highlights the importance of 
S. pneumoniae as a pathogen of adults in Portugal.  
The current burden of pneumococcal infections together with the present need 
for epidemiological studies evaluating the possible herd effects of the use of PCVs in 
children on adults motivated the studies presented in this thesis. In summary, our 
data suggested that even a relatively moderate uptake of PCV13 in children possibly 
changed the serotype distribution of the pneumococcal population responsible for 
IPD in adults (Horácio et al., 2016b), as what was seen before with PCV7 in Portugal 
(Aguiar et al., 2008). There were also major changes in the serotype distribution of 
the pneumococcal population responsible for adult NIPP during the time of PCVs use 
in children, with some of these changes possibly reflecting herd protection promoted 
by childhood vaccination with PCVs (Horácio et al., 2014; Horácio et al., 2018).  
The wide effect of PCVs in preventing pneumococcal disease in non-vaccinated 
adults, may question the need of universal vaccination of adults ≥ 65 yrs with PCV13, 
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which has been ongoing in some countries since age-based recommendations for 
adults were made (Castiglia et al., 2014; Tomczyk, et al., 2014; Sings et al., 2017). In 
Portugal, the national health authority recommends the sequential vaccination with 
PCV13 and PPV23 of adults having increased risk for IPD, but no recommendations 
have been made to vaccinate adults more broadly, such as all immunocompetent 
adults ≥ 65 yrs (Direção-Geral da Saúde, 2015b). Several other countries also have risk-
based recommendations (Castiglia et al., 2014; Sings et al., 2017). The differences 
between countries concerning pneumococcal vaccination policies in adults show this 
is a debatable subject.  
If possible, vaccine policies should be based on cost-effectiveness analysis and 
up to date predictions using the most recent data. According to the last studied years 
in this thesis (Horácio et al., 2016b; Horácio et al., 2018), 38% of adult IPD in 2014 and 
30% of adult NIPP in 2015 were due to PCV13 serotypes. In addition, PPV23 serotypes 
were expressed by 75% of adult IPD isolates collected in 2014 and 56% of adult NIPP 
isolates collected in 2015 (Horácio et al., 2016b; Horácio et al., 2018). These 
proportions are relevant and suggest a potential role of vaccination for the prevention 
of pneumococcal disease in adults. Since vaccine serotypes were more represented in 
adult IPD that in adult NIPP throughout the entire post-PCVs period (Horácio et al., 
2014; Horácio et al., 2018), and because both PCV13 and PPV23 are more able to 
prevent adult IPD than adult NIPP (Ochoa-Gondar et al., 2014; Bonten et al., 2015), 
vaccination of adults in Portugal would have a role especially in the prevention of 
adult IPD. However, and as stated above, the potential coverage of pneumococcal 
vaccines in adults likely decreased after 2015. In addition, no cost-effectiveness study 
regarding the use of pneumococcal vaccines in adults in Portugal is available. In other 
countries, studies evaluating the cost-effectiveness of adult PCV13 vaccination 
reached different conclusions (Dirmesropian et al., 2015; van Hoek and Miller, 2016). 
This situation might represent real differences between countries or might have been 
due to differences is study design and in the different evidence used as backup in each 
study (Dirmesropian et al., 2015; van Hoek and Miller, 2016). 
Despite all the reports showing that the incidence of PCV13-type IPD in adults 
declined following the use of PCV13 in children (e.g. Moore et al., 2015; Waight et al., 
2015), a steady state in the incidence of adult IPD is yet to be announced in the post-
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PCV13 period, not only regarding the serotypes included in PCV13, but also 
concerning those not covered by this vaccine. Increases in the incidence of non-
PCV13-type IPD were noticed in several countries post-PCV13 introduction (e.g. 
Waight et al., 2015; Regev-Yochay et al., 2017) and it is currently uncertain if these 
continued thereafter, and if so, to what extent. Given that some non-PCV13 serotypes 
have been shown to have high invasive disease potential (Sá-Leão et al., 2011), the 
possibility of serotype replacement in disease after continued use of PCV13, as what 
happened in some countries following PCV7 use (Lepoutre et al., 2008; Miller et al., 
2011b), cannot be ignored. In England and Wales, the increase in non-PCV13 type IPD 
in children < 5 yrs in 2013-2014 period resulted in a higher overall incidence of invasive 
pneumococcal disease in this age group, compared with 2012-2013 period (Waight et 
al., 2015). Our data showed there were significant increases of some non-PCV13 
serotypes in adult IPD since the late post-PCV7 period, suggesting emerging serotypes 
in disease. However, we also noted a significant decrease in the number of invasive 
isolates recovered from younger adults relative to each of the other two adult age 
groups considered when comparing the periods 2009-2011 and 2012-2014, with this 
suggesting a reduction in incidence of IPD in adults 18-49 yrs (Horácio et al., 2016b).  
Despite the lack of age-based recommendations from the national health 
authority, two pneumococcal vaccines are available for use in immunocompetent 
adults in Portugal, the PPV23 since 1996, and the PCV13 since 2012 (Horácio et al., 
2012). In addition, the sequential vaccination of adults ≥ 65 yrs with PCV13 and PPV23 
was recommended by two Portuguese medical societies (Sociedade Portuguesa de 
Pneumologia and Sociedade Portuguesa de Medicina Geral e Familiar). The lack of 
wider recommendations from the national health authority in Portugal results in the 
autonomy of physicians to decide whether to vaccinate immunocompetent adults. In 
our studies information on the uptake of these vaccines in adults was not available 
and therefore we could not conclude on the role of adult pneumococcal vaccination 
in the PCVs era. However, given that indications for the use of PCV13 in adults became 
available only in late-2011 in Europe, and because studies reporting on the use of 
PPV23 in adults in the post-PCV7 period in Portugal found it to be very low (Sousa et 
al., 2009; Fedson et al., 2011), it is unlikely that pneumococcal vaccination of adults in 
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Portugal have had a significant effect in the results presented in the studies 
composing this thesis.  
The possible impact of PCV10 was also mostly disregarded in the studies 
presented in this thesis. Even though this vaccine was available for private use in 
children from mid-2009 to June 2015, PCV13 was the most frequently used 
pneumococcal vaccine in this period (Horácio et al., 2016b). Given that the use of 
PCV10 in children is also associated with the induction of herd effects in adults (Tin 
Tin Htar et al., 2015), there is a possibility that the low use of this vaccine in children 
in Portugal contributed to the results obtained in the studies presented in this thesis. 
In spite of the uncertainties concerning the possible contribution of adult 
pneumococcal vaccination and childhood PCV10 vaccination for the results obtained 
in the studies presented in this thesis, we know that other factors besides vaccination 
were important. The relevance of these other factors became clear, for example, with 
the significant reductions of serotypes 1 and 5 in adult IPD, which are serotypes 
targeted by PCV10 and PCV13, immediately before indirect effects of these vaccines 
could have been possible in Portugal (Horacio et al., 2013). If the reductions of 
serotypes 1 and 5 in adult IPD had been detected few years later, we could have 
thought they reflected herd protection with the use of the new vaccines in children. 
This highlights the importance of carefully evaluating changes in the serotype 
distribution of pneumococci following the use of PCVs.  
Using the current CLSI guidelines (Clinical and Laboratory Standards Institute, 
2015), the great majority of pneumococcal isolates collected from non-meningitis 
cases was susceptible to penicillin (Horácio et al., 2016b; Horácio et al., 2018). As 
stated before, our results agree with the empirical antimicrobial treatment 
recommended for pneumonia in Portugal. However, the still high number of deaths 
associated with pneumonia in Portugal (INE, 2015) and in other countries (GBD 2015 
Mortality and Causes of Death Collaborators, 2016), is of concern. To prevent 
pneumococcal associated deaths, not only effective antimicrobial treatment must be 
available, but antimicrobial therapy should start as soon as possible (Cillóniz and 
Torres, 2012). In addition, antibiotics should reach the people in need, which is still 
an issue in several countries (http://www.who.int/news-room/fact-
sheets/detail/pneumonia).      
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Epidemiological surveillance of pneumococcal disease is important in countries 
using pneumococcal vaccines, in those preparing to adopt pneumococcal vaccines 
and in those with high burden of pneumococcal disease. Even though pneumococcal 
populations may be more similar between neighboring countries than between those 
far away, and it may be useful to use data from one country to represent countries 
around, especially in the context of low income countries, several factors may 
contribute to widen disparities regarding the characteristics of pneumococcal 
populations causing disease in each country. Examples of such factors are differences 
in pneumococcal vaccine policies, use of antibiotics and migratory flows. Portugal 
and Spain are two neighboring countries presenting significant differences regarding 
the pneumococcal populations causing disease in adults. For example, when 
comparing post-PCV13 adult IPD data from Portugal (Horácio et al., 2016b) with adult 
IPD data from Spain in a similar period (Càmara et al., 2017), serotype 8, 22F, 20 and 
15A increased significantly in Portugal, while in Spain serotype 8 decreased 
significantly, serotype 22F increased slightly and no important changes were detected 
for serotypes 20 and 15A. In addition, serotype 6C increased significantly in Spain, but 
the same was not reproduced in Portugal. These findings underscore the need to set 
up epidemiological surveillance networks of pneumococcal disease in all geographic 
regions, if possible.   
Several questions emerged from the results obtain in the studies presented in 
this thesis and deserve further study: 1) Our data showed there were important 
changes in the serotype distribution of pneumococci causing adult IPD and adult 
NIPP, with decreases of PCV13 serotypes in both adult IPD and adult NIPP and 
increases of specific non-PCV13 serotypes only in adult IPD (Horácio et al., 2016b; 
Horácio et al., 2018). Therefore, it is important to evaluate how these trends continued 
in most recent years, if there is evidence of a steady state in the serotype distribution 
and what is the remaining proportion of disease potentially preventable by the 
available pneumococcal vaccines. 2) PCV7 serotypes persisted as causes of disease in 
adults throughout the entire period of private PCVs use in children (Horácio et al., 
2016b; Horácio et al., 2018). It would be interesting to see if these serotypes 
disappeared as causes of adult IPD and adult NIPP with the introduction of PCV13 in 
the national immunization program of children. 3) There is a believe that with the 
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continued use of PCV13, PCV7 serotypes will become more represented in disease 
than the additional serotypes included in PCV13, due to the higher circulation of PCV7 
serotypes before introduction of PCV7 (van Hoek and Miller, 2016). It would be 
interesting to evaluate this hypothesis, since the effectiveness of PCV13 against 
serotype 3 is currently not well understood (Steens et al., 2013; Harboe et al., 2014; 
Moore et al., 2015; Waight et al., 2015; Horácio et al., 2016b). 4) If PCV13 use in children 
can reduce serotype 3, we expect this serotype to no longer be the most prevalent 
serotype in adult IPD and adult NIPP (Horácio et al., 2016b; Horácio et al., 2018). It is 
important to evaluate this possibility. In addition, even though serotype 19A showed 
an important decrease in adult IPD (Horácio et al., 2016b), its decrease in adult NIPP 
was less relevant (Horácio et al., 2018). The evolution of this serotype as a cause of 
adult NIPP should also be followed. 5) The most important genetic lineage among 
serotype 3 isolates from adult IPD was CC180, which we found to have increased 
within this serotype in the post-PCV13 period (Horácio et al., 2016a). This lineage also 
seemed to have emerged within serotype 3 causing adult IPD elsewhere (Càmara, et 
al., 2017). Given the importance of serotype 3 as a cause of disease in adults in 
Portugal, it would be interesting to evaluate why CC180 was selected in relation to 
other genetic lineages associated with serotype 3 in this period. 6) We found that 
within the most important serotypes contributing to antimicrobial resistance in adult 
IPD, which were serotypes 14 and 19A, there were decreases in the proportion of 
resistant isolates in the post-PCV13 period (Horácio et al., 2016b). Since antimicrobial 
resistance was highly associated with genotype (Horácio et al., 2016a), these changes 
in antimicrobial susceptibility might have been associated with changes in the genetic 
lineages of these two serotypes. We only determined the MLST-defined clonal 
composition of the isolates causing adult IPD from 2008 to 2011 (Horácio et al., 2016a). 
It is therefore important to evaluate the clonal composition of serotypes 14 and 19A 
from 2012 onwards to better understand these changes. 7) We found that half of the 
isolates expressing serotype 24F in the post-PCV7 period represented CC230 (Horácio 
et al., 2016a), which was the genetic lineage associated with the expansion of serotype 
19A in the post-PCV7 period in Portugal (Aguiar et al., 2010b). Hence, there is a 
concern that serotype 24F may increase in the post-PCV13 period. This possibility 
could be evaluated by additional MLST characterization of serotype 24F from 2012 
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onwards. 8) Almost all isolates expressing serotype 1 in 2008-2011 were from CC306, 
but two isolates represented CC217 instead of CC306. Representatives of CC217 were 
associated with high mortality in Africa (Harvey et al., 2011) and therefore the clonal 
composition of serotype 1 isolates in Portugal should be monitored. 9) In spite of the 
great diversity of serotypes causing disease in adults, few serotypes were significantly 
more detected than others (Figures V.S2 and V.S5). It would be important to 
understand what characteristics promoted the higher frequency of these serotypes 
and respective genetic lineages when comparing with the other less frequent 
serotypes. It would also be important to understand why particular serotypes were 
either associated with adult IPD or adult NIPP (Horácio et al., 2014; Horácio et al., 
2018). MLST could be used to evaluate the clonal composition of adult NIPP isolates, 
as was done with adult IPD (Horácio et al., 2016a). A comparison of adult NIPP and 
adult IPD clonal compositions may give rise to new questions, which perhaps can be 
answered by WGS. 
Even though co-morbidities increase with increasing age, old age itself was 
found to be an independent predictor of mortality among patients with IPD (Regev-
Yochay et al., 2017). Contradicting the todays accelerated increase in the World 
population, in Portugal the population is estimated to decrease from 10,3 million in 
2015 to 7,5 million in 2080 (INE, 2017). However, the fraction of the population 
represented by adults ≥ 65 years is estimated to continue to increase until 2040, the 
moment it will start to decrease due to the inclusion in this age group of people born 
in the context of low natality rates. If the predictions are correct, the 2,1 million adults 
≥ 65 years in 2015 will change to 2,8 million in 2080 (INE, 2017). Therefore, the number 
of people at high risk for pneumococcal disease is expected to increase in our country 
during this century, highlighting the importance of continuing epidemiological 
surveillance of adult pneumococcal disease in Portugal. Since some of the risk factors 
associated with the development of pneumococcal disease are preventable (e.g. 
alcohol abuse and smoking), another way to prevent pneumococcal disease, besides 
vaccination, would be through the adoption of a heathier life style by each individual. 
Perhaps more campaigns could be done in this regard in the targeted populations.
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Figure V.S1 Proportion of isolates expressing serotypes included in pneumococcal vaccines causing invasive pneumococcal disease in adult patients (≥ 18 years) in Portugal, 1999–2014. 
The data up to 2008 were presented previously (Serrano et al., 2004; Aguiar et al., 2008a; Horácio et al., 2012), while the data from 2009 to 2014 were presented in the two studies composing 
chapter II of this thesis (Horácio et al., 2013; Horácio et al., 2016b).
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Figure V.S2 - Distribution of the 10 most frequent serotypes causing invasive pneumococcal disease in adult patients (≥ 18 years) in Portugal, 1999–2014. The data up to 2008 were 
presented previously (Serrano et al., 2004; Aguiar et al., 2008a; Horácio et al., 2012), while the data from 2009 to 2014 were presented in the two studies composing chapter II of this thesis 
(Horácio et al., 2013; Horácio et al., 2016b).
  
 
 
Figure V.S3 – Proportion of penicillin non-susceptible pneumococci (PNSP) and erythromycin resistant pneumococci (ERP) among the isolates causing invasive 
pneumococcal disease in adult patients (≥ 18 years) in Portugal, 1999–2014. The data up to 2008 were presented previously (Serrano et al., 2004; Aguiar et al., 2008a; Horácio 
et al., 2012), while the data from 2009 to 2014 were presented in the two studies composing chapter II of this thesis (Horácio et al., 2013; Horácio et al., 2016b).
  
 
 
Figure V.S4 - Proportion of isolates expressing serotypes included in pneumococcal vaccines causing non-invasive pneumococcal pneumonia in adult patients (≥ 18 years) in Portugal, 
1999–2015. Data from 1999 to 2011 were presented in the first study of chapter IV of this thesis (Horácio et al., 2014), while data from 2012 to 2015 were presented in the second study of chapter 
IV (Horácio et al., 2018). 
  
 
 
Figure V.S5 - Distribution of the 10 most frequent serotypes causing non-invasive pneumococcal pneumonia in adult patients (≥ 18 years) in Portugal, 1999–2015. Data from 1999 to 
2011 were presented in the first study of chapter IV of this thesis (Horácio et al., 2014), while data from 2012 to 2015 were presented in the second study of chapter IV (Horácio et al., 2018).
  
 
 
Figure V.S6 – Proportion of penicillin non-susceptible pneumococci (PNSP) and erythromycin resistant pneumococci (ERP) among the isolates causing non-invasive pneumococcal 
pneumonia in adult patients (≥ 18 years) in Portugal, 1999–2015. Data from 1999 to 2011 were presented in the first study of chapter IV of this thesis (Horácio et al., 2014), while data from 
2012 to 2015 were presented in the second study of chapter IV (Horácio et al., 2018).
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Abstract
In Portugal, pneumococcal conjugate vaccines have been administered to children outside of the national immunization
plan since 2001. We determined the serotype and antimicrobial susceptibility of 1265 isolates responsible for adult invasive
pneumococcal infections (IPD) between 2009 and 2011 and compared the results with previously published data from 1999
to 2008. Serotypes 3 (12.6%), 7F (10.0%), 19A (9.1%), 14 (8.4%), 1 (6.9%) and 8 (6.2%) were the most frequent and together
accounted for 53.2% of adult IPD. Serotypes 1 and 5 declined significantly while serotype 34, not included in any vaccine,
increased. Taken together, the serotypes included in the 13-valent conjugate vaccine (PCV13) peaked among adult IPD
isolates in 2008 (70.2%) and declined since then reaching 53.5% in 2011. The decline in the serotypes included in the 23-
valent polysaccharide vaccine since 2007 was also significant but much more modest with 79.2% of the isolates causing IPD
in 2011 expressing these serotypes. Since the changes in serotypes causing IPD in adults coincided with the 10-valent and
PCV13 introduction in children, it is unlikely that vaccination triggered these changes although it may have accelerated
them. The proportion of IPD caused by serotypes included in the 7-valent conjugate vaccine remained stable (19.0%). Both
penicillin non-susceptibility and erythromycin resistance increased in the study period, with serotypes 14 and 19A
accounting for the majority of resistant isolates.
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Introduction
Streptococcus pneumoniae (pneumococcus) remains a significant
cause of morbidity and mortality throughout the world affecting
disproportionally the extremes of life. Prevention of these
infections in persons $2 years belonging to risk groups and
particularly among adults $65 years has relied on a vaccine
including 23 of the 94 capsular polysaccharides known in
pneumococci. Although older age is a recognized risk factor for
pneumococcal disease, in Europe different countries have distinct
recommendations regarding the use of the 23-valent polysaccha-
ride vaccine (PPV23), ranging from the absence of national
guidelines, to recommendations of universal or risk group
vaccination starting at 60 or 65 years [1]. Perhaps because of an
ongoing debate on PPV23 efficacy [2,3,4], in most European
countries there is a low overall uptake of PPV23 [5]. In Portugal
PPV23 uptake is at the lower end of the spectrum with estimates
that approximately 10% of adults $65 years are vaccinated [6].
The remarkable efficacy of the seven-valent conjugate vaccine
(PCV7) against the serotypes included in its formulation resulted in
a sharp decline in the proportion of invasive pneumococcal
infections (IPD) caused by these serotypes not only in vaccinated
children [7,8,9,10,11,12] but also across the entire population [6].
This ‘‘herd effect’’ is attributed to the reduced transmission of
these serotypes from children to adults. In Europe, although there
were epidemiological changes in the serotypes causing IPD in the
non-vaccinated population in all countries where the vaccine was
administered, the large reduction in the overall number of invasive
infections in adults observed in the USA was not replicated in
countries such as Spain, England and Wales and the Netherlands
[10,12,13] where significant increases in non-vaccine serotypes
(NVT) occurred.
Since the PCV7 serotypes represented a significant fraction of
resistant isolates, vaccination was also anticipated to affect
resistance. However, the effect of PCV7 on antibiotic resistance
in Europe was variable. While a decrease in penicillin non-
susceptibility was noted in all countries among isolates responsible
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73704
for pediatric IPD in the post-PCV7 period [7,13,14], such decline
was not apparent in adults in Portugal and Spain [6,13,14].
Serotype 19A has consistently been identified as a dominant
non-vaccine serotype but other emerging non-vaccine serotypes
differ between geographic locations and also between age groups
[6,7,8,9,14]. Even within serotype 19A, different genetic lineages
emerge in different geographic locations [15]. These data highlight
the importance of the characteristics of the local pneumococcal
population and of local selective forces in conditioning the
outcomes of vaccination [16].
On the other hand, it is known that serotypes responsible for
IPD may have significant temporal variations in the same
geographic region as documented in Spain and Denmark
[17,18], even with limited antibiotic selective pressure and in the
absence of PCV use. In addition, the divergent prevalence of the
various serotypes in different geographic regions also conditions
the potential benefits of vaccination. A much lower prevalence of
serotype 1 IPD is documented in the USA than elsewhere
[6,9,14,18,19,20]. Although serotype 1 is frequently associated
with outbreaks and significant yearly variations of the proportion
of IPD caused by this serotype are documented, a considerable
fraction of IPD was consistently caused by this serotype in the last
decades in Europe [17,18].
Two new pneumococcal conjugate vaccine (PCV) formulations
are now commercially available and used in children. A 10-valent
formulation (PCV10) including, in addition to the PCV7
serotypes, serotypes 1, 5 and 7F and a 13-valent conjugate
vaccine (PCV13), including all PCV10 serotypes plus serotypes 3,
6A and 19A. The introduction of these vaccines into clinical
practice has the potential to once again change the characteristics
of pediatric IPD, with initial data showing the capacity of PCV13
to blunt or even reverse the rise of some of the most successful
serotypes that have emerged as causes of pediatric IPD since the
introduction of PCV7 [21,22,23].
PCV13 was recently licensed for use in adults $50 years and
this was soon followed by a recommendation in the USA for its use
in adults with immunocompromising conditions [24]. Approval of
PCV13 for adults was based on immunogenicity studies and the
results of a large study that is currently underway in the
Netherlands [25] comparing it to placebo for the prevention of
vaccine-serotype community acquired pneumonia in adults are
expected to become available in late 2013. The observed benefits
of conjugate vaccines in children launched a discussion about the
potential benefits of vaccinating the adult population with these
vaccines instead of PPV23 [2,3,4,26]. Independently of the
immunological arguments, the potential benefits of adult vaccina-
tion with either PCV13 or PPV23 are a moving target since
secular trends in pneumococcal serotypes and the herd effect
provided by PCV7, and now also hoped for the use of PCV13 in
children, would be expected to reduce the importance of the
serotypes included in conjugate vaccines in adult IPD.
In Portugal PCVs were not included in the National Immuni-
zation Plan but there has been a steady increase in PCV7 uptake
since 2001, reaching 75% of children #2 yrs in 2008 [14]. The
expanded valency PCVs for childhood vaccination – PCV10 and
PCV13– became available in mid-2009 and early-2010, respec-
tively. In previous studies, we showed that significant changes in
the serotypes causing IPD in children followed PCV7 availability
[7,14] and that there was evidence for a herd effect in the adult
population [6,14]. This study aimed at documenting the continued
changes on serotype distribution and antimicrobial resistance in
different adult groups and evaluating the proportion of potentially
vaccine preventable adult IPD in Portugal immediately prior to
the approval in January 2012 of PCV13 use in adults .50 yrs.
Materials and Methods
Ethics Statement
Case reporting and isolate collection were considered to be
surveillance activities and were exempt from evaluation by the
Review Board of the Faculdade de Medicina da Universidade de
Lisboa.
Bacterial Isolates
Since 1999, the Portuguese Group for the Study of Streptococ-
cal Infections has monitored pneumococci causing invasive
infections in Portugal. This is a laboratory-based surveillance
system, in which 30 microbiology laboratories throughout
Portugal are asked to identify all isolates responsible for IPD and
to send them to a central laboratory for characterization. A case of
invasive disease is defined by an isolate of S. pneumoniae recovered
from a normally sterile body site such as blood or CSF. Although
the laboratories were contacted periodically to submit the isolates
to the central laboratory, no audit was performed to ensure
compliance, which may be variable in this type of study. Isolates
recovered up to 2008 were previously characterized [6,14,27].
Only isolates recovered from adult invasive infections, i.e.
recovered from patients $18 yrs, between 2009 and 2011 were
included in the present study. One isolate from each patient in
each year was considered. All strains were identified as S.
pneumoniae by colony morphology and hemolysis on blood agar
plates, optochin susceptibility and bile solubility.
Serotyping and Antimicrobial Susceptibility Testing
Serotyping was performed by the standard capsular reaction test
using the chessboard system and specific sera (Statens Serum
Institut, Copenhagen, Denmark). Serotypes were grouped into
conjugate vaccine serotypes, i.e., those included in PCV13
(serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F)
and that comprise all the serotypes found in the lower valency
vaccines, those included in PPV23 (all serotypes included in
PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B,
17F, 20, 22F and 33F), and non-vaccine serotypes (NVT). Etest
strips (AB Biodisk, Solna, Sweden) were used to determine the
MICs for penicillin and cefotaxime. In 2008, the CLSI changed
the recommended breakpoints used to interpret MIC values.
Unless otherwise stated we have used the CLSI-recommended
breakpoints prior to 2008 [28] as epidemiological breakpoints that
allow the comparison with previous studies. According to these
recommendations, intermediate level penicillin resistance was
defined as MIC 0.12–1.0 mg/ml and high level resistance as MIC
$2.0 mg/ml. Isolates that fell into either of these classes were
designated penicillin non-susceptible. Susceptibility to cefotaxime
was defined as MIC #1.0 mg/ml for non-meningitis cases and an
MIC #0.5 mg/ml for meningitis cases.
Isolates were further characterized by determining their
susceptibility to erythromycin, clindamycin, vancomycin, linezolid,
tetracycline, levofloxacin, trimethroprim-sulfamethoxazole and
chloramphenicol by the Kirby-Bauer disk diffusion technique,
according to the CLSI recommendations and interpretative
criteria [29].
Macrolide resistance phenotypes were identified using a double
disc test with erythromycin and clindamycin according to a
previously published procedure [30]. Simultaneous resistance to
erythromycin and clindamycin defines the MLSB phenotype
(resistance to macrolides, lincosamides and streptogramin B) while
non-susceptibility only to erythromycin indicates the M pheno-
type.
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The prevalence of the various serotypes was compared with
already published data from 1999–2008 [6,14,27]. We established
previously that no significant changes in serotype distribution
occurred until 2003 in adult IPD and have therefore considered
1999–2003 as the pre-vaccine period [14].
Statistical Analysis
Simpson’s index of diversity (SID) and respective 95%
confidence intervals (CI95%) was used to measure the population
diversity [31]. Adjusted Wallace (AW) coefficients were used to
compare two sets of partitions [32]. The calculation of these
indices was done using the online tool www.comparingpartitions.
info. Differences were evaluated by the Fisher exact test and the
Cochran-Armitage test was used for trends with the false discovery
rate (FDR) correction for multiple testing [33]. A p,0.05 was
considered significant for all tests.
Results
Isolate Collection
Between 2009 and 2011 a total of 1265 isolates were recovered
from normally sterile sites: 448 in 2009, 404 in 2010 and 413 in
2011. Isolates were recovered from blood (n = 1121, 88.6%), CSF
(n = 97, 7.7%), pleural fluid (n = 30, 2.4%), peritoneal fluid (n = 10,
0.8%) and other normally sterile sites (n = 7, 0.5%). Regarding age
distribution, 353 isolates (27.9%) were recovered from patients 18–
49 yrs, 272 (21.5%) from patients 50–64 yrs and 640 (50.6%) from
patients $65 yrs.
The 1265 isolates recovered in 2009–2011 are in line with the
1100 isolates recovered in 2006–2008 and reported previously [6].
This suggests that the surveillance network is stable and that no
major changes are affecting IPD reporting in the two periods.
However, although unlikely, we cannot completely exclude the
possibility that there was an increase in reporting that may have
compensated for a potential decrease in IPD incidence.
Serotype Distribution
We detected 50 different capsular types among the 1265
isolates. The most frequent, that accounted for 53.2% of all adult
IPD, were serotypes 3 (n = 160, 12.6%), 7F (n = 126, 10.0%), 19A
(n = 115, 9.1%), 14 (n = 106, 8.4%), 1 (n = 87, 6.9%) and 8 (n = 79,
6.2%). During the study period (2009–2011), the only significant
changes found in individual serotype prevalence after FDR
correction were of serotype 1, that decreased from 10.7% to
4.1% (Cochran-Armitage test of trend p,0.001), serotype 5, that
decreased from 2.0% to 0% (Cochran-Armitage test of trend
p = 0.003) and serotype 34, that did not cause any invasive
infections in 2009 and 2010 but was detected in 1.9% of the
isolates causing IPD in 2011 (Cochran-Armitage test of trend
p,0.001).
Fig. 1 shows the evolution of vaccine preventable IPD between
1999 and 2011. For the period 1999–2003, defined previously as
the pre-PCV7 period [14], the results were averaged over the
entire period. After the significant decline of IPD caused by PCV7
serotypes between 2004 and 2005, from 30.8% to 16.5%
(p,0.001), a steady and low prevalence was seen until 2011. As
previously documented [6], in spite of the decrease of PCV7
serotypes, the increase in serotypes 1, 19A and 7F resulted in an
overall increase in PCV13 serotypes in the post-PCV7 period,
from 61.9% in 1999–2003 to 70.2% in 2008 (Cochran-Armitage
test of trend p = 0.014). However, 2008 was an inflection point
(Fig. 1) and the proportion of isolates presenting PCV13 serotypes
started to decline from then onwards such that in 2011 only 53.5%
of the isolates presented PCV13 serotypes (from 2008 to 2011,
Cochran-Armitage test of trend p,0.001). This change was mainly
Figure 1. Proportion of isolates expressing serotypes included in pneumococcal vaccines causing invasive infections in adults in
Portugal (1999–2011). The data up to 2008 were presented previously [6,14,27]. The period of 1999–2003, previously identified as the pre-PCV7
period [14], was analyzed together.
doi:10.1371/journal.pone.0073704.g001
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driven by a decrease in prevalence of serotypes 1 and 5 from
13.5% and 2.9% in 2008 to 4.1% and 0% in 2011, respectively
(Cochran-Armitage test of trend p,0.001 for both, significant after
FDR) (Table S1).
The proportion of PPV23 serotypes also increased slightly but
non-significantly up to 2007. From 2007 onwards there was a
slight but significant decrease in the proportion of IPD caused by
PPV23 serotypes, from 85.0% in 2007 to 79.2% in 2011
(Cochran-Armitage test of trend p = 0.018). Initially this decline
occurred in spite of the increase in PCV13 serotypes that peaked
in 2008. Later, the decline of PCV13 serotypes was opposed by an
important increase in the proportion of IPD caused by the
additional serotypes found in PPV23 but absent from PCV13,
from 13.7% in 2008 to 25.9% in 2011 (Cochran-Armitage test of
trend p,0.001). When looking individually at these serotypes,
although several increased in frequency, only serotype 8 increased
significantly from 3.7% in 2008 to 8.0% in 2011 (Cochran-
Armitage test of trend p,0.002, significant after FDR).
Fig. 2 shows the distribution of the individual serotypes included
in the conjugate vaccines, stratified by the age group of the
patients. Fig. 3 shows the distribution of the additional serotypes
found in PPV23 that are not included in the conjugate vaccines.
To analyze the serotype diversity within each age group, SIDs
were calculated. The serotypes of the isolates causing invasive
infections in any of the age groups considered were highly diverse
(18–49 yrs [SID: 0.939, CI95%: 0.930–0.947]; 50–64 yrs [SID:
0.949, CI95%: 0.941–0.958]; $65 yrs [SID: 0.934, CI95%: 0.926–
0.943]). The only significant difference was a higher diversity of
serotypes in the 50–64 yrs age group relative to$65 yrs age group
(p = 0.013). A similar analysis was performed for determining the
serotype diversity in each study year but no significant changes
occurred between 2009 and 2011 nor were changes in diversity
noted between the 2004–2008 period and 2009–2011 (data not
shown).
Although the frequency of each serotype varies according to the
age groups considered, only for serotypes 1, 3, 8 and 19A were
these differences significant. While the frequency of serotype 1
decreases with age (18–49 yrs –11.0%, 50–64 yrs –7.7%, $65 yrs
–4.2%; Cochran-Armitage test of trend p,0.001), the frequency of
serotype 3 increases with age (18–49 yrs –7.6%, 50–64 yrs –
10.7%, $65 yrs –16.3%; Cochran-Armitage test of trend
p,0.001). For serotypes 8 and 19A a trend with age was not
evident. However, serotype 8 was more frequent in the youngest
group (18–49 yrs –10.5%) than in either of the oldest age groups
(50–64 yrs –4.8%, p = 0.011 and $65–4.5%, p,0.001), and
serotype 19A showed a higher prevalence in older adults
($65 yrs; 10.5%) than in younger adults (18–49 yrs; 5.9%,
p = 0.019). Taking together the three years of the study (2009–
2011), the proportion of IPD caused by the serotypes included in
both conjugate vaccines and in PPV23 was roughly the same in all
age groups considered (Table 1).
When analyzing individual serotypes with three or more CSF
isolates, a positive association with CSF was found for serotypes 6B
(p = 0.002), 16F (p = 0.009) and 19F (p = 0.002), all significant after
FDR (Table S2).
Antimicrobial Susceptibility
Resistance to the tested antimicrobials is summarized in table 2
and figures 2 and 3. Overall 266 isolates (21.0%) were penicillin
non-susceptible pneumococci (PNSP) –205 (16.2%) expressed low
level resistance (MIC = 0.12–1.0) and 61 (4.8%) high level
resistance (MIC $2 mg/ml). Considering current CLSI break-
points for parenteral penicillin where susceptibility is defined as
MIC ,0.06 mg/ml for meningitis cases [29], 17 isolates (17.5%)
from CSF would have been considered resistant and 27 isolates
(2.3%) from non-meningitis cases would have been considered
non-susceptible –24 (2.1%) intermediately resistant and 3 (0.3%)
fully resistant. Erythromycin resistant pneumococci (ERP) ac-
counted for19.4% of the isolates (n = 245), of which 194 isolates
(79.2%) expressed the MLSB phenotype and 51 (20.8%) the M
phenotype. All isolates were susceptible to vancomycin and
linezolid. The simultaneous expression of erythromycin resistance
and penicillin non-susceptibility (EPNSP) was found in 13.0% of
the isolates.
Resistance to penicillin, erythromycin and clindamycin in-
creased with the age group considered (table 2). While the increase
in erythromycin and clindamycin were statistically supported
(Cochram-Armitage test of trend, p = 0.035 and p = 0.039,
respectively) the increase in penicillin non-susceptibility was not
(p = 0.057). For the other tested antimicrobials no significant
differences were noted. The proportions of PNSP and ERP in
2009–2011 were higher than those previously reported (Figure S1).
The proportion of PNSP increased from being previously stable
(from an average value of 16.7% in 1999–2008 to 21.0% in 2009–
2011, p = 0.002). On the other hand, there was a consistent
increase in the proportion of ERP since PCV7 introduction (from
1999–2003 to 2011, Cochran-Armitage test of trend p,0.001).
Although the overall proportion of ERP has been increasing, when
analyzing changes within the study period a significant decrease
was noted from 2010 to 2011, from 23.8% to 15.7% (p = 0.005).
Similarly, the proportion of PNSP also decreased from 23.8% in
2010 to 19.6% in 2011, but this change was not statistically
significant (p = 0.174).
The correlation between serotype and antimicrobial resistance
was high. The AW for serotype and penicillin non-susceptibility
was 0.539 (CI95% 0.476–0.601), higher than the AW for serotype
and erythromycin resistance (0.403, CI95% 0.336–0.470). Togeth-
er, serotypes 19A and 14 contributed greatly to penicillin non-
susceptibility (59.0%) and to erythromycin resistance (53.1%)
(Fig. 2). Serotypes included in PCV7 represented 47.4%, 36.7%
and 35.8% of PNSP, ERP and EPNSP, respectively, while
serotypes included in PCV13 constituted 76.7%, 71.4% and
72.1%, respectively. Considering the serotypes included in PPV23,
only a modest increase relative to the PCV13 serotypes is noted
(80.2%, 75.1% and 74.5%, of PNSP, ERP and EPNSP,
respectively) since most of the remaining resistant isolates express
NVTs (Fig. 3). Among the EPNSP expressing NVTs, serotypes 6C
(45.2%) and 15A (28.6%) were dominant.
Discussion
The effect of childhood vaccination in the distribution of IPD
serotypes in adults was always found to be delayed in relation to
the effects seen in children in the countries where the vaccine is
available [12,14,34]. Given this prior experience with PCV7, the
introduction of PCV13 in childhood vaccination in early 2010 in
Portugal would only be expected to have an effect in the
distribution of serotypes causing IPD in adults around 2011. If
one considers the serotypes common to PCV10, then the
introduction of PCV10 in childhood vaccination in mid-2009
would raise the possibility that an effect on these serotypes could
occur earlier. However, the significant increase in adult IPD in the
post-PCV7 period of serotypes 1, 7F (common to both PCVs) and
19A (exclusively found in PCV13) peaked in 2008 [6]. While
serotypes 7F and 19A remained stable from then onwards, the
number of serotype 1 isolates started to decline in 2009 (Table S1).
This was accompanied by a significant reduction of serotype 5 and
a strong reduction of serotype 6A (not included in PCV10) in the
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same period, that were responsible for the overall fall in PCV13
serotypes (Fig. 1). The fact that the decline started in 2009, before
PCV13 introduction and shortly after PCV10 became available,
strongly argues that the changes seen here were not triggered by
the use of PCVs, although they may have been accelerated by
PCV use.
Serotype 3 remains the most prevalent serotype in adult IPD
after PCV7 introduction and continued to be significantly
associated with older adults [6]. Similarly, serotype 7F remains
the second most frequently identified serotype. Although serotypes
3 and 7F were not as frequent, these were also important among
IPD in children [7] and were commonly found among patients
with pleural parapneumonic effusion of all ages in the same period
(unpublished data), attesting to their virulence. In spite of their
continued dominance, both serotype 3 and 7F isolates remain
mostly susceptible to all tested antimicrobials (Fig. 1), as previously
described in Portugal and elsewhere [18,35].
The increase in serotype 19A as a cause of IPD in both children
[7] and adults [6] plateaued in the study period in adults with the
overall proportion of IPD isolates expressing this serotype
remaining stable at around 9%. Serotype 19A as a whole, did
not have an enhanced propensity to cause invasive infections [36],
but particular lineages within this serotype were found to have
different preferences in their association with the human host [15].
In Portugal it was shown that the lineage that was expanding was
associated with antimicrobial resistance [15], as was also seen here
(Fig. 2). While no association with particular adult age groups was
seen previously for serotype 19A IPD, this serotype was now
significantly associated with older adults ($65 yrs) rather than
younger adults (18–49 yrs). This could be driven in part by a
higher antimicrobial consumption in this age group, a trend that
may be emerging in developed countries [37]. However, in
Norway the post-PCV7 rise of serotype 19A was mostly dominated
by a penicillin susceptible clone [38], suggesting that selection for
antimicrobial resistance alone cannot explain the post-PCV7 rise
of this serotype.
Despite 10 years of PCV7 use in children, serotype 14 was still
responsible for a significant fraction of IPD in all adult age groups
(Fig. 2) in contrast to what happens elsewhere, where more
significant reductions of serotype 14 in adult IPD followed PCV7
use in children [12,34]. Serotype 14 isolates were mostly resistant
to either erythromycin or penicillin or both (101/106, 95%)
(Fig. 2). A high proportion of penicillin non-susceptibility,
erythromycin resistance and erythromycin and penicillin non-
susceptibility has been a characteristic of serotype 14 isolates since
before PCV7 introduction [14,27,35], a feature that was
accentuated in the post-PCV7 period in both pediatric and adult
IPD [6,7].
Figure 2. Number of isolates expressing serotypes included in conjugate vaccines causing invasive infections in Portugal (2009–
2011). The number of isolates expressing each serotype in each of the age groups considered is indicated. Isolates recovered from patients 18 to
49 yrs are indicated by black triangles. Isolates recovered from patients 50 to 64 yrs are indicated by open squares. Isolates recovered from patients
$65 yrs are indicated by open circles. Isolates presenting both erythromycin resistance and penicillin non-susceptibility (EPNSP) are represented by
closed black bars. Penicillin non-susceptible isolates (PNSP) are indicated by dark hatched bars. Erythromycin resistant pneumococci(ERP) are
indicated by light hatched bars. Isolates susceptible to both penicillin and erythromycin are represented by white open bars. The serotypes included
in each of the conjugate vaccines are indicated by the arrows. NVT – non-vaccine serotypes, i.e., serotypes not included in any of the currently
available vaccines (PCV13 and PPV23). Twenty-eight NVT were detected representing 236 isolates as follows: 6C (n = 36); 23A (n = 20); 12B (n = 19); 16F
(n = 18); 23B and 33A (n = 16 each); 15A and 29 (n = 15 each); 24F (n = 13); non-typable (n = 10); 31, 34 and 35F (n = 8 each); 7C, 25A and 35B (n = 5
each); 21 (n = 4); 18A (n = 3); 13 and 17A (n = 2 each); 7A, 11C, 15F, 24A, 25F, 28A, 28F and 37 (n = 1 each).
doi:10.1371/journal.pone.0073704.g002
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Serotype 1 traditionally accounts for a higher proportion of
pediatric IPD in Europe than in North America. In Portugal
serotype 1 was the second most important serotype in adult IPD
between 2006–2008 [6]. In neighboring Spain, outside the Madrid
area where PCV7 was available but not included in the national
immunization plan similar to Portugal, an increased importance of
serotype 1 in IPD both in the group targeted for PCV7 vaccination
as well as in older children and adults was also documented [39].
The decline in the importance of serotype 1 as a cause of IPD with
age in adults reported previously [6] was also seen in this period.
However, serotype 1 dropped from the second most frequent
overall cause of IPD in adults to fifth. As discussed above, the
trigger of this decline cannot be solely attributed to a possible herd
effect of PCV use in children since it started before vaccination of
children with the expanded valency PCVs that include this
serotype. Since serotype 1 remains mostly susceptible to antimi-
crobials (Fig. 2), the continued pressure of antimicrobial use could
be invoked to explain this reduction. However, this does not seem
plausible since serotypes 3, 4 and 7F, all also included in PCV13
Figure 3. Number of isolates expressing serotypes present in the 23-valent polysaccharide vaccine but not included in conjugate
vaccines causing invasive infections in Portugal (2009–2011). See the legend of figure 1. Out of the 11 serotypes present in the 23-valent
polysaccharide vaccine PPV23 but absent from the 13-valent conjugate vaccine PCV13, serotype 2 was not found in our collection.
doi:10.1371/journal.pone.0073704.g003
Table 1. Isolates expressing serotypes included in
pneumococcal vaccines (2009–2011).
No. isolates (%)
18–49 yrs 50–64 yrs $65 yrs
2009 24 (18.2) 21 (22.8) 49 (21.9)
PCV7 2010 22 (19.6) 20 (24.7) 30 (14.2)
2011 24 (22.0) 21 (21.2) 29 (14.1)
2009 80 (60.6) 63 (68.5) 150 (67.0)
PCV13 2010 65 (58.0) 48 (59.3) 125 (59.2)
2011 64 (58.7) 56 (56.6) 101 (49.3)
2009 104 (78.8) 78 (84.8) 187 (83.5)
PPV23 2010 97 (86.6) 66 (81.5) 159 (75.4)
2011 96 (88.1) 77 (77.8) 154 (75.1)
doi:10.1371/journal.pone.0073704.t001
Table 2. Antimicrobial resistance of the isolates responsible
for invasive infections in adults (2009–2011).
No. resistant isolates (%)a
18–49 yrs 50–64 yrs $65 yrs
(n = 353) (n = 272) (n = 640)
PEN 62 (17.6) 58 (21.3) 146 (22.8)
MIC90 1 1 1
MIC50 0.023 0.023 0.023
CTX 14 (4.0) 12 (4.4) 24 (3.8)
MIC90 0.75 0.75 0.75
MIC50 0.023 0.023 0.023
LEV 0 (0) 0 (0) 2 (0.3)
ERY 53 (15.0) 58 (21.3) 134 (20.9)
CLI 40 (11.3) 51 (18.8) 108 (16.9)
CHL 7 (2.0) 11 (4.0) 11 (1.7)
SXT 68 (19.3) 62 (22.8) 117 (18.3)
TET 49 (13.9) 51 (18.8) 118 (18.4)
aPEN – penicillin; CTX – cefotaxime; LEV – levofloxacin; ERY – erythromycin; CLI
– clindamycin; CHL – chloramphenicol; SXT – trimethoprim/sulphamethoxazole;
TET – tetracycline. All isolates were susceptible to vancomycin and linezolid.
doi:10.1371/journal.pone.0073704.t002
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and mostly susceptible to antimicrobials similarly to serotype 1
isolates, remain important and stable serotypes in IPD in adults in
Portugal in the post-PCV7 period. Serotypes 1 and 7F were found
to have an enhanced invasive disease potential [36] and were thus
candidates to increase in prevalence in IPD in the post-PCV7
period, as indeed happened [6]. The decline in serotype 1 could be
due to unexplained temporal trends that have been known to
affect this serotype [17,18]. These temporal trends may have
subsequently been accelerated by PCV use.
Two other serotypes with enhanced invasive disease potential –
serotypes 5 and 8 [36]– showed opposite trends. Serotype 5 was
shown to cause outbreaks in open communities [40] and a
significant increase in cases had been noted in 2008, although we
have no evidence that these cases correspond to an outbreak. The
subsequent decline of serotype 5 isolates could then be the natural
dynamics of a putative outbreak. The suggestion that PCV use
could have contributed to the decline of serotype 5 is supported by
the observation that 2011 is the only year since surveillance started
in 1999 when no isolates expressing serotype 5 were detected
among IPD cases in adults. Serotype 8 on the other hand is a non-
PCV serotype that has been increasing since 2008 and that is now
the sixth most frequent serotype in IPD in adults (Fig. 3). Serotype
34 is a NVT that increased in the study period, although it is
responsible for a modest number of cases. Although this serotype
as a whole was associated with carriage, different lineages
expressing this serotype showed distinct capacities to cause
invasive disease [36]. It is therefore possible that its increase in
IPD documented here is driven by a limited expansion of
particularly virulent lineages. The other non-PCV serotypes that
are among the ten most frequently found in adult IPD (Fig. 3) have
all increased in frequency, although this was not statistically
supported, and included the PPV23 serotypes 22F, 11A and 9N
and the NVT serotype 6C. The latter was also notable for being
frequently resistant to both erythromycin and penicillin. Serotypes
6C and 22F were also found among the most frequent in adult
IPD in Canada in 2010 [34]. Since these are not covered by
currently available PCVs, these serotypes may emerge as
important causes of adult IPD in the post-PCV era.
In spite of the large reduction in the number of PCV7 serotypes,
the five serotypes included in this vaccine and that were
traditionally associated with resistance (6B, 9V, 14, 19F and
23F), still accounted for a significant fraction of isolates resistant to
either erythromycin, penicillin or both (45%), and this proportion
declined only slightly from what was seen in 2006–2008 (47%) [6].
Both penicillin and erythromycin non-susceptibility, that is
concentrated in the serotypes included in PCVs, has risen in
adult IPD. The emergence of multiresistant serotype 19A isolates
in the post-PCV7 period in adult IPD played a major role in
preventing the decline of resistance in IPD in Portugal by
compensating the decline of resistant isolates expressing PCV7
serotypes. The significant decrease of erythromycin resistance
noted in 2011 may signal a change in this trend, but there were
multiple serotypes responsible for this decline and no significant
concentration in PCV13 serotypes was noted.
In contrast to our expectations, the use of PCV7 and now of
PCV13 has not resulted in further declines of the PCV7 serotypes as
causes of adult IPD. The continued importance of these serotypes is
in contrast to the massive declines that lead to the almost
elimination of PCV7 serotypes as causes of adult IPD in the USA
[9,16]. The reasons behind this difference are possibly multifactorial
and may include: 1) differences in the transmission dynamics of
these serotypes in the USA and Portugal; 2) differences in the clonal
composition or in the selective pressures exerted upon the
pneumococcal populations; 3) a relatively slow uptake of PCV7 in
Portugal when compared to the USA; and 4) a lower coverage of
PCV7 vaccination in children in Portugal. Although we cannot
formally exclude the first two possibilities, we believe that their
impact would be transient since the pneumococcal population
would adapt to these new circumstances. On the other hand, the
later two possibilities are particularly interesting and suggest that in
order to obtain the full public health benefits of vaccinating children
with PCV13, one should aim at the rapid introduction of the
vaccine and at vaccination coverage higher than the 75% currently
achieved in Portugal. The proportion of PCV7 serotypes has shown
little change since 2005, when the proportion of PCV7 serotypes
causing IPD in adults declined from pre-PCV7 levels to its current
values. It is therefore likely that the stability of PCV7 serotypes in
the intervening six years corresponds to a new steady-state related to
the lower vaccination coverage of children in Portugal relative to
that in the USA or England and Wales [12,19].
The recent replacement with the 13-valent formulation for the
vaccination of children in Portugal, as has happened in many
countries, may equally lead to herd effects in the additional
serotypes included in this vaccine. The approval for the use of
PCV13 in adults raises the possibility that adult vaccination may
not only reduce IPD due to vaccine serotypes in vaccinees but also
lead to reduced carriage of the serotypes included in the vaccine,
as was seen in children, further compounding the herd effect noted
from childhood vaccination. However, even without adult
vaccination, continued use of conjugate vaccines in children and
the herd effects they produce together with sustained high
antimicrobial usage, are likely to drive alterations in the serotypes
causing adult IPD that will influence the fraction of potentially
vaccine preventable disease in this age group.
Our study was not designed to allow the estimate of the
incidence of IPD and it therefore does not evaluate potential
changes in incidence with time and in particular since PCV7
introduction. However, the design based on the reporting of all
laboratory confirmed IPD cases with isolation of the etiological
agent within the surveillance network, the large number of isolates
studied, the wide coverage of the country by the network and the
stable number of isolates reported in each year, guarantees that the
data accurately represents IPD in Portugal and can be used to
evaluate changes in the relative importance of the different
serotypes. PPV23 availability since 1996 had only minor effects on
the proportion of adult IPD caused by PPV23 serotypes but due to
its limited use in the country [6] maybe none should be expected.
The proportion of infections potentially covered by PPV23 in
Portugal remained always above 80% since surveillance was
started in 1999, except in 2011 when it dropped slightly below that
level (Fig. 1). This occurred despite significant serotype changes in
this period. In contrast, the fraction of adult IPD potentially
preventable by PCV13 that had increased diminished in recent
years reaching 53.5% in 2011 and may be even lower in patients
with co-morbidities [41]. PCV13 use could still potentially prevent
more than half of adult IPD in Portugal at the time it was licensed
for use in adults .50 yrs. The dynamics of the serotypes causing
IPD in adults justify the continued surveillance of these infections
in order to evaluate the potential coverage afforded by each of the
two currently available vaccines with an adult indication.
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Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the
7-valent vaccine (PCV7) as the leading pneumococcal vaccine used in children through
the private sector. Although, neither of the PCVs were used significantly in adults,
changes in adult invasive pneumococcal disease (IPD) were expected due to herd
protection. We characterized n = 1163 isolates recovered from IPD in adults in
2012–2014 with the goal of documenting possible changes in serotype prevalence and
antimicrobial resistance. Among the 54 different serotypes detected, the most frequent,
accounting for half of all IPD, were serotypes: 3 (14%), 8 (11%), 19A (7%), 22F (7%),
14 (6%), and 7F (5%). The proportion of IPD caused by PCV7 serotypes remained
stable during the study period (14%), but was smaller than in the previous period
(19% in 2009–2011, p = 0.003). The proportion of IPD caused by PCV13 serotypes
decreased from 51% in 2012 to 38% in 2014 (p < 0.001), mainly due to decreases
in serotypes 7F and 19A. However, PCV13 serotype 3 remained relatively stable and
the most frequent cause of adult IPD. Non-PCV13 serotypes continued the increase
initiated in the late post-PCV7 period, with serotypes 8 and 22F being the most important
emerging serotypes. Serotype 15A increased in 2012–2014 (0.7% to 3.5%, p = 0.011)
and was strongly associated with antimicrobial resistance. However, the decreases in
resistant isolates among serotypes 14 and 19A led to an overall decrease in penicillin
non-susceptibility (from 17 to 13%, p = 0.174) and erythromycin resistance (from 19 to
13%, p = 0.034). Introduction of PCV13 in the NIP for children, as well as its availability
for adults may further alter the serotypes causing IPD in adults in Portugal and lead to
changes in the proportion of resistant isolates.
Keywords: Streptococcus pneumoniae, conjugate vaccines, polysaccharide vaccine, antimicrobial resistance,
invasive disease, serotype
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INTRODUCTION
Two types of pneumococcal vaccines are licensed to prevent
invasive pneumococcal disease (IPD), both targeting a restricted
number of serotypes out of the 94 serotypes currently recognized
in Streptococcus pneumoniae: strictly polysaccharide based
vaccines and polysaccharide-protein conjugate based vaccines
(PCVs) (Ramirez, 2014). The first licensed pneumococcal
conjugate vaccine was the 7-valent pneumococcal conjugate
vaccine (PCV7), which targets serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F. PCV7 became available for children in the USA in
2000 and in Europe in 2001. Two additional conjugate vaccines
became available more recently: a 10-valent vaccine (PCV10),
which includes PCV7 serotypes and serotypes 1, 5, and 7F; and
a 13-valent vaccine (PCV13), which includes PCV10 serotypes
and serotypes 3, 6A, and 19A. PCVs proved to be highly effective
in reducing the number of IPD episodes caused by vaccine
serotypes (Pilishvili et al., 2010; Aguiar et al., 2014). Moreover, a
decrease in IPD caused by PCV serotypes was also noted in non-
vaccinated individuals (a phenomenon termed herd protection)
(Horácio et al., 2013; Moore et al., 2015). However, use of PCVs
was also accompanied by replacement of vaccine serotypes by
non-vaccine types (NVTs) as causes of IPD, both in vaccinated
children and in non-vaccinated adults. The overall impact of this
phenomenon varied greatly around the world (Pérez-Trallero
et al., 2009; Guevara et al., 2014; Harboe et al., 2014; Moore
et al., 2015; Waight et al., 2015). The switch to the higher valency
vaccines PCV10 and PCV13 also affected emerging serotypes.
For instance, serotypes 7F and 19A were reported as emerging in
IPD in the post-PCV7 period (Aguiar et al., 2010; Steens et al.,
2013; Guevara et al., 2014; Harboe et al., 2014; Waight et al.,
2015) but several studies have already shown that they decrease
following PCV13 use (Aguiar et al., 2014; Moore et al., 2015;
Waight et al., 2015). A 23-valent strictly polysaccharide vaccine
(PPV23) includes 12 of the serotypes found in PCV13 (except 6A)
and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F.
This vaccine has been used for two decades in older children and
adults and has proven efficacy in the prevention of IPD (Moberley
et al., 2013).
PCV7, PCV10 and PCV13 became available in Portugal in
late-2001, mid-2009 and in early-2010, respectively. However,
in contrast to many European countries, in Portugal PCV7 was
not included in the national immunization program (NIP) and
the uptake of PCV7 in children increased gradually over time,
reaching 75% in 2008 (Aguiar et al., 2008). PCV13 replaced
PCV7 since its availability and has been the most widely used
pneumococcal vaccine since then, with estimates of 63% coverage
in 2012 (Aguiar et al., 2014). PCV13 received an indication
for adults ≥50 years in 2012 and in 2013 its indication was
extended to all ages, but use of these vaccines in adults in Portugal
was believed to be low until 2014. PCV13 was introduced into
the NIP for children in 2015, being given free of charge to all
children born from January 2015 onwards, with a 2+1 schedule
(Direcção Geral de Saúde, 2015b). PPV23 is also available in
Portugal since 1996, but its uptake among adults is estimated to
be low (∼10%) (Horácio et al., 2012). Since 2015, guidelines from
the national health authorities recommend vaccinating adults in
particular risk groups with both PCV13 and PPV23 (Direcção
Geral de Saúde, 2015a). However, these groups will constitute a
minority of the overall population and there are no guidelines
recommending vaccinating adults more broadly with any of the
pneumococcal vaccines.
In spite of the gradual increase in PCV uptake in children
and the relatively modest coverage, we found significant changes
in serotype distribution and antimicrobial susceptibility of
pneumococci causing adult IPD that could be attributed at least
in part to herd protection. The proportion of adult IPD caused
by PCV13 serotypes was highest in 2008 (70%), but a gradual
decrease took place until 2011, when only 54% of the isolates
causing adult IPD expressed PCV13 serotypes (Horácio et al.,
2012, 2013). In the present study we continued monitoring
potential changes in serotype distribution and antimicrobial
susceptibility of isolates causing adult IPD after PCV13 received
an adult indication and before the introduction of PCV13 in the
NIP for children.
MATERIALS AND METHODS
Ethics Statement
Case reporting and isolate collection were considered to be
surveillance activities and were exempt from evaluation by the
Review Board of the Faculdade de Medicina of Universidade de
Lisboa. The data and isolates were de-identified so that these were
irretrievably unlinked to an identifiable person.
Bacterial Isolates
Invasive pneumococcal infections have been monitored in
Portugal since 1999 by the Portuguese Group for the Study
of Streptococcal Infections (Serrano et al., 2004). This is a
laboratory-based surveillance system, in which 31 microbiology
laboratories throughout Portugal are asked to identify all isolates
responsible for IPD and to send them to a central laboratory
for characterization. Although, the laboratories were contacted
periodically to submit the isolates to the central laboratory,
no audit was performed to ensure compliance, which may be
variable in this type of study. A case of IPD was defined by the
isolation of pneumococci from a normally sterile fluid, such as
blood, pleural fluid or cerebral spinal fluid (CSF). The isolates
included in the study were recovered from adult patients (≥18
years) with IPD between January 2012 and December 2014.
Only one isolate from each patient in each year was included
in the study. All isolates were identified as pneumococci by
colony morphology, hemolysis on blood agar plates, optochin
susceptibility and bile solubility.
Serotyping and Antimicrobial Susceptibility
Testing
Serotypes were determined by the standard capsular reaction
test using the chessboard system and specific sera (Sørensen,
1993) (Statens Serum Institut, Copenhagen, Denmark). Serotypes
were classified into vaccine serotypes, i.e., those included in
PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), in PCV10
(all PCV7 serotypes plus serotypes 1, 5, and 7F), in PCV13
(all PCV10 serotypes plus 3, 6A, and 19A) or in PPV23 (all
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PCV13 serotypes, except serotype 6A and serotypes 2, 8, 9N,
10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F) and non-vaccine
serotypes (NVT). Given the high frequency of spontaneous
switching between serotypes 15B and 15C we have opted to
group isolates with these serotypes into a single group. Due to
difficulties in phenotypically distinguishing isolates of serotype
25A and serogroup 38 these were also grouped together into the
25A/38.
Minimal inhibitory concentrations (MICs) for penicillin and
cefotaxime were determined using Etest strips (Biomérieux,
Marcy l’Étoile, France). In 2008, the CLSI changed the
recommended breakpoints used to interpret MIC values.
Unless otherwise stated we have used the CLSI-recommended
breakpoints prior to 2008 (Clinical and Laboratory Standards
Institute, 2007) as epidemiological breakpoints that allow
the comparison with previous studies. Isolates were
further characterized by determining their susceptibility
to erythromycin, clindamycin, vancomycin, linezolid,
tetracycline, levofloxacin, trimethroprim-sulfamethoxazole and
chloramphenicol by the Kirby-Bauer disk diffusion technique,
according to the CLSI recommendations and interpretative
criteria (Clinical and Laboratory Standards Institute, 2014).
Macrolide resistance phenotypes were identified using
a double disc test with erythromycin and clindamycin, as
previously described (Melo-Cristino et al., 2003). Simultaneous
resistance to erythromycin and clindamycin defines the
MLSB phenotype (resistance to macrolides, lincosamides and
streptogramin B) while non-susceptibility only to erythromycin
indicates theM phenotype.
Statistical Analysis
Simpson’s index of diversity (SID) and respective 95% confidence
intervals (CI95%) was used to measure the population diversity
(Carriço et al., 2006). Adjusted Wallace (AW) coefficients
were used to compare two sets of partitions (Severiano et al.,
2011). These indices were calculated using the online tool
available at http://www.comparingpartitions.info. Differences
were evaluated by the Fisher exact test and the Cochran-Armitage
test (CA) was used for trends with the false discovery rate (FDR)
correction for multiple testing (Benjamini and Hochberg, 1995).
A p < 0.05 was considered significant for all tests.
RESULTS
Isolate Collection
A total of 1163 isolates were collected from adults with invasive
pneumococcal disease between 2012 and 2014: 404 in 2012, 383
in 2013 and 376 in 2014. The majority were recovered from blood
(n = 1066, 91.7%) and the remaining from CSF (n = 59, 5.1%),
pleural fluid (n = 26, 2.2%), peritoneal fluid (n = 9, 0.8%) and
other normally sterile sites (n = 3, 0.3%).
Serotype Distribution
Between 2012 and 2014, a total of 54 different serotypes were
identified. The most frequent, which accounted for half of the
isolates were serotypes 3 (n = 161, 13.8%), 8 (n = 123,
10.6%), 19A (n = 84, 7.2%), 22F (n = 79, 6.8%), 14 (n =
73, 6.3%), and 7F (n = 61, 5.2%). Figures 1–3 represent the
number of isolates expressing serotypes included in PCVs, the
additional serotypes found in PPV23, and the number of isolates
expressing NVTs stratified by age group. Serotype diversity was
high (2012–2014 SID = 0.944, CI95%: 0.939–0.949). Although,
diversity was >0.93 in all the studied years, there was a small
but significant increase in serotype diversity between 2012 (SID
= 0.935, CI95%: 0.924–0.945) and 2013 (SID = 0.950, CI95%:
0.942–0.958) (p = 0.019).
Serotype distribution varied according to age group but
serotype diversity was not different in the three age groups
considered (18–49 years, SID = 0.948, CI95%: 0.938–0.958;
50–64 years, SID = 0.945, CI95%: 0.933–0.957; ≥65 years, SID
= 0.939, CI95%: 0.931–0.946). Only for serotype 1 were the
differences in age distribution statistically supported after FDR
correction with the proportion of serotype 1 decreasing with
age (accounting for 6.5, 2.6, and 0.6% of the isolates recovered
from patients aged 18–49 years, 50–64 years and ≥65 years,
respectively, CA p < 0.001). In contrast, the proportion of IPD
caused by the group of additional serotypes found only in PCV13
(3, 6A, and 19A) increases with age (15.2% in 18–49 years, 19.9%
in 50–64 years and 24.7% in≥65 years, CA p = 0.002, significant
after FDR).
When considering serotypes presenting three or more CSF
isolates, we found a positive association with CSF for serotypes
19F (p = 0.006) and 23B (p = 0.005), both significant after FDR
correction (Table S1). No significant associations with serotype
were found for isolates recovered from pleural fluid.
Figure 4 shows the proportion of potentially vaccine
preventable IPD during the study period and, for comparison
purposes, also from 2008 to 2011 since important changes in
serotype distribution initiated in this period (Horácio et al.,
2013). Considering the current study period only (2012–2014),
the overall proportion of IPD caused by PCV7 serotypes
remained stable, while there was a decrease in the proportion of
IPD caused by the additional serotypes found in both PCV10
and PCV13 (serotypes 1, 5, 7F; from 11.1 to 4.8%, p = 0.001,
significant after FDR) and in PCV13 only (serotypes 3, 6A, and
19A; from 26.5 to 19.9%, p = 0.024, significant after FDR).
This resulted in the overall decrease in the proportion of IPD
caused by PCV13 serotypes from 51.2% in 2012 to 38.0% in
2014 (p < 0.001, significant after FDR). The proportion of IPD
caused by PPV23 serotypes and NVTs did not suffer significant
changes during the study period (Figure 4). However, the
proportion of IPD caused by the additional serotypes found
only in PPV23 (PPV23 add) significantly increased, from 27.2
to 38.0% (p = 0.001, significant after FDR). When considering
the evolution of potentially vaccine preventable IPD in the entire
period from 2008 to 2014, there was a decrease in the overall
proportion of IPD caused by PCV13 serotypes, although this was
temporarily interrupted in 2012, mainly due to a slight increase
of serotype 3 (see below).
Table 1 shows the evolution of individual serotypes causing
adult IPD from 2008 to 2014. When looking for trends in
the proportion of individual serotypes during the current
study period (2012–2014), the only significant change that was
supported after FDR correction was the decrease in serotype
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FIGURE 1 | Serotypes of isolates causing invasive pneumococcal disease in adult patients (≥18 years) in Portugal, 2012–2014. The number of isolates
expressing each serotype in each of the age groups considered is indicated. Isolates recovered from patients 18–49 years are indicated by black triangles, from
patients 50–64 years by open squares, and from patients ≥65 years by open circles. Isolates presenting both erythromycin resistance and penicillin non-susceptibility
(EPNSP) are represented by black bars. Penicillin non-susceptible isolates (PNSP) are indicated by dark hatched bars. Erythromycin resistant pneumococci (ERP) are
indicated by light hatched bars. Isolates susceptible to both penicillin and erythromycin are represented by white bars. The serotypes included in the seven-valent
conjugate vaccine (PCV7) and in the 13-valent conjugate vaccine (PCV13) are indicated by the arrows. NVT, non-vaccine serotypes; PPV23, 23-valent polysaccharide
vaccine.
7F (from 8.2% in 2012 to 4.7% in 2013 and 2.7% in 2014, CA
p < 0.001). No significant changes in the proportion of
individual serotypes were detected during the study period when
stratifying by age group (data not shown).
When considering together data from 2008 to 2014 there were
changes (significant after FDR) in the proportion of individual
serotypes. There were decreases in the proportion of IPD caused
by serotypes: 1 (from 13.4 to 1.9%, CA p < 0.001), 5 (from 2.9 to
0.3%, CA p < 0.001), 9V (from 3.4 to 0.3%, CA p < 0.001) and
19A (from 11.7 to 5.6%, CA p = 0.005). In contrast, there were
increases in the proportion of IPD caused by PPV23 serotypes: 8
(from 3.7 to 12.2%, CA p < 0.001), 22F (from 2.4 to 8.2%, CA
p < 0.001) and 20 (from 1.0 to 3.7%, CA p = 0.001); and an
increase of the NVT 15A (from 1.0 to 3.5%, CA p = 0.002). Even
though these changes were statistically supported when analyzing
data from 2008 to 2014, in the case of serotypes 19A and 15A,
the more disparate values were only detected from 2013 onwards,
while for serotype 20, this occurred from 2012 onwards.
Table 2 shows the evolution of IPD serotypes during the study
period (2012–2014) according to vaccine serotypes and stratified
by age group. Recapitulating what was seen when considering
all age groups together (Figure 4), a decrease in the overall
proportion of IPD caused by PCV13 serotypes was detected in
the three age groups considered; however, only for individuals
≥65 years was this statistically supported (Table 2). Moreover,
only for this age group was the decrease in the additional
serotypes found in both PCV10 and PCV13 (serotypes 1, 5 and
7F) statistically supported after FDR correction (Table 2). When
analyzing the evolution of each serotype from 2008 to 2014
stratifying by age group, only serotype 1 decreased in all age
groups considered (CA p < 0.001 for each, significant after FDR
correction), while the increase of serotype 8 was significant only
in the two older groups (≥50 years) (CA p < 0.001 for both,
significant after FDR correction), and the changes in serotypes
5, 7F, 19A, 20, and 22F were statistically supported only in
individuals ≥65 years (CA p < 0.001 for serotypes 5 and 7F,
CA p = 0.007 for serotype 19A, CA p = 0.003 for serotype
20 and CA p = 0.001 for serotype 22F, all significant after FDR
correction).
Antimicrobial Susceptibility
Resistance to the antimicrobials tested is summarized in Table 3.
A total of n = 179 isolates (15.4%) were classified as penicillin
non-susceptible pneumococci (PNSP): n = 160 (89.4%)
presenting low level resistance and n = 19 (10.6%), high level
resistance. Considering current CLSI breakpoints for penicillin,
n = 12/59 CSF isolates (20.3%) would have been considered
resistant and only n = 5/1104 non-CSF isolates (0.5%) would
have been considered intermediately resistant. A total of n =
198 isolates (17.0%) were classified as erythromycin resistant
pneumococci (ERP). Of these, n = 159 presented the MLSB
phenotype, while the remaining (n = 39, 19.7%) presented theM
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FIGURE 2 | Isolates expressing serotypes present in PPV23 but not included in conjugate vaccines causing invasive pneumococcal disease in adult
patients (≥18 years) in Portugal, 2012–2014. See legend of Figure 1. Out of the 11 serotypes present in PPV23 but absent from PCV13, serotype 2 was not
found in our collection.
phenotype. Isolates simultaneously non-susceptible to penicillin
and erythromycin (EPNSP) accounted for 10.4% of the collection
(n = 121).
Antimicrobial resistance did not change significantly
between age groups. In 2012–2014, there was a significant
decrease in antimicrobial resistance for several antimicrobials—
erythromycin resistance decreased from 18.8 to 13.0% (CA
p = 0.034), clindamycin resistance decreased from 16.1 to 10.4%
(CA p = 0.022) and tetracycline resistance decreased from 13.4
to 7.7% (CA p = 0.010). Although, not statistically supported,
there was also a decrease in penicillin non-susceptibility, from
16.8% in 2012 to 13.3% in 2014 (CA p = 0.174).
There was some correlation between serotype and
antimicrobial resistance (Figures 1–3). The AW for serotype
and PNSP was 0.569 (CI95%: 0.507–0.631) and the AW for
serotype and ERP was 0.527 (CI95%: 0.458–0.596). Serotypes
14 and 19A were the most frequent serotypes among PNSP and
ERP. Serotype 14 accounted for 35.2% of PNSP and 22.2% of
ERP while serotype 19A occurred in 21.2% of PNSP and 21.2%
of ERP. Taken together, PCV7 serotypes accounted for 48.6%
of PNSP, 37.9% of ERP and 40.5% of EPNSP. Considering the
PCV13 serotypes, these constituted 71.5, 61.1, and 67.8% of
PNSP, ERP and EPNSP, respectively. The additional serotypes
found in PPV23 but not in PCV13 accounted for only 2.8, 6.6,
and 1.7% of PNSP, ERP and EPNSP, respectively. The proportion
of resistant isolates was higher among isolates expressing NVTs:
25.7, 32.3, and 30.6% of PNSP, ERP and EPNSP, respectively
(Figures 1–3). The most frequent NVTs among PNSP and ERP
were serotypes 6C and 15A, which together accounted for 19.0%
of PNSP and 18.2% of ERP (Figure 3).
DISCUSSION
The decrease in PCV13 serotypes observed previously (Horácio
et al., 2012, 2013) continued during the present study period
resulting in only 38.0% of the isolates collected in 2014
expressing PCV13 serotypes (Figure 4). However, different
serotypes underlie the changes in 2008–2011 and 2012–2014.
The timeframes of the decreases seen for serotypes 7F and
19A are consistent with a possible herd protection of childhood
vaccination with the most recently introduced PCVs. Similar
decreases in serotypes 7F and 19A as causes of adult IPD
followed the use of PCV13 in children in the USA (Moore
et al., 2015) and in several European countries (Steens et al.,
2013; Guevara et al., 2014; Harboe et al., 2014; Waight et al.,
2015). Decreases in the incidence of IPD caused by these two
serotypes were also documented among children in Portugal
(Aguiar et al., 2014). In Portugal the decrease in serotype 7F
preceded that of serotype 19A in adult IPD. This could have
been attributed to the use of PCV10 in children, since PCV10
includes serotype 7F but not serotype 19A. Moreover, this
vaccine was introduced in Portugal months earlier than PCV13.
However, in children, serotype 19A decreased as a cause of
IPD before an effect of PCV13 was expected and before any
decrease in serotype 7F (Aguiar et al., 2014). This points to
the importance of other factors besides vaccination in triggering
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FIGURE 3 | Isolates expressing serotypes not included in any pneumococcal vaccine causing invasive pneumococcal disease in adult patients (≥18
years) in Portugal, 2012–2014. See legend of Figure 1. NT, non-typable. Isolates expressing serotype 25A and 38 could not be distinguished phenotypically and
are represented together. Only serotypes including n > 3 isolates are discriminated.
FIGURE 4 | Proportion of isolates expressing serotypes included in pneumococcal vaccines causing invasive pneumococcal disease in adult patients
(≥18 years) in Portugal, 2008–2014. The data up to 2011 were presented previously (Horácio et al., 2012, 2013).
changes in serotype prevalence and suggest that the initial
changes seen in serotype 7F IPD in adults are the result of secular
trends.
In contrast to these serotypes, there was no overall reduction
of serotype 3. These results are concordant with other studies that
failed to show a consistent reduction of serotype 3 among adult
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TABLE 1 | Serotypes of the isolates responsible for invasive pneumococcal disease in adult patients (≥18 years), 2008–2014.
Serotype No. of isolates (%) CAa CA
Current study period
2008 2009 2010 2011 2012 2013 2014 2012–2014 2008–2014
PCV13
1 55 (13.4) 48 (10.7) 22 (5.4) 17 (4.1) 12 (3.0) 7 (1.8) 7 (1.9) 0.289 <0.001
3 51 (12.5) 53 (11.8) 59 (14.6) 48 (11.6) 66 (16.3) 45 (11.7) 50 (13.3) 0.209 0.613
4 10 (2.4) 12 (2.7) 17 (4.2) 14 (3.4) 6 (1.5) 8 (2.1) 9 (2.4) 0.361 0.352
5 12 (2.9) 9 (2.0) 4 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 0.211 <0.001
6A 6 (1.5) 8 (1.8) 2 (0.5) 1 (0.2) 2 (0.5) 1 (0.3) 4 (1.1) 0.315 0.062
6B 1 (0.2) 7 (1.6) 3 (0.7) 9 (2.2) 5 (1.2) 5 (1.3) 5 (1.3) 0.909 0.272
7F 48 (11.7) 48 (10.7) 35 (8.7) 43 (10.4) 33 (8.2) 18 (4.7) 10 (2.7) 0.001 <0.001
9V 14 (3.4) 7 (1.6) 8 (2.0) 5 (1.2) 4 (1.0) 4 (1.0) 1 (0.3) 0.255 <0.001
14 29 (7.1) 45 (10.0) 30 (7.4) 31 (7.5) 29 (7.2) 26 (6.8) 18 (4.8) 0.172 0.045
18C 0 (0) 6 (1.3) 1 (0.2) 1 (0.2) 1 (0.2) 4 (1.0) 2 (0.5) 0.588 0.675
19A 48 (11.7) 33 (7.4) 44 (10.9) 38 (9.2) 39 (9.7) 24 (6.3) 21 (5.6) 0.027 0.005
19F 7 (1.7) 13 (2.9) 8 (2.0) 5 (1.2) 9 (2.2) 12 (3.1) 6 (1.6) 0.576 0.956
23F 6 (1.5) 4 (0.9) 5 (1.2) 9 (2.2) 1 (0.2) 3 (0.8) 9 (2.4) 0.005 0.618
PPV23 add
8 15 (3.7) 19 (4.2) 27 (6.7) 33 (8.0) 34 (8.4) 43 (11.2) 46 (12.2) 0.081 <0.001
9N 10 (2.4) 12 (2.7) 13 (3.2) 11 (2.7) 8 (2.0) 13 (3.4) 18 (4.8) 0.030 0.122
10A 3 (0.7) 8 (1.8) 7 (1.7) 6 (1.5) 2 (0.5) 8 (2.1) 8 (2.1) 0.062 0.294
11A 7 (1.7) 13 (2.9) 10 (2.5) 16 (3.9) 16 (4.0) 18 (4.7) 15 (4.0) 0.974 0.012
12F 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – 0.334
15B/C 8 (2.0) 4 (0.9) 3 (0.7) 8 (1.9) 5 (1.2) 9 (2.3) 8 (2.1) 0.353 0.096
17F 3 (0.7) 2 (0.4) 4 (1.0) 4 (1.0) 5 (1.2) 2 (0.5) 2 (0.5) 0.255 0.981
20 4 (1.0) 8 (1.8) 5 (1.2) 7 (1.7) 14 (3.5) 11 (2.9) 14 (3.7) 0.851 0.001
22F 10 (2.4) 17 (3.8) 16 (4.0) 22 (5.3) 25 (6.2) 23 (6.0) 31 (8.2) 0.261 <0.001
33F 0 (0) 0 (0) 1 (0.2) 0 (0) 1 (0.2) 1 (0.3) 1 (0.3) 0.959 0.180
NVTb
6C 4 (1.0) 13 (2.9) 13 (3.2) 10 (2.4) 8 (2.0) 14 (3.7) 6 (1.6) 0.757 0.600
15A 4 (1.0) 5 (1.1) 5 (1.2) 5 (1.2) 3 (0.7) 11 (2.9) 13 (3.5) 0.011 0.002
23A 6 (1.5) 8 (1.8) 8 (2.0) 4 (1.0) 9 (2.2) 8 (2.1) 9 (2.4) 0.879 0.317
16F 3 (0.7) 8 (1.8) 3 (0.7) 7 (1.7) 13 (3.2) 3 (0.8) 7 (1.9) 0.161 0.233
24F 3 (0.7) 6 (1.3) 5 (1.2) 2 (0.5) 5 (1.2) 9 (2.3) 9 (2.4) 0.241 0.027
12B 10 (2.4) 5 (1.1) 3 (0.7) 11 (2.7) 6 (1.5) 8 (2.1) 4 (1.1) 0.649 0.700
35B 2 (0.5) 5 (1.1) 10 (2.5) 5 (1.2) 6 (1.5) 4 (1.0) 8 (2.1) 0.480 0.222
35F 2 (0.5) 3 (0.7) 2 (0.5) 3 (0.7) 7 (1.7) 4 (1.0) 2 (0.5) 0.110 0.350
23B 4 (1.0) 3 (0.7) 7 (1.7) 6 (1.5) 4 (1.0) 5 (1.3) 3 (0.8) 0.801 0.958
31 2 (0.5) 2 (0.4) 1 (0.2) 5 (1.2) 5 (1.2) 2 (0.5) 4 (1.6) 0.786 0.197
NT 0 (0) 3 (0.7) 4 (1.0) 3 (0.7) 1 (0.2) 3 (0.8) 6 (1.6) 0.042 0.060
33A 1 (0.2) 4 (0.9) 8 (2.0) 4 (1.0) 2 (0.5) 5 (1.3) 2 (0.5) 0.929 0.913
25A/38 2 (0.5) 3 (0.7) 0 (0) 2 (0.5) 3 (0.7) 3 (0.8) 2 (0.5) 0.726 0.583
29 0 (0) 0 (0) 0 (0) 0 (0) 4 (1.0) 2 (0.5) 2 (0.5) 0.433 0.009
34 2 (0.5) 0 (0) 0 (0) 8 (1.9) 3 (0.7) 1 (0.3) 4 (1.1) 0.605 0.138
7C 2 (0.5) 2 (0.4) 2 (0.5) 1 (0.2) 1 (0.2) 4 (1.0) 1 (0.3) 0.942 0.883
18A 6 (1.5) 0 (0) 1 (0.2) 2 (0.5) 0 (0) 3 (0.8) 0 (0) 0.959 0.080
21 3 (0.7) 0 (0) 0 (0) 4 (1.0) 0 (0) 0 (0) 0 (0) – 0.108
Othersc 8 (2.0) 1 (0.2) 8 (2.0) 3 (0.7) 7 (1.7) 9 (2.3) 8 (2.1) – –
Total 409 448 404 413 404 383 376 – –
aCA, Cochran Armitage test of trend. In bold are the serotypes with significant p-values (p < 0.05) after FDR correction.
bNVT, non-vaccine serotypes.
cOnly serotypes detected in ≥3 isolates in at least one year are shown; the remaining are represented in “Others.”
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TABLE 2 | Number of isolates responsible for invasive pneumococcal
disease in adult patients (≥18 years), according to vaccine serotype
groups and age groups, 2012–2014.
Serotype
groups
No. isolates (%) CAa
2012 2013 2014
18–49 years PCV7b 18 (21.4) 12 (15.0) 8 (11.9) 0.112
1, 5, and 7F 15 (17.9) 10 (12.5) 8 (11.9) 0.286
3, 6A, and 19A 12 (14.3) 12 (15.0) 11 (16.4) 0.719
PCV13c 45 (53.6) 34 (42.5) 27 (40.3) 0.094
PPV23 addd 26 (31.0) 29 (36.3) 24 (35.8) 0.511
NVTse 13 (15.5) 17 (21.3) 16 (23.9) 0.191
50–64 years PCV7b 7 (9.2) 14 (13.9) 15 (16.7) 0.164
1, 5, and 7F 10 (13.2) 6 (5.9) 4 (4.4) 0.037
3, 6A, and 19A 20 (26.3) 19 (18.8) 14 (15.6) 0.087
PCV13c 37 (48.7) 39 (38.6) 33 (36.7) 0.124
PPV23 addd 17 (22.4) 34 (33.7) 37 (41.1) 0.011
NVTse 22 (28.9) 28 (27.7) 20 (22.2) 0.316
≥65 years PCV7b 30 (12.3) 36 (17.8) 27 (12.3) 0.947
1, 5, and 7F 20 (8.2) 9 (4.5) 6 (2.7) 0.008
3, 6A, and 19A 75 (30.7) 39 (19.3) 50 (22.8) 0.042
PCV13c 125 (51.2) 84 (41.6) 83 (37.9) 0.004
PPV23 addd 67 (27.5) 65 (32.2) 82 (37.4) 0.022
NVTse 52 (21.3) 53 (26.2) 54 (24.7) 0.384
aCA, Cochran Armitage test of trend. In bold are the serotype groups with significant p-
values (p < 0.05) after FDR correction.
bPCV7, serotypes included in the 7-valent pneumococcal conjugate vaccine.
cPCV13, serotypes included in the 13-valent pneumococcal conjugate vaccine.
dPPV23 add, the additional 11 serotypes present in the 23-valent pneumococcal
polysaccharide vaccine but absent from the 13-valent pneumococcal conjugate vaccine.
eNVTs, serotypes not included in any of the currently available pneumococcal vaccines.
IPD after the use of PCV13 in children (Steens et al., 2013; Harboe
et al., 2014; Moore et al., 2015; Waight et al., 2015) and with a
study that demonstrated a low and non-significant effectiveness
of PCV13 against serotype 3 IPD in children (Andrews et al.,
2014).
The proposed higher efficacy of PCV13 against serotype 19F
(Dagan et al., 2013) cannot explain the decrease in proportion
of PCV7 serotypes, since serotype 19F was uncommon in our
collection and no significant decrease was seen between the two
periods (Table 1). The reduction of the overall proportion of IPD
caused by PCV7 serotypes was instead related with decreases
in serotypes 4, 9V and 14 (Table 1). Among these, serotype 4
exhibited the most significant decrease. Since the most significant
decrease of serotype 14 IPD was detected in 2014, it remains
uncertain if it will be sustained in the following years. Serotype
14 has been the most frequent PCV7 serotype causing adult
IPD in Portugal, both before and after PCV7 use in children.
This could be associated with particular characteristics of the
highly successful and resistant clone Spain14-ST156, to which this
serotype was found to be associated (Horácio et al., 2016). High
antimicrobial consumption in our country could also contribute
significantly to maintain resistant clones such as this one in
circulation.
TABLE 3 | Antimicrobial resistance of the isolates responsible for invasive
pneumococcal disease in adult patients (≥18 years) in Portugal,
2012–2014.
No. resistant isolates (%)
18–49 years (n = 231) 50–64 years (n = 267) ≥65 years (n = 665)
PEN 40 (17.3) 32 (12.0) 107 (16.1)
MIC90 0.38 0.125 0.25
MIC50 0.016 0.012 0.016
CTX 4 (1.7) 3 (1.1) 6 (0.9)
MIC90 0.25 0.19 0.25
MIC50 0.016 0.016 0.016
LEV 0 (0) 1 (0.4) 6 (0.9)
ERY 34 (14.7) 37 (13.9) 127 (19.1)
CLI 31 (13.4) 30 (11.2) 100 (15.0)
CHL 5 (2.2) 6 (2.2) 8 (1.2)
SXT 30 (13.0) 39 (14.6) 93 (14.0)
TET 23 (10.0) 21 (7.9) 79 (11.9)
PEN, penicillin; CTX, cefotaxime; LEV, levofloxacin; ERY, erythromycin; CLI, clindamycin;
CHL, chloramphenicol; SXT, trimethoprim/sulphamethoxazole; TET, tetracycline. All
isolates were susceptible to vancomycin and linezolid.
The non-PCV serotypes that increased the most since the
late-post PCV7 period were those found in PPV23, especially
serotypes 8, 22F, and 20 (ranked by frequency); but also the
non-PPV23 serotype 15A (Table 1). Serotypes 15A and 22F
were found in carriage in adults in Portugal (Almeida et al.,
2014), while serotypes 8 and 20 were not found in carriage
in adults and were shown to have a high invasive disease
potential (Sá-Leão et al., 2011). Serotype 8 was the second
most frequent cause of IPD during the current study period
and in 2013 and 2014 was the most frequent cause of IPD
among younger adults (18–49 years). Serotype 8 increased in
importance as a cause of IPD in other countries, being the most
frequent cause of IPD in patients aged >5 years in England
and Wales after the introduction of PCV13 (Waight et al.,
2015) and also important in adult IPD elsewhere (Guevara
et al., 2014; Regev-Yochay et al., 2015). Serotype 22F became
the second most frequent cause of IPD in adults aged ≥65
years in 2013 and 2014. In the USA, this serotype was the
most common cause of adult IPD in the post-PCV13 period
(Moore et al., 2015). An increase of serotype 22F after PCV13
use was also reported in Canada (Demczuk et al., 2013) and
in some European countries (Steens et al., 2013; Lepoutre
et al., 2015). Serotype 20 increased more modestly and only
among individuals aged ≥65 years. An increase of this serotype
was also noted in Canada, although mostly among individuals
aged 15–49 years (Demczuk et al., 2013). Taken together, these
observations indicate that, although there may be some regional
differences, there are serotypes that seem to be consistently
emerging in different geographic locations in the post-PCV13
period. These may reflect circulating serotypes in asymptomatic
carriers but also serotypes with an enhanced invasive disease
potential.
In 2014, the last year of the study, serotype 15A surpassed
serotype 19A and 14 to become the most frequent serotype
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among ERP and was the second most frequent serotype among
PNSP behind serotype 14. The overall decreases observed in
PNSP and ERPwere not only due to decreases in the total number
of isolates expressing serotypes 14 and 19A, which were not
compensated by the increase in serotype 15A (Table 1), but also
to an unexpected decrease in the proportion of resistant isolates
within serotypes 14 and 19A. While 72% of serotype 14 and 64%
of serotype 19A were ERP in 2012, only 44% of serotype 14 and
33% of serotype 19A were ERP in 2014 (p = 0.071 and p = 0.031,
respectively). Similarly, there was a decrease in the proportion of
PNSP among serotype 19A, from 59% in 2012 to 24% in 2014
(p = 0.014).
Our surveillance system is exclusively laboratory based and
lacks compliance audits, so our study was not designed to
estimate the incidence of adult IPD. However, we did note a
slight decrease in the number of isolates sent to us in 2013
and 2014 (Figure 4). This could reflect a net reduction of adult
IPD following PCV13 use in children, as reported by others
(Guevara et al., 2014; Harboe et al., 2014; Lepoutre et al., 2015;
Moore et al., 2015; Regev-Yochay et al., 2015) and seen with
IPD in children in Portugal (Aguiar et al., 2014). Alternatively,
this could reflect lower reporting by participating laboratories.
We also noted a marked decrease in the number of isolates
recovered from younger patients relative to either of the older age
groups when comparing 2009–2011 to 2012–2014 (p < 0.001)
(Figure 1) (Horácio et al., 2013). Even if the decrease in number
of isolates is attributed to lower reporting, we have no reason to
believe that this would affect preferentially a particular age group.
We also have no indication of changes in clinical practice (such
as blood culturing practices), which could influence these results.
We therefore believe that the most likely explanation is a true
reduction in incidence of IPD in 18–49 years old individuals,
in agreement with a study from the UK that found that this
group was the one where the decrease in IPD incidence was more
pronounced and followed more closely PCV13 use in children
(Waight et al., 2015).
As discussed above, our study was not designed to allow the
estimate of the incidence of IPD and it therefore does not evaluate
potential changes in incidence with time. Specifically, although
we include the majority of medical centers in Portugal our
surveillance is not comprehensive and we did not perform audits
to ensure that participating centers reported all cases, namely we
did not include cases for which no viable pneumococcal isolate
was received for characterization. However, the design based on
the reporting of all isolates causing IPD within the surveillance
network, the large number of isolates studied, the wide coverage
of the country by the network and the stable number of reporting
centers, guarantees that the data accurately represents IPD in
Portugal and can be used to evaluate changes in the relative
importance of the different serotypes.
In spite of relatively modest vaccine coverage (63% in 2012),
there were major changes in the serotype distribution of the
pneumococcal population responsible for adult IPD in Portugal
following the use of PCVs in children consistent with herd
protection. These changes have contributed also to significant
reductions in antimicrobial resistance. The recent inclusion of
PCV13 in the NIP for children in Portugal may have an even
greater impact on IPD in adults. This remarkable effect of PCVs
in protecting non-vaccinated individuals may question the need
of using PCV13 directly in vaccinating adults. Still, data from
2014 indicates that the overall proportion of adult IPD caused
by PCV13 serotypes remained significant (38%) and that isolates
expressing PPV23 serotypes accounted for 75% of all IPD. Taken
together this suggests a key role of vaccination in any effective
management strategy of IPD.
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Abstract
Among the 1660 isolates recovered from invasive pneumococcal disease (IPD) in adults
(> = 18 yrs) in 2008–2011, a random sample of50% of each serotype (n = 871) was cho-
sen for MLST analysis and evaluation for the presence and type of pilus islands (PIs). The
genetic diversity was high with 206 different sequence types (STs) detected, but it varied
significantly between serotypes. The different STs represented 80 clonal complexes (CCs)
according to goeBURST with the six more frequent accounting for more than half (50.6%) of
the isolates—CC156 (serotypes 14, 9V and 23F), CC191 (serotype 7F), CC180 (serotype
3), CC306 (serotype 1), CC62 (serotypes 8 and 11A) and CC230 (serotype 19A). Most of
the isolates (n = 587, 67.3%) were related to 29 Pneumococcal Molecular Epidemiology
Network recognized clones. The overall proportion of isolates positive for any of the PIs was
small (31.9%) and declined gradually during the study period (26.6% in 2011), mostly due
to the significant decline of serotype 1 which is associated with PI-2. The changes in sero-
types that occurred in adult IPD after the introduction of the seven-valent pneumococcal
conjugate vaccine (PCV7) for children were mostly due to the expansion of previously circu-
lating clones, while capsular switching was infrequent and not related to vaccine use. The
reduction of IPD caused by PCV7 serotypes in the years following PCV7 implementation
did not result in a decline of antimicrobial resistance in part due to the selection of resistant
genotypes among serotypes 14 and 19A.
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Introduction
The 7-valent conjugate vaccine (PCV7) was available for children through the private sector in
Portugal from 2001 onwards until it was replaced in the beginning of 2010 by the 13-valent
conjugate vaccine (PCV13). In 2012, PCV13 received approval for use also in adults> 50 years
of age with an extension being made to all ages in 2013. Additionally, PCV13 entered the Por-
tuguese National Immunization Program (NIP) in June 2015 for children born from January
2015 onwards. Two other vaccines, the 23-valent pneumococcal polysaccharide vaccine
(PPV23) and the 10-valent conjugate vaccine (PCV10), have also been available in Portugal
since 1996 and 2009, respectively, but with a low uptake [1].
Among the more than 90 different pneumococcal serotypes identified, only a few cause the
majority of IPD. While for some serotypes the capsular polysaccharide is the dominant deter-
minant of invasiveness, for others distinct genotypes show important differences in invasive-
ness [2]. Additionally, there are other features that are strongly associated with genotype
independently of serotype, such as antimicrobial susceptibility and the presence and type of
pilus islands [3,4]. With the availability of pneumococcal conjugate vaccines that efficiently tar-
get particular serotypes, important changes have been reported regarding not only serotype but
also genotype distributions of pneumococci causing IPD [5–9]. Interestingly, while non-vac-
cine serotypes have emerged as a cause of IPD, in some cases distinct clones expressing the
same serotype have risen in frequency in different geographic regions [10,11].
While numerous studies have addressed the serotype distribution of IPD, information
regarding the clonal composition of pneumococcal populations has been scarcer. In a previous
study we defined the clonal composition of pneumococci causing IPD in both children and
adults in the pre-PCV7 period [11]. In a subsequent study we documented major changes in
the potential coverage of PCV13 starting in 2009, due to decreases in prevalence of serotypes 1
and 5 [12]. In the present study we aimed to characterize the clonal composition of pneumo-
cocci causing adult IPD in Portugal between 2008 and 2011, a period characterized by extensive
use of PCV7 and the adoption of PCV13 in children and prior to the use of PCV13 in adults.
Materials and Methods
Bacterial isolates
The isolates included in this study were recovered from adult patients (18 yrs) with invasive
pneumococcal disease between 2008 and 2011 and were characterized in previous studies
regarding serotype distribution and antimicrobial susceptibility [1,12]. A case of invasive dis-
ease was defined by the recovery of pneumococci from a normally sterile source, such as blood
or cerebral spinal fluid (CSF). Serotypes were grouped into conjugate vaccine serotypes, i.e.,
those included in PCV13 (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F) that com-
prise all serotypes found in lower valency vaccines (PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F; and
PCV10: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F), those included in PPV23 (all serotypes included
in PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F), and
non-vaccine serotypes (NVT). The isolates that were not typable with any of the complete set
of sera available from the Staten Serum Institute (Copenhagen, Denmark) were considered
non-typable (NT). Given the high frequency of spontaneous switching between serotypes 15B
and 15C we opted to include strains with these serotypes into a single group. Due to the diffi-
culty in distinguishing a set of isolates that were positive for both serotypes 25A and 38 we
opted to include strains with these serotypes into a single group.
From a total of 1660 isolates recovered, a random sample of50% of the isolates (n = 871)
from each serotype and from each year was chosen to be characterized by MLST and tested for
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the presence of the pilus islands. Briefly, among the 1660 isolates, there were 52 different sero-
types, with the 10 most frequent being serotypes 3 (13.0%), 7F (10.0%), 19A (9.8%), 1 (8.5%),
14 (8.1%), 8 (5.7%), 22F (3.9%), 4 (3.2%), 9N (2.8%) and 11A (2.8%). However, the 10 most fre-
quent serotypes were different in each of the age groups. In the 18–49 yr olds (n = 472) these
were serotypes 1 (14.0%), 7F (11%), 8 (9.1%), 14 (8.7%), 3 (7.6%), 19A (6.1%), 9N (4.2%), 4
(3.8%), 22F (3.2%), 11A (2.8%). In the 50–64 yr olds (n = 358) these were serotypes 3 (12%),
19A (10.3%), 1 (9.5%), 7F (9.2%), 14 (6.1%), 4 (5.0%), 8 (4.5%), 11A (3.4%), 22F (3.4%), 9V
(2.8%). In the65 yr olds (n = 830) these were serotypes 3 (15.8%), 19A (11.6%), 7F (10.2%),
14 (8.7%), 1 (4.9%), 22F (4.6%), 8 (4.2%), 6C (3.0%), 11A (2.5%), 9N (2.3%). Overall, the pro-
portions of PCV7, PCV13 and PPV23 serotypes were 18.4%, 61.9% and 79.4%, respectively.
Non-susceptibility to penicillin, defined as either intermediate level penicillin resistance (MIC
0.12–1.0 μg/ml) or high level resistance (MIC2.0 μg/ml) as discussed previously [1,12], was
found in 330 isolates (19.9%), while 315 isolates (19.0%) were resistant to erythromycin. The
age and sex of the patients and the source of the isolates randomly chosen for further study was
similar to that of the 1660 isolates. In the genotyped group the age distribution was as follows:
28.5% of the isolates were from individuals 18–49 yrs, 21.2% from 50–64 yrs and 50.3% from
65 yrs. The majority of the isolates were collected from blood (87.9%), 8.4% from CSF, 2.5%
from pleural fluid and 1.2% from other normally sterile sources.
MLST
MLST was performed as described previously [13]. The DNA sequences were analyzed using
Bionumerics software (Applied-Maths, Sint-Martens-Laten, Belgium) and the alleles and
sequence types were assigned according to the pneumococcal MLST database available at
http://pubmlst.org/spneumoniae/. The goeBURST algorithm [14] implemented in the PHY-
LOViZ software [15] was used to establish relationships between STs. Clonal complexes were
defined at the single-locus-variant (SLV) and double-locus-variant (DLV) levels.
Detection of Pilus Islands
The presence of pilus islets (PI) was evaluated by PCR. Briefly, for PI-1 in the absence of the
pilus islet, a product of 1-3Kb was expected using primers PFL-up and P-dn flanking the islet
[4]. In strains yielding no PCR product, the rlrA gene was detected using primers RLRA-up
and RLRA-dn. A similar approach was followed to detect the presence of PI-2 [16].
Statistical Analysis
Sample diversity was evaluated using the Simpson’s index of diversity (SID) and the respective
95% confidence intervals (CI95%) [17]. To compare two sets of partitions the Adjusted Wal-
lace (AW) coefficients were calculated [18] using the online tool available at http://www.
comparingpartitions.info. Differences were evaluated by the Fisher exact test with the false dis-
covery rate (FDR) correction for multiple testing [19] and the Cochran-Armitage test was used
for trends. A p<0.05 was considered significant for all tests.
Results
Sequence Type Distribution and Relationship with Serotype
The 871 isolates analyzed by MLST presented 206 different STs (SID = 0.971, CI95%: 0.967–
0.976) grouping into 80 CCs (SID = 0.948, CI95%: 0.942–0.953) according to goeBURST analy-
sis, when including all STs deposited in the database. The 14 most frequent STs, which
accounted for more than half of the genotyped isolates (50.6%) were, in decreasing order,
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ST191 (9.9%), ST306 (7.0%), ST180 (6.9%), ST53 (4.5%), ST156 (4.0%), ST276 (3.6%), ST433
(3.2%), ST66 (2.8%), ST408 (1.7%), ST232 (1.7%), ST260 (1.5%), ST143 (1.4%), ST179 (1.3%)
and ST289 (1.3%).
Twenty new allelic combinations and 19 new alleles were identified. The new allelic combi-
nations were identified as STs: 6176, 6177, 6180, 6181, 6182, 6973, 8866, 9955, 9956, 9957,
9958, 9960, 9963, 9966, 9969, 9970, 9971, 9979, 9982 and 9986. The novel alleles identified
were designated 200, 307 and 309 for aroE, 429, 636 and 637 for ddl, 294, 295, 428 and 430 for
gdh, 437 and 438 for gki, 273 for recP and 588, 589, 590, 592, 593 and 605 for xpt.
There was a strong correlation between CC and the vaccine serotype groups (AW = 0.810,
CI95%: 0.763–0.857), with the six most prevalent CCs being mainly composed of isolates pre-
senting vaccine serotypes (95.5%). Table 1 shows the age distribution and serotypes of the most
frequent STs found in the 22 major CCs (n10 isolates), together accounting for 83.7% of the
genotyped isolates. The major CC (CC156, n = 101) included mostly isolates expressing PCV7
serotypes, namely 14, 9V and 23F, while four of the remaining five most frequent CCs were
mainly composed of isolates presenting the additional serotypes found in PCV13 (mainly 7F,
3, 1 and 19A). The other most frequent lineage, CC62, consisted mostly of isolates expressing
serotypes included only in PPV23 (serotypes 8 and 11A). The age distribution and serotypes of
the STs found in CCs with<10 isolates are shown in S1 Table.
Fig 1 shows the STs expressing each of the 13 serotypes included in PCV13 and Fig 2 the
STs expressing each of the 10 most frequent serotypes found among those not included in any
of the conjugate vaccines. The STs found in the remaining serotypes are indicated in S2 Table.
The genetic diversity varied greatly with serotype, with serotypes, 4, 6A, 6B, 9V, 18C, 19A, 20
and 23A being highly diverse (SID>0.8) and serotypes 1, 5, 7F, 9N and 22F displaying very
limited diversity (SID<0.3). In general, there was a predominance of high genetic diversity
among PCV13 serotypes and low genetic diversity among the 10 most frequent non-PCV13
serotypes. For serotypes 9V, 14 and 23A, the wide variety of STs did not result in a high diver-
sity of CCs, with a maximum of two CCs being detected in each. The genetic diversity of each
serotype was independent of the serotype’s frequency. Examples of this are the low frequency
serotypes 6B and 18C that presented a high genetic diversity and no dominant ST.
A total of 587 isolates (67.3%) presented STs related to 29 of the 43 clones recognized by the
Pneumococcal Molecular Epidemiology Network (PMEN) [20], sharing at least five MLST
alleles with these clones (357 isolates had the same ST, 133 were SLVs and 97 were DLVs).
When considering these isolates the predominant clones were Netherlands7F-191 (n = 88),
Spain9V-156 (n = 71), Netherlands3-180 (n = 68), Netherlands8-53 (n = 63), Sweden1-306
(n = 63), Denmark14-230 (n = 47), Tennessee14-67 (n = 24), Tennessee23F-37 (n = 24) and
Netherlands15B-199 (n = 21) (Figs 1 and 2 and S2 Table). Additionally, another 63 isolates were
included in the same CCs of other four PMEN clones.
The correlation between ST and serotype was high (AW = 0.942, CI95%: 0.912–0.973), but
there were STs that presented more than one serotype (Table 1 and S1 and S2 Tables). The
serotype distribution along the studied years for the STs expressing more than one serotype is
shown in Table 2.
Variation of STs with Time
When analyzing the evolution of STs between 2008 and 2011 we identified some fluctuations,
although the majority reflected changes in serotype prevalence occurring in this period. How-
ever, while for ST306 (serotype 1) there was a decline, significant after correcting for multiple
testing (from 11.0% to 2.8%, Cochran-Armitage test of trend p = 0.014), for the other STs the
changes were only significant before FDR correction. The STs for which there was a significant
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Table 1. Age distribution and the serotypes of the most frequent STs found in the 22 major CCs (n10 isolates) identified by goeBURST.
no. of isolates per age group
CC (n) ST Total [18–49] [50–64] > = 65 Dominant serotype (n) Other serotypes
156 (101) 156 35 13 5 17 14 (31) 9V (3), 10A (1)
143 12 2 2 8 14 (12) -
338 10 3 1 6 23F (7) 23A (2), 19F (1)
162 6 2 1 3 9V (4) 19F (1), 24A (1)
2944 5 0 3 2 14 (5) -
Othersa 33 8 6 19 9V (10) 14 (8), 6B (5), 6C (3), 23F (3), 35F (2), 17F (1), 17A (1)
191 (88) 191 86 31 15 40 7F (83) 7A (1), NTb (2)
Othersa 2 0 2 0 7F (2) -
180 (68) 180 60 8 17 35 3 (60) -
Othersa 8 2 1 5 3 (8) -
306 (68) 306 61 26 14 21 1 (61) -
350 5 1 2 2 1(5) -
Othersa 2 2 0 0 1(2) -
62 (67) 53 39 15 8 16 8 (37) NTb (2)
408 15 6 4 5 11A (14) 11C (1)
62 7 1 2 4 11A (7) -
Othersa 6 3 0 3 8 (2), 11A (2) 18C (1), 22F (1)
230 (47) 276 31 3 7 21 19A (31) -
230 6 1 1 4 24F (4) 19A (2)
Othersa 10 4 3 3 19A (8) 10A (1), 24F (1)
81 (30) 66 24 12 3 9 9N (23) NTb (1)
Othersa 6 1 0 5 24F (4) 4 (2)
433 (29) 433 28 4 5 19 22F (28) -
Othersa 1 0 0 1 22F (1) -
439 (25) 439 7 0 3 4 23B (7) -
42 5 1 3 1 23A (4) 6A (1)
Othersa 13 3 2 8 23A (7) 23B (3), 23F (3)
15 (24) 9 8 3 0 5 14 (8)
1201 7 3 0 4 19A (4) 7C (3)
Othersa 9 1 2 6 14 (5) 34 (2), 6B (1), 7C (1)
177 (24) 179 11 4 4 3 19F (11) -
Othersa 13 3 5 5 19A (5) 19F (3), 21 (3), 15A (1), 15 B/C (1)
199 (21) 416 8 1 2 5 19A (8) -
411 7 1 2 4 15B/C (7) -
199 6 2 2 2 19A (3) 15B/C (2), 18C (1)
378 (19) 232 15 3 5 7 3 (15) -
Othersa 4 2 0 2 3 (4) -
113 (16) 123 5 1 0 4 17F (5) -
1766 5 2 0 3 31 (5) -
Othersa 6 1 2 3 22F (3) 17F (1), 18C (1), 31 (1)
460 (16) 97 10 2 3 5 10A (10) -
Othersa 6 3 1 2 6A (4) 10A (1), 35F (1)
260 (15) 260 13 2 3 8 3 (13) -
Othersa 2 1 0 1 3 (2) -
218 (13) 218 10 3 2 5 12B (10) -
Othersa 3 1 1 1 12B (2) 12F (1)
(Continued)
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p-value in the Cochran-Armitage test for trends but unsupported after FDR correction were:
ST53 (serotype 8), that increased from 3.3% to 6.5% (p = 0.043); ST289 (serotype 5), that
accounted for 2.4% of IPD in 2008 and 0% in 2011 (p = 0.020); ST717 (serotypes 33A and 33F)
that increased from 0% to 1.4% (p = 0.048); and STs 193 (serotype 19A) and 409 (serotype 14)
that were only detected in 2008 (1.9% and 1.4%, respectively; p = 0.001 and p = 0.020, respec-
tively). Regarding changes in CCs with time, these reflected the changes identified in STs, with
only CC306 declining significantly after FDR correction (from 12.9% to 2.8%, Cochran-Armi-
tage test of trend p = 0.001).
Relationship of STs with Patient Age and Isolate Source
When grouping the isolates according to the three patient age groups– 18–49 yrs, 50–64 yrs
and> = 65 yrs—only CC5902 showed a statistically significant association with age. The seven
isolates belonging to this CC were all recovered from individuals with 18–49 yrs (p = 0.011, sig-
nificant after FDR correction, S1 Table).
When testing for associations between STs and CCs and isolate source, the only significant
association found was between CC460 and CSF, with 6 out of 16 isolates being collected from
CSF (p = 0.012, significant after FDR correction).
Presence of Pilus Islands
A total of 278 isolates, representing 31.9% of the genotyped collection, carried at least one PI.
Among these, 107 (38.5%) had only PI-1, 165 (59.4%) only PI-2 and 6 (2.2%) presented the
two PIs simultaneously.
While the proportion of PI-1 positive isolates remained stable between 2008 and 2011
(from 10.0% to 11.6%, Cochran-Armitage test of trend p = 0.857), there was a significant
decline of PI-2 carrying isolates (from 24.8% to 15.8%, Cochran-Armitage test of trend
p = 0.007). This also resulted in an overall increase in the proportion of isolates lacking any of
the pilus islands, from 63.8% in 2008 to 72.6% in 2011 (p = 0.013).
The presence and variants of the PIs were more strongly associated with ST (AW = 0.950,
CI95%: 0.933–0.967) than with serotype (AW = 0.711, CI95%: 0.651–0.771). The STs that were
Table 1. (Continued)
no. of isolates per age group
CC (n) ST Total [18–49] [50–64] > = 65 Dominant serotype (n) Other serotypes
289 (13) 289 11 5 2 4 5 (11) -
Othersa 2 1 0 1 5 (2) -
30 (11) 30 10 2 2 6 16F (10) -
Othersa 1 0 0 1 16F (1) -
63 (11) 63 8 3 0 5 15A (7) 15F (1)
Othersa 3 0 1 2 3 (1), 7F (1), 15A (1) -
315 (11) 386 7 1 1 5 6C (6) 6B (1)
Othersa 4 0 1 3 6C (3) 6B (1)
404 (10) 404 9 5 0 4 8 (9) -
Othersa 1 1 0 0 8 (1) -
a Sequence types that accounted for less than 5 isolates each were grouped together in “Others”.
b NT-non typable.
doi:10.1371/journal.pone.0153602.t001
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significantly associated with PI-1 and PI-2 are shown in Table 3. All isolates included in CC320
(n = 3) and CC2669 (n = 3) presented the two PIs simultaneously.
Among the 105 isolates presenting only PI-1, 87.9% expressed PCV7 serotypes, namely
serotypes 14 (n = 49), 4 (n = 15), 19F (n = 13), 9V (n = 11) and 6B (n = 6). The remaining iso-
lates were from serotypes 19A (n = 9) and 7F, 24A and 35B (n = 1, each). PI-2 positive isolates
were from serotypes 7F (n = 85), 1 (n = 68), 11A (5), 19A (n = 2), 3, 7A and 31 (n = 1, each)
and NT (n = 2). The isolates presenting simultaneously the two types of PIs were from sero-
types 19A (n = 5) and 19F (n = 1).
No associations between isolate source and type of PI were detected. Still, there was a low
proportion of PI-2 positive isolates among isolates recovered from the CSF, with only 6 of the
73 CSF isolates presenting PI-2, and while 7 of the 15 isolates recovered from pleural fluid car-
ried PI-2, none carried PI-1.
Fig 1. Distribution of STs according to serotype of the isolates causing adult IPD in 2008–2011 and expressing serotypes included
in the conjugate vaccines. The STs that were considered by goeBURST as founders of a CC are indicated by “f”. The STs that matched the
STs of PMEN clones are indicated by “p”. Marked either with “*” or “†” are STs belonging to the same CC in each serotype. The respective
SID values are indicated on top of the bars and in parenthesis are the respective confidence intervals. In grey are represented the isolates
included in STs with <3 isolates. These were: serotype 4 –ST801 (n = 2) and STs 244, 246, 259 and 1866 (n = 1, each); serotype 6B –
ST176 (n = 2), STs 138, 273, 386, 473, 1518, 6175, 9957, 9970, 9986 and 10051 (n = 1, each); serotype 9V –STs 280 and 10044 (n = 2,
each) and STs 239, 1762 and 10054 (n = 1, each); serotype 14 –ST15 (n = 2) and STs 2511, 2616, 4573, 4576 and 10041 (n = 1, each);
serotype 18C –STs 102, 113, 199, 1233 and 10033 (n = 1, each); serotype 19F –ST177 (n = 2), STs 89, 162, 271, 338 and 391 (n = 1,
each); serotype 23F –ST10039 (n = 2) and STs 1135 and 9579 (n = 1, each); serotype 1 –STs 217, 228, 1233, 3081 and 4578 (n = 1, each);
serotype 3 –ST1220 (n = 2) and STs 505, 1230, 6014, 9162 and 10038 (n = 1, each); serotype 5 –STs 280 and 10044 (n = 2, each), STs
239, 1762 and 10054 (n = 1, each); serotype 6A –ST1876 (n = 2) and STs 42, 460 and 10055 (n = 1, each); serotype 7F –STs 1062, 1589
and 3130 (n = 1, each) and serotype 19A –STs 230, 242, 320, 2013 and 6174 (n = 2, each) and STs 241, 878, 2102, 2669, 2732, 4197,
4847, 6178, 6973, 9963 and 10042 (n = 1, each).
doi:10.1371/journal.pone.0153602.g001
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Antimicrobial Resistance
Similarly to pilus islands, resistance to antimicrobials was more strongly associated with ST
than with serotype. The AW for ST or serotype and penicillin susceptibility was, respectively,
0.785 (CI95%: 0.729–0.841) and 0.389 (CI95%: 0.326–0.452), while the AW for ST or serotype
and erythromycin susceptibility was, respectively, 0.711 (CI95%: 0.598–0.824) and 0.315
(CI95%:0.217–0.413). The sequence types that were associated with penicillin non-susceptible
pneumococci (PNSP) and erythromycin resistant pneumococci (ERP) are presented in
Table 4.
Discussion
In spite of several years of PCV7 use in children, the most frequent CC was CC156 (11.6%,
Table 1), a lineage that expressed mainly PCV7 serotypes (89.1%) and which was also the most
frequent in IPD in the pre-PCV7 period [11]. We had previously shown that the serotype dis-
tribution of pneumococci causing adult IPD had changed significantly in the post-PCV7
period, with the proportion of PCV7 serotypes declining to values below 20% [1,12,21]. Adult
Fig 2. Distribution of STs according to serotype of the isolates causing adult IPD in 2008–2011 and expressing the 10 most
frequent serotypes not included in any of the conjugate vaccines. The respective SID values are shown on top of the bars and in
parenthesis are the respective confidence intervals. In grey are represented the isolates included in STs with <3 isolates. These were:
serotype 8 –ST1012 (n = 2) and ST 9969 (n = 1); serotype 22F –STs 10053 and 10220 (n = 1, each); serotype 9N –ST3982 (n = 1);
serotype 11A –STs 9955, 9960 and 10052 (n = 1, each); serotype 6C –STs 1150, 1692 and 3396 (n = 2, each) and STs 1390, 1715, 2667
and 4310 (n = 1, each); serotype 12B –ST6180 (n = 2); serotype 10A –STs 156, 816 and 3135 (n = 1, each); serotype 20 –STs 1483,
1871, 7221, 9958 and 10047 (n = 1, each); serotype 23A –ST338 (n = 2) and STs 190, 311, 438, 6177, 7960, 8866 and 10048 (n = 1, each);
serotype 16F –STs 570 and 5902 (n = 1, each).
doi:10.1371/journal.pone.0153602.g002
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vaccination with anti-pneumococcal vaccines was low to negligible and prior work indicated
that these changes were due to a combination of secular trends and herd effect from children
vaccination, which although occurring through the private market reached a coverage of 75%
of children2 yrs in 2008 [1,12,21]. Due to these changes one could expect that CC156 would
Table 2. Serotype distribution for the STs expressing more than one serotype between 2008–2011.
Serotype (n)
STa (n) 2008 2009 2010 2011
156 (35) 14 (6), 9V (1) 14 (12), 9V (1) 14 (7), 10A (1) 14 (6), 9V (1)
338 (10) - 23F (3) 23F (2), 23A (1), 19F (1) 23F (2), 23A (1)
717 (9) - 33A (1) 33A (4), 33F (1) 33A (2), 3 (1)
63 (8) 15A (2) 15A (3) 15A (2), 15F (1) -
386 (7) - 6C (2) 6C (2) 6C (2), 6B (1)
1201 (7) 19A (2), 7C (1) 19A (1), 7C (1) 19A (1), 7C (1) -
162 (6) 9V (3), 19F (1) - 9V (1) 24A (1)
199 (6) 15B/C (1) 15B/C (1), 19A (2), 18C (1) - 19A (1)
230 (6) 24F (2) - 24F (2), 19A (1) 19A (1)
42 (5) 6A (1) 23A (2) 23A (2) -
241 (5) 18A (3) - 18A (1), 19A (1) -
a Only the sequence types that presented  5 isolates are shown.
doi:10.1371/journal.pone.0153602.t002
Table 3. Sequence types that were associated with pilus island 1 (PI-1) and pilus island 2 (PI-2).
Type of Pilus ST Yes No ORa (95% CI) P-valueb
Pilus 1 156 26 9 24.68 (10.79–61.89) <0.001
143 12 0 Inf (20.32-Inf) <0.001
179 10 1 72.89 (10.18–3133.46) <0.001
416 8 0 Inf (12.04-Inf) <0.001
162 6 0 Inf (8.16-Inf) <0.001
205 6 0 Inf (8.16-Inf) <0.001
2944 5 0 Inf (6.30-Inf) <0.001
1221 5 0 Inf (6.30-Inf) <0.001
4575 3 0 Inf (2.8-Inf) 0.002
838 3 0 Inf (2.8-Inf) 0.002
191 0 86 0 (0–0.27) <0.001
306 0 61 0 (0–0.39) <0.001
180 0 60 0 (0–0.40) <0.001
Pilus 2 191 86 0 Inf (181.20-Inf) <0.001
306 61 0 Inf (99.04-Inf) <0.001
350 5 0 Inf (3.81-Inf) <0.001
180 0 60 0 (0–0.24) <0.001
53 0 39 0 (0–0.39) <0.001
156 0 35 0 (0–0.44) <0.001
a OR—Odds ratio.
b Only significant values after FDR correction are shown.
doi:10.1371/journal.pone.0153602.t003
Genetic Lineages of Adult Invasive Pneumococcal Disease in Portugal
PLOS ONE | DOI:10.1371/journal.pone.0153602 May 11, 2016 9 / 16
also decrease (this CC accounted for 21.7% of all IPD in 1999–2003 [11]) and potentially lose
its dominance. During the study period CC156 accounted for an approximately constant pro-
portion of the characterized isolates in each year (varying slightly between 5.5% and 7.0%). The
observed persistence of this CC may be explained by three different factors: 1) while it is true
that PCV7 serotypes have declined in importance, it is also true that they still account for
approximately one fifth of adult IPD and 57% of the isolates expressing PCV7 serotypes in
2008–2011 belonged to this CC; 2) this CC is strongly associated with antimicrobial resistance,
with n = 70/101 isolates being resistant to at least two different classes of antibiotics; and 3) the
genomic diversity of CC156 is high, with one study reporting the presence of 10 unrelated
genetic subgroups [22], suggesting that this CC may be particularly suited to adapt to different
selective pressures. Regarding the last point, in our study we found representatives of three dif-
ferent clones recognized by the PMEN included in CC156: Spain9V-156, Colombia23F-338 and
Greece6B-273 [20].
Table 4. Sequence types that were positively associated with penicillin non-susceptibility, erythromycin resistance, erythromycin and penicillin
non-susceptibility simultaneously andmulti drug resistance.
Antimicrobial resistancea ST Yes No ORb (95% CI) P-valuec Penicillin MIC range (μg/ml)
PNSP 156 34 1 153.83 (25.29–6036.47) <0.001 0.5–3
276 31 0 Inf (34.58-Inf) <0.001 0.19–3
143 12 0 Inf (10.84-Inf) <0.001 0.75–3
338 10 0 Inf (8.65-Inf) <0.001 0.064–0.19
63 8 0 Inf (6.52-Inf) <0.001 0.094–1
386 7 0 Inf (5.48-Inf) <0.001 0.064–0.19
179 7 4 6.69 (1.68–31.50) <0.001 0.047–2
230 6 0 Inf (4.45-Inf) <0.001 0.38–0.75
2944 5 0 Inf (3.45-Inf) <0.001 2–8
ERP 276 30 1 150.50 (24.56–5946.55) <0.001 0.19–3
179 11 0 Inf (10.96-Inf) <0.001 0.047–2
143 10 2 21.90 (4.60–206.95) <0.001 0.75–3
717 9 0 Inf (8.52-Inf) <0.001 0.008–0.032
9 8 0 Inf (7.32-Inf) <0.001 0.016–0.064
63 8 0 Inf (7.32-Inf) <0.001 0.094–1
386 7 0 Inf (6.15-Inf) <0.001 0.064–0.19
350 5 0 Inf (3.87-Inf) <0.001 0.004–0.023
230 5 1 21.27 (2.36–1006.44) 0.001 0.38–0.75
EPNSP 276 30 1 274.20 (44.39–10466.80) <0.001 0.19–3
143 10 2 36.81 (7.69–350.14) <0.001 0.75–3
63 8 0 Inf (12.17-Inf) <0.001 0.064–0.19
386 7 0 Inf (10.19-Inf) <0.001 0.064–0.19
179 7 4 12.52 (3.12–59.31) <0.001 0.047–2
230 5 1 35.15 (3.88–1669.53) <0.001 0.38–0.75
4575 3 0 Inf (2.83-Inf) 0.002 2–3
a PNSP—Penicillin non-susceptible pneumococci, ERP—Erythromycin resistant pneumococci, EPNSP—Erythromycin and penicillin non-susceptible
pneumococci.
b OR—odds ratio. Inf—infinite.
c Only significant values after FDR correction are shown.
doi:10.1371/journal.pone.0153602.t004
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Overall, the clones recognized by the PMEN were strongly represented in our collection
with up to 67.3% of the isolates being at most DLVs of one of the 29 different PMEN clones
identified. Among the 22 major CCs occurring in the study period (Table 1), only six did not
include a PMEN clone: CC433, CC378, CC460, CC260, CC30 and CC404. The most frequent
of these, CC433 (mainly ST433, Table 1), was the eighth most frequent CC, included mostly
isolates susceptible to antimicrobials, and is now an important cause of IPD worldwide [23–
27].
The eight more frequent CCs (Table 1) were mainly composed of isolates expressing one of
the top 10 serotypes causing adult IPD in 2008–2011, excluding serotype 4 that presented a
high genetic diversity and no dominant CC (Fig 1). In fact, the clonal composition of the 10
most frequent serotypes causing adult IPD in Portugal in 2008–2011 (Figs 1 and 2) presented
both similarities and differences with other geographic regions in similar periods, with most
matching results coming from countries in Europe and the Americas, especially for serotypes 3
(Netherlands3-180), 7F (Netherlands7F-191), 22F (ST433) and 9N (ST66) [23–26,28–30]. Most
of these lineages, with the exception of ST66, were also dominant among isolates expressing
the same serotypes and causing IPD in children in Japan [27]. Among the isolates expressing
serotypes 19F and 23F, the lineages that dominated in the present study where either absent or
represented a minority of the isolates of the same serotype in the recent studies from the United
States and Japan [26,27], indicating the persistence of different lineages expressing PCV7 sero-
types in different countries. Serotype 19A, which increased as a cause of IPD after PCV7 imple-
mentation in several countries, was associated in Portugal with the expansion of the PMEN
clone Denmark14-230 while in the USA and Asia it was associated with the emergence of the
PMEN clone Taiwan19F-236, as previously described [3]. Serotype 1 was mostly represented by
the Sweden1-306 European clone [31]. However, we detected for the first time in Portugal two
serotype 1 isolates belonging to the hypervirulent PMEN clone Sweden1-217 (STs 217 and
3081), which has been responsible for epidemics with high mortality in Africa [31,32]. The
detection of these genotypes in Portugal is not surprising, since they were found in neighboring
Spain [28] and Portugal has a significant community of citizens of African descent. Still, the
two isolates detected were collected in 2011, the last year of the study period, so it will be
important to monitor the potential emergence of this genotype as a cause of adult IPD in Por-
tugal. Serotypes 14 and 8 were found mainly among representatives of Spain9V-156 and Neth-
erlands8-53, respectively, similarly to Spain [28]. Serotype 11A was found mainly among
representatives of ST408 in our study, while the most common lineage in both Spain and the
USA was its SLV, ST62 [26,28]. For serotype 4, in spite of the higher diversity some similarity
was also found with Spain, with Sweden4-205 and ST246 being common to the two collections
of isolates [28].
When comparing our results with those from a recent carriage study in adults in Portugal
[33] in addition to the difference in serotype distribution due to the recognized differences in
invasiveness of the various serotypes [2], there was also a marked difference between the clonal
compositions of serotype 19A, since the majority of isolates expressing this serotype among
asymptomatic carriers represented ST1201 (CC15), while in our study the most frequent was
ST276, indicating possible differences in virulence between these two serotype 19A lineages.
After the introduction of PCV7, several studies documented a general decrease in IPD inci-
dence. However, the benefits of vaccination were also partly overcome by increases in incidence
of non-vaccine serotypes [5,7,34,35]. This could occur through the persistence of a successful
lineage now expressing a different serotype not covered by the conjugate vaccines, a phenome-
non described as capsular switching. Among our collection a notable case of possible capsular
switching was the detection of five isolates related to the PMEN clone Denmark14-230 (ST230,
n = 4 and ST4253, n = 1) expressing the non-PCV13 serotype 24F (Table 2). This combination
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has already been reported in Portugal in colonized children [36], in Italy [37], Spain and other
European countries (http://pubmlst.org/). In Portugal, in the pre-PCV7 period, serotype 24F
was predominantly CC81 and mostly susceptible to antimicrobials. In 2008–2011, among the
nine isolates genotyped, four represented CC81 and were mainly antimicrobial susceptible as
before, while five represented CC230 and were EPNSP. The detection of this genotype express-
ing serotype 24F in Portugal is of concern since ST276, an SLV of ST230, was behind the
expansion of serotype 19A as a cause of IPD in Portugal in the post-PCV7 era [3]. Among
other possible capsular switches detected in our collection (Table 2), most reflected the occa-
sional detection of a single isolate of a different serotype, suggesting that even if these result
from capsular switching they did not persist in the population at a significant frequency. Taken
together this data indicates that capsular switching in our collection was infrequent and cannot
be attributed to vaccine pressure, in agreement with other studies [38,39]. However, even
though these events were rare they can be important since the uncommon combinations may
proliferate in the future if the conditions become favorable maintaining successful clones in
circulation.
Clonal expansion of previously less frequent lineages was a major contributor to the expan-
sion of non-PCV7 serotypes, since the 22 most frequent CCs occurring in 2008–2011 (Table 1)
were already in circulation in 1999–2003 [11]. When comparing these two periods the most
relevant changes were the expansion of CC191 (serotype 7F) and CC439 (serotypes 23B and
23A) and the decline of CC260 and CC458 (both associated with serotype 3), CC1381 (serotype
18C) and that of CC156 discussed above. The variations in frequency of CC191, CC439 and
CC1381 followed the changes occurring in the respective serotypes. Regarding the clonal com-
position of serotype 3, we found that the decrease in CC260 and CC458 was accompanied by
an expansion of CC180 among serotype 3 isolates, explaining the relative stability of this sero-
type among IPD in adults [12], with CC180 accounting for 40% of serotype 3 IPD in 1999–
2003 but for 64% in 2008–2011. Given that isolates belonging to CC180, CC260 or CC458 were
mostly susceptible to all tested antimicrobials and that only one isolate from CC180 and
another from CC458 carried a PI, this different behavior in time cannot be attributed to differ-
ences in these characteristics.
The presence and type of the PIs was more strongly associated with genotype than with
serotype, as previously reported [4]. The genotypes that carried PIs in our study (Table 3) were
essentially the same reported recently in USA [26], although the proportions of these genotypes
differed considerably between the two studies. The proportion of PI-1 carrying isolates
increased in the post-PCV7 period in the USA associated with the emergence of the non-PCV7
serotypes 19A and 35B [40]. Although serotype 19A also increased in Portugal, the genotype
behind this increase does not carry a PI (ST276) and an actual decrease of PI-1 positive isolates
occurred when compared to the pre-PCV7 period, when 24% of the adult isolates presented
PI-1 [4]. The proportion of isolates presenting only PI-2 declined during the study period,
from 25% in 2008 to 15% in 2011. This was expected since serotype 1 isolates are significantly
associated with PI-2 and these decreased as a cause of adult IPD during the study period [12].
Since PCV13 also includes serotype 7F, which in Portugal was strongly associated with PI-2,
continued use of PCV13 may further reduce the proportion of isolates carrying PI-2. In 2011,
the proportion of isolates carrying any of the PIs was down to 26.6% of the isolates. As sug-
gested for isolates causing IPD in children [16], continued PCV13 use has the potential to vir-
tually eliminate PI carrying isolates.
Antimicrobial resistance is not a crucial pre-requisite for the success of serotypes in IPD,
as demonstrated by serotypes 1, 3 and 7F that were frequent in the post-PCV7 period and are
mostly susceptible to antimicrobials. Still, the presence of resistant clones may help the persis-
tence of serotypes targeted by vaccines, as was possibly the case with serotypes 14 and 19A.
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The highest proportions of penicillin and erythromycin resistance among adult IPD since the
beginning of epidemiological surveillance were registered in 2010, although these declined
again in 2011 [12]. Between 2008 and 2009, when only the increase in PNSP was significant,
this was due to an increase in PNSP expressing serotypes 14 and 19A. In contrast, between
2009 and 2010, the increase in both PNSP and ERP was due to an increase in genetically unre-
lated resistant isolates expressing different serotypes. Since the number of isolates collected
yearly between 2008 and 2011 did not suffer significant fluctuations, two possibilities could
explain the initial increase in PNSP isolates expressing serotypes 14 and 19A: 1) an increase
in the overall proportions of serotypes 14 and 19A, including PNSP STs or 2) an increase in
the proportion of PNSP STs within each of these serotypes, with a concomitant decrease of
susceptible STs. Regarding serotype 14 isolates, which increased slightly during the study
period, these were by 2008 almost equally distributed into only two CCs: CC15, which
includes ST409 and that is almost entirely penicillin susceptible, and CC156, in which all
serotype 14 isolates were PNSP. From 2009 onwards, CC156 became the dominant lineage,
accounting for over 90% of the isolates expressing serotype 14, a change that was not only due
to a decline in frequency of CC15 but also to a slight overall increase in frequency of CC156
among all adult IPD isolates. Among serotype 19A isolates, the increase in proportion of
PNSP between 2008 and 2009 was due to the disappearance of ST193, which was fully suscep-
tible to penicillin, and to an increase of ST276, which represented solely PNSP isolates
(Table 4). Although PNSP and ERP returned in 2011 to values similar to those found prior to
2010, this was due to a decrease in frequency of resistant isolates representing multiple STs
and expressing different serotypes, while the emerging clones (CC156 among serotype 14 and
ST276 among serotype 19A) persisted as important causes of adult IPD. Continued surveil-
lance of resistant isolates should focus particularly on the evolution of serotype 24F since
50% of the isolates expressing this serotype in our study were associated with the PMEN
clone Denmark14-230 (S2 Table) which was a major clone in the expansion of serotype 19A
in the post-PCV7 period in Portugal.
The significant differences in genetic variation, as documented here by MLST, within the
various serotypes remain unexplained and should be the object of future study. We have
shown that the changes in serotypes occurring during the study period have been driven mostly
by the expansion of previously circulating clones or to declines in the majority of the lineages
expressing a given serotype. However, in some serotypes, such as 14 and 19A, changes in sero-
type frequency were driven mostly by changes in particular lineages. In the case of serotype 3,
although its proportion remained constant with time, there were significant changes in the
dominant lineages. These observations raise the possibility that lineage-specific properties may
condition the dynamics of particular serotypes. Serotype switching played a minor role in this
population but may be an important source of new variants that may increase in the post PCVs
period. Taken together, these observations reinforce the importance of determining the clonal
lineages of pneumococci to better understand the changes in the bacterial population occurring
following the use of PCVs.
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Abstract
There is limited information on the serotypes causing non-invasive pneumococcal pneumonia (NIPP). Our aim was to
characterize pneumococci causing NIPP in adults to determine recent changes in serotype prevalence, the potential
coverage of pneumococcal vaccines and changes in antimicrobial resistance. Serotypes and antimicrobial susceptibility
profiles of a sample of 1300 isolates recovered from adult patients ($18 yrs) between 1999 and 2011 (13 years) were
determined. Serotype 3 was the most frequent cause of NIPP accounting for 18% of the isolates. The other most common
serotypes were 11A (7%), 19F (7%), 19A (5%), 14 (4%), 22F (4%), 23F (4%) and 9N (4%). Between 1999 and 2011, there were
significant changes in the proportion of isolates expressing vaccine serotypes, with a steady decline of the serotypes
included in the 7-valent conjugate vaccine from 31% (1999–2003) to 11% (2011) (P,0.001). Taking together the most recent
study years (2009–2011), the potential coverage of the 13-valent conjugate vaccine was 44% and of the 23-valent
polysaccharide vaccine was 66%. While erythromycin resistance increased from 8% in 1999–2003 to 18% in 2011 (P,0.001),
no significant trend was identified for penicillin non-susceptibility, which had an average value of 18.5%. The serotype
distribution found in this study for NIPP was very different from the one previously described for IPD, with only two
serotypes in common to the ones responsible for half of each presentation in 2009–2011 – serotypes 3 and 19A. In spite of
these differences, the overall prevalence of resistant isolates was similar in NIPP and in IPD.
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Introduction
Pneumonia is a common infection that causes high rates of
morbidity and mortality worldwide. Streptococcus pneumoniae
(pneumococcus) is thought to be the major cause of pneumonia,
responsible for up to half of all cases [1]. Only a small fraction of
pneumococcal pneumonias are bacteremic, with non-invasive
pneumococcal pneumonia (NIPP) estimated to be three to ten-
times more frequent than invasive pneumococcal pneumonia
[2,3]. While bacteremic pneumonia is a more severe form of
pneumonia, it is less clear if bacteremia can be considered an
independent predictor of mortality [4,5]. In adults, bacteremic
pneumonia accounts for most of the cases of invasive pneumo-
coccal disease (IPD). While the serotype distribution of IPD and
NIPP have been sometimes assumed to be the same [6], it is
becoming increasingly clear that this is not so [5,7]. This
observation is in agreement with the recognition that some
serotypes, and even different genetic lineages expressing the same
serotype, may have different invasive disease potentials [8], leading
to the expectation that less invasive serotypes would be more
abundantly represented in NIPP than in IPD.
In developed countries, pneumonia is believed to be a major
cause of morbidity among older adults, and, together with
influenza, is the leading cause of death from infectious disease in
the US considering the entire population [9]. Until recently, the
only available vaccine for adults was the 23-valent polysaccharide
vaccine (PPV23) that, while potentially effective in preventing
IPD, may be less efficacious against NIPP [10,11]. Possibly due to
the ongoing debate on the usefulness of PPV23 vaccination, in the
majority of the European countries, including Portugal, there has
been a low uptake of this vaccine [12,13]. On the other hand, the
7-valent conjugate vaccine (PCV7) was introduced in many
European countries for vaccinating children, rapidly reaching high
coverages in the targeted age groups. PCV7 was available in
Portugal for vaccination of children between 2001 and 2009 and,
although not part of the national immunization program, its
uptake was estimated to have grown continuously, albeit slower
that in countries where it was part of the national immunization
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e103092
program [14]. Changes in the serotype distribution of isolates
causing IPD, compatible with an effect of PCV7 occurred in both
children and adults in Portugal and elsewhere [13–17], the latter
potentially resulting from a herd effect. The 10-valent (PCV10)
and the 13-valent conjugate vaccines (PCV13) became available in
Portugal in 2009 and in 2010, respectively. In September 2011,
PCV13 received the European Medicines Agency approval for use
in adults $50 yrs and in July 2013 was approved for adults $
18 yrs, for the prevention of IPD. Currently PCV13 is approved
for all ages from 6 weeks up and there is now initial evidence of its
efficacy against pneumococcal pneumonia in adults caused by the
serotypes included in the vaccine [18].
The aim of this study was to determine the serotype distribution
and antimicrobial resistance of pneumococci causing NIPP in
adults in Portugal during a 13-year period, when the three
conjugate vaccines were available for children, and to compare
these data to the information available for IPD published
previously [19].
Materials and Methods
Ethics Statement
Case reporting and isolate collection were considered to be
surveillance activities and were exempt from evaluation by the
Review Board of the Faculdade de Medicina da Universidade de
Lisboa. The data and isolates were de-identified so that these were
irretrievably unlinked to an identifiable person.
Bacterial Isolates
Isolates were provided by a laboratory-based surveillance system
that includes 30 microbiology laboratories throughout Portugal.
These were asked to identify and send to our laboratory all
pneumococci causing infections. Although the laboratories were
contacted periodically to submit the isolates to the central
laboratory, no audit was performed to ensure compliance, which
may be variable in this type of study. After arrival, all isolates were
confirmed as S. pneumoniae by colony morphology and hemolysis
on blood agar plates, optochin susceptibility and bile solubility.
The isolates included in this study were recovered from adult
patients ($18 yrs) with a clinical diagnosis of pneumonia between
1999 and 2011. A total of 1300 isolates, 100 isolates randomly
chosen from among the isolates received in each of the 13 years of
the study were included. The total number of isolates submitted to
the central laboratory in each year was 161 in 1999, 184 in 2000,
319 in 2001, 282 in 2002, 265 in 2003, 341 in 2004, 338 in 2005,
392 in 2006, 525 in 2007, 601 in 2008, 473 in 2009, 519 in 2010
and 445 in 2011. We believe this reflects increasing compliance
with the surveillance activities with time. Only isolates recovered
from sputum, bronchial secretions or bronchoalveolar lavage were
considered. Isolates were not included when pneumococci were
simultaneously isolated from blood or another usually sterile
product, and when other potential bacterial pathogens besides
pneumococci were detected in the sample (such as Haemophilus
influenzae that was frequently detected). Only one isolate from
each patient in each year was considered. Among the 1300 isolates
selected, 103 (7.9%) were isolates from bronchoalveolar lavage
fluid.
Serotyping and Antimicrobial Susceptibility Testing
Serotyping was performed by the standard capsular reaction test
using the chessboard system and specific sera (Statens Serum
Institut, Copenhagen, Denmark). Serotypes were grouped into
conjugate vaccine serotypes, i.e., those included in PCV13
(serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F)
that comprise all the serotypes found in the lower valency vaccines
(PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F; and PCV10: 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F, 23F), those included in PPV23 (all serotypes
included in PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A,
12F, 15B, 17F, 20, 22F and 33F), and non-vaccine serotypes
(NVT). The isolates that were not typable with any of the complete
set of sera were considered non-typable (NT).
Minimum inhibitory concentrations (MICs) for penicillin and
cefotaxime were determined using Etest strips (Biome´rieux,
Marcy-L’Etoile, France). The results were interpreted using the
Clinical and Laboratory Standards Institute (CLSI) recommended
breakpoints prior to 2008 [20], as these allows the comparison
with previously published data. According to these criteria,
intermediate level penicillin resistance is defined as MIC 0.12–
1.0 mg/ml and high level resistance as MIC$2.0 mg/ml. Isolates
that fell into either one of these classes were designated penicillin
non-susceptible. Susceptibility to cefotaxime was defined as MIC#
1.0 mg/ml. The Kirby-Bauer disk diffusion assay was used to
determine susceptibility to levofloxacin, erythromycin, clindamy-
cin, chloramphenicol, trimethoprim/sulphamethoxazole, tetracy-
cline, vancomycin and linezolid, according to the CLSI recom-
mendations and interpretative criteria [21]. Macrolide resistance
phenotypes were identified using a double disc test with
erythromycin and clindamycin, as previously described [22].
The MLSB phenotype (resistance to macrolides, lincosamides and
streptogramin B) was defined as the simultaneous resistance to
erythromycin and clindamycin, while the M phenotype (resistance
to macrolides) was defined as non-susceptibility only to erythro-
mycin.
Statistical Analysis
Sample diversity was measured using Simpson’s index of
diversity (SID) and the respective 95% confidence intervals
(CI95%) [23]. To compare two sets of partitions the Adjusted
Wallace (AW) coefficients were calculated [24] using the online
tool available at www.comparingpartitions.info. Differences were
evaluated by the Fisher exact test with the false discovery rate
(FDR) correction for multiple testing [25] or the Chi-squared test,
and the Cochran-Armitage test was used for trends. A P,0.05 was
considered significant for all tests.
Results
Serotype Distribution
Serotype diversity was high [SID: 0.941, CI95%: 0.935–0.948],
with 57 different serotypes detected among the 1300 isolates. The
most frequent serotypes, which accounted for more than half of
the isolates, were serotypes: 3 (17.8%), 11A (6.7%), 19F (6.7%),
19A (5.2%), 14 (4.1%), 22F (4.1%), 23F (3.8%) and 9N (3.5%).
Serotype distribution in each of the studied years is represented in
Figure 1. We chose to represent an average of the yearly values
between 1999 and 2003, because it was shown previously that this
period corresponded to the years before an effect of children
vaccination with PCV7 was noted in the distribution of adult IPD
serotypes [14]. The yearly distribution on the 10 overall most
frequent serotypes between 1999 and 2003 is represented in Figure
S1. In spite of yearly variations, serotype diversity was high in all
studied years with the lowest SID detected in 2008 [SID: 0.901,
CI95%: 0.857–0.945] and the highest value found in both 2004 and
2009 [SID: 0.957, CI95%: 0.840–0.973].
The change in distribution of vaccine types along the study
years is shown in Figure 2 and Figure S2. The serotypes included
in PCV7 declined gradually from 31% in 1999–2003 to 11% in
2011 (Cochran-Armitage test of trend P,0.001). Among the
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PCV7 serotypes, those that contributed mostly to this decline were
serotypes 6B (from 4.6% to 0%, Cochran-Armitage test of trend
P,0.001), 9V (from 3.2% to 0%, Cochran-Armitage test of trend
P,0.001) and 23F (from 6.6% to 1.0%, Cochran-Armitage test of
trend P,0.001). Despite fluctuations throughout the study period
in the number of isolates representing PCV13 and PPV23
serotypes, no consistent trend was noted. However, a decline of
the isolates expressing serotypes included in these vaccines, and a
consequent increase in the prevalence of NVTs, can be
distinguished between 2008 and 2009. This can be attributed to
a fall in serotype 3, from 28% to 9%, between these two years (P,
0.001, Figure 1). Although in subsequent years the proportion of
isolates expressing serotype 3 returned to values similar to those
found previously (Figure 1), this did was not reflected in an
increase in the proportion of isolates expressing PCV13 serotypes,
which remained close to 43% (Figure 2). In contrast, the decline in
the proportion of isolates expressing PPV23 serotypes noted in
2009 was not sustained, with the increases in the following years
bringing this value back into the range found in the previous
decade (Figure 2).
The distribution of the 10 most frequent serotypes found
between 1999 and 2011, stratified by age group, is shown in table
S1. The serotype distribution is similar for each of the age groups
considered (P = 0.398) and no significant associations, after
correction for FDR, could be found between specific serotypes
and age groups. When considering only the three last years of the
study, corresponding to the years immediately prior to PCV13
receiving approval for use in adults (2009–2011), the overall
proportion of isolates expressing serotypes included in the various
vaccines were 10.3% for PCV7, 43.7% for PCV13 and 66.0% for
PPV23. There was also no correlation between the proportion of
isolates causing NIPP included in the vaccines and the different
age groups (table S2).
Antimicrobial susceptibility
The proportion of isolates resistant to the tested antimicrobials
between 1999 and 2011 is summarized in table 1. Penicillin non-
susceptible pneumococci (PNSP) accounted for 18.5% of the
isolates (n = 241). Among these, 211 isolates (16.2%) expressed low
level resistance (MIC = 0.12–1 mg/mL) and 30 isolates (2.3%) high
level resistance (MIC$2 mg/mL). Considering the current CLSI
guidelines for parenteral penicillin in non-meningitis cases, where
high level resistance is defined as MIC$8 mg/mL and interme-
diate resistance as MIC$2 mg/mL [21], only 16 strains (1.2%)
would have been considered non-susceptible to penicillin, with
only one of these expressing high level resistance.
Erythromycin resistant pneumococci (ERP) accounted for
16.3% of the isolates (n = 212), with 84.0% (n = 178) of these
expressing the MLSB phenotype and 16.0% (n = 34) the M
phenotype. A total of 9.8% (n = 127) of the isolates were
simultaneously non-susceptible to penicillin and resistant to
erythromycin (EPNSP).
Resistance to levofloxacin was low overall (1.3%, n = 17), but
higher in the older age groups than in the youngest group
Figure 1. Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia in adults in Portugal (1999–2011).
Only the overall 10 most frequent serotypes are shown. The other serotypes found between 1999 and 2011 were serotypes 6B, 7F and 15A (n = 32,
each), 23B (n = 30), 15B (n = 28), 10A (n = 27), 9V and non-typable (n = 26, each), 23A (n = 24), 1 (n = 22), 8 (n = 20), 16F (n = 19), 29 (n = 18), 4 (n = 17), 31
(n = 16), 34 (n = 15), 18C (n = 14), 17F and 33A (n = 13, each), 21 and 35F (n = 11, each), 15C and 35C (n = 10, each), 20 (n = 9), 12B and 17A (n = 8, each),
13, 25F and 25A/38 (n = 7, each), 7C and 28A (n = 5, each), 5 (n = 4), 11F, 18A and 19C (n = 3, each), 12A, 12F, 35A, 35B, 38 (n = 2, each) and 9L, 10F, 15F,
16A, 19B, 33F, 39 and 42 (n = 1, each). The value shown for 1999–2003 refers to the yearly average of the 500 isolates studied that were isolated in
these 5 years. This period was analyzed together since previously published IPD data indicated that these corresponded to a pre-PCV7 serotype
distribution [14].
doi:10.1371/journal.pone.0103092.g001
Streptococcus pneumoniae Pneumonia in Adults
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e103092
(Table 1, 18–49 yrs versus 50–64 yrs, P = 0.014 and 18–49 yrs
versus $65 yrs, P = 0.012). No other significant associations with
age were found for the other antimicrobials tested. All isolates
were susceptible to vancomycin and linezolid.
The proportion of erythromycin and clindamycin resistant
isolates increased between 1999–2003 and 2011. Erythromycin
resistance increased from 8.0% to 18.0% (Cochran-Armitage test
of trend P,0.001) and clindamycin resistance increased from
Figure 2. Proportion of isolates expressing serotypes included in pneumococcal vaccines causing non-invasive pneumococcal
pneumonia in adults in Portugal (1999–2011). The value shown for 1999–2003 refers to the yearly average of the 500 isolates studied that were
isolated in these 5 years. This period was analyzed together since previously published IPD data indicated that these corresponded to a pre-PCV7
serotype distribution [14].
doi:10.1371/journal.pone.0103092.g002
Table 1. Antimicrobial resistance of the isolates responsible for non-invasive pneumococcal pneumonia in adults in Portugal,
stratified by age groups (1999–2011).
No. resistant isolates (%)a
[18–49] yrs [50–64] yrs $65 yrs Total
(n =481) (n=293) (n =526) (n =1300)
PENb 95 (19.8) 57 (19.5) 89 (16.9) 241 (18.5)
MIC90 0.25 0.38 0.25 -
MIC50 0.023 0.023 0.023 -
CTX 4 (0.8) 3 (1.0) 2 (0.4) 9 (0.7)
MIC90 0.19 0.125 0.094 -
MIC50 0.012 0.012 0.012 -
LEV 1 (0.2) 6 (2.0) 10 (1.9) 17 (1.3)
ERY 76 (15.8) 54 (18.4) 82 (15.6) 212 (16.3)
CLI 66 (13.7) 44 (15.0) 68 (12.9) 178 (13.7)
CHL 17 (3.5) 12 (4.1) 22 (4.2) 51 (3.9)
SXT 89 (18.9) 46 (15.7) 84 (16.0) 219 (16.8)
TET 61 (12.7) 42 (14.3) 63 (12.0) 166 (12.8)
aPEN – penicillin; CTX – cefotaxime; LEV – levofloxacin; ERY – erythromycin; CLI – clindamycin; CHL – chloramphenicol; SXT – trimethoprim/sulphamethoxazole; TET –
tetracycline. All isolates were susceptible to vancomycin and linezolid.
bNon-susceptibitily to penicillin was determined using the CLSI breakpoints prior to 2008 [20].
doi:10.1371/journal.pone.0103092.t001
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7.0% to 15.0% (Cochran-Armitage test of trend P = 0.004). No
other significant changes were noted for the other antimicrobials
tested.
There was an association between serotype and antimicrobial
resistance. The AW for serotype and PNSP was 0.588 (CI95%:
0.541–0.634) and the AW for serotype and ERP was 0.489 (CI95%:
0.419–0.558). Table 2 shows the serotypes that presented at least
10 PNSP and ERP isolates, respectively. Among the major
serotypes expressed by PNSP, only serotype 19F was not
significantly associated with PNSP. Among the major serotypes
expressed by ERP, only serotypes 23F and 6C were not
significantly associated with ERP. The PCV7, PCV13 and
PPV23 serotypes accounted for 56.0%, 70.5% and 69.7% of
PNSP, respectively, and 42.9%, 60.8% and 66.5% of ERP,
respectively.
Discussion
Serotype 3 was the most important serotype in NIPP in adults in
Portugal. This serotype was the most frequently detected in all
studied years, with the exception of 2009, when it ranked third
(Figure 1). A predominance of serotype 3 was also found in two
studies that focused on the serotype distribution of pneumococcal
pneumonia isolates [5,26], and this serotype was among the most
frequent in two recent studies using urinary antigen detection
assays to diagnose pneumococcal pneumonia [7,27], although
these last studies included both NIPP and bacteremic pneumonia.
In Portugal, serotype 3 is not only a leading cause of NIPP but also
of IPD, as can be seen in Figure S3, showing the distribution of the
most frequently detected serotypes immediately prior to the
licensure of PCV13 for adult immunization (2009–2011).
Although both IPD and NIPP were characterized by a high
serotype diversity (for NIPP SID = 0.943, CI95%: 0.932–0.955; and
for IPD SID = 0.942, CI95%: 0.937–0.946; considering 2009–
2011), the actual serotype distribution is quite different (Figures 3,
Figure S3 and Table S3). Among the most frequent serotypes,
accounting for half of the characterized isolates in 2009–2011,
only two serotypes were common to both NIPP and IPD, which
were serotypes 3 and 19A (Figure S3). When comparing the
serotype distribution, serotypes 6A, 11A, 15C, 19F and 23B were
significantly more abundant among NIPP isolates, whereas
serotypes 1, 4,7F and 14 were significantly more abundant among
IPD isolates (Figure 3 and Table S3). These four serotypes,
together with serotype 3, were already shown to have an enhanced
invasive disease potential in a study evaluating the serotypes and
clones circulating in Portugal [8]. On the other hand, serotypes
6A, 11A and 19F were associated with carriage [8], suggesting
their lower invasive disease potential, consistent with the
association with NIPP determined here (Figure 3 and Table S3).
A recent study described the serotype distribution among
isolates recovered in 2011 causing bacteremic and non-bacteremic
pneumonia in adults in Denmark [5]. When considering only the
isolates recovered in 2009–2011 in Portugal, the serotype
distribution is, perhaps surprisingly, remarkably similar in both
studies. Among the differences are the more significant fractions of
non-typable isolates among NIPP and of serotype 1 isolates in
bacteremic pneumonia in Denmark relative to Portugal. Serotype
1 was always an important serotype among isolates causing IPD in
both children and adults in Portugal, but its significance has
Table 2. Serotype distribution of PNSP and ERP causing non-invasive pneumococcal pneumonia in adults in Portugal (1999–2011).
Serotypea No. of resistant isolates (%) OR (CI95%) P-value
b
PEN 23F 39 (16.2) 12.6 (6.2–27.7) ,0.001
14 37 (15.4) 8.1 (4.3–15.9) ,0.001
19A 28 (11.6) 2.3 (1.3–3.9) 0.002
15A 27 (11.2) 18.2 (6.8–61.3) ,0.001
19F 27 (11.2) 1.4 (0.8–2.3) 0.193
9V 23 (9.5) 25.5 (7.6–133.7) ,0.001
6C 18 (7.5) 3.0 (1.5–6.2) 0.001
Othersc 42 (17.4) - -
ERY 19F 37 (17.5) 3.4 (2.1–5.4) ,0.001
19A 31 (14.6) 3.7 (2.2–6.4) ,0.001
15A 28 (13.2) 31.9 (11.0–126.2) ,0.001
14 21 (9.9) 2.8 (1.5–5.1) ,0.001
6B 15 (7.1) 3.7 (1.7–8.0) ,0.001
23F 14 (6.6) 1.6 (0.8–3.1) 0.151
33A 10 (4.7) 13.8 (3.5–79.0) ,0.001
6C 10 (4.7) 1.5 (0.6–3.3) 0.296
NTd 10 (4.7) 2.6 (1.0–6.1) 0.025
Otherse 36 (17.0) - -
aOnly the serotypes that presented at least 10 non-susceptible isolates are shown.
bSignificant P-values after FDR correction are highlighted in bold.
cOther serotypes found among PNSP: 6B (n = 8), non-typable (n = 7), 6A and 29 (n = 5, each), 23B and 24F (n = 3, each), 7C (n = 2), 1, 3, 4, 11A, 15B, 15F, 22F, 23A, 35A
(n = 1, each).
dNT – non typable.
eOther serotypes found among ERP: 9V and 11A (n = 4, each), 3, 15B, 22F, 23A, 24F (n = 3, each), 6A (n = 2), 1, 7F, 8, 9N, 15F, 16F, 17F, 23B, 29, 33F and 35F (n = 1, each).
doi:10.1371/journal.pone.0103092.t002
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declined in recent years [13,15,19,28]. This change cannot be
attributed entirely to the use of higher valency vaccines, such as
PCV13, although vaccination was potentially a contributing factor
[19,28]. Another important difference is the persistence of
serotype 14 isolates among both NIPP and IPD in Portugal, in
contrast to Denmark where this serotype was found at a lower
frequency [5]. Serotype 14 was already included in PCV7, and
continued vaccine use could be expected to significantly reduce its
prevalence. A lower and more protracted vaccine uptake in
Portugal compared to Denmark, together with a higher antibiotic
consumption, could contribute to the differences observed
between the two countries.
In previous studies, we showed that immunization of children
with PCV7 resulted in the decline of PCV7 serotypes as causes of
adult IPD [13,19]. In the present study, we show that a decline of
PCV7 serotypes also occurred among isolates causing NIPP in
adults. However, while in IPD this decline was abrupt, occurring
between 2004 and 2005, in NIPP this decline was gradual and
occurred over the entire post-PCV7 period (Figure 2 and Figure
S2). The proportion of isolates expressing PCV7 serotypes in the
most recent years of the study was different between NIPP and
IPD (10.3% versus 19.0% in 2009–2011, P,0.001, Figure 3).
Taken together, the isolates expressing PCV13 serotypes also
declined in IPD and in NIPP, a change that was observed from
2008 onwards for both disease presentations. However, again
there were important differences. While in IPD this decline
occurred from 2008 to 2011 and was mostly due to decreases in
serotypes 1 and 5, in NIPP this decline occurred between 2008
and 2009 and was predominantly caused by a decrease in serotype
3. In neither case can we attribute these changes to the
introduction of PCV13 in Portugal, since this vaccine only
became available for children in the beginning of 2010 and
received an indication for adults in the beginning of 2012. In
NIPP, one possible explanation for the change observed could be
the H1N1pdm09 pandemic that occurred between 2009 and
2010. Individuals infected by influenza are at high risk of
developing secondary bacterial infections, especially with pneu-
mococci [29]. Consistent with the hypothesis that influenza
allowed the emergence of multiple serotypes as causes of NIPP,
the decrease of serotype 3 from 2008 to 2009 was accompanied by
an increase in serotype diversity.
Another remarkable difference between NIPP and IPD is the
proportion of isolates that expresses serotypes included in the
available vaccine formulations with an adult indication. When
analyzing data from 2009 to 2011, we found that the number of
IPD cases that could have been potentially prevented by PCV13
and PPV23 was 59%, and 80%, respectively [19], while the
proportion of isolates expressing these serotypes was only 44% and
66%, respectively, among our collection of NIPP isolates. The
higher proportion of vaccine types among IPD isolates was also
documented in Denmark [5]. The efficacy of the conjugate
vaccines is well established and adults could now benefit directly
from PCV13 use. However, according to our sample more than
half of NIPP cases could not have been prevented by vaccination
with PCV13.
In the present study we could not find any significant
associations between serotypes and age groups. This is in contrast
to our previous studies with invasive isolates, where serotypes 3
and 19A were associated with older patients and serotypes 1 and 8
were associated with younger patients [19]. However, if we do not
consider the correction for multiple testing, serotype 3 was more
frequent in older adults than in the youngest (14% in 18–49 yrs
versus 20% in $50 yrs, P = 0.005, Table S1). The lack of
association for the other three serotypes with age is likely the
result of their small numbers in our NIPP sample, particularly in
what concerns serotypes 1 and 8.
A high proportion of the resistant isolates recovered between
1999 and 2011 are of serotypes included in PCV7 (Table 2),
accounting for 56% of PNSP and 43% of ERP in the entire study
period. Unlike what could have been expected, the introduction of
PCV7 in Portugal did not reduce the proportion of resistant
isolates, neither in NIPP nor in IPD [14,19]. Actually, for both
presentations there was an increase in ERP between 1999 and
2011, and for IPD there was also an increase in PNSP. However,
when we considered the most recent data (2009 to 2011) we found
that only 22% of PNSP and 26% of ERP causing NIPP,
represented serotypes included in PCV7. This means that resistant
isolates expressing serotypes that are not included in PCV7 have
emerged and expanded in the post-PCV7 period.
When considering the entire study period, antimicrobial
resistance among NIPP isolates was similar to the values reported
recently for IPD [19] (Table 1). Given the association between
serotype and antimicrobial resistance, and the different serotype
distributions between NIPP and IPD, how can we explain the
similar overall resistance? For the most part, the explanation can
be found in the more gradual decrease of resistant PCV7
serotypes, albeit to a lower level, in NIPP when compared to
IPD. This was accompanied by the rise of a different set of
serotypes including resistant isolates that are not included in
PCV7, resulting in similar overall resistance levels. Resistance
among NIPP isolates is partly due to the proliferation of resistant
serotype 19A isolates, probably representing a lineage which has
been expanding as a cause of IPD in children and adults [19,30],
and that became the single most important serotype among PNSP
and ERP in the last three years of the study. This was
accompanied by increases in serotypes including resistant isolates
not represented in PCV13, such as serotypes 6C, 15A, 29, 33A, as
well as non-typable isolates, each including n.5 PNSP or ERP
during the entire study period (table 2).
The major limitation of this study is that we do not know if
blood cultures were performed for all patients, and so we cannot
exclude the possibility that some of the isolates attributed to NIPP
were in fact reflecting cases of invasive disease. However, the
distinct serotype distribution between IPD and NIPP and the
similar distribution found in this study and among isolates causing
NIPP in Denmark in a similar period [5], in spite of the different
epidemiological contexts, strongly argues against a significant bias
in our sample. Another possible confounder could be that a
fraction of our isolates are reflecting colonization and not
infection. Again we consider this unlikely. The fluids included
are not present in healthy subjects (sputum and bronchial
secretions) or are not obtained unless there is a strong suspicion
of pneumonia (bronchoalveolar lavage). The participating labora-
tories used criteria to exclude low quality samples, which would be
Figure 3. Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia and invasive pneumococcal disease
in adults in Portugal (2009–2011). Data from IPD were published previously [19]. Serotypes associated with NIPP or IPD are marked by asterisks.
The odds ratio was used to measure the association between serotype and disease presentation and only significant values (P,0.05) after FDR
correction are indicated. The P values for the serotypes associated with NIPP were: P = 0.001 for 19F, P = 0.007 for 6A, P = 0.004 for 11A, P = 0.001 for
15C, P,0.001 for 23B. The P values for the serotypes associated with IPD were: P = 0.007 for 4, P,0.001 for 14, P,0.001 for 1 and P,0.001 for 7F.
doi:10.1371/journal.pone.0103092.g003
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more likely to reflect upper airway microbiota. Finally, adult
colonization is known to be rare [31] and would be therefore
unlikely to account for a significant fraction of the isolates. Taken
together, these arguments support a role for the pneumococci
analyzed in infection and not asymptomatic colonization. The
decision to collect specimens for microbiological analysis was the
responsibility of the attending physician that did not receive
specific guidelines. We are not aware of significant changes in
practice during the study period, although differences between the
participating centers may exist. However, since these are expected
to be minor and stable during the study period we do not feel these
constitute a significant source of bias.
In this study, we found a different serotype distribution and
dynamics in NIPP and IPD in the same population. This was
highlighted by the fact that the potential coverage of the currently
available pneumococcal vaccines with an adult indication is lower
in NIPP than in IPD. The distinct dynamics of NIPP, the
availability of PCV13 for adults together with the issues raised
regarding the efficacy of PPV23 in the context of NIPP, and the
fact that NIPP is a frequent cause of morbidity and mortality
among adults, all underscore the relevance of considering the use
of PCV13 in adults. However, the expected herd protection
conferred by vaccinating children with PCV13 could reduce the
benefits of direct adult vaccination. We documented here ongoing
changes in the serotypes causing NIPP that are potentially due to
long-term PCV7 use, but there is uncertainty regarding the
ultimate reduction in vaccine serotypes one can expect from this
effect, as well as regarding the kinetics of such a decline.
Continued surveillance is essential to evaluate the changing
potential benefits of direct adult vaccination.
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Abstract
Non-invasive pneumococcal pneumonia (NIPP) is a frequent cause of morbidity and mortal-
ity worldwide. The 13-valent pneumococcal conjugate vaccine (PCV13) was included in the
national immunization program of children living in Portugal in 2015. Until then, PCV7 (since
late 2001) and PCV13 (since early 2010) were given through the private market. We deter-
mined the serotype distribution and antimicrobial susceptibility of isolates causing adult
NIPP in 2012–2015 and compared the results with previously published data (2007–2011).
There were 50 serotypes among the 1435 isolates. The most common were serotypes: 3
(14%), 11A (8%), 19F (6%), 23A (5%), 6C (5%), 19A (4%), 23B (4%), 9N (4%) and non-typ-
able isolates (4%). When considering data since the availability of PCV13 for children in the
private market, the proportion of PCV13 serotypes declined from 44.0% in 2010 to 29.7% in
2015 (p < 0.001), mainly due to early decreases in the proportions of serotypes 3 and 19A.
In contrast, during the same period, PCV7 serotypes (11.9% in 2012–2015) and the sero-
types exclusive of the 23-valent polysaccharide vaccine (26.0% in 2012–2015), remained
relatively stable, while non-vaccine types increased from 27.0% in 2010 to 41.9% in 2015
(p<0.001). According to the Clinical and Laboratory Standards Institute (CLSI) breakpoints,
penicillin non-susceptible and erythromycin resistant isolates accounted for 1% and 21.7%,
respectively, of the isolates recovered in 2012–2015, with no significant changes seen since
2007. Comparison of NIPP serotypes with contemporary invasive disease serotypes identi-
fied associations of 19 serotypes with either disease presentation. The introduction of
PCV13 in the national immunization program for children from 2015 onwards may lead to
reductions in the proportion of NIPP due to vaccine serotypes but continued NIPP surveil-
lance is essential due to a different serotype distribution from invasive disease.
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Introduction
Pneumococcal pneumonia is among the most frequent causes of death due to infection world-
wide, particularly among young children and older adults [1]. Non-invasive pneumococcal
pneumonia (NIPP) is three to ten times more frequent than bacteremic pneumonia [2], but
studies evaluating NIPP are less abundant than those evaluating invasive pneumococcal dis-
ease (IPD).
After the introduction of pneumococcal conjugate vaccines (PCVs) for children, several
studies reported a reduction of IPD in children [3,4]. Given that young children are the main
reservoirs and transmitters of pneumococcus in the community and because the PCVs reduce
pneumococcal colonization, several studies also reported reductions of IPD due to vaccine
serotypes in the non-vaccinated population [5–8].
Despite the lower number of studies, there is also evidence of herd protection in adult NIPP
[9–12]. One study from the Netherlands suggested that, based on the similarity of vaccine sero-
type trends between NIPP and IPD, their national IPD data could be used to extrapolate the
trends of NIPP [13]. However, there are also reasons to question predictions of NIPP trends
from IPD data in all settings. Perhaps the most significant is that serotype distribution and the
proportion of disease that is due to vaccine serotypes differs geographically and between IPD
and NIPP [14,15]. Moreover, vaccine serotypes are free to circulate in unvaccinated people so
that, especially in countries where the PCVs are not included in national immunization pro-
grams, these can persist as causes of disease, both of NIPP and IPD.
In Portugal, PCVs were available only outside the national immunization program for
pediatric use until mid-2015. The first PCV to become available was the 7-valent formulation
(PCV7), in late-2001. Although the cost of vaccination was fully supported by the parents, the
initially modest uptake of PCV7 increased steadily, reaching 75% in 2008 [16]. A 13-valent for-
mulation (PCV13) replaced PCV7 in early-2010 but uptake declined, although it stayed above
60% [17]. In June 2015, PCV13 was included in the national immunization program to be
given free of charge to all children born from January 2015 onwards, with a 2+1 schedule [17].
Besides children, sequential vaccination with PCV13 and the 23-valent pneumococcal polysac-
charide vaccine (PPV23) is recommended since 2015 by the national health authorities, but
only for specific risk groups [18]. In addition, two Portuguese medical societies (respiratory
society and general practitioner society) have issued recommendations for the sequential
vaccination with PCV13 and PPV23 of all immunocompetent adults�65 years [19,20]. Still,
pneumococcal vaccine uptake in adults is generally believed to be low, with a study finding
that<9% of all adults�65 years had received PPV23 [21,22].
In a previous study we analyzed the distribution of serotypes in a randomly selected sample
of 100 isolates/year collected from adult NIPP between 1999 and 2011 [14]. In the present
study we aimed to gain further insights regarding vaccine serotype trends in adult NIPP in the
years that followed. We characterized isolates causing adult NIPP throughout Portugal from
2012 to 2015 for serotype distribution and antimicrobial susceptibility. We also wanted to
compare the NIPP data with contemporary adult IPD data obtained by the same network.
Materials and methods
Ethics statement
The study was approved by the Institutional Review Board of the Centro Acade´mico de
Medicina de Lisboa. These were considered surveillance activities and were exempt from
informed consent. All methods were performed in accordance with the relevant guidelines
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and regulations. The data and isolates were de-identified so that these were irretrievably
unlinked to an identifiable person.
Bacterial isolates
Isolates were provided by a laboratory-based surveillance system that includes 30 microbiology
laboratories throughout Portugal. These were asked to submit all consecutively collected pneu-
mococci causing infections to the central laboratory. Although the laboratories were contacted
periodically to submit the isolates to the central laboratory, no audit was performed to ensure
compliance, which may be variable in this type of study. The identification of all isolates as
Streptococcus pneumoniae was confirmed by colony morphology and hemolysis on blood agar
plates, optochin susceptibility and bile solubility.
The isolates included in this study were recovered from sputum, bronchial secretions or
bronchoalveolar lavage of adult patients (�18 yrs) with a presumptive diagnosis of pneumonia
between 2012 and 2015. Isolates were not included when pneumococci were simultaneously
isolated from blood or another usually sterile product, and when other potential bacterial path-
ogens besides pneumococci were detected in the sample (such as Haemophilus influenzae,
which was also frequently detected). Only one isolate from each patient in each year was
considered.
Serotyping and antimicrobial susceptibility testing
Serotyping was performed by the standard capsular reaction test using the chessboard system
and specific sera (Statens Serum Institut, Copenhagen, Denmark) [23]. Serotypes were classi-
fied into vaccine serotypes, i.e., those included in PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F,
23F), in PCV13 (all PCV7 serotypes and the additional serotypes present only in PCV13,
addPCV13: 1, 3, 5, 6A, 7F and 19A), in PPV23 (all PCV13 serotypes, except serotype 6A, and
the additional serotypes present only in PPV23, addPPV23: 2, 8, 9N, 10A, 11A, 12F, 15B, 17F,
20, 22F, and 33F) and non-vaccine serotypes (NVT, including all other serotypes). Given the
high frequency of spontaneous switching between serotypes 15B and 15C we have opted to
group isolates with these serotypes into a single group. Due to difficulties in phenotypically
distinguishing isolates of serotype 25A and serogroup 38 and of serogroup 29 and serotype
35B these were also grouped together into the 25A/38 and 29/35B groups. The isolates that
were not typable with any of the complete set of sera were considered non-typable (NT).
Minimum inhibitory concentrations (MICs) for penicillin and cefotaxime were determined
using Etest strips (Biome´rieux, Marcy-L’Etoile, France). Unless otherwise stated, the results
were interpreted using the Clinical and Laboratory Standards Institute (CLSI) recommended
breakpoints prior to 2008 [24], corresponding to the current breakpoints of oral penicillin V
allowing the comparison with previously published data. According to these criteria, interme-
diate resistance to penicillin is defined as MIC 0.12–1.0 μg/ml and high-level resistance as
MIC�2.0 μg/ml. Isolates that fell into either one of these classes were designated penicillin
non-susceptible (PNSP). The interpretation according to the current CLSI guidelines was also
performed [25]. According to these criteria, for non-meningitis cases, intermediate resistance
to penicillin is defined as MIC between 2–8 μg/ml and high-level resistance as MIC>8 μg/ml.
Susceptibility to cefotaxime was defined as MIC�1.0 μg/ml. The Kirby-Bauer disk diffusion
assay was used to determine susceptibility to levofloxacin, erythromycin, clindamycin, chlor-
amphenicol, trimethoprim/sulfamethoxazole, tetracycline, vancomycin and linezolid, accord-
ing to the CLSI recommendations and interpretative criteria [25]. Macrolide resistance
phenotypes were identified using a double disc test with erythromycin and clindamycin, as
previously described [14]. The MLSB phenotype (resistance to macrolides, lincosamides and
Serotypes and antimicrobial resistance of pneumococcal pneumonia: Portugal (2012-2015)
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streptogramin B) was defined as the simultaneous resistance to erythromycin and clindamy-
cin, while the M phenotype (resistance to macrolides) was defined as non-susceptibility only
to erythromycin.
Statistical analysis
Sample diversity was measured using Simpson’s index of diversity (SID) and the respective
95% confidence intervals (CI95%) [26]. To compare two sets of partitions the Adjusted
Wallace (AW) coefficients were calculated [26] using the online tool available at www.
comparingpartitions.info. Differences were evaluated by the Fisher exact test with the false
discovery rate (FDR) correction for multiple testing [27] or the Chi-squared test, and the
Cochran-Armitage test was used for trends. A p<0.05 was considered significant for all tests.
Results
Serotype distribution
A total of 1435 isolates were collected from adults with non-invasive pneumococcal pneumo-
nia: n = 368 in 2012, n = 319 in 2013, n = 311 in 2014 and n = 437 in 2015. Stratifying by age
group, 339 isolates (23.6%) were recovered from patients 18–49 years old, 382 (26.6%) from
patients 50–64 years old and 714 (49.8%) from patients�65 years old. Most of the isolates
were recovered from sputum (n = 787, 54.8%), 531 (37.0%) were recovered from bronchial
secretions and 117 (8.2%) were recovered from bronchoalveolar lavage fluid. A total of 50
different serotypes were detected. The most frequent serotypes, which accounted for 52% of
the isolates, were serotypes 3 (n = 196, 13.7%), 11A (n = 120, 8.4%), 19F (n = 85, 5.9%), 23A
(n = 67, 4.7%), 6C (n = 64, 4.5%), 19A (n = 58, 4.0%), 23B (n = 56, 3.9%), 9N (n = 52, 3.6%)
and NT isolates (n = 50, 3.5%).
The S1 Fig represent the number of isolates expressing serotypes included in PCVs, the
addPPV23, and the number of isolates expressing NVTs, respectively, stratified by age group.
Serotype diversity was high—SID = 0.952, CI95%: 0.948–0.956 –with no difference between
SIDs of different years. No individual serotype (n>15 isolates) showed differences in age dis-
tribution, statistically supported after FDR correction.
Fig 1 shows the proportion of potentially vaccine preventable NIPP during the study period
and, for comparison purposes, also the previously published data from 2007–2011, since these
years represent the late post-PCV7 period (2007–2009) and the first two years of PCV13 use
in children (2010–2011) [14]. Considering the evolution during the current study period
only (2012–2015), there was a decline in the proportion of NIPP caused by PCV13 serotypes,
from 34.5% in 2012 to 29.7% in 2015, but this was not statistically supported (p = 0.090). This
decline was associated with slight and non-significant decreases in both the proportion of
NIPP caused by PCV7 serotypes (from 13.6% to 11.0%, p = 0.177) and addPCV13 (from
20.9% to 18.8%, p = 0.377). In contrast, there was a non-significant increase in the proportion
of NIPP caused by addPPV23 (from 24.7% in 2012 to 28.4% in 2015, p = 0.325), while the
proportion of NIPP caused by NVTs remained relatively stable from 2012 to 2015 (40.8% vs
41.9%, respectively, p = 0.460).
We then evaluated possible serotype trends since 2010 when PCV13 started being used in
children through the private market. The overall proportion of PCV13 serotypes declined
from 44.0% in 2010 to 29.7% in 2015 (p<0.001), while that of addPCV13 decreased from
36.0% in 2010 to 18.8% in 2015 (p<0.001). This was accompanied by an increase of NVTs
from 27.0% in 2010 to 41.9% in 2015 (p = 0.002). The PCV7 and addPPV23 serotypes
remained relatively stable.
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Table 1 shows the evolution of the individual serotypes causing NIPP in adults during the
current study period (2012–2015). Only serotype 25A/38 significantly changed its proportion
after FDR correction (from 1.9% in 2012 to 0.0% in 2015, p = 0.001). When considering
the evolution of individual serotypes since 2007 (Table 1 and S1 Table), only four serotypes
significantly changed their proportion after FDR correction (S2 Fig), which were serotypes 3
(declined from 22.0% in 2007 to 12.1% in 2015, p<0.001), 19A (declined from 6.0% in 2007 to
3.2% in 2015, p = 0.003), 7F (declined from 3.0% in 2007 to 1.1% in 2015, p = 0.004) and 35F
(increased from 0% in 2007 to 3.2% in 2015, p = 0.003). The declines in proportion of sero-
types 3 and 19A showed important yearly fluctuations and these were also found for several
other serotypes (Table 1 and S2 Table).
When analyzing the evolution of individual vaccine serotypes and of vaccine serotype
groups in 2012–2015 stratified by age group (Table 2), there were no significant changes after
FDR correction. When considering data since 2007, only for serotype 3 and for adults aged
�65 years old did the change remain statistically supported after FDR correction (serotype 3
declined from 27.5% in 2007 to 11.1% in 2015, p<0.001).
Antimicrobial susceptibility
Susceptibility to the tested antimicrobials between 2012 and 2015 stratified by the age groups
considered is summarized in Table 3. When considering all isolates, a total of n = 258 isolates
(18.0%) were classified as PNSP of which n = 229 (88.8%) expressed low-level resistance and
n = 29 (11.2%), high-level resistance. According to the current CLSI guidelines for parental
Fig 1. Proportion of isolates expressing serotypes included in each of the pneumococcal vaccines causing non-invasive pneumococcal
pneumonia in adult patients (�18 years) in Portugal, 2007–2015. The data up to 2011 were presented previously [14].
https://doi.org/10.1371/journal.pone.0206912.g001
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Table 1. Serotypes of the isolates responsible for non-invasive pneumococcal pneumonia in adult patients (�18 years), 2012–2015.
Serotype No. of isolates (%) CAa
2012 2013 2014 2015 2012–2015
PCV13
1 2 (0.5) 0 (0) 0 (0) 1 (0.2) 0.399
3 48 (13.0) 54 (16.9) 41 (13.2) 53 (12.1) 0.408
4 1 (0.3) 1 (0.3) 2 (0.6) 3 (0.7) 0.329
5 0 (0) 0 (0) 0 (0) 0 (0) -
6A 5 (1.4) 7 (2.2) 6 (1.9) 9 (2.1) 0.547
6B 7 (1.9) 4 (1.3) 4 (1.3) 6 (1.4) 0.578
7F 5 (1.4) 4 (1.3) 4 (1.3) 5 (1.1) 0.800
9V 0 (0) 5 (1.6) 0 (0) 0 (0) 0.275
14 12 (3.3) 6 (1.9) 6 (1.9) 10 (2.3) 0.426
18C 4 (1.1) 1 (0.3) 1 (0.3) 1 (0.2) 0.106
19A 17 (4.6) 9 (2.8) 18 (5.8) 14 (3.2) 0.645
19F 22 (6.0) 22 (6.9) 15 (4.8) 26 (5.9) 0.746
23F 4 (1.1) 2 (0.6) 4 (1.3) 2 (0.5) 0.483
PPV23 only
8 7 (1.9) 10 (3.1) 6 (1.9) 16 (3.7) 0.222
9N 11 (3.0) 13 (4.1) 16 (5.1) 12 (2.7) 0.942
10A 11 (3.0) 6 (1.9) 5 (1.6) 10 (2.3) 0.519
11A 29 (7.9) 29 (9.1) 22 (7.1) 40 (9.2) 0.703
12F 0 (0) 0 (0) 0 (0) 0 (0) -
15B/C 6 (1.6) 11 (3.4) 7 (2.3) 10 (2.3) 0.807
17F 8 (2.2) 4 (1.3) 8 (2.6) 4 (0.9) 0.319
20 5 (1.4) 5 (1.6) 6 (1.9) 8 (1.8) 0.557
22F 14 (3.8) 8 (2.5) 6 (1.9) 21 (4.8) 0.448
33F 0 (0) 0 (0) 2 (0.6) 3 (0.7) 0.048
NVTb
6C 19 (5.2) 16 (5.0) 7 (2.3) 22 (5.0) 0.627
23A 24 (6.5) 12 (3.8) 14 (4.5) 17 (3.9) 0.130
23B 15 (4.1) 8 (2.5) 15 (4.8) 18 (4.1) 0.631
NT 9 (2.4) 8 (2.5) 16 (5.1) 17 (3.9) 0.123
15A 10 (2.7) 9 (2.8) 8 (2.6) 16 (3.7) 0.465
31 15 (4.1) 7 (2.2) 14 (4.5) 12 (2.7) 0.587
16F 7 (1.9) 10 (3.1) 3 (1.0) 20 (4.6) 0.070
29/35B 12 (3.3) 6 (1.9) 6 (1.9) 10 (2.3) 0.426
35F 5 (1.4) 3 (0.9) 6 (1.9) 14 (3.2) 0.033
34 3 (0.8) 8 (2.5) 5 (1.6) 8 (1.8) 0.445
21 3 (0.8) 6 (1.9) 7 (2.3) 8 (1.8) 0.265
24F 4 (1.1) 2 (0.6) 6 (1.9) 10 (2.3) 0.082
33A 6 (1.6) 1 (0.3) 5 (1.6) 0 (0) 0.052
25A/38 7 (1.9) 2 (0.6) 0 (0) 0 (0) 0.001
35A 2 (0.5) 3 (0.9) 4 (1.3) 2 (0.5) 0.946
7C 2 (0.5) 2 (0.6) 6 (1.9) 1 (0.2) 0.946
13 2 (0.5) 3 (0.9) 1 (0.3) 1 (0.2) 0.333
37 1 (0.3) 4 (1.3) 1 (0.3) 3 (0.7) 0.802
Othersc 4 (1.1) 8 (2.5) 8 (2.6) 4 (0.9) -
(Continued)
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penicillin in non-meningitis cases [25], only n = 15 isolates (1.0%) would have been considered
PNSP, with only 2 of these expressing high-level resistance. A total of n = 311 isolates (21.7%)
were classified as erythromycin resistant pneumococci (ERP). Of these, n = 246 isolates
(79.1%) expressed the MLSB phenotype, while the remaining (n = 65, 20.9%) presented the M
phenotype. A total of 12.3% (n = 176) of the isolates were simultaneously non-susceptible to
penicillin and resistant to erythromycin (EPNSP).
There were no significant variations in antimicrobial resistance during the current study
period (2012–2015), nor were there significant changes in antimicrobial resistance when con-
sidering NIPP from 2007 [14]. Although with moderate overall AW values [the AW for sero-
type to PNSP was 0.441 (CI95%: 0.386–0.496) and the AW for serotype to ERP was 0.443
(CI95%: 0362–0.524)], there was an association between certain serotypes and antimicrobial
Table 1. (Continued)
Serotype No. of isolates (%) CAa
2012 2013 2014 2015 2012–2015
Total 368 319 311 437 -
aCA, Cochran Armitage test of trend. In bold is the only serotype with significant p-value (p < 0.05) after FDR correction.
bNVT, non-vaccine serotypes, i.e., serotypes not included in any of the currently available pneumococcal vaccines.
cOnly serotypes detected in�3 isolates in at least one year are shown; the remaining are grouped together under “Others.”
https://doi.org/10.1371/journal.pone.0206912.t001
Table 2. Number of isolates responsible for non-invasive pneumococcal pneumonia in adult patients (�18 years), according to vaccine serotype groups and age
groups, 2012–2015.
Serotype Groupsb No. isolates (%) 2015 CAa
2012 2013 2014
18–49 years PCV7 12 (12.9) 11 (16.4) 8 (10.3) 16 (15.8) 0.782
1, 5 and 7F 1 (1.1) 1 (1.5) 2 (2.6) 1 (1.0) 0.926
3, 6A and 19A 19 (20.4) 11 (16.4) 10 (12.8) 20 (19.8) 0.800
PCV13 32 (34.4) 23 (34.3) 20 (25.6) 37 (36.6) 0.983
addPPV23 25 (26.9) 15 (22.4) 28 (35.9) 30 (29.7) 0.417
NVTs 36 (38.7) 29 (43.3) 30 (38.5) 34 (33.7) 0.385
50–64 years PCV7 12 (14.1) 7 (8.4) 7 (7.4) 8 (6.7) 0.328
1, 5 and 7F 3 (3.5) 0 (0) 1 (1.1) 1 (0.8) 0.656
3, 6A and 19A 15 (17.6) 23 (27.7) 23 (24.2) 19 (16.0) 0.095
PCV13 30 (35.3) 30 (36.1) 31 (32.6) 28 (23.5) 0.026
PPV23 add 45 (18.8) 50 (27.7) 53 (24.2) 65 (32.8) 0.082
NVTs 39 (45.9) 30 (36.1) 41 (24.2) 52 (32.8) 0.531
�65 years PCV7 26 (13.7) 23 (13.6) 17 (12.3) 24 (1.1) 0.381
1, 5 and 7F 3 (1.6) 3 (1.8) 1 (0.7) 4 (1.8) 0.976
3, 6A and 19A 36 (18.9) 36 (21.3) 32 (23.2) 37 (17.1) 0.665
PCV13 65 (34.2) 62 (36.7) 50 (36.2) 65 (30.0) 0.332
PPV23 add 50 (26.3) 48 (28.4) 27 (19.6) 55 (25.3) 0.078
NVTs 75 (39.5) 59 (34.9) 61 (44.2) 97 (44.7) 0.125
a CA, Cochran Armitage test of trend.
b PCV7, serotypes included in the 7-valent pneumococcal conjugate vaccine. PCV13, serotypes included in the 13-valent pneumococcal conjugate vaccine. addPPV23,
the additional 11 serotypes present in the 23-valent pneumococcal polysaccharide vaccine but absent from PCV13. NVTs, serotypes not included in any of the currently
available pneumococcal vaccines.
https://doi.org/10.1371/journal.pone.0206912.t002
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resistance (S1 Fig). The serotypes that were positively associated with PNSP after FDR correc-
tion were serotypes 6C, 14, 15A, 19F, 19A and 23F. Among these, serotypes 19F (15.5%), 14
(12.4%), 6C (12.0%) and 19A (11.6%) accounted for half of all PNSP. The serotypes which
were positively associated with ERP after FDR correction were serotypes 6B, 6C, 14, 15A, 19F,
19A, 33A and 35A, of which serotypes 19F (20.3%), 19A (10.6%), 6C (9.6%) and 15A (8.0%)
accounted for half of all ERP. The PCV7, PCV13 and PPV23 serotypes accounted for 33.7%,
47.3% and 53.5% of PNSP, respectively, and 33.4%, 49.5% and 54.3% of ERP, respectively.
Discussion
The present study documented a decline of PCV13 serotypes in adult NIPP in the post-PCV13
period. This occurred mostly in 2011–2012 but continued, albeit more moderately, in recent
years, from 44.0% in 2010 to 29.7% in 2015. It was also noted that during 2007–2015 there
were several important yearly fluctuations in the proportion of individual serotypes, both
among PCV13 and non-PCV13 serotypes (Table 1 and S1 Table). This suggests that variations
of the PCV13 serotypes in the post-PCV13 period in adult NIPP could be the result of, not
only the herd protection conferred by childhood vaccination with PCV13, but also of temporal
trends, which had been documented in adult NIPP in Portugal previously [14].
The evolution of PCV13 serotypes in adult NIPP from 2010 onwards (when PCV13 was
being used for children vaccination in the private market) was different from the one previ-
ously found for adult IPD in Portugal in a similar period [6]. While in NIPP the sharpest
decrease in addPCV13 serotypes in the post-PCV13 period occurred from 2011 to 2012, in
IPD this occurred only from 2012 to 2013. Although the decrease of addPCV13 serotypes in
adult NIPP may have been also influenced by temporal trends, the sustained lower values
found from 2013 onwards suggest an important contribution of herd protection resulting
from PCV13 childhood vaccination.
Serotypes 3 and 19A had a major influence in the decrease of PCV13 serotypes in adult
NIPP in the post-PCV13 period (2010–2015), although these changes were also most
Table 3. Antimicrobial resistance of the isolates responsible for non-invasive pneumococcal pneumonia in adult
patients (�18 years) in Portugal, 2012–2015.
No. resistant isolates (%)a
18–49 years (n = 339) 50–64 years (n = 382) �65 years (n = 714)
PENb 57 (16.8) 70 (18.3) 131 (18.3)
MIC90 0.19 0.19 0.38
MIC50 0.012 0.012 0.012
CTX 7 (2.1) 7 (1.8) 4 (0.6)
MIC90 0.25 0.25 0.38
MIC50 0.015 0.016 0.016
LEV 2 (0.6) 3 (0.8) 16 (2.2)
ERY 73 (21.5) 70 (18.3) 168 (23.5)
CLI 56 (16.5) 58 (15.2) 136 (19.0)
CHL 7 (2.1) 7 (1.8) 4 (0.6)
SXT 57 (16.8) 66 (17.3) 104 (14.6)
TET 59 (17.4) 55 (14.4) 115 (16.1)
aPEN, penicillin; CTX, cefotaxime; LEV, levofloxacin; ERY, erythromycin; CLI, clindamycin; CHL, chloramphenicol;
SXT, trimethoprim/sulfamethoxazole; TET, tetracycline. All isolates were susceptible to vancomycin and linezolid.
bNon-susceptibitily to penicillin was determined using the CLSI breakpoints prior to 2008 [24].
https://doi.org/10.1371/journal.pone.0206912.t003
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significant in the first years (Table 1 and S1 Table). Similarly, in adult IPD two serotypes
accounted for most of the decline in the prevalence of PCV13 serotypes in the post-PCV13
period, but in this case these were serotypes 7F and 19A [6]. In contrast with the declines of
serotypes 3 and 19A in adult NIPP, the decreases of serotypes 7F and 19A in adult IPD were
more pronounced and sustained.
Serotype 3 has been the dominant serotype in adult NIPP and IPD in Portugal, both before
and after the introduction of PCV13 for children [6,14]. The decline in serotype 3 in NIPP is
surprising because this serotype did not show major changes in adult IPD in the post-PCV13
period in Portugal [6] nor in other countries [7,8,28–30]. However, reductions in incidence
of serotype 3 NIPP was reported in other studies, including a study from England [10]. The
reduced efficacy of PCV13 in preventing pediatric complicated pneumonias caused by sero-
type 3 [17] and the use of PCV13 outside of the national immunization program with some-
what modest uptake, raise the possibility of continued circulation of this serotype in carriage,
potentially explaining its persistence in disease. Since serotype 3 is heterogeneous in its inva-
sive disease potential, meaning that there are different clones expressing this serotype that dif-
fer in their capacity to cause invasive disease [31], it is possible that more invasive clones of
serotype 3 have increased post-PCV use for reasons that remain unknown. In adult IPD,
there was an expansion of the multilocus sequence type clonal complex CC180 among isolates
expressing serotype 3 [32], prior to the use of PCV13 in children, but no information is avail-
able in the post-vaccine period.
Serotype 19A emerged in Portugal in the late post-PCV7 period, to become one of the most
important serotypes in both adult NIPP [14] and IPD [5,6,33]. A decrease of serotype 19A in
adult IPD and in NIPP in the post-PCV13 period was documented not only for Portugal but
for other countries [7,8,10,11,30]. Given the compelling evidence of herd protection in adult
IPD resulting from PCV13 use in children in serotype 19A, the lack of a more significant
reduction of serotype 19A in adult NIPP in the post-PCV13 period could be due to a particular
propensity of this serotype to cause NIPP. A clearer picture of the impact of PCV13 use in chil-
dren in reducing the importance of serotypes 3 and 19A in adult NIPP may only be provided
by further studies following the epidemiology of adult NIPP after the inclusion of PCV13 in
the national immunization plan.
A decrease in serotype 7F was also detected but its contribution to the reduction of PCV13
serotypes in NIPP was minor since this serotype was an uncommon cause of NIPP in the pre-
PCV13 period.
Contrasting with the declining trend of PCV13 serotypes, no significant trend was seen
for PCV7 serotypes in adult NIPP and this was mostly due to the persistence of serotype 19F,
which occurred in 49% of the isolates expressing a PCV7 serotype in 2012–2015. Despite being
targeted by all PCVs available to date, serotype 19F remained common in nasopharyngeal car-
riage of children in Portugal in the late post-PCV7 period [34] and in the post-PCV13 period
[35], including among vaccinated children. The inability of the PCVs to eliminate this serotype
from carriage in children, at least in a non-universal coverage scenario, together with its likely
intrinsic propensity to cause NIPP rather than IPD [14] as was also shown here, may have con-
tributed to why this serotype remained the third most frequent cause of adult NIPP in the
post-PCV13 period in Portugal.
The decrease of PCV13 serotypes in the post-PCV13 period was accompanied by an
increase in the proportion of NVTs, while the addPPV23 serotypes remained relatively stable.
However, among the NVTs, only one serotype was clearly emerging (serotype 35F) and only
in the last year of the study period. Most of the remaining increase in NVTs was based in
increases in the proportion of serotypes 16F, 24F and NTs (Table 1 and S1 Table), which were
not significant if considered independently. This contrasts with results from adult IPD, in
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which there were several non-PCV13 emerging serotypes (serotypes 8, 22F, 20 and 15A), most
of them included in PPV23 [6]. These differences are not surprising, since isolates responsible
for adult NIPP and adult IPD are known to have different serotype distributions [14,15].
When comparing the serotype distribution of isolates causing adult NIPP in 2012–2014
with the serotype distribution of isolates causing adult IPD in the same period (S2 Table), sero-
types 11A, 19F, 23A, 23B, 31, NT, 17F, 6A, 21 and 37 (ranked by their frequency in NIPP)
were significantly associated with NIPP, while serotypes 8, 19A, 22F, 14, 7F, 20, 1, 4 and 12B
(ranked by their frequency in IPD) were significantly associated with IPD. Most of these asso-
ciations had been already recognized in the pre-PCV13 period [14], while the new associations
in adult IPD reflect mainly the emerging serotypes in the post-PCV13 period.
While antimicrobial resistance declined in adult IPD in the post-PCV13 period, no decline
was found for adult NIPP in this study. In NIPP, the small decrease in proportion of the mostly
antimicrobial resistant serotype 19A isolates, was balanced by an increase of NT isolates,
which were also associated with antimicrobial resistance. NTs were found to be frequent colo-
nizers of the nasopharynx of children in the post-PCV13 period [34] and were more frequently
found in NIPP than in IPD (S2 Table). The stability of PCV7 serotypes in the post-PCV13
period also helped maintaining antimicrobial resistance rates in adult NIPP [14].
The study presented has the limitations discussed previously [14]. These include the possi-
bility that some of the isolates we identified as being responsible for NIPP were in fact causing
bacteremic pneumonia or reflected colonization and not disease. Despite the general recom-
mendation that both blood and respiratory tract samples should be collected for the etiologic
diagnosis of pneumonia, we cannot guarantee that this was done in all cases. However, we con-
sider these to account, at most, for a small fraction of the isolates and therefore not to intro-
duce a significant bias. Moreover, the distinct serotype distribution found in this study for IPD
and NIPP, strongly argues against this possibility. Since our study is laboratory-based, it was
not designed to collect information important to assess the severity of the infections caused by
the different serotypes (e.g. hospitalization, ICU admission, 30-day mortality). However, this
does not compromise our approach of comparing the serotype distribution of IPD and NIPP
cases. Our temporal analyses were based on previously published data reporting the character-
istics of a random sample of 100 isolates per year [14]. Since not all available isolates before
2012 were characterized, it is possible that some of the changes in the serotype distribution
occurring from 2011 to 2012 are due to this sampling process.
In this study it was found that the overall proportion of PCV13 serotypes decreased only
moderately in adult NIPP in the post-PCV13 period. In 2015, 30% of NIPP was due to PCV13
serotypes and 28% was due to the addPPV23 serotypes, highlighting the potential role of vacci-
nation in disease prevention. However, the inclusion of PCV13 in the national immunization
program for children in 2015 and the anticipated declines in at least some of the PCV13 sero-
types due to herd effect, raise important issues regarding the cost-effectiveness of a universal
adult vaccination program. However, because the magnitude and timeframe of this herd effect
remains poorly defined, particularly in NIPP, further surveillance is essential to document
future trends in pneumococcal serotype prevalence in adult NIPP, as these seem to differ from
adult IPD.
Supporting information
S1 Fig. Number of isolates expressing each serotype causing non-invasive pneumococcal
pneumonia in adult patients (�18 yrs), Portugal, 2012–2015. The number of isolates
expressing each serotype in each of the age groups considered is indicated. Isolates recovered
from patients 18–49 years are indicated by black triangles. Isolates recovered from patients
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50–64 years are indicated by open squares. Isolates recovered from patients� 65years are indi-
cated by open circles. Isolates presenting both erythromycin resistance and penicillin non-sus-
ceptibility (EPNSP) are represented by closed black bars. Penicillin non-susceptible isolates
(PNSP) are indicated by dark hatched bars. Erythromycin resistant pneumococci (ERP) are
indicated by light hatched bars. Isolates susceptible to both penicillin and erythromycin are
represented by white open bars. Panel A—Serotypes included in conjugate vaccines. The
serotypes included in the seven-valent conjugate vaccine (PCV7) and in the 13-valent conju-
gate vaccine (PCV13) are indicated by the arrows. NVT, non-vaccine serotypes; addPPV23,
the additional serotypes included in the 23-valent polysaccharide vaccine but not included in
PCV13. Panel B—Additional serotypes included in the 23-valent polysaccharide vaccine
but not included in the 13-valent conjugate vaccine. Out of the 11 addPPV23 serotypes only
serotype 2 was not found in our collection. Panel C—Serotypes not included in any pneumo-
coccal vaccine NT, non-typable. Isolates expressing serotypes 25A and 38 and serotypes 29
and 35B could not be distinguished phenotypically and are represented together. Only sero-
types including n>3 isolates are discriminated, all remaining serotypes are grouped together
under the “Others” category grouping isolates of serotypes: 10B, 12B, 17A, 18A (n = 3 each);
10F, 11F, 11B and 47F (n = 2 each) and 28A, 35C, 36 and 42 (n = 1 each).
(PDF)
S2 Fig. Isolates expressing serotypes that changed in proportion after FDR correction caus-
ing non-invasive pneumococcal pneumonia in adult patients (�18 years) in Portugal,
2007–2015. The data up to 2011 were presented previously [14].
(PDF)
S1 Table. Serotypes of the isolates responsible for non-invasive pneumococcal pneumonia
in adult patients (�18 years), 2007–2011. These data were presented previously [14].
(PDF)
S2 Table. Serotype distribution of the isolates causing non-invasive pneumococcal pneu-
monia and invasive pneumococcal disease in adults in Portugal (2012–2014).
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